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Abstract 
Many blood markers have been associated with stroke. I set out to determine 
whether blood markers can be applied to: (i) improve the accuracy of the clinical 
diagnosis of stroke or TIA, and/or (ii) improve the prediction of poor outcome in 
patients who are still symptomatic at the time of admission with stroke or TIA. 
I systematically reviewed the existing literature on the diagnostic performance of a 
range of blood markers measured soon after stroke onset, to inform the choice of 
markers for my subsequent prospective studies in this thesis. Many studies had 
deficiencies in their design, which may have explained the apparently – and 
perhaps spuriously - impressive diagnostic performance of several markers. In the 
light of these data I was able to improve the design of my own studies and suggest 
how future studies of diagnostic markers could be improved. 
In order to define an appropriate comparator test for assessing the diagnostic 
accuracy of blood markers, I first examined the performance of emergency room 
nurses and doctors. I assessed the accuracy of their diagnosis of TIA or stroke 
(‘acute cerebrovascular disease’) in patients presenting with symptoms of suspected 
stroke, and compared them with a number of stroke diagnostic scales. In the 405 
patients recruited to the study, the sensitivity of emergency department staff was 
77% and specificity 58%. Each stroke diagnostic scale had a slightly better 
sensitivity, though worse specificity, than an emergency department clinician. I 
decided to use the diagnosis by an emergency department clinician of ‘probable or 
definite acute cerebrovascular disease’ as the best clinical performance reference 
standard. 
In blood taken from the same cohort of 405 patients, accredited research laboratories 
measured markers of inflammation, thrombosis, thrombolysis, cardiac strain and 
cerebral damage. Tissue plasminogen activator and loge N-terminal pro brain 
natriuretic peptide were associated positively with a diagnosis of acute 
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cerebrovascular disease, though each marker did not add diagnostic value to the 
diagnosis of an emergency department doctor or nurse. 
I systematically reviewed the literature examining the association between the levels 
of blood markers with poor outcome (i.e. death or dependency) after stroke. I found 
that although almost all markers studied had a positive association with poor 
outcome, there were methodological problems with many studies, chiefly small 
sample size, publication bias or within study reporting biases, and lack of 
adjustment for important confounders such as age or stroke severity. 
With data from the Edinburgh Stroke Study, I examined the association between 
circulating markers of the inflammatory response (white cell count, interleukin-6, C-
reactive protein and fibrinogen) and poor outcome after stroke. After adjustment for 
age, whether the patient lived alone, was independent of activities of daily living, 
was orientated, able to lift both arms and able to walk, I found that higher levels of 
interleukin-6, white cell count and glucose were associated with poor outcome. The 
relevant test of a biological marker is not its predictive ability alone, but whether, 
when added to a validated predictive model based on clinical variables, it improves 
the prediction of outcome. No individual marker improved the prediction of poor 
outcome when added to a validated prognostic model based on clinical variables 
alone. 
From my cohort of 405 patients with suspected stroke 285 patients had a confirmed 
diagnosis. Follow up of these 285 patients with confirmed acute cerebrovascular 
disease showed that, after adjustment for neurological impairment and age, only 
interleukin-6 and N-terminal pro brain natriuretic peptide were significantly 
associated with death or disability at 3 months. Neither marker improved the 
predictions of a model to predict poor outcome based on clinical variables alone. 
To examine the relationship between circulating markers of the inflammatory 
response and recurrent stroke, myocardial infarction, and vascular death (‘recurrent 
vascular events’), again I used data from the Edinburgh Stroke Study. After 
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adjustment for clinical predictors (age, prior MI, stroke, or TIA and AF) I found that 
higher levels of interleukin-6, C-reactive protein and fibrinogen remained 
significantly associated with an increased risk of recurrent vascular events. 
However, the relationship with deaths from all causes was somewhat stronger for 
each marker, perhaps suggesting that higher marker levels were associated with 
debility rather than vascular events per se.  
 
In conclusion, I found no marker measured could improve on the diagnostic 
accuracy of an emergency department clinician for acute cerebrovascular disease, 
nor improve the prediction of poor outcome by a prognostic model based upon 
clinical variables. The work of this thesis does not support the routine use of blood 
markers as an aid to the diagnosis of, or the prediction of outcome of, acute stroke. 
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Chapter 1.  Introduction 
The importance of diagnosis and prognosis 
Many important decisions rest upon the diagnosis and prognosis of stroke. For 
example, whether to admit a patient to a stroke unit or a medical ward, to start 
aspirin to reduce the risk of future stroke or heart attack, or to consider nursing 
home care or a period of rehabilitation. Usually, clinicians determine the probability 
of a stroke diagnosis and its likely prognosis with an informal assessment of the 
clinical features of the presenting syndrome, past history and brain imaging. 
However the clinical diagnosis of stroke is often difficult to make, and prediction of 
outcome is hard. 
It is possible to monitor physiological processes in patients with acute stroke by 
measuring circulating markers in the blood. The acute inflammatory response may 
be measured by C-reactive protein (CRP), turnover of thrombosis by D-dimer and 
axonal damage by tau protein. These ‘biomarkers’ could add value to the bedside 
clinical evaluation and to radiological investigations performed in routine clinical 
practice, to improve the diagnosis of patients with suspected stroke and the 
prediction of outcome in patients with confirmed stroke. 
Aims of the thesis 
The main aims of this thesis are therefore to: 
(1) Examine whether blood markers of inflammation, thrombosis, thrombolysis, 
cardiac strain, neuronal and glial damage improve the accuracy of the 
clinical diagnosis of stroke. 
(2) Determine if blood markers of inflammation, thrombosis, thrombolysis, 
cardiac strain, neuronal and glial damage predict stroke outcome, and if so, 
whether they add prognostic utility to existing clinical models. 
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Stroke and population health 
In each age group, fewer Western Europeans will die from stroke this year than at 
any time over the past 50 years (Levi et al. 2009). The dramatic 80% fall in age 
specific stroke death rates over this period is most likely due to falls in the incidence 
of stroke as populations change to healthier lifestyles. This conclusion is supported 
by a falling trend of age specific stroke incidence in well conducted epidemiological 
studies (Anderson et al. 2005, Rothwell et al. 2004a). Alternative explanations may 
be that improvements in the care of people after stroke have led to reductions in 
case fatality, or there has been an improvement in the attribution of deaths to stroke 
over time with better diagnostic techniques, particularly brain imaging. 
Despite these falls in mortality, stroke remains a global health priority. Stroke kills 
5.5 million people a year and leads to the loss of 38 million years of healthy life 
worldwide (Mackay J & Mensah G.A. 2004). It is the third leading cause of death 
after coronary heart disease and all cancers combined. As stroke incidence rises with 
age, and the proportion of elderly people in the population rises, the demands that 
stroke places on health services are likely to remain steady or even rise (Mathers & 
Loncar 2006). 
The definition of stroke 
Strokes are a group of diseases of the brain vasculature that share a clinical 
syndrome: the rapid onset of a focal cerebral disturbance. The World Health 
Organisation definition of the clinical stroke syndrome is the most widely used; 
A stroke [is] defined as rapidly developing clinical signs of 
focal (or global) disturbance of cerebral function, lasting 
more than 24 h[ours] or leading to death with no apparent 
cause other than that of vascular origin 
(Hatano 1976) 
In the standard definition, focal symptoms that last for less than 24 hours are 
classified as transient ischaemic attacks (TIA). However, this threshold presents 
difficulties when assessing patients within 24 hours of symptom onset. Researchers 
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need to follow up patients assessed within hours of focal neurological symptoms for 
full recovery – itself difficult to define - until the end of the 24 hours period, to 
determine short term prognosis and to differentiate transient ischaemic attacks from 
strokes. 
Implicit in the differentiation of transient ischaemic attack from stroke is a 
difference in prognosis, aetiology or patho-physiology between patients with 
clinical syndromes classified as ‘stroke’ and clinical syndromes classified as ‘TIA’. 
Some advocate that these important differences are captured by measuring the 
duration of symptoms, and others (Saver 2008) believe that the most important 
distinction is the presence or absence of objective evidence of cerebral tissue damage 
as evidenced by changes on diffusion weighted MR imaging.  
Stroke subtypes 
The two major mechanisms of stroke are damage to brain tissue due to a failure of 
arterial blood supply (i.e. cerebral ischaemia), and intracranial haemorrhage. The 
most common causes of occlusion of cerebral arteries are: (i) emboli from the heart, 
(ii) emboli from the arch of the aorta, carotid artery or larger intracerebral vessels, 
(iii) thrombosis forming in the intracerebral arteries, and (iv) occlusion in the small 
penetrating arteries of the deep white matter, which may be due to in-situ 
thrombosis or oedema. Attributing a mechanism to a particular stroke patient is 
difficult, as several potentially causative lesions may co-exist in the same patient, 
and the investigations necessary to attribute a cause may be difficult to obtain.  
The aetiology of intracerebral haemorrhage is less clear. The risk of haemorrhage is 
higher in patients with risk factors for atherosclerotic vascular disease – such as 
smoking and hypertension – though whether most haemorrhages are due to rupture 
of an atherosclerotic vessel or other mechanisms is not certain. A small proportion 
of intracerebral haemorrhages are due to structural lesions, such as intracranial 
vascular abnormalities, though the proportion that can be attributed to these causes 
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is limited by the difficulty and risks of performing invasive vascular imaging in 
acutely unwell people. 
The clinical diagnosis of stroke 
Much depends upon a correct diagnosis of stroke. In the early stages, a correct 
diagnosis leads to rapid assessment by the right clinical team, referral for timely 
brain imaging and stroke unit care. The positive diagnosis that a stroke is due to 
ischaemia, rather than intracerebral haemorrhage, means a number of interventions 
may be used appropriately: intravenous thrombolysis, antiplatelet agents to prevent 
recurrent vascular events, anticoagulants to prevent recurrent cardiac embolism in 
patients with atrial fibrillation (AF), and carotid artery imaging to identify stenosis. 
A stroke specialist is rarely the first health professional the patient encounters after 
the onset of stroke symptoms. Instead, it is usually either a general practitioner 
(GP), ambulance crew member or one of the emergency department (ED) staff – so 
called ‘first responders’ – who refer patients to stroke services when they suspect a 
stroke. The diagnostic performance of first responders is therefore of great 
importance. If their diagnostic approach is not sufficiently specific, large numbers of 
patients without stroke could overwhelm stroke services: if not sufficiently 
sensitive, patients with stroke may not receive important treatments. The benefits of 
improving tools for the diagnosis of stroke are therefore potentially large. The main 
methods to diagnose stroke are clinical examination and brain imaging; the best 
method used to improve the clinical diagnosis of stroke will depend on the health 
care setting. 
 Pre-hospital clinical diagnostic scales 
Ambulance staff have a variety of diagnostic stroke scales to choose between to 
assess patients with suspected stroke: the face arm speech test (FAST), the Los 
Angeles pre-hospital stroke scale (LAPSS), the Cincinatti prehospital stroke scale 
(CPSS) and the Melbourne ambulance stroke screen (MASS) (Bray et al. 2005, 
Harbison et al. 2003b, Kidwell et al. 2000, Kothari et al. 1999). The diagnostic 
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performance of these scales as assessed in their original (development) cohorts is 
summarised in Table 1.1. The important comparison between an ambulance crew 
member’s diagnosis of stroke with and without the use of one of these scales was 
not made in any of these studies.
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Table 1.1 The sensitivity and positive predictive value of diagnostic stroke scales for a diagnosis of stroke, when performed by ambulance crews. 




Sensitivity          
(%, 95% CI) 
Specificity          
(%, 95% CI) 
PPV              
(%, 95% CI) 
FAST Acute stroke unit 
referrals by ambulance 
crews 
Facial weakness, arm weakness, 
speech disturbance 
Review of medical notes by 
medical assessors, 
unblinded  
487/? ~79* NC 78 (72 to 84) 
CPSS Sample of patients 
from emergency 
department 
Facial weakness, arm weakness, 
speech disturbance 
Review of medical notes for 
diagnoses of stroke made by 
a stroke service 
n/a 59 (51 to 67)† 89 (86 to 91) NC 
LAPSS All ambulance 
transfers in 7 months 
Facial weakness, grip weakness, 
arm weakness, blood sugar, no 
seizure, not wheelchair user, >45 
yrs, symptoms <24 hours 
Diagnosis by study 
neurologist soon after 
paramedic assessment 
206/1298 91 (76 to 98) 97 (93 to 99) 86 (70 to 95) 
MASS All ambulance 
transfers in 12 months 
Facial weakness, grip weakness, 
arm weakness, blood sugar, 
speech disturbance, >45 yrs, not 
wheelchair user 
Medical notes reviewed for 
discharge diagnosis 
100/3,327 90 (81 to 96) 74 (53 to 88) 90 (81 to 96) 
FAST: face arm speech test; CPSS: Cincinnati pre-hospital stroke scale; LAPSS: Los Angeles pre-hospital stroke scale; MASS: Melbourne ambulance stroke 
screen; NC: not calculated; n/a not available. * non-referrals to stroke unit not reviewed, so approximate †sensitivity and specificity calculated by completion 
of 860 scales in 171 patients by 24 ambulance crew members
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These stroke scales were often evaluated as part of multi-faceted interventions to 
improve the speed of transfer of patients with acute stroke to hospital. These studies 
showed that, with such complex interventions, the identification of patients with 
stroke by paramedics could either remain the same or improve (Frendl et al. 2009, 
Wojner-Alexandrov et al. 2005). The additional effect of introducing a rating scale to 
the other components of the new intervention (such as extra training or stroke 
teams) was not clear. With the use of formal clinical scales, ambulance crews appear 
to have an acceptable performance in the diagnosis of patients with stroke, though 
additional effect of scales on paramedics’ clinical skills is uncertain.  
Hospital based stroke scales 
A scale to improve the diagnostic ability for stroke of emergency department staff 
(recognition of stroke in the emergency room scale, ROSIER) was developed in 
Newcastle (Nor et al. 2005g). After developing a logistic regression model in 343 
patients presenting to the emergency department, the authors derived a 7 item 
scoring system (the items: asymmetrical facial, arm, or leg weakness, speech 
disturbance, visual field defect, evidence of syncope, seizure) which they validated 
in a separate cohort of 160 patients from the same institution. A positive ROSIER – 
i.e. one or more item positive - had a sensitivity of 93% and specificity of 83% for a 
stroke diagnosis, and in their population, a positive predictive value of 90%. 
Although ROSIER performed better than the CPSS, LAPSS and FAST scores in this 
cohort, it did so at the expense of additional complexity. 
In a group of patients presenting to a medical admissions unit with suspected stroke 
from Edinburgh, Hand derived predictors for the diagnosis of stroke (Hand et al. 
2006c). A model with eight variables correctly classified 80% of patients into 
stroke/not stroke categories, with an area under a receiver operator curve (AUROC) 
of 0.87. The eight variables were: cognitive impairment, time of symptom onset, 
focal neurological symptoms, abnormal vascular findings, abnormal findings in 
other organ systems, laterisable symptoms, Oxford community stroke project 
(OCSP) classification possible, and neurological impairment measured by the 
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National Institutes of Health stroke scale (NIHSS). Hand also developed simpler 
models for use by paramedics and emergency department nursing staff, with fewer 
variables that might be easier to apply. 
 The effect of applying a scale may be limited, as although doctors can disagree 
about individual aspects of a patient’s history and examination (Hand et al. 2006b, 
Lindley et al. 1993), they tend to agree with one another – albeit imperfectly - about 
the diagnosis of stroke within hours of symptom onset (κ =0.77) (Hand et al. 2006a). 
After training, there seems to be good inter-observer agreement for a measure of 
neurological impairment, the NIHSS scale, between doctors (Goldstein, Bertels, & 
Davis 1989) and doctors with nurses, though the NIHSS alone was not designed as a 
diagnostic tool (Goldstein & Samsa 1997a, Hand et al. 2006h).  
Clinical scoring systems designed to differentiate ischaemic from haemorrhagic 
stroke have not proved sufficiently discriminatory to be useful for patients 
presenting with suspected stroke (Allen 1983, Besson et al. 1995, Poungvarin, 
Viriyavejakul, & Komontri 1991). As they are unable reliably to exclude 
haemorrhage, they are not useful when making decisions about treatments that 
could potentially exacerbate intracranial haemorrhage – such as thrombolysis, 
heparin and aspirin.  
Therefore, though clinical scales may help to identify patients with a high 
probability of stroke amongst the many presenting with suspected stroke, it is not 
clear whether they add discrimination to a doctor’s routine diagnostic abilities.  
Difficulties of acute imaging 
Brain imaging is essential for the accurate diagnosis of stroke and its subtypes. 
Imaging seeks to identify non-vascular causes of a clinical stroke syndrome, such as 
brain tumors, and amongst patients with stroke positively to identify brain 
ischaemia or haemorrhage.  
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Brain computerised tomography 
In the acute stages almost all intracranial haemorrhages are potentially visible on 
brain imaging that is of good quality and performed within hours of symptom 
onset. There are several case reports of patients who have had an intracerebral 
haemorrhage whilst in a CT scanner that confirm haemorrhage is visible 
immediately after onset of symptoms (Franke, Ramos, & van 1990, Masson et al. 
1984). However, less experienced observers may overlook haemorrhages or mistake 
non-pathological calcification for blood (Schriger et al. 1998).  
In the early stages of stroke, cerebral ischaemia may be difficult to identify 
positively on CT. About 60% of patients with acute stroke have early CT signs of 
infarction (Wardlaw & Mielke 2005), depending upon case mix. Neurologists 
detected early signs of infarction 14% less frequently than neuroradiologists 
(Wardlaw et al. 2007a). More experienced readers and the use of a scoring system 
improved the detection of early ischaemic change (Coutts et al. 2004, Wardlaw et al. 
2007b). Estimates of the sensitivity of CT for changes of cerebral ischaemia range 
from 11 to 75% (median 45%), but specificity is in general very high – 100% 
(Brazzelli et al. 2008). 
In summary, signs of intracranial haemorrhage are almost always evident on a CT 
soon after stroke onset, and most observers are able to identify it reliably. Positive 
evidence of cerebral ischaemia is seen less frequently, and may be harder for 
observers to detect, particularly if they have not had special training in radiology or 
stroke medicine. 
Brain magnetic resonance imaging 
MRI is currently the main alternative to CT for brain imaging in the early stages of 
stroke. Some authors state that intracerebral haemorrhage can easily be detected on 
MRI in the acute stages of stroke by observers of different levels of imaging 
experience though considerable uncertainty exists (Brazzelli et al 2008, Fiebach et al. 
2004, Kidwell et al. 2004). Diffusion weighted imaging (DWI) is the most sensitive 
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sequence to detect early signs of ischaemic stroke. In patients with minor stroke, 
DW MRI is sensitive to early ischaemic signs, and may be more sensitive than CT. 
Estimates of sensitivity – which may be overly optimistic - range from 73% to 100% 
(median 100%) and specificity from 86 to 100% (median 100%) (Brazzelli et al 2008, 
Chalela et al. 2007). However, DW MRI does not always show changes in patients 
with ischaemic stroke (Ay et al. 1999, Doubal, Dennis, & Wardlaw). MRI is more 
expensive than CT, and is less rapidly available for patients with acute stroke 
services, in the UK and elsewhere (Kane et al. 2008, Leys et al. 2007). There are also 
practical barriers to performing MRI in unwell patients with acute stroke (Hand et 
al. 2005b). MR scanning may not be possible in patients who are too medically 
unstable to enter the isolated environment of the scanning room, too confused to lie 
still for the investigation, or who have medical implants (such as pacemakers) or 
loose metallic foreign bodies. 
Potential advantages of blood markers for stroke diagnosis 
Blood markers for diagnosis of diseases other than stroke 
Blood markers are used routinely in the management of several diseases. In patients 
presenting to hospital with chest pain, a raised cardiac troponin is indicative of 
myocardial infarction, rather than angina or other causes of chest pain (Brott et al. 
1989c): the measurement of troponin is recommended in the early stages of 
assessment of all patients with suspected acute coronary syndromes (NICE 2009). In 
patients presenting to hospital with suspected pulmonary embolus (PE), a raised 
serum D-dimer measured with a quantitative ELISA has a sensitivity of 96% and 
specificity of 44% for a diagnosis of PE in the subsequent months; measurement of 
D-dimer is therefore recommended as part of a clinical pathway to rule out the 
diagnosis of PE, and helps to reduce inappropriate use of more resource intensive 
diagnostic methods with a higher hazard from radiation (e.g. CT pulmonary 
angiography) (British Thoracic Society 2003).  
Near patient testing 
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Blood markers could have a number of advantages compared with current 
techniques in the diagnosis of stroke. If simple, rapid assays were available for the 
measurement of blood proteins in patients with stroke (as they are for patients with 
myocardial infarction (McDonnell et al. 2009)), blood markers would have the 
advantages of: 
(i) Speed: Near patient devices for the measurement of troponin and D-
dimer give results within minutes. The small immunometric chips could 
be adapted to other blood proteins, were they of value in stroke. 
(ii) Ease of use: Almost all point of care devices are designed to be used by 
people with little training, and without extensive laboratory preparation 
(Warsinke 2009). 
(iii) Reduced costs: Implementation of point of care testing devices in patients 
with myocardial infarction led to estimates of substantial cost savings, 
by shortening hospital stay and reducing the demand for further 
diagnostic resources (Apple et al. 2006).  
However, there are a number of concerns about point of care testing. The machines 
may not be as reliable as those designed for laboratory use; the tests may be 
inappropriately over- or under-used; and the direct costs of the test and machines 
fall on the ED budget, though savings accrue elsewhere in the health service 
(predominantly in specialist services). 
Role of new tests 
Often a new diagnostic test does not overturn previous diagnostic methods. Brain 
imaging has been an exception. Since it became widely available, several 
uncomfortable and potentially harmful tests have been abandoned - such as air 
encephalograms and intra-arterial angiography by direct carotid puncture. Blood 
markers are unlikely to revolutionise diagnosis to the same extent; it is more likely 
that if they prove useful they will form part of a management or diagnostic 
pathway. 
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Predicting outcome after stroke 
Tools for the reliable prediction of outcome after stroke could be very useful. 
Patients, clinicians and health care planners might use predictions to guide 
decisions about medical treatment, select an appropriate level and type of care, or 
for planning services. Auditors could compare observed with predicted outcome to 
assess the performance of stroke services. There are three main methods – each with 
their own advocates – to predict outcome after the onset of illness: usual bedside 
clinical judgement, single predictive measures and multivariable statistical models. 
Usual bedside clinical judgment 
The most widely used method to predict outcome in clinical practice is the 
judgment of the assessing doctor. However, such predictions can often be improved 
upon. For example, only 24% of physicians gave an accurate prediction of recurrent 
cardiovascular events in patients with cardiac vascular disease, most often making 
an overestimate (Pignone et al. 2003). When predicting operative mortality, cardiac 
surgeons overestimated the chance of death and the need for intensive care (Ivanov 
et al. 2000b). In stroke, clinicians were over-optimistic about the chance of recovery: 
only 65% of those predicted to recover had gained independence by one year 
(Counsell, Dennis, & McDowall 2004e). 
Single predictive measures 
A single easily remembered measurement – for example stroke severity – might be 
predictive for outcome after stroke. However, the relationship between outcome 
and a single variable may demonstrate both ceiling and floor effects, and the 
relationship between a measurement scale (e.g. the NIHSS) and the outcome of 
interest may not be linear. As relationships between a scale and outcome are not 
always simple, they cannot always be interpreted without computation. 
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Multivariable models 
Multivariable models may make better predictions of outcome than clinicians. For 
example, in patients with coronary vascular disease the predictions of survival from 
a validated Cox regression model were better (and more consistent) than a 
cardiologist’s clinical judgment; furthermore in this case, more senior clinicians did 
not perform better than the model (Kong et al. 1989). By contrast, in stroke, the 
predictions from a simple model were as good as those of an experienced clinician 
(Counsell, Dennis, & McDowall 2004d). 
The best prediction of outcome after stroke will very likely come from multivariable 
models, rather than single predictor variables. Many models have been developed 
for predicting death and disability in patients soon after acute stroke, though only 
two – the six simple variable score (Counsell et al. 2002g) and a score containing the 
NIHSS and age (Konig et al. 2008b) – have been extensively validated. Both these 
scores contain a measure of stroke severity (the NIHSS score or 3 dichotomous 
variables with ability to walk, lift arms and orientation to time, place and person) 
and age; in addition the six simple variable model contains a measure of premorbid 
function (whether the patient was independent prior to stroke) and a factor that 
might influence the chance of returning home (whether the patient lived alone 
before the stroke).  
Role of prediction in clinical practice 
Although the results of clinical decision rules based upon prognostic models may be 
reliable, they may not alter clinical decisions (Lee et al. 1995, Reilly et al. 2002, Selker 
et al. 1998). For example when cardiothoracic surgeons were given access to the 
results of a reliable clinical prognostic model they did not revise their own personal 
judgement of a poor outcome (Ivanov et al. 2000a). The key characteristics of a rule 
that is robust enough to change a clinician’s behaviour are not yet defined. 
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Blood markers in improving prediction of stroke outcome  
In stroke, the performance of validated prognostic models to predict stroke outcome 
could be improved. The major components of the two valid prognostic models do 
not include measurements of a number of key patho-physiological processes that 
might help to refine predictions of a poor outcome, such as cardiac dysfunction, the 
extent of neuronal or glial damage and activation of inflammatory pathways.  
In other fields of medicine, blood markers may improve the prediction of outcome, 
over and above existing clinical risk scores. For example the addition of CRP seems 
to add prognostic information to the Framingham risk score for the prediction of 
vascular events (Ridker et al. 2002), and the addition of brain natriuretic peptide to 
the GRACIE score improves the prediction of outcome after myocardial infarction 
(Lorgis et al. 2009), though further validation of both of these tests is needed before 
they are introduced into routine clinical practice.  
Blood markers might therefore be useful in addition to validated prognostic models 
in predicting outcome after stroke. 
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Chapter 2.  Blood markers in the diagnosis of ischaemic stroke: a 
systematic review 
Introduction 
A rapid blood test to confirm a clinical and imaging diagnosis of ischaemic stroke 
(or to aid risk-stratification in confirmed cases), based on a simple and low-cost 
near-patient technology, would be extremely useful. At the moment, the diagnosis 
of ischaemic stroke is based on an experienced stroke clinician’s examination of the 
patient, supplemented by the results of brain imaging. However, in people who 
suddenly become unwell with a suspected stroke,  the clinical assessment within the 
first few hours is not always straightforward. Many patients with acute stroke are 
not assessed by a stroke specialist; the initial evaluation is often by a GP, paramedic 
or triage nurse. For those assessed in hospital, interpretation of brain imaging 
appearances can be difficult, as computerised tomography (CT) is often normal after 
the onset of  ischaemia and may remain normal in patients with mild ischaemic 
strokes. Magnetic resonance imaging (MRI), though undoubtedly more sensitive in 
detecting ischaemia than CT, especially in the diagnosis of mild stroke, is still not 
100% sensitive or specific. MRI may not be feasible in acutely ill patients because 
they are restless, have a contraindication to MRI or MRI may not be immediately 
available (Chalela et al 2007). 
Achieving an accurate  diagnosis quickly  in patients with suspected acute stroke is 
extremely important. Patients with ischaemic stroke, even with relatively mild 
symptoms, may be eligible for intravenous thrombolysis or other means of brain 
reperfusion if treatment can be started within a  few hours of symptom onset. 
Patients who are not suitable for such acute treatments are at risk of early recurrent 
stroke: 8% of high risk patients have a recurrent stroke within the first 2 days 
(Johnston et al. 2007). Prompt initiation of secondary preventative treatment can 
substantially reduce the risk of further stroke. 
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The development of blood biomarkers for ischaemic stroke diagnosis faces  
difficulties. The blood-brain barrier, even when damaged, slows the release of brain 
tissue proteins into blood after stroke, delaying the release of glial and neuronal 
proteins. Many potential  blood markers of cerebral ischaemia and inflammation are 
found in other conditions that may mimic stroke, such as severe myocardial 
infarction and brain infection. Also, the volume of damaged tissue in the acute 
phase may not correlate with the risk of subsequent disability; small volumes of 
tissue damaged by ischaemia in an ‘eloquent’ area of the brain can lead to a more 
disabling deficit than a large volume of brain damaged by stroke in another part of 
the brain.  
There has been a substantial investment in translational medical research 
programmes to discover new diagnostic markers. I therefore wished to undertake a 
systematic review of published reports to assess the accuracy of blood markers for 
the diagnosis of ischaemic stroke as a precursor to my own study of the subject. I 
aimed to describe the methodological quality of the studies, to compare the 
accuracy of diagnostic markers and assess the extent to which  methodological 
weaknesses might have biased diagnostic test accuracy.  
Methods 
Study identification 
I searched Medline and EMBASE from 1966 to 15th March 2007 for all studies of the 
use of diagnostic blood biomarkers in stroke. I maximised retrieval  by searching 
using both generic biomarker terms and individual biomarkers (and their 
synonyms) obtained from a previous search of the literature (Anderson 2005, 
Marcovina et al. 2007, Ridker et al. 2004, Vasan 2006b). The search strategy included 
13 terms for ischaemic stroke, 4 for generic biomarkers and 780 specific biomarker 
terms. Diagnostic studies were identified by searching for the words ‘sensitivity’, 
‘specificity’, ‘likelihood ratio’ or ‘diagnosis’ in the title or abstract and keywords. 
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The full search strategy is listed in the appendix. The search was not restricted by 
language. 
I searched the reference lists of relevant papers, conference abstract books and my 
personal files. I also searched the internet for patents (using 
www.freepatentsonline.com and www.google.com) and papers citing each relevant 
paper with the ‘Google Scholar’ tool (http://scholar.google.com/). 
Studies were eligible for inclusion if they examined the ability of a single or a set of 
several venous blood (not CSF) markers to discriminate between patients with 
ischaemic stroke and a group without stroke (either controls without disease, with 
stroke mimics or with other neurological diseases), or between ischaemic and 
haemorrhagic stroke, where a cutoff value for the test had been calculated (or 
arbitrarily set) and there was sufficient information to fill a 2x2 contingency table. 
There was no minimum sample size for study inclusion. Both conference abstracts 
and published papers were included. 
Data extraction 
I and a colleague, Dr. Mei-Chiun Tseng, reviewed the list of titles and abstracts of 
potentially relevant papers independently; I then obtained full copies of papers 
meeting my eligibility criteria and we independently extracted data from the 
eligible papers. Any disagreements were resolved by discussion. We assessed the 
quality of the study reports with a modified QUADAS instrument (Whiting et al. 
2003) (see appendix). Where a study examined more than one cohort within a study, 
the results for each cohort were extracted separately. 
Statistical analysis 
I calculated 95% confidence intervals for the estimates of sensitivity and specificity 
in each cohort (Agresti & Coull 1998).  I made no attempt to assess for publication 
bias, although this probably exists, as there are currently no well-established  
methods to assess the scale and direction of this form of bias in studies of diagnostic 
test accuracy (Begg 2005). 
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Results 
The MEDLINE/Embase search identified 3093 studies. A further 8 were found 
through reading conference reports and the reference lists of relevant papers. All the 
abstracts were read, and 70 publications were read in full.  21 publications were 
relevant to the review - 6 conference abstracts and 15 papers (Abboud et al. 2007, 
Allard et al. 2007, Allard et al. 2005i, Allard et al. 2005h, Allard et al. 2004a, 
Dambinova et al. 2003b, Dambinova et al. 2003a, Delgado et al. 2005, Fassbender et 
al. 1997d, Foerch et al. 2006d, Hill et al. 2000f, Laterza et al. 2006d, Lynch et al. 
2004h, Montaner et al. 2005, Rainer et al. 2007, Reynolds et al. 2003h, Rouanet et al. 
2006, Takahashi et al. 1999a, Tomitori et al. 2005d, Turck et al. 2006, Zimmermann-
Ivol et al. 2004a) (Table 2.1). 
Methodological assessment 
I used a modified QUADAS instrument to assess the quality of the reports of 
diagnostic biomarkers (Table 2.2). The performance of blood biomarkers was 
examined in patients with suspected stroke – the clinical scenario for any stroke test 
-  in 4/21 studies (Laskowitz et al. 2005a, Lynch et al. 2004g, Reynolds et al. 2003g, 
Rouanet et al 2006). The remaining studies compared cohorts of patients with a 
diagnosis of stroke with a control group. The sensitivity and sensitivity of a 
biomarker with a prespecified threshold for a positive test was examined in 6/21 
studies (Abboud et al 2007, Fassbender et al. 1997c, Hill et al. 2000e, Laterza et al. 
2006c, Rouanet et al 2006, Tomitori et al. 2005c). The remainder  derived a diagnostic 
threshold cut-off value from the cohort examined. Of the 15 studies that employed a 
data-dependent cutoff, none validated the sensitivity estimates in a separate cohort. 
Only 2/21 studies reported that the assessment of biomarker diagnostic accuracy 
was performed blinded to stroke status (Dambinova et al 2003b, Foerch et al. 2006c). 
All diagnoses of stroke appeared to be blinded to biomarker status. 
The clinical comparisons in each study were different. Some studies classified TIA 
as an acute ischaemic stroke though others did not (Abboud et al 2007, Allard et al 
2007, Allard et al 2005i, Allard et al. 2005g, Allard et al. 2004b, Lynch et al. 2004f, 
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Reynolds et al. 2003f, Turck et al 2006, Zimmermann-Ivol et al. 2004b). However the 
number of patients symptomatic at the time blood was drawn was not defined and 
there were no explicit means of measuring recovery at 24 hours. Most studies 
classified a patient as having a definite ischaemic stroke only if they had both 
appropriate symptoms and a visible appropriate lesion on imaging, even though it 
is well recognised that many patients with definite stroke can have initially normal 
neuroimaging. Six studies classified subarachnoid haemorrhage (which generally 
has a very different clinical presentation to acute stroke) as a haemorrhagic stroke 
though most did not (Allard et al 2007, Allard et al. 2005f, Allard et al. 2004c, 
Takahashi et al. 1999b, Turck et al 2006). Only one study examined a cohort of 
suspected stroke patients, and compared the performance of a panel of biomarkers 
to another assessment method (in this case a triage nurse): both performed with a 
similar sensitivity and specificity (Rouanet et al 2006). 
Nine studies reported the delay between symptom onset and blood taking for 
biomarkers – the range was between 30 minutes and 5 days after stroke (Abboud et 
al 2007, Allard et al 2007, Allard et al. 2005e, Dambinova et al 2003b, Hill et al. 
2000d, Lynch et al. 2004e, Rainer et al 2007, Reynolds et al. 2003e, Zimmermann-Ivol 
et al. 2004c). Four  only examined diagnostic performance within the first 24 hours 
of symptom onset (Abboud et al 2007, Hill et al. 2000c, Lynch et al. 2004d, Rainer et 
al 2007). One study  reported the sensitivity of a biomarker panel for a diagnosis of 
stroke at different time points, though there was no clear relationship between the 
delay to blood taking and sensitivity (Reynolds et al. 2003d).  
Markers measured 
The 21 studies tested 58 single biomarkers and 7 panels of made up of several 
markers. The exact number of cohorts, and therefore the total number of patients 
involved, was difficult to calculate as some studies examine part cohorts from other 
studies included in the review (Table 2.1). The estimated upper limit was 2928 
stroke patients and 1569 controls in 24 cohorts.There was sufficient information to 
extract 2x2 tables on 21 markers for the diagnosis of ischaemic stroke vs not stroke 
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or control (Figure 1). Of these markers, 5 had reported sensitivities over 90% 
(NDKA, PARK7,  UFD-1, NMDA receptor (NR) 2 fragment, NR2A/B antibodies) 
and 14 had a specificity over 90% (PARK 7/RNA-BP , UFDP, NDKA, GSTP, 
ischaemia modified albumin (IMA), visin like protein (VLP-1), beta globin DNA, 
NR2 fragments, S100 B, FABP, neurone specific enolase (NSE), NR2A/2B Ab, myelin 
basic protein (MBP) and thrombomodulin). For 5 biomarkers (S100 beta, MBP, 
thrombomodulin, NSE and beta globin DNA) the specificity was defined by a 95% 
or 98% reference interval in subjects without disease. Five markers were tested in 
more than one cohort of patients, though only neurone specific enolase (NSE) and 
S100 beta were tested by different research groups. Only S100 B was tested in 
different cohorts of patients using the same cutoff for a postive result (0.02μg/L). 
Information about 4 panels of markers was extracted (Figure 2); in no case was the 
regression equation given for the marker panel (i.e. the formula which permits a 
calculation of the probability of stroke if the results of the individual component 
biomarker tests are known) in the original publication, though one became available 
subsequently. No panel of markers was validated in an independent cohort of 
patients.  
Chiefly as a result of the very substantial clinical heterogeneity of the populations 
studied, and heterogeneity of results, I did not perform a meta-analysis to derive  an 
overall summary receiver operator curve for any of the individual markers or any of 
the panels of markers.  
In 5 studies, 6 individual markers and 2 panels of markers were assessed to 
determine the ability of blood biomarkers to distinguish between ischaemic and 
haemorrhagic stroke. There was sufficient information to extract 2x2 tables on 6 
markers and 4 panels (Figure 3). Most studies used the  diagnosis of haemorrhagic 
stroke as the diagnosis of interest in a population of haemorrhagic and ischaemic 
stroke patients. Two (Allard et al. 2004d, Dambinova et al 2003a) reported a positive 
test as a diagnosis of ischaemic stroke in a mixed population, both with a high 
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sensitivity and specificity. No single marker or panel of markers was reported in 
more than one cohort of patients. 
Discussion 
I set out to assess the utility of blood biomarker tests for improving the diagnosis of 
ischaemic stroke in the acute phase. Most of the studies in this review reported 
biomarkers with high sensitivity and specificity which, if confirmed in validation 
studies, could be useful in clinical practice. However, all the blood biomarker 
studies had weaknesses in their methodology. Thus the apparently very high 
specificities and sensitivities reported may be substantially due to bias and not 
reflect the true clinical utility of the test. The main problems identified in this review 
were: small sample size; poor choice of reference standard (lesions required on 
imaging rather than clinical diagnosis supported by imaging); poor choice of 
controls (rarely reflecting the clinical setting in which the test would be used); data-
dependent thresholds and lack of validation. 
Implications of this review for subsequent studies 
The important diagnostic questions in the management of acute ischaemic stroke 
can be summarised as follows: 
• Does this patient have a stroke – especially if brain imaging is normal? 
• Does this patient have an ischaemic or a haemorrhagic stroke? 
• What is the short term prognosis of patients with these acute symptoms?  Is 
the prognosis sufficiently grave to merit more intensive diagnostic 
investigation requiring ionising radiation or administration of contrast e.g. 
CT angiography or CT perfusion or potentially risky treatments such as 
intravenous or intra-arterial thrombolysis? 
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Methodological aspects of the diagnosis of stroke in the emergency department 
before scanning or expert assessment 
If a test is designed to be used for the diagnosis of ischaemic stroke in unselected 
patients by clinicians in an emergency setting, then cohorts of suspected stroke 
patients for biomarker development or validation should be recruited by clinicians 
in the emergency department. In this systematic review, only one (Rouanet et al 
2006) attempted this explicitly; three other studies examined suspected stroke 
patients  though it was unclear from the reports whether non-expert clinicans 
recruited patients, and they also used healthy controls to enlarge the control group 
(Lynch et al. 2004c, Montaner et al 2005, Reynolds et al. 2003c). Studies should also 
evaluate whether biomarker tests perform better than the clinical judgement of non-
expert clinicians or prehospital screening tools such as the FAS test (Harbison et al. 
2003a). 
Two useful diagnostic tests employing a biomarker in venous blood for conditions 
other than stroke, that are used in a similar setting, are BNP for exclusion of 
diagnosis of congestive cardiac failure and D-dimer for the exclusion of a diagnosis 
of PE. Both are very sensitive. BNP has a sensitivity range between 68 to 98% (Wang 
et al. 2005) and D-dimer ELISA has a sensitivity for PE of 96% (Stein et al. 2004). D-
dimer is used as part of  a diagnostic algorithm that includes an initial assessment of 
the clinical probability of PE by means of a validated scale. Similarly blood 
biomarkers of stroke might be most useful when combined either with clinical 
judgement alone or with clinical judgement plus brain imaging. 
Differentiating haemorrhagic from ischaemic stroke before brain imaging 
In the developed world a blood test that aims to differentiate between patients with 
haemorrhagic and ischaemic stroke would be of greatest utility before brain 
imaging (e.g. during ambulance transfer to hospital). In the developing world, 
where brain imaging is not available, a low cost blood test to supplement the 
bedside diagnosis would be extremely useful. In studies to evaluate such a test, the 
Whiteley W.N. Blood Markers in Stroke University of Edinburgh 2010 
 
Chapter 2  Blood Markers in the Diagnosis of Stroke: A Systematic Review 48 
patients should be recruited at the earliest possible opportunity and certainly before 
brain imaging is ordered. CT is a rapid test, and very good at identifying acute 
intracranial haemorrhage, so a biomarker test is likely to be redundant after imaging 
has been performed. However, in the studies in this review, which compared 
diagnostic test accuracy for distinguishing ischaemic from haemorrhagic strokes, 
there were no patients in whom stroke was suspected, who turned out to have an 
alternative diagnosis on imaging. Hence the cohorts were too highly selected to be 
useful to assess the diagnostic utility of biomarkers in this particular setting. 
Supporting a diagnosis of ischaemic stroke  in patients with normal CT brain 
In many countries, most patients with suspected stroke have a brain CT as their first 
investigation. When CT is normal, clinicians are often uncertain whether the 
diagnosis of stroke is secure enough to justify thrombolysis or the use of aggressive 
stroke preventative treatments. In patients with clinical symptoms of stroke, but a 
normal CT brain scan, a blood biomarker could be useful, as ischaemic stroke may 
be the condition most likely to lead to a rise in specific proteins. Studies evaluating a 
blood biomarker in this setting should recruit patients in whom the clinicians are 
uncertain about the appearances of an imaging test, with blood drawn immediately 
after the CT. If advanced CT or MR scanning become more widely available in the 
emergency departments, the diagnostic performance of blood biomarkers would 
need to be compared with these techniques. 
Short term prognosis after non-disabling stroke or TIA 
In patients with non-disabling  stroke or TIA, short term prognosis has a major 
influence on patient management: it informs decisions about admission to hospital, 
the intensity and speed of investigation, and the likelihood of successful early 
discharge.  In this context, studies of diagnostic test accuracy should identify 
whether patients were still symptomatic when they were first assessed and how 
their recovery was measured. In patients with very short-duration symptoms, 
imaging tests are much less likely to give positive confirmation, so the place of 
Whiteley W.N. Blood Markers in Stroke University of Edinburgh 2010 
 
Chapter 2  Blood Markers in the Diagnosis of Stroke: A Systematic Review 49 
imaging as part of the reference standard diagnosis of stroke or transient ischaemic 
attack (TIA) is altered, though imaging remains of value  to exclude stroke mimics. 
In this context, expert clinicial assessment, and detailed clinical follow up to detect  
recurrent clinical events are the key methodological determinants. 
Defining the reference standard 
It is very difficult to define a test which can act as a reference standard test for the 
diagnosis of stroke; it is recognised that CT, MR and even autopsy may be 
‘negative’, even in patients considered to have a clinically definite acute stroke by all 
other criteria. Therefore the reference standard for a diagnosis of ischaemic stroke 
remains a diagnosis by an expert clinician, based on the initial clinical features, 
supported by  appropriate imaging and the patient’s subsequent clinical course 
suuported where necessary by repeated imaging on follow-up.  
Validation studies 
In this review, I found validation studes were limited. Only a few studies examined 
the same diagnostic threshold for the same marker in more than one cohort. In one 
set of papers, different diagnostic thresholds have been calculated in different 
cohorts for the same biomarker to optimise sensitivity and specificity by AUROC 
analysis, though the same diagnostic threshold was not examined in more than one 
cohort (Allard et al 2007, Allard et al. 2005d, Turck et al 2006). 
Choice of patient cohorts and controls 
It has been proposed that biomarker development should take a linear path; 
identification of blood biomarker candidates either in animal or human models, 
before testing them in cohorts of stroke patients versus normal controls before 
testing them in cohorts of suspected stroke patients (Pepe et al. 2001, Vasan 2006a). 
However, when considering genomic, proteomic or metabonomic approaches to 
discovery of biomarker candidates, there are compelling reasons to use cohorts of 
patients with suspected disease (after all this is the context that the test will be used 
in) for the discovery phase.  
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The biomarkers identified in this review are expressed in diverse cell types and part 
of many different cellular processes (Table 2.3). Some proteins are found mainly in 
the nervous system: B-type neurotrophic growth factor, S100B, myelin basic protein, 
neurone specific enolase and visin like protein; others indicate endothelial 
processes: matrix metalloproteinase-9, thrombomodulin, vascular cell adhesion 
molecule and von Willebrand factor. Some are not clearly linked to stroke 
pathogenesis, such as acrolein, nucleoside disphosphate kinase, antibodies to 
NR2A/2B and glutathione S transferase. Two studies have examined messenger 
RNA expression in peripheral blood leucocytes  soon after stroke (Moore et al. 2005, 
Tang et al. 2006). The results of prediction analysis for microarrays (PAM)  
algorithm were different in the two studies; of a PAM gene list of 22 in one study 
and 29 in the other, there was overlap only of N-acetyl neuraminate pyruvate lyase. 
This review has a number of shortcomings. The searching for studies was hampered 
by the lack of a suitably sensitive yet specific electronic bibliographic search strategy 
to identify reports of studies which focus on diagnostic test accuracy. This is in 
distinct contrast to other research designs, especially randomised controlled trials, 
for which highly sensitive yet specific search strategies have been developed. 
Searching the ‘grey’ literature was very difficult to perform comprehensively, so it is 
likely that there are unpublished reports of biomarker sensitivity and specificity that 
have not been identified. In this study, the assessment of report quality was 
necessarily limited, as many of the studies were conference abstracts, with  limited 
space to report the details  of the methods of their studies. It is likely that the timing 
of sampling after stroke onset will affect the performance of a blood biomarker test: 
in these studies, it was not possible to analyse this because of a paucity of data. 
Implications for research 
• There are a number of blood biomarkers that perform impressively well in 
their development cohorts 
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• To estimate the sensitivity and specificity  of markers in clinical practice, 
they need be examined in unselected cohorts of patients with suspected 
stroke . 
• The design of and reporting of studies of blood biomarkers for the diagnosis 
of ischaemic stroke could be improved (Table 2.4).  
Implications for practice 
• No marker can be recommended yet for use in routine clinical practice. 
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Tables 














Analysis Markers measured Marker model 
(Abboud et al 2007) 102 84 
Symptoms + MR 
lesion 
18 16 






Ischemia modified Albumin No 
35 
27 (IS) +  
6 (TIA) 
Symptoms + visible 
imaging lesion 








UFD-1, RNA-BP, NDKA No 
53 
24 (IS) + 
23  (TIA) 
Symptoms + visible 
imaging lesion 
(CT/MR) + TIA  
6 30 Unclear 
IS+TIA+ICH 
+ SAH vs 
control 
UFD-1, RNA-BP, NDKA No 
(Allard et al 2005i)  
(3 cohorts) 
533 
183 (IS) + 
124  (TIA) 
Symptoms + visible 
imaging lesion 
(CT/MR) + TIA  
226 100 Unclear 
IS+TIA+ICH 
+ SAH vs 
control 
RNA-BP, NDKA No 
36 
27 (IS) +  
6 (TIA) 
Symptoms + visible 
imaging lesion 












Symptoms + visible 
imaging lesion 
(CT/MR) + TIA  
6 30 Unclear 
IS+TIA+ICH 
+ SAH vs 
control 
PARK 7, NDKA No 
(Allard et al. 2005c) 
(3 cohorts) 
533 
183 (IS) + 
124  (TIA) 
Symptoms + visible 
imaging lesion 
(CT/MR) + TIA  
226 100 Unclear 
IS+TIA+ICH 
+ SAH vs 
control 
PARK 7, NDKA No 
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Analysis Markers measured Marker model 
          
(Allard et al. 2004e) 45 26 
Symptoms + visible 
imaging lesion 







ApoC-I, ApoCIII, Serum 




22 (IS) +  
6 (TIA) 
Symptoms + visible 
imaging lesion 






UFD-1, PARK 7 NDKA No 
49 
29 (IS) +  
5 (TIA) 
Unclear 10 29 Unclear 
IS+TIA+ICH 
vs control 
UFD-1, PARK 7 NDKA No 
(Allard et al 2007) 
(1 unique of 3 cohorts) 
53 
24 (IS) + 
23 (TIA) 
Symptoms + visible 
imaging lesion 
(CT/MR) + TIA 
6 30 Unclear 
IS+TIA+ICH 
+ SAH vs 
control 
UFD-1, PARK 7 NDKA No 






IS vs control NR2A/2B antibodies No 
(Dambinova et al 2003a) 48 48 Unclear - 28 Normal, ICH 
IS vs control 
+ICH 
NR2 fragment No 
(Fassbender et al. 1997b) 24 24 
Symptoms with 
lesion on CT 
- 24 Unclear IS vs control NSE No 
(Foerch et al. 2006b) 135 93 
Symptoms with 
lesion on imaging 
42 - - IS vs ICH GFAP No 
(Hill et al. 2000b) 28 28 Unclear - - - IS vs control 
NSE, MBP, S100b, 
Thrombomodulin 
Any positive 
(Laskowitz et al. 2005b) 130 130 Unclear 23 - - IS vs control 







(Laterza et al. 2006b) 18 18 Unclear  39 Healthy controls IS vs control VLP-1 No 
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Analysis Markers measured Marker model 
(Lynch et al. 2004b) 44 44 
Symptoms >24 hrs 
and imaging 
appearance 
- 21 + 157 
TIA, syncope, misc + 
no vascular disease 
IS vs TIA + 
SS + control 
S100b, GFAP, MMP-9, 
VCAM, IL-6, ICAM, TNF, 
NCAM, IL-1rA, IL-1b, IL-8, 
MCP-1, VEGF, vWF, TAT3, 
DD, CPK, TF, MBP, PLP, Mal, 
BNP, Caspase 3, Calbindin D, 







(Montaner et al 2005) 1,100 
776(IS) + 
185 (TIA) 





Stroke vs SS 
CRP, DD, RAGE, MMP-9, 
S100b, BNP, NT3, casopase-
3, chimerin, secretagogin 
All above/below 
normal range: 
















(Reynolds et al. 2003b) 185 82 




214 + 38 + 
51 
Healthy volunteers + 
closed head injury + 
TIA 
IS + ICH vs 
control 
S100b, BNGF, vWF, MMP-9, 
MCP-1 









(Rouanet et al 2006) 131 
85 (IS) + 
33 (TIA) 
Senior neurologist 13 65 
Referred suspected 
stroke, neurologist not 
stroke 
IS + TIA + 
ICH vs 
control 
BNP, DD, MMP-9, S100b 





(Takahashi et al. 1999c) 32 
26 (IS) + 2 
(TIA) 
unclear 3+1 103 Healthy subjects 
IS+TIA+ICH 
+ SAH vs 
control 
S100b  
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Analysis Markers measured Marker model 
(Tomitori et al. 2005b) 62 62 
Focal imaging 
abnormality 
0 35 Unclear IS vs control 
acetylpolyamine oxidase, 




22 (IS) + 6 
(TIA) 
Symptoms + visible 
imaging lesion 
(CT/MR) + TIA 
- 29 + 13 
Unclear + conditions 
mimicking stroke (MS, 
nerve palsy) 
IS+TIA+ICH 




29 (IS) 5 
(TIA) 
 - 29 Unclear 
IS+TIA+ICH 
vs SS + 
control 
GSTP-1, UFD-1 No 
(Turck et al 2006) 
47 
24 (IS) 23 
+ (TIA) 
Symptoms + visible 
imaging lesion 
(CT/MR) + TIA 
- 29 Unclear 
IS+TIA+ICH 
+ SAH vs 
control 
UFD-1 No 
(Zimmermann-Ivol et al. 
2004d) 
22 
IS (11) +  
5 (TIA) 
Symptoms + visible 
imaging lesion 
(CT/MR) + TIA 
6 22+20 No disease + AMI 
IS+TIA+ICH 
vs control 
H-FABP, CK-MB, TnI, NSE, 
S100b 
No 
Abbreviations: AMI: acute myocardial infarction, TIA: transient ischaemic attack, IS: ischaemic stroke, SAH: subarachnoid haemorrhage, ICH: intracerebral haemorrhage; ApoC-I: apolipoprotein 
CI, ApoCIII: apolipoprotein CI, BNP: brain natriuretic peptide, BNGF: B-type neurotrophic growth factor, CK-MB: creatinine kinase MB, CPK: creatinine phosphokinase,  CRP: C-reactive protein, 
DD: D-dimer, GFAP: glial fibrillary acidic protein,  GSTP-1 glutathione S-transferase P, H-FABP: heart fatty acid binding protein, HSP: heat shock protein, IL6: interleukin 6, IL-1RA : interleukin 1 
receptor antagonist, IL-1b : interleukin 1 beta, IL-8 : interleukin 8, ICAM: intracellular adhesion molecule, MBP: myelin basic protein, MCP- 1 : monocyte chemoattractant protein, MMP-9 matrix 
metalloproteinase 9, NDKA: nucleoside diphosphate kinase A, NCAM: neuronal cell adhesion molecule,  NSE: neurone specific nolase, NT3: neurotrophin 3, PARK 7: DJ-1 protein, PLP: 
proteolipid protein, RAGE: receptor of advanced glycosylation end products, RNA-BP : RNA binding protein, TAT3: thrombin –antithrombin 3, TF: tissue factor, TNF: tumour necrosis factor,  
TnI: troponin I, UFD-1: ubiquitin fusion degradation protein, VLP 1:Visin –like protein 1, VCAM: vascular cell adhesion molecule, VEGF : vascular endothelial growth factor,  vWF: von 
Willebrand factor 
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Table 2.2 Modified QUADAS instrument to assess quality of reporting of results 
 




BM + or BM- 
Marker not 


















(Abboud et al 2007)    ?     
(Allard et al 2005i) ? ?  ? ? ?   
(Allard et al. 2005b)      ?   
(Allard et al. 2004f)    ?     
(Allard et al 2007) ?   ?     
(Dambinova et al 2003b)         
(Dambinova et al 2003a) ? ?  ? ? ? ?  
(Fassbender et al. 1997a)    ?     
(Foerch et al. 2006a)         
(Hill et al. 2000a)    ?     
(Laskowitz et al. 2005c) ? ?  ? ? ?   
(Laterza et al. 2006a) ?   ?     
(Lynch et al. 2004a)    ?     
(Montaner et al 2005) ? ?  ?     
(Rainer et al 2007)    ?     
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BM + or BM- 
Marker not 


















(Reynolds et al. 2003a)      ?   
(Rouanet et al 2006)   ? ? ?    
(Takahashi et al. 1999d)    ?     
(Tomitori et al. 2005a)    ?     
(Turck et al 2006) ? ? ? ? ? ? ?  
(Zimmermann-Ivol et al.    ?  ?   
 : No,  : Yes, ?: insufficient information 
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Table 2.3 Putative biological role of markers in the diagnostic systematic review 
Biomarker Description 
Acetyl polyamine oxidase Polyamine catabolism (the function of polyamines is not clear) 
Acrolein Polyamine catabolism 
Apolipoprotein C1 Plasma protein found in LDL and VLDL 
Apolipoprotein C3 Component of VLDL, HDL and LDL, produced in liver 
Beta globin DNA DNA released after cell damage 
Brain natriuretic peptide Hormone secreted from the ventricular myocardium during periods 
of increased ventricular stretch and wall-tension 
B-type neurotrophic growth factor Supporting neuronal growth and differentiation  
C-reactive protein Acute phase protein 
D-dimer Breakdown product of fibrin after factor XIII stabilisation; indicative 
of thrombus formation 
Fatty acid binding protein Proteins involved in intracellular transport, oxidation of fatty acids 
and membrane lipid trafficking 
Glial fibrillary acidic protein Intermediate filament protein, found mainly in astrocytes 
Glutathione S transferase P One of many glutathione transferases, role in cellular detoxification 
Ischaemic modified albumin Altered cobalt binding on the N-terminus of albumin 
Matrix metalloproteinase 9 Collagenase, associated with destruction of plaque matrix and 
endothelial damage 
Myelin basic protein Constituent of the CNS myelin synthesized by oligodendrocytes 
and Schwann cells 
Neurone specific enolase Dimeric neuronal glycolytic enzyme 
NR2A/2B antibodies Antibodies to NMDA receptor fragments 
Nucleoside diphosphate kinase A An enzyme catalysing the transfer of phosphate groups between 
nucleoside triphosphates and nucleoside diphosphates (eg. ATP 
to GDP) 
PARK 7 RNA binding protein regulatory subunit 
S100 beta Acidic calcium binding protein found in glia and Schwann cells 
Spermine oxidase Polyamine catabolism 
Thrombomodulin Endothelial cell thrombin receptor that converts thrombin from a 
procoagulant to an anticoagulant enzyme 
Total polyamine oxidase Polyamine catabolism 
Ubiquitin fusion degradation 
protein 
Enzyme in the pathway for degrading ubiquitin-protein conjugates 
Vascular cell adhesion molecule Part of the immunoglobulin superfamily important in inflammation, 
immune responses and in intracellular signalling events 
Visin like protein Intracellular neuronal calcium sensor 
von Willebrand factor Binds to factor VIII form a stable complex.  
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Table 2.4 Recommendations for good quality studies of blood biomarkers for acute stroke diagnosis 
Patients 
Prospectively collected, consecutive patients with suspected stroke from an emergency setting 
Recruit patients in whom non-expert clinicians suspect stroke 
Recruit patients at a clear point in the diagnostic pathway for example, pre-hospital, emergency 
department, pre- or post CT brain scan 
Record pre test probability of stroke, using either clinician judgement or a recognised clinical rating 
scale 
Define the delay between stroke symptom onset and initial assessment & blood sampling 
Define whether stroke symptoms still present at time of blood sampling 
Reference standard diagnosis 
Expert clinical opinion, with appropriate brain imaging supplemented by data from other test results and 
the patient’s subsequent clinical course 
Reference standard diagnosis made blind to biomarker status 
Define stroke type – haemorrhagic or ischaemic 
Biomarker measurement 
Fully describe laboratory technique for marker measurement 
Describe intra- and inter- assay reliability of tests 
Fully describe logistic regression models of biomarkers 
Measurement blind to clinical status 
Validate biomarker and diagnostic threshold in an independent cohort 
Give numerical value of threshold for a positive test 
Reporting 
Show raw data wherever possible 
Use the STARD (Bossuyt et al. 2003b) guideline when preparing study reports 
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Figure 1 Sensitivity and specificity of individual blood biomarkers for the diagnosis of stroke 
(ischaemic or any stroke)  
The size of markers is proportional to study size, and 95% confidence intervals.
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MMP9/vWF/VCAM (< 6hours stroke)
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(logistic regression <24 hours)
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(logistic regression <12 hours)
MCP/vWF/MMP9/S100beta/BNGF
(3 above reference range 0-24 hrs)
MCP/vWF/MMP9/S100beta/BNGF
(3 above reference range 0-6 hrs)
BNP/D dimer/MMP 9/S100b 
(cutoff 1.3)
BNP/CRP/D-Dimer/MMP-9/S100b




Figure 2 Sensitivity and specificity for blood biomarker models for the diagnosis of stroke 
The size of the marker is proportional to the study size and lines show 95% confidence intervals. 
The markers in each model are shown. BNP: brain natriuretic pepetide; CRP: C-reactive protein; 
MMP-9: matrix metalloproteinase-9; BNGF: B-type neurotrophic growth factor; vWF: von 
Willebrand Factor; VCAM: vascular cell adhesion molecule 
Whiteley W.N. Blood Markers in Stroke University of Edinburgh 2010 
 






































Figure 3 Sensitivity and specificity of biomarkers for the diagnosis of haemorrhagic stroke in studies of 
patients with haemorrhagic and ischaemic stroke.  
The size of them markers is proportional to the size of the study and the lines show with 95% 
confidence intervals. GFAP: glial fibrillary acidic protein; RFU: relative fluorescence units; NR2A/2B 
Abs: antibodies to the NR2A/2B subunits of the NMDA receptor.  
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Chapter 3.  Validation of clinical scores for the diagnosis of stroke and 
transient ischaemic attack: BBISS, a prospective cohort study 
Introduction 
The gold standard for the diagnosis of acute stroke and transient ischaemic attack 
(from here on I will refer to them together as ‘acute cerebrovascular diseases’) 
includes an assessment by a senior stroke physician, careful review of timely brain 
imaging by a neuro-radiologist and follow up of a patient’s clinical course. 
However, very soon after symptom onset, a gold standard diagnosis is difficult to 
achieve. In particular, the first person to assess patients with suspected stroke is 
often an emergency department nurse or doctor, who may not have particular 
expertise in the diagnosis of acute cerebrovascular diseases or rapid access to brain 
imaging. 
Formalised assessment tools based upon easily collected clinical variables may 
improve the sensitivity or specificity of emergency staff in their diagnosis of acute 
cerebrovascular disease (Hand 2002, Nor et al. 2004a, Nor et al. 2005f). Accurately 
identifying the patients with acute cerebrovascular disease in the emergency 
department with a more sensitive clinical test could lead to faster referral of patients 
for thrombolysis, stroke unit care or secondary preventative agents. However, an 
instrument with a high sensitivity but poorer specificity that identifies most patients 
with acute cerebrovascular disease will also misclassify patients with stroke mimics. 
These misclassified patients without acute stroke could overwhelm the future 
capacity of a stroke service, if the predictive value of a positive test were too low. 
The sensitivity and specificity of a diagnostic instrument may vary with the study 
cohort (Feinstein 2002). External validation of diagnostic scales in different clinical 
cohorts is therefore important to ensure they perform well in different clinical 
settings. In a small emergency department validation cohort (n=160), the face arm 
speech test (FAST) had a sensitivity of about 82% and specificity of 83%, and the 
recognition of stroke in the emergency room (ROSIER) instrument a sensitivity of 
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93% and specificity of 83% (Nor et al. 2005e). If these scales had a similar 
performance in different emergency departments, we would be more confident to 
introduce them into routine emergency practice. 
A new diagnostic tool should improve upon existing diagnostic methods. A new 
instrument for identifying patients with acute cerebrovascular disease should have 
better sensitivity than the informal opinion of an emergency department clinician, 
identifying more patients with stroke, but have no worse specificity, avoiding over-
referral of patients without stroke.  
In this chapter, I will: 
• describe the recruitment of the Blood Biomarkers in Suspected Stroke 
(BBISS) cohort of patients with suspected stroke in an emergency 
department in Edinburgh 
• summarise the clinical features of the patients with and without acute 
cerebrovascular disease  
• compare the sensitivity and specificity of the FAST (Nor et al. 2004b) and the 
ROSIER scoring systems (Nor et al. 2005d) and two previously developed 
multivariate logistic regression models for the diagnosis of stroke (Hand 
2002) with the clinical opinion of emergency department staff and stroke 
specialists. 
Methods 
BBISS cohort recruitment 
I prospectively recruited consecutive patients with suspected stroke who presented 
to the Acute Receiving Unit (ARU), an emergency department (ED) in the Western 
General Hospital, Edinburgh. Patients were referred to the emergency department 
from: (i) general practitioners (GPs) in the North of Edinburgh and East Lothian, (ii) 
paramedical ambulance staff, and (iii) a walk in clinic in the hospital grounds. 
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I made strenuous efforts to ascertain all cases, as soon after arrival in the emergency 
department as possible (a ‘very hot’ pursuit model) by: (i) holding a pager as first 
point of contact for all patients brought into the unit with suspected stroke, (ii) 
visiting the emergency department every 2 hours during the working day and 
screening admission logs in real time, (iii) assessing patients with suspected stroke 
admitted to the medical admissions unit and stroke unit within 24 hours of 
symptom onset, (iv) periodically advertising the study to any new staff in the ED, 
and (v) providing teaching sessions about acute stroke for nursing and medical staff 
in the department.  
During active recruitment to the study, NHS Scotland had set a target for all 
emergency departments to assess and discharge each patient within four hours 
(either home or to another unit). This target was an additional incentive to refer 
patients to the study as, in general, I assessed and discharged patients more rapidly 
than more junior emergency medical staff, freeing doctors for other work in the 
department. When I was unavailable, other stroke fellows recruited patients (Dr. 
Ralph Thomas, Dr. Evan Mamaloukas, Dr. Bartosz Karaszewski, Dr. Rayessa 
Rayessa, and Dr. Enda Kerr). I took a history from and examined each patient, and 
for those who consented to take part in the study, recorded my assessment with a 
structured proforma (see appendix). Emergency department staff recorded their 
clinical impression and assessment on the same form.  
BBISS inclusion criteria 
I recruited patients with suspected stroke. I defined suspected stroke patients as those: 
(i) whose symptoms began less than 24 hours before admission, (ii) who were still 
symptomatic at the time of assessment and, (iii) suspected to have stroke by a GP, a 
paramedic or a member of the emergency department staff. 
Emergency department nurse or doctor assessment 
I asked nurses and emergency department doctors to record whether they felt that 
acute cerebrovascular disease (TIA or stroke) was: (i) definite, where they were sure 
the diagnosis was TIA or stroke, (ii) probable where they thought that TIA or stroke 
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was the most likely of a number of other diagnosis, and (iii) possible, where they 
thought that TIA or stroke was possible, though other diagnoses were more likely. 
They then recorded their own assessment with the Face Arm Speech Test (FAST) 
and the Recognition of Stroke in the Emergency Room (ROSIER) instrument (Nor et 
al. 2004c, Nor et al. 2005c). I considered patients to be ‘FAST positive’ when an 
emergency clinician found they had one of facial weakness, arm weakness or speech 
disturbance. I calculated a ROSIER score from clinical variables determined by a 
member of the emergency staff (Equation 1), and the stroke fellow who measured 
the variables ‘syncope’ and ‘seizure’. I considered patients to be ‘ROSIER positive’ 
when their score was 1 or more. 
Equation 1 ROSIER Score 
ROSIER score = -1 x (syncope) -1 x (seizure) +1 x (face weak) 
+1 x (arm weak) + 1 x (leg weak) +1 x (speech disturbance) +1 
x (visual field defect),  if blood sugar >3.5mmol/l  
(Nor et al. 2005b) 
Variables take the value 1 if present and 0 if absent. 
Fellow assessment and variable definition 
I recorded demographic details (date of birth, GP and contact information); the time 
of stroke onset, or where that was unknown, the last time the patient was seen well; 
and the time of assessment in the emergency department. I defined variables 
collected during my assessment as follows: 
The presenting event 
• Focal symptoms: symptoms that could arise from focal cerebral disturbance 
such as hemiparesis, aphasia, hemisensory loss, hemianopia, unilateral 
ataxia, facial or hand weakness. I did not define as focal any events that 
could be attributed to dysfunction of a single cranial nerve (such as isolated 
diplopia) or where the neurological symptoms were poorly localized, for 
example isolated dysarthria or vertigo. In this, I have followed prior 
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convention (Warlow C.P et al. 2008), although I acknowledge that sometimes 
these symptoms can be due to cerebral damage from ischaemia.  
• Headache at onset: a headache at any time between the onset of symptoms and 
the assessment of the patient in the emergency department reported by the 
patient. 
• History of infection: symptoms best explained by infectious aetiology, for 
example productive cough, fever, dysuria, diarrhoea, or definite diagnosis of 
infection by a GP or hospital doctor, within the 2 weeks preceding 
assessment. I did not routinely classify the type or grade the severity of 
infection, as I expected too few events for subgroup analysis. 
Previous diagnoses 
• Cardiac vascular disease: prior myocardial infarction, angina or coronary 
artery procedure (bypass grafting or angioplasty) recorded in GP or hospital 
notes, or by the patient where neither where available. The accuracy of self 
report of myocardial infarction in self administered questionnaires in 
population based epidemiological studies is high (Okura et al. 2004a), 
though probably is less so in the emergency department where the effects of 
acute illness may affect the patient’s accuracy of recall. 
• Cardiac failure: a diagnosis of cardiac failure made prior to admission, either 
on clinical grounds, or with the support of echocardiography, or where a 
patient was prescribed drugs commonly used for the treatment of heart 
failure (e.g. spironolactone). 
• Prior stroke or TIA: a stroke or TIA prior recorded in GP or hospital notes. 
Patient reports were confirmed by inspection of the GP or hospital records 
where they were available at the initial assessment. A patient’s recall of TIA 
or stroke is less good than MI (Okura et al. 2004b). 
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• Migraine: a report of intermittent severe headache and nausea and 
photophobia with complete recovery, with or without focal features to 
suggest a migraine aura, or record of migraine diagnosis in GP or hospital 
records.  
• Epilepsy: a prior diagnosis of epilepsy, recorded in GP or hospital records. 
• Atrial fibrillation (AF): persistent or paroxysmal atrial fibrillation, in the past 
(recorded in GP or hospital records) or at admission, observed on an 
electrocardiogram (ECG). 
• Cognitive impairment: report by a carer of cognitive impairment sufficient to 
interfere with activities of daily living prior to the onset of suspected stroke 
symptoms. 
Medications 
• Drugs: each patient’s medications were obtained either from the GP 
summary record (by inspection or by telephone), a repeat prescription, or 
dosette box. 
Prior handicap 
• Independence of activities of daily living: patients who were able to wash, dress, 
toilet and feed themselves without any assistance were ‘independent’. I 
attempted to quantify the extent of pre-admission impairment by judging 
the Oxfordshire Handicap Scale prior to admission to hospital after 
discussion with patients and their relatives or carers (Bamford et al. 1989b). 
Neurological impairment 
• National Institute of Health Stroke Scale (NIHSS): I, or another  stroke fellow, 
measured the NIHSS in all patients with suspected stroke after appropriate 
training (American Heart Association 2009, Brott et al. 1989b). I used the 
NIHSS rather than developing a new impairment scale for the project, as 
although there is no generally agreed measure of neurological impairment 
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for undifferentiated patients with neurological disease, the NIHSS measures 
many important domains of the neurological examination, is familiar to 
stroke physicians and has good  inter-rater reliability (intraclass correlation 
coefficient >0.9 (Goldstein & Samsa 1997b)). 
• The severity of impairment was also measured with dichotomous variables: 
whether the patient was able to speak in sentences, whether the patient was 
orientated (could give the correct time of day (morning or afternoon), was 
able to describe where they were, and able to give their date of birth), 
whether the patient was able to take steps without help, and whether the 
patient was able to lift both arms from the bed (Counsell et al. 2002f). 
Other examination findings 
• Temperature, blood pressure and pulse: were measured on admission by nursing 
staff using routine clinical equipment. The first measurement of each was 
recorded. 
• Pedal pulse: I palpated the dorsalis pedis and posterior tibial pulses 
bilaterally. 
After recording these variables, I noted my own clinical impression: whether I felt 
the symptoms were definitely, probably or possibly due to acute cerebrovascular 
disease, with same definitions as 0. If I diagnosed a mimic of acute cerebrovascular 
disease, I also specified an alternative diagnosis. At the time of clinical assessment, I 
also assigned the stroke syndrome according to the Oxford Community Stroke 
Project classification (Bamford et al. 1991c). 
Imaging 
Patients had CT or MR brain imaging for the following reasons: (i) where it was part 
of their routine clinical care, (ii) as part of another research project, or (iii) where the 
diagnosis was substantially uncertain, and MR imaging could improve diagnostic 
certainty. In almost all cases, brain imaging was performed after the stroke fellow 
had made a provisional diagnosis. MR brain imaging in the SFC Brain Imaging 
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Research Centre included at least the following sequences: T1 weighted spin echo, 
diffusion weighted (DWI), fluid-attenuated inversion-recovery (FLAIR), T2 
weighted fast spin echo, and T2 gradient recall echo. Other research studies 
performed further imaging sequences in a few patients.  
Gold standard diagnosis 
A panel of stroke experts met weekly and reviewed each patient’s clinical 
assessment, imaging, and clinical progress. The panel determined whether the 
diagnosis of stroke or transient ischaemic attack was definite, probable or possible 
and clarified non-stroke diagnoses as far as practicable. Over the course of the two 
years of recruitment, the members of the panel varied somewhat, but always 
included at least one experienced consultant in stroke medicine, a stroke 
neuroradiologist, a stroke fellow, and often a neurologist. Most meetings included 
more than one member of each category.  
The fellow who had assessed the patient (usually myself), first presented the history 
and the findings on examination. The panel reviewed the relevant imaging and 
clinical progress, and then reached a consensus diagnosis through discussion. 
Where additional clinical or radiological information became available at a later 
date, a fellow presented the case again and altered the final diagnosis if appropriate. 
Definitions of diagnostic entities 
• Stroke. I diagnosed stroke in those patients with a focal neurological deficit 
that lasted for more than 24 hours, and the panel judged the cause to be an 
ischaemic stroke or intracranial haemorrhage. 
• Ischaemic stroke: I diagnosed ischaemic stroke where the patient presented 
with focal neurological symptoms, brain imaging either showed positive 
evidence of cerebral infarction in a relevant location (an appearance 
consistent with the time after stroke onset), or was normal, and the panel 
judged brain ischaemia to be the cause of the symptoms. 
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• Intracranial haemorrhage: I diagnosed intracranial haemorrhage where the 
patient presented with focal neurological symptoms, and brain imaging 
showed positive evidence of acute intracranial haemorrhage, either into the 
brain parenchyma, ventricles or subarachnoid space relevant to the patient’s 
clinical features. 
• Transient ischaemic attack (TIA): I diagnosed TIA in those patients with a focal 
neurological deficit that lasted for less than 24 hours, where the panel judged 
the cause to be brain ischaemia or haemorrhage (though all proved to be 
ischaemic). I did not include cases of amaurosis fugax. 
• Acute cerebrovascular disease (ACvD): I defined acute cerebrovascular diseases 
as those patients who were symptomatic at the point of admission and had a 
final diagnosis either of stroke or transient ischaemic attack.  
• Mimic: Those patients with suspected stroke who had neither stroke nor TIA. 
• Definite, probable and possible: these terms were used to describe different 
levels of certainly. Whilst these do not map onto numerical prior 
probabilities for use in a Bayesian analysis, they do have thresholds easily 
understood by diagnosticians. A definite diagnosis was one where no other 
diagnosis could be countenanced to explain the symptoms. A probable 
diagnosis was one where other diagnostic entities were considered, though 
felt to be less likely. A possible diagnosis was one where other diagnostic 
entities were felt to be more likely. I analysed definite and probable cases of 
stroke and TIA together as acute cerebrovascular disease, and possible cases 
of stroke and TIA with stroke mimics. 
Data checking 
I employed a number of methods to ensure data consistency. I piloted the data 
collection form (see appendix) with several patients and made modifications to 
ensure ease of use before starting recruitment. I used categorical answers to force 
yes/no decisions for each variable where possible. The data collection form was very 
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similar in design to the screen appearance of the Access database used for data entry 
and management to reduce transcription errors. I personally entered the data into 
the database immediately after collecting it, to allow a rapid check of missing fields 
at the time when the medical records were still easily available.  
The data entry system of the database permitted only very few fields to have 
missing data and had a number of range checks to ensure continuous data were 
within reasonable bounds. At the end of the project, all the clinical diagnoses were 
checked against the discharge diagnoses available through TRAK (the hospital 
electronic record system) in NHS Lothian, to ensure no other illness had developed 
that could have explained the presenting symptoms (for example, a changed 
diagnosis to a malignant brain tumour or to multiple sclerosis). I checked the whole 
dataset for missing or incomplete records of blood pressure and checked these 
against the clinical notes. I performed a number of consistency checks between the 
database record and clinical notes prior to analysis: whether the name matched the 
sex; if time to imaging was more than 1 day; if the pre-morbid modified Rankin 
scale was greater than 2 and the patient was recorded ‘independent’. 
Data management 
I designed a Microsoft Access 97 database for data entry, storage and coordinating 
follow up. Access, a relational database, gives flexibility in data collection, 
particularly where there are an unpredictable and large number of events. However, 
the problem of translation of data from a relational database to a flat field 
spreadsheet for statistical analysis was not trivial and needed considerable 
programming input. 
I added data into each patient’s record at three time points: once after their initial 
assessment, once after discussion of their diagnosis and relevant imaging and with 
the results of three months follow up. 
The database was housed on the central server in the Division of Clinical 
Neurosciences. This had three advantages (i) regular backup of data to tapes held 
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with the Division and to the University’s central server, (ii) secure access on the 
local area network (LAN) to locations outside DCN (for example the WTCRF), and 
(iii) data security. I permitted only named users on the University network (itself 
password protected) who also knew the current password to access the database. 
Each user was only able to access areas of the database that were relevant to their 
role. 
To determine the number of stroke patients admitted to the Western General 
Hospital over the period of recruitment, Mike McDowall queried the Scottish Stroke 
Care Audit Database on 14th October 2009. 
Statistical analysis  
Baseline analyses 
I made comparisons between patients with and without acute cerebrovascular 
disease with Student’s t test for normally distributed continuous variables with the 
Stata command ttest, Wilcoxon rank-sum test for positively skewed variables 
with ranksum and χ2 tests for dichotomous variables with the chi command. To 
measure the association between variables and ACvD I fitted a series of univariate 
logistic regression models with the logistic command, and report odds ratios, 
their 95% confidence in intervals as a measure of uncertainty of estimates and Wald 
tests to test the null hypothesis that OR=1. 
The performance of ROSIER, FAS and clinical opinion 
I assessed the diagnostic stroke scales FAST and ROSIER at their published 
thresholds, and the clinical impression of an emergency department clinician and a 
stroke fellow at two thresholds: (a) ‘definite cerebrovascular events’ (b) ‘definite or 
probable cerebrovascular events’. I calculated the sensitivity, specificity, positive 
and negative predictive values and likelihood ratios at these thresholds and their 
95% confidence intervals, using the gold standard diagnosis of acute 
cerebrovascular disease or stroke made by the panel. As each patient had more than 
one test performed, and each is correlated with another, I used McNemar’s test for 
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paired proportions (Equation 2) to compare the results of the clinical scoring 
systems to the baseline assessment by a member of the emergency staff (for example 
see Table 3.1 for the comparison of test sensitivities), and report the McNemar’s 
significance probability, and the exact test where the number of discordant pairs 
was less than 20 (Leisenring, Alonzo, & Pepe 2000, McNemar 1947). 










I also tested the performance of the clinical scoring systems for patients in whom the 
eventual diagnosis was stroke rather than acute cerebrovascular disease, for patients 
seen less than six hours after the onset of their symptoms, and those for whom the 
first recorded assessment was by a nurse rather than a doctor. 
Logistic regression models for the diagnosis of stroke 
I examined the calibration and discrimination of a previously developed logistic 
regression models for the diagnosis of stroke, and examined their sensitivity and 
specificity at the suggested thresholds (Hand 2002, Hand et al. 2006g).The first 
model was designed for use by a registrar in stroke medicine (: 
Equation 3): 
Equation 3 Model to predict stroke diagnosis, stroke/neurology registrar  
loge(odds of stroke)=                                                                                  
-3.324                                                                                                   
- [1.118 x (known cognitive impairment)]                                                
- [0.824 x (abnormal findings in any other system)]                   
+ [0.952 x (exact time of onset determined)]                               
+ [1.975 x (definite history of focal neurological symptoms)]   
+ [0.934 x (any abnormal vascular findings)]                               
+ [0.651 x (NIHSS 1 to 4)]                                                                  
+ [1.145 x (NIHSS 5 to 10)]                                                             
+ [1.979 x (NIHSS >10)]                                                                    
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+ [0.707 x (signs lateralisable to right or left)]                             
+ [1.627 x (OCSP classification possible)] 
Variables take the value 1 if present and 0 if absent. 
(Hand 2002) 
The second model (Equation 4) was designed for use by emergency department 
nurses: 
Equation 4 Model to predict a stroke diagnosis, emergency department nurse  
loge(odds of stroke)=                                                                                  
-3.080                                                                                                
+ [1.047 x exact time of onset determined)]                                 
+ [2.483 (definite history of focal neurological symptoms)]        
+ [0.595 x (abnormal verbal output)]                                           
+ [1.637 x (arm weakness)]  
(Hand 2002) 
In my cohort, I defined the variables as follows: 
• Onset time known: time found = time last seen well 
• Definite history of focal neurological symptoms: collected by stroke fellow or 
registrar. 
• Abnormal vascular findings: systolic blood pressure>150 or AF or heart 
murmur or absent pulses 
• Abnormal findings in other systems: suspected infection 
• Abnormal verbal output and arm weakness: where measured by the 
emergency department clinician in the FAS test. 
I used : 
Equation 3 and Equation 4 to calculate loge(odds of stroke) and subsequently 
Equation 5 to calculate the predicted probability of stroke or acute cerebrovascular 
disease. 
Whiteley W.N. Blood Markers in Stroke University of Edinburgh 2010 
 
Chapter 3  BBISS: Clinical features and the diagnosis of stroke  76 












I assessed the performance of the logistic regression models as follows. First, I 
assessed calibration, or how well predicted probabilities of an acute cerebrovascular 
disease diagnosis compared with observed probabilities of stroke, by plotting 
predicted against observed probabilities, and calculation of the Hosmer-Lemeshow 
χ2 goodness of fit test with the hl command in Stata (Lemeshow & Hosmer, Jr. 
1982). This statistic compares the estimated to observed likelihood of acute 
cerebrovascular disease in deciles of predicted probability. The smaller the χ2 the 
closer the predicted is to the observed probability of acute cerebrovascular disease. 
Second, I assessed discrimination by measuring the area under a receiver operator 
curve (AUROC) and its exact binomial confidence intervals with the roctab 
command in Stata. This can be interpreted as the chance a randomly chosen patient 
with acute cerebrovascular disease has a higher predicted probability of stroke than 
a randomly chosen patient without stroke. An AUROC of 0.5 indicates a model with 
no better discrimination than chance and an AUROC of 1 a model with perfect 
discrimination. 
Thirdly, I assessed the sensitivity and specificity of the logistic regression models at 
the thresholds suggested in their development cohorts. The registrar model aimed 
to be specific, with a threshold of predicted probability of stroke of Pr=0.9. The 
nurse model aimed to be sensitive at a predicted probability of stroke of Pr=0.3. 
I investigated the role of the clinical assessment scales in series by calculating the 
sensitivity and specificity of a strategy combining the clinical opinion of a member 
of the emergency department staff with the negative variables in the ROSIER scale. 
Stata 10 was used for all statistical analysis. Because of the number of comparisons, I 
considered a P<0.01 to be statistically significant. All P values are two sided. 
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Ethical considerations 
I explained the study to each participant or their welfare guardian and gave them an 
information sheet to read. Each participant then gave consent or their welfare 
guardian gave assent to taking part in the study (see appendix for forms). The 
Multi-centre Research Ethics Committee for Scotland (A) gave ethical oversight to 
the study (Reference No. 06/MRE00/119). This committee has responsibility for 
studies of adults with incapacity. Approval was also received from the Lothian 
Local Research Ethics Committee (Reference No. 06/S11ADMIN/161) and the NHS 
Lothian Research and Development Office (Reference No. 2006/W/NEU/09). 
Sample size 
I based the sample size of the study on the reports of the sensitivity and specificity 
of a biomarker tests for the diagnosis of stroke (Laskowitz et al. 2005d).  
Feasibility: About 380 patients present to the Western General Hospital each year 
with definite stroke (Scottish Stroke Care Audit 2006) of whom about 300 present 
within 24 hours of their symptom onset. As about two thirds of patients with 
suspected stroke have a stroke in settings similar to ours (Hand et al. 2006f), I 
expected personally to be able to recruit 330 patients with symptoms of acute stroke 
during the working week per year. Over 2.5 years of recruitment, about 800 patients 
might therefore be eligible to enter the study.  
Precision of estimates Laskowitz found a panel of four biomarkers had a sensitivity of 
80% and specificity of 70%. This sample size would give reasonably narrow 
confidence intervals should the panel of markers have a similar performance in my 
cohort (95% confidence intervals for sensitivity ± 3% and specificity ± 5%).  
Revised feasibility: After a few months of recruitment, it was clear that the 
recruitment of 800 patients within 24 hours of their symptom onset would not be 
feasible. This may have been due to: (a) a reconfiguration of emergency services in 
Lothian just before the start of the project, leading to fewer ambulance service 
referrals to the Western General Hospital, (b) though patients were admitted within 
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24 hours of symptoms, stroke was not suspected until later in the admission, or       
(c) suspected strokes were missed in the emergency department. In an attempt to 
increase the rate of recruitment I enlisted the help of my clinical colleagues at the 
Royal Infirmary of Edinburgh: this led to the recruitment of an additional 5 patients. 
I redoubled my efforts to recruit patients from the ARU, but found this did not 
increase the rate of recruitment (~0.9 patients/working day). I estimated that the 
study would recruit 400 patients over two years if it continued to recruit at the 
initial rate (Figure 4). 
I recalculated the confidence intervals we would expect around a biomarker panel 
test if recruitment continued at the observed rate and the biomarker test had a 
similar performance. The 95 % confidence intervals around sensitivity were ± 5% 
and specificity ± 7%. These estimates were sufficiently narrow to justify 
continuation of the study. I used Confidence Interval Analysis v2.1.2 to calculate 
these estimates. This ‘sample size samba’ is common (Schulz & Grimes 2005), and I 
communicated the revised sample size to both the ethics committee and the funder 
of the project, the Chief Scientist’s Office.  
This chapter was prepared with reference to the Standards for Reporting of 
Diagnostic accuracy (STARD) checklist (Bossuyt et al. 2003a). 
Results 
Recruitment 
Between 21st March 2007 and 27th February 2009 during working hours I recruited 
405 patients with suspected stroke to the study, of whom 285 (70%) had symptoms 
due to probable or definite acute cerebrovascular diseases, and 120 (30%) due to 
other illness. During the recruitment period, a total of 823 stroke and 89 TIA 
patients were admitted to the Western General Hospital. Of the stroke patients, 545 
were admitted on the first day of their symptoms (46 haemorrhagic and 499 
ischaemic) (Table 3.2). No data were available on the timing of admission, relative to 
their symptom onset, of patients with TIA. Of these potentially eligible patients, I 
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saw 230/499 (47%) of the patients admitted with ischaemic stroke in the first day 
after symptoms, 15/46 (32%) of the patients admitted with haemorrhagic stroke and 
40/89 (45%) of the patients with TIA. The age and routinely collected measures of 
neurological impairment of the study patients and all those patients seen less than 
24 hours in the Western General Hospital were similar (Table 3.3). 
Baseline characteristics 
Just over half the patients were women (207/405, 51%). Patients with acute 
cerebrovascular disease were: older (74 versus 68 years, t=-5, P<0.0001); had more 
severe symptoms measured by the median NIHSS (4 versus 1, Z=-5.7, P<0.0001); 
more often had arm weakness and were able to talk, though there was no 
appreciable difference in the proportion of patients with confusion between the two 
groups at the time of baseline assessment (Table 3.3, Table 3.4). There was no 
significant difference between the two groups in the number of patients with 
cardiac, or peripheral vascular disease or prior stroke/TIA. Those who had 
symptoms due to mimics were more likely to have lost consciousness (14% versus 
5%, χ2=7.6, P=0.006), to have had a seizure (14% versus 5%, χ2=3.0, P<0.0001), a prior 
diagnosis of epilepsy (9% versus 2%, χ2=10.3, P=0.001), or a headache (30% versus 
15%, χ2=10.9, P=0.001) at the onset of symptoms. When I restricted the analysis to 
those who were able to talk normally, although headache was more common in 
patients with mimic, this difference was not statistically significant (31% versus 20 
% χ2 =2.1, P=0.15). Patients with acute cerebrovascular disease had higher systolic 
and diastolic blood pressures (systolic 157 versus 143, t=-4.16, p<0.0001, diastolic 86 
versus 80 t=-2.8, P=0.006) and were more likely to have a missing peripheral pulse. 
There was no evidence that patients with acute cerebrovascular disease (ACvD) 
were seen faster those with other diagnoses (last seen well to admission: ACvD 6 hr 
20 minutes versus other diagnoses 6 hrs). 
Brain imaging 
Most patients had brain imaging (Table 3.5). Almost all patients with acute 
cerebrovascular disease had either a CT or MR brain scan (98%), and the majority of 
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patients with mimics (81%). About a third of patients with stroke, TIA and mimics 
had an MR brain at some point during their admission to hospital. Most patients 
with acute cerebrovascular disease had a relevant ischaemic lesion on brain 
imaging, more in patients with stroke (72%) than TIA (34%). 
Differential diagnosis 
Table 3.6 summarises the diagnoses in patients with suspected stroke. Ischaemic 
stroke was the most common diagnosis, making up just over a half of all patients 
seen, and about four fifths of those with acute cerebrovascular disease. The 
remaining patients with acute cerebrovascular disease had a cerebral TIA (14%), 
intracerebral haemorrhage (6%) or subarachnoid haemorrhage (1%).  
The most frequent non-cerebrovascular diagnoses were primary headache disorders 
(14% of patients with mimics), seizures (12%), non-neurological sepsis (11%) and 
functional symptoms (10%). It is worth noting that, in most of the patients with non-
cerebrovascular disorders, the diagnosis was not made positively with 
neuroimaging. Imaging only contributed to the positive diagnosis of non-stroke in 
brain tumours, (4%), subdural haematomas (2%), and one case of brainstem 
compression due to an intracranial aneurysm.  
Emergency clinicians, ROSIER and FAS scores and the diagnosis of acute 
cerebrovascular disease  
Where a member of the emergency department staff thought that a patient probably 
or definitely had acute cerebrovascular disease, their assessment had a sensitivity of 
77 % (95% CI: 72 to 82%) and specificity of 58% (49 to 67%) versus the gold standard 
diagnosis of acute cerebrovascular disease (Table 3.7 and Table 3.9). The clinical 
impression of an emergency department clinician was more specific than the FAS 
test (58% versus 37%) and had a similar sensitivity (77% versus 82%). The clinical 
impression of an emergency department clinician was a little less sensitive (77 
versus 82%) though more specific than the ROSIER scale (58% versus 42%).  
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A diagnosis of definite or probable cerebrovascular disease by a stroke fellow was 
more sensitive (92% versus 77%) and specific (84% versus 58%) than an emergency 
department clinician’s diagnosis.  
I found no qualitative or important quantitative difference in these results where I 
compared emergency department opinion, FAS and ROSIER against a diagnosis of 
stroke rather than acute cerebrovascular disease (Table 3.8, Table 3.9). In patients 
seen less than six hours after the onset of their symptoms (Table 3.10), the sensitivity 
of an emergency department clinician’s impression was similar to the FAS and 
ROSIER scales though poorer than the stroke fellow’s assessment. An emergency 
department clinician’s clinical impression had a better sensitivity than the FAS score 
though was worse than the stroke fellow’s clinical assessment (Table 3.10). Where a 
patient’s first recorded assessment was by a nurse, rather than a doctor, each of the 
stroke scales had a better sensitivity than the clinical impression, though each scale 
had a worse specificity (Table 3.11). 
Validation of multivariate diagnostic models from (Hand 2002) 
Stroke or neurology registrar model: The predicted probability of acute cerebrovascular 
disease was on average higher in patients with a final diagnosis of acute 
cerebrovascular disease than in those without (mean 0.9 versus 0.5 t=13, P<0.0001) 
(Figure 5). A calibration plot (Figure 6) showed the model was reasonably calibrated 
though the difference from perfect calibration is statistically significant (Hosmer 
Lemeshow χ2=29.4, P=0.0003). The discrimination of the model was good (Figure 7) 
with an area under a receiver operator curve of 0.80 (95% CI: 0.74 to 0.85). At the 
suggested threshold (Pr=0.90) the model had a sensitivity of 43% (38 to 49%) and 
specificity of 86% (79 to 91%) for a diagnosis of acute cerebrovascular disease. The 
sensitivity was worse than the performance of a stroke registrar though specificity 
was not (Table 3.7). 
Emergency nurse model: The calibration of this model in this dataset was poor 
(Hosmer Lemeshow χ2= 95.4, P<0.0001) (Figure 8) though discrimination, measured 
by the area under the receiver operator curve was reasonable (0.70, 95% CI: 0.65 to 
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0.75). At the suggested probability threshold (Pr=0.3) the model had a sensitivity of 
94% (90 to 96%) and specificity of 43.9 (35 to 53). The sensitivity was better than the 
performance of an emergency department clinician though the specificity was 
probably worse (Table 3.7). 
The addition of stroke scales to clinical opinion. 
Where an emergency department clinician thought that a patient probably or 
definitely had a stroke, and that patient had none of the positive variables in the 
ROSIER scale or had one of the two negative features, the serial combination of 
these two tests had a sensitivity of 72% (95% CI: 67 to 78%) and specificity of 64% 
(54 to 72%). 
Discussion 
Key results 
Each stroke scale had a better sensitivity, though worse specificity, than a member 
of the emergency team diagnosing a patient’s ongoing symptoms as definitely or 
probably due to acute cerebrovascular disease. The specificity of the FAS, ROSIER 
and Hand nurse model were similar to one another (~40%), though the Hand nurse 
model had the best sensitivity (94%). Therefore no scale or model had better 
specificity and better specificity than an emergency department clinician. This 
finding was robust to patients seen very early (<6 hours) after their stroke, and to 
whether they were seen only by a nurse, rather than doctor. 
When an emergency department clinician’s clinical opinion was combined in series 
with a specific test (i.e. none of the positive features of the ROSIER scale, or one of 
the negative features), the specificity of the two tests in combination was better than 
either in isolation, though at the expense of worse sensitivity.  
A stroke fellow or registrar had better sensitivity and specificity for the diagnosis of 
acute cerebrovascular disease than an emergency department clinician or the 
ROSIER, FAS or Hand models though the Hand nurse model that had a very similar 
sensitivity.  
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Limitations 
Incorporation bias: The gold standard diagnosis of stroke and TIA relies heavily 
upon the presenting symptoms. The components of a clinical stroke scale, if 
measured with sufficient accuracy, form part of the gold standard diagnosis of 
stroke and TIA: incorporation of these elements into the final clinical diagnosis is 
inevitable. This need not preclude the use of a diagnostic study design to evaluate 
these scales, but does need acknowledgement that the gold standard is being 
compared with some of its components (albeit imperfectly measured). 
Selection bias: Over the period of the study, I was unable to recruit all potentially 
eligible patients, because: (a) I was only able to recruit during working hours and on 
weekdays, and (b) some patients were not identified in the ARU, despite intensive 
efforts. Furthermore, the origin of referral to the Western General Hospital may 
have may have skewed the spectrum of patients towards milder symptom severity. 
Despite this the proportion of mimics in my cohort is similar to previous studies 
(Hand et al. 2006e), and the age and neurological impairment of the recruited 
patients were similar to all stroke patients admitted to the Western General 
Hospital. 
Completion of some of the scales and missing data: I was unable to collect a 
clinical opinion, ROSIER and FAS score for each patient. Emergency staff completed 
the more complex scale (ROSIER) in only 85% of patients. As I have analysed only 
cases with complete information, rather than imputed missing data, it is possible 
that I have over-estimated the sensitivity and specificity of the ROSIER score as a 
result of this bias. 
Measurement of variables: The emergency department clinician only measured the 
variables that were components of the FAS and ROSIER scales. The stroke fellow, 
rather than a member of the emergency department staff measured two of the 
variables in the Hand model designed for use by the nursing staff.  As I probably 
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measured these variables with greater accuracy and consistency than the emergency 
department staff, the reported sensitivity and specificity of this model are likely to 
be overestimates. It is also possible that the training of the nurses included the FAS 
test, and they already incorporated the results of the test into their informal 
assessment of clinical probability. 
Accuracy of stroke and acute cerebrovascular diagnosis: The definition of the gold 
standard diagnosis of stroke adds a tension to the design and interpretation of a 
study. The simpler the gold standard, the more easily it can be applied to all 
patients, which avoids bias from the exclusion of patients unable to undergo more 
complex investigations and the uncertainly of measurement of associations because 
of small sample sizes. A more complex gold standard, perhaps with compulsory 
MR imaging, is less likely to misclassify patients, avoiding bias from the random 
misclassification of patients, and so attenuation of important associations that 
maybe found in studies with a simpler gold standard definition. This study follows 
a middle path, though is not immune to random misclassification of patients. 
Study strengths 
It is worth considering the strengths of the study. I have recruited consecutive 
patients where stroke was suspected by a member of the emergency team, rather 
than, for example, examining the performance of stroke scales in patients referred to 
a stroke service. The study therefore has immediate relevance to the use of these 
scales by staff in emergency departments. The gold standard diagnosis was 
consistently and prospectively made after a uniform delay soon after admission, 
when both relevant clinical information and short term follow up were easily 
available, rather than retrospectively obtained from patient discharge records. Most 
of the variables that were relevant to the scores FAS and ROSIER were measured by 
members of the emergency staff rather than a stroke physician, and so importantly 
have the measurement errors one would expect from their routine use in the 
emergency department. 
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Interpretation 
It therefore seems unlikely that the ROSIER, FAS or various logistic regression 
models simultaneously improve on the sensitivity of the assessment of a member of 
the emergency department staff and the specificity of their assessment. Using a scale 
in combination with a clinical assessment improves the overall specificity though at 
the expense of lower sensitivity. 
It is extremely difficult, and perhaps impossible, to measure separately the 
diagnostic performance of a clinical diagnostic scale and clinical judgment. 
However, the impacts of two strategies; clinical judgment versus clinical judgment + 
a clinical scale can be compared. In this study, a strategy based upon clinical 
judgment alone, where clinical judgment deemed acute cerebrovascular disease 
probable or definite would miss about a fifth of patients with stroke or TIA, and of 
those patients positively identified, four fifths would have acute cerebrovascular 
disease. A strategy of using the FAS or ROSIER scale in patients where clinical 
judgment deemed acute cerebrovascular disease possible would miss about a fifth 
of patients with acute cerebrovascular disease and of those patents positively 
identified about three quarters would have acute cerebrovascular disease. A 
strategy of identifying patients where clinical judgment deemed acute 
cerebrovascular disease probable or definite, and patients had none of the positive 
features of the ROSIER or one of the negative features would identify about three 
quarters of patients with acute cerebrovascular disease, and of those patient 
positively identified about four fifths would have acute cerebrovascular disease. 
Note that the sensitivity of each scale increases as the clinical suspicion of the 
emergency department member for stroke increases; for example the sensitivity of 
the FAS score for acute cerebrovascular disease in the whole sample is 82%, though 
in those where the emergency department staff was definite or probable about the 
diagnosis of acute cerebrovascular disease this increased to 94%, and in those where 
the emergency department staff was definite about the diagnosis of acute 
cerebrovascular disease this increased to 98%.  
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The ROSIER scale was first developed and validated in Newcastle in patients 
referred to a stroke service and was evaluated by emergency department doctors 
(Nor et al. 2005a). The association of individual variables of the ROSIER scale with a 
diagnosis of stroke was much stronger in the original dataset than mine – for 
example arm weakness (OR 5.3 versus 1.7), leg weakness (4.1 versus 1.3) and facial 
weakness (4.8 versus 2.4), though seizures (0.1 versus 0.1) and LOC (0.1 versus 0.3) 
were similar. Nor et al found, in a smaller validation cohort, that the sensitivity and 
specificity of the ROSIER was 93% and 83% respectively. In a small Irish series of 50 
patients, the ROSIER had a sensitivity of 98% and specificity of 25%, though the 
authors used an earlier version of the ROSIER scale which included hand weakness 
(Jackson et al. 2008a). 
Generalisability 
The results of this study are probably generalisable to emergency departments 
where staff have a similar level of training to those in the UK and the case mix was 
similar to patients in my study. 
Implications for research 
• We are unable to exclude a training effect from the use of these scales in the 
apparent performance of the clinical opinion of emergency department staff. 
• It is reasonable to compare the performance of new diagnostic methods with 
the informal clinical opinion of a member of an emergency staff member. 
Implications for practice 
• About two thirds of patients with suspected stroke prove to have a stroke or 
TIA 
• The results of clinical scales alone do not perform a great deal better for the 
diagnosis of stroke than the informal opinion of a trained member of the 
emergency department staff. 
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Tables 
Table 3.1 Comparing the sensitivity of two tests for the diagnosis of acute cerebrovascular disease 
Test 1 Subjects with acute cerebrovascular disease 
Positive Negative 
Positive a b 
Test 2 
Negative c d 
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Table 3.2 All patients admitted to the Western General Hospital with a discharge diagnosis of stroke from 21st March 2007 to 27th February 2009.  
Data from the Scottish Stroke Care Audit System. There were no records of delay to admission of patients with TIA. ICD-10 codes I61, I63, I64X were used to define stroke 
and its subtypes. 
 
Stroke type 
Stroke onset to admission  
(days) 
 
Haemorrhagic (n, %) Ischaemic (n, %) Uncertain (n, %) 
 
Total (n, %) 
0  46 (72) 499 (67) 8 (8)  553 (67) 
1  6 (9) 107 (14) 1 (1)  114 (14) 
2  6 (9) 41 (5) 1 (1)  48 (6) 
3  2 (3) 23 (3) -  25 (3) 
4  - 23 (3) -  23 (3) 
5  - 5 (1) -  5 (1) 
>5  4 (6) 51 (7) -  55 (7) 
Total  64 (100) 749 (100) 10 (100)  823 (100) 
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Table 3.3 Comparison of routinely collected data of stroke severity and age with study cohort 
 SSCA data 21st March 2007 to 27th February 2009 Current study data 
 All patients Patients admitted <24 hours Stroke patients 
Number 873 579 245 
Age (mean, SD) 74.5 (13.1) 75.4 (13.1) 74.9 (12.3) 
Living alone (n, %) 355 (40.7) 232 (40.1) 80 (32.7) 
Able to talk (n, %) 694 (79.5) 436 (75.3) 178 (72.7) 
Orientated to time, place and person (n, %) 553 (63.3) 338 (58.3) 172 (70.2) 
Able to lift arms (n, %) 591 (67.7) 353 (61.0) 146 (59.6) 
Able to walk without help (n, %) 346 (39.6) 200 (34.5) 92 (37.6) 
NIHSS score (median, IQR) 4 (2 to 9)* 5 (2 to 12)
†
 4 (2 to 11) 
* recorded in 580 patients † recorded in 392 patients. SSCA: Scottish Stroke Care Audit, a record of all stroke admissions at the Western General Hospital. 
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Table 3.4 Baseline clinical characteristics of patients with suspected stroke 
   Diagnosis  Odds ratio (95% CI)  
 All (n=405)  ACvD* (n=285) Mimic† (n=120)  ACvD vs mimic P  value 
Male sex (n, %) 198 (46.7)  136 (47.7) 53 (44.2)  1.15 (0.75 to 1.77) 0.513 
Age (years) (mean, SD) 72.4 (13.9)  74.4 (12.4) 67.5 (15.9)  1.43 (1.22 to 1.67)
‡
 <0.001 
Fellow collected variables  n, %  n, % n, %    
Head trauma  11 (2.7)  8 (2.8) 2 (2.5)  1.12 (0.29 to 4.33) 0.860 
Loss of consciousness 31 (7.8)  15 (5.4) 16 (13.5)  0.37 (0.17 to 0.76) 0.008 
Seizure at onset 20 (5.0)  3 (1.1) 17 (14.3)  0.07 (0.02 to 0.23) <0.001 
Headache at onset 80 (20.1)  44 (15.8) 36 (30.3)  0.43 (0.26 to 0.71) 0.001 
Infective symptoms 47 (11.6)  27 (9.5) 20 (16.7)  0.52 (0.28 to 0.98) 0.041 
Prior cardiac vascular disease 90 (22.3)  67 (23.5) 23 (19.3)  1.28 (0.75 to 2.18) 0.358 
Prior peripheral vascular disease 20 (5.0)  17 (6.0) 3 (2.5)  2.47 (0.71 to 8.60) 0.155 
Prior TIA or stroke 121 (30.0)  76 (26.8) 45 (37.8)  0.60 (0.37 to 0.94) 0.026 
Prior heart failure 29 (7.3)  22 (7.8) 7 (5.9)  1.36 (0.56 to 3.27) 0.494 
AF (prior or during ED) 93 (23.0)  74 (26.0) 19 (15.8)  1.92 (1.13 to 3.26) 0.015 
Prior epilepsy 17 (4.3)  6 (2.1) 11 (9.2)  0.21 (0.08 to 0.59) 0.003 
Diabetes mellitus 46 (11.4)  37 (13.0) 9 (7.5)  1.84 (0.86 to 3.94) 0.117 
Prior cognitive impairment 57 (14.2)  39 (13.7) 18 (15.3)  0.88 (0.48 to 1.62) 0.691 
Migraine 44 (11.1)  26 (9.3) 18 (15.3)  0.57 (0.30 to 1.08) 0.086 
Independent prior to admission 341 (84.2)  247 (86.7) 94 (78.3)  1.80 (1.03 to 3.12) 0.037 
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Table 3.3 continued   Diagnosis  Odds ratio (95% CI)  
 All (n=405)  ACvD* (n=285) Mimic† (n=120)  ACvD vs mimic P  value 
Living alone 136 (33.6)  96 (33.7) 40 (33.3)  1.02 (0.64 to 1.59) 0.946 
Able to talk 321 (79.3)  216 (75.8) 105 (87.5)  0.45 (0.24 to 0.81) 0.009 
Orientated to time place & person 297 (73)  210 (73.7) 87 (72.5)  1.06 (0.66 to 1.71) 0.806 
Able to lift arms 279 (68.9)  181 (63.5) 98 (81.7)  0.39 (0.23 to 0.66) <0.001 
Able to walk without help 195 (48.2)  127 (44.6) 68 (56.7)  0.61 (0.40 to 0.94) 0.027 
Medications n, %  n, % n, %    
Any antiplatelet agent 172 (42.5)  121 (42.5) 51 (42.5)  1.00 (0.65 to 1.53) 0.993 
Warfarin 24 (6.0)  13 (4.6) 11 (9.2)  0.48 (0.21 to 1.10) 0.081 
Antihypertensive 213 (52.6)  155 (54.4) 58 (48.3)  1.27 (0.83 to 1.95) 0.266 
Statin 146 (36.5)  99 (35.2) 47 (39.5)  0.83 (0.54 to 1.30) 0.418 
Current smoker 94 (23.4)  65 (23.1) 29 (24.2)  0.94 (0.57 to 1.55) 0.809 
Examination findings n, %  n, % n, %    
Any focal neurological deficit 323 (81.0)  261 (92.9) 62 (52.5)  11.78 (6.5 to 21.1) <0.001 
Normal pedal pulses 208 (51.7)  133 (47.0) 75 (63.0)  0.52 (0.34 to 0.81) 0.004 
Heart Murmur 35 (8.8)  25 (8.9) 10 (8.4)  1.06 (0.49 to 2.29) 0.873 
Carotid Bruit 15 (3.7)  13 (4.6) 2 (1.7)  2.83 (0.63 to 12.73) 0.175 
Continuous variables (mean,SD) n, %  n, % n, %    
Systolic BP (mmHg) 153 (29)  157 (30) 143 (25)  1.18 (1.09 to 1.28)
¶
 <0.001 





C) 36.4 (0.7)  36.4 (0.6) 36.4 9 (0.8)  0.95 (0.69 to 1.30) 0.727 
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Table 3.3 continued   Diagnosis  Odds ratio (95% CI)  
 All (n=405)  ACvD* (n=285) Mimic† (n=120)  ACvD vs mimic P  value 
Continuous variables  median, IQR  median, IQR median, IQR    
Last seen well to admission (hrs)  6.2 (12.4)  6.3 (13.4) 6.0 (9.9)  1.00 (0.98 to 1.02)
§
 0.800 
Found unwell to admission (hrs)  4.2 (6.2)  3.8 (6.5) 4.6 (5.3)  1.00 (0.97 to 1.01)
 §
 0.424 
Admission to stroke fellow (hrs)  0.9 (1.4)  0.9 (1.4) 0.9 (1.4)  1.02 (0.98 to 1.07) 0.294 
NIHSS (per unit) 3 (7)  4 (8) 1 (5)  1.11 (1.06 to 1.17)
║
 <0.001 
ED collected variables (n, %) n, %  n, % n, %    
Arm weakness   205 (55.1)  152 (58.9) 53 (46.5)  1.65 (1.06 to 2.57) 0.027 
Facial weakness  149 (39.8)  119 (45.8) 30 (26.3)  2.36 (1.46 to 3.83) <0.001 
Leg weakness  144 (38.8)  105 (40.9) 39 (34.2)  1.32 (0.83 to 2.1) 0.226 
Speech disturbance  166 (44.5)  134 (51.7) 32 (28.1)  2.75 (1.71 to 4.42) <0.001 
Visual disturbance  52 (14.5)  47 (18.9) 5 (4.6)  4.83 (1.86 to 12.53) 0.001 
Percentages are given as a proportion subjects with complete data.  Odds ratios >1 indicate a variable is positively associated with a diagnosis of ACvD. I used Wald tests to 
calculate P values. 
*ACvD: acute cerebrovascular disease (probable or definite cerebral ischaemia or intracerebral haemorrhage responsible for symptoms at time of clinical assessment) †ACvD 
definitely not, or only possibly responsible for symptoms at time of clinical assessment ‡ per 10 years, § per hour ║ per unit increase NIHSS ¶ per 10mmHg increase
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Table 3.5 Brain imaging findings in patients with acute cerebrovascular disease or mimic.  
    ACvD    Mimic  
 All (n=405)  All (n=285) Stroke (n=243) TIA (n= 40)  (n=120)  
First imaging modality (n, %)         
CT  301 (74)  228 (80) 193 (79) 33 (83)  73 (61)  
MR  75 (19)  51 (18) 46 (19) 5 (13)  24 (20)  
No imaging 29 (7)  6 (2) 4 (2) 2 (5)  23 (19)  
Ever MR imaging 126 (31)  93 (33) 83 (34) 10 (25)  33 (28)  
Imaging findings (n, %) n=376  n=279 n=239 n=38  n=97  
Relevant ischaemic lesion (first scan)
 ‡
  162 (40)  162 (58) 151 (63) 11 (28)  0  
 Cortical
§
 109 (67)  109 (67) 103 (68) 6 (55)  0  
 Lacunar
§
  33 (20)  33 (20) 29 (19) 4 (36)  0  
 Brainstem§  16 (10)  16 (10) 15 (6) 1 (9)  0  
 >1 lesion 4 (2)  4 (2) 4 (2) 0  0  
Relevant ischaemic lesion (any scan)
 ‡
  186 (49)  186 (66) 173 (72) 13 (34)  0  
Relevant haemorrhagic lesion
‡





  6 (1.6)  0 0 0  6 (5)  
Non-relevant infarction
‡
  125 (33)  88 (31) 47 (34) 115 (34)  37 (38)  
Relevant lesions are those considered to be responsible for the presenting symptoms.* definite or probable acute cerebrovascular disease ‡as a percentage of 
those with a scan § as a percentage of those with a relevant ischaemic lesion ¶2 patients with subdural haematoma. 
Whiteley W.N. Blood Markers in Stroke University of Edinburgh 2010 
 
Chapter 3  BBISS: Clinical features and the diagnosis of stroke  94 
 Table 3.6 Diagnoses of patients with suspected stroke seen in the emergency department of 
the Western General Hospital, Edinburgh. 
 N % ACvD % total (n=405) 
Acute cerebrovascular disease (ACvD) 285  70.4 
Ischaemic stroke 230 80.7 56.8 
 Definite 205 71.9 50.6 
 Probable 25 8.8 6.2 
Transient ischaemic attack 40 14.0 9.9 
 Definite 31 10.9 7.7 
 Probable 9 3.2 2.2 
Intracerebral haemorrhage 13 5.6 3.2 
Subarachnoid haemorrhage 2 0.7 0.5 
 N % mimics % total 
Mimics 120 100 29.6 
Primary headache disorders 17 14.2 4.2 
Seizures 14 11.7 3.5 
Sepsis 13 10.8 3.2 
Functional disorders 12 10 2.5 
Peripheral nerve disorders 10 8.3 2.5 
Syncope 8 6.7 2.0 
Vestibulopathy 8 6.7 2.0 
Metabolic* 6 5.0 1.5 
Brain tumours
†
 4 3.3 1.0 
Dementia fluctuation 4 3.3 1.0 
Musculoskeletal disorders 3 2.5 0.7 
Other cancers 2 1.7 0.5 
Subdural haematoma 2 1.7 0.5 
Transient global amnesia 2 1.7 0.5 
Other diagnoses
‡
 15 12.5 3.7 
*alcohol (3), hypoglycaemia (1) hypothermia (1), symptoms due to nitrazepam (1);
 †
glioma(2), 
meningioma (1), metastatic (1); 
‡
transient symptoms after invasive procedures (3), aneurysmal 
brainstem compression(1), conjunctivitis (1), uncertain (3) 
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Table 3.7 Diagnostic performance of different diagnostic approaches for a diagnosis of acute cerebrovascular disease among patients with stroke 
suspected by emergency staff, compared with ‘gold standard’ 
  Sensitivity  Specificity 
 N % (95% CI) P*  % (95% CI) P* 
ED staff informal diagnosis of definite or probable ACvD 389 77 (72 to 82) Reference  58 (49 to 67) Reference 
Stroke fellow informal diagnosis of definite or probable ACvD 405 92 (90 to 96) <0.001  84 (77 to 90) 0.009 
FAS, measured by ED staff 374 82 (76 to 86) 0.07  37 (29 to 46) <0.001 
ROSIER, variables measured by ED staff/stroke fellow 350 82 (77 to 87) 0.007  42 (33 to 52) <0.001 
Logistic regression model designed for nurse use (Hand 2002) ‡ 369 94 (90 to 96) <0.001  44 (35 to 53) 0.017 
Logistic regression model designed for stroke fellow (Hand 2002) § 398 43 (38 to 49) <0.001†  86 (79 to 91) 0.37† 
* P obtained by comparing the sensitivity or specificity of an emergency department clinician’s assessment with the other diagnostic scales in a series of paired 
comparisons, using a McNemar’s test. Where the number of discordant pairs is <20, I have reported the Exact McNemar’s P †compared to stroke 
fellow.‡predicted probability threshold=0.3 §predicted probability threshold=0.9 
ED: emergency department; FAS: face, arm speech tests; ROSIER: recognition of stroke in the ED.  
A P<0.01 indicates a statistically significant difference over ED staff informal diagnosis of acute cerebrovascular disease. ROSIER & FAS (375 assessments) were 
assessed using data collected by the first qualified ED assessor (104 doctors, 27.7%, 270 nurses, 72%, 1 paramedic, 0.27%)  
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Table 3.8 Diagnostic performance of different diagnostic approaches for a diagnosis of stroke among patients with stroke suspected by 
emergency staff, compared with ‘gold standard’ 
 n Sensitivity (95% CI) Specificity (95% CI) 
ED staff informal diagnosis of definite stroke 389 35 (29 to 41) 93 (88 to 96) 
ED staff informal diagnosis of definite or probable stroke 389 80 (75 to 85) 58 (0 to 61) 
FAS, measured by ED staff 374 85 (80 to 89) 37 (30 to 45) 
ROSIER, variables measured by ED staff/stroke fellow 350 86 (81 to 90) 41 (33 to 49) 
Stroke fellow informal diagnosis of definite stroke 405 68 (62 to 74) 83 (76 to 88) 
Stroke fellow informal diagnosis of definite or probable stroke 405 93 (89 to 95) 66 (58 to 73) 
 
ED: Emergency department, FAS: face, arm speech tests, ROSIER: recognition of stroke in the ED.  
ROSIER & FAS (375 assessments) were assessed using data collected by the first qualified ED assessor (104 doctors, 27.7%, 270 nurses, 72%, 1 paramedic, 0.27%) 
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Table 3.9 Positive and negative predictive values and likelihood ratios of stroke scales for a diagnosis of acute cerebrovascular disease or stroke. 
 N PPV (95% NPV(95% CI) LR+(95% CI) LR-(95% CI) 
For a diagnosis of acute cerebrovascular diseases amongst patients with suspected stroke 
ED staff informal diagnosis of definite ACvD 389 93 (86 to 97) 38 (33 to 44) 6.3 (2.8 to 14) 0.7 (0.7 to 0.8) 
ED staff informal diagnosis of definite or probable ACvD 389 81 (75 to 85) 53 (45 to 62) 1.9 (1.5 to 2.3) 0.4 (0.3 to 0.5) 
FAS, measured by ED staff 374 75 (69 to 79) 47 (37 to 58) 1.3 (1.1 to 1.5) 0.5 (0.4 to 0.7) 
ROSIER, variables measured by ED staff/stroke fellow 350 77 (71 to 82) 51 (40 to 61) 1.4 (1.2 to 1.7) 0.4 (0.3 to 0.6) 
Stroke fellow informal diagnosis of definite ACvD 405 97 (94 to 99) 54 (48 to 61) 13 (6.1 to 9.1) 0.4 (0.3 to 42) 
Stroke fellow informal diagnosis of definite or probable ACvD 405 94 (90 to 96) 82 (74 to 88) 5.8 (3.9 to 8.8) 0.1 (0.1 to 0.1) 
For a diagnosis of stroke amongst patients with suspected stroke 
ED staff informal diagnosis of definite stroke 389 88 (80 to 93) 49 (44 to 55) 5.0 (2.7 to 9.0) 0.7 (0.6 to 0.8) 
ED staff informal diagnosis of definite or probable stroke 389 72 (66 to 77) 65 (56 to 73) 1.7 (1.5 to 21) 0.4 (0.3 to 0.5) 
FAS, measured by ED staff 374 67 (61 to 72) 63 (53 to 72) 1.4 (1.2 to 1.6) 0.4 (0.3 to 0.6) 
ROSIER, variables measured by ED staff/stroke fellow 350 68 (62 to 73) 67 (56 to 76) 1.5 (1.3 to 1.7) 0.3 (0.2 to 0.5) 
Stroke fellow informal diagnosis of definite stroke 405 86 (81 to 90) 63 (56 to 69) 3.9 (2.8 to 5.5) 0.4 (0.3 to 0.5) 
Stroke fellow informal diagnosis of definite or probable stroke 405 81 (76 to 85) 85 (78 to 91) 2.7 (2.2 to 3.3) 0.1 (0.1 to 0.2) 
ACvD: acute cerebrovascular disease; PPV: positive predictive value, NPV: negative predictive value, LR+: positive likelihood ratio, LR-: negative likelihood 
ratio; ED: Emergency department, FAS: face, arm speech tests, ROSIER: recognition of stroke in the ED.  
ROSIER & FAS (375 assessments) were assessed using data collected by the first qualified ED assessor (104 doctors, 27.7%, 270 nurses, 72%, 1 paramedic, 0.27%) 
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Table 3.10 Diagnostic performance of different diagnostic approaches for a diagnosis of acute cerebrovascular disease among patients seen less 
than 6 hours after symptom onset with stroke suspected by emergency staff, compared with ‘gold standard’  
   Sensitivity  Specificity 
 N  % 95% CI P*  % 95% CI P 
ED staff informal diagnosis of definite or probable ACvD 185  83 75 to 88 Ref  59 47 to 71 Reference 
FAS, measured by ED staff 178  85 78 to 91 0.42  41 29 to 54 0.03 
ROSIER, variables measured by ED staff/stroke fellow 170  86 78 to 91 0.21  51 38 to 64 0.21 
Logistic regression model designed for nurse use (Hand 2002) 175  94 88 to 97 <0.01  44 31 to 57 0.06 
Stroke fellow informal diagnosis of definite or probable ACvD 185  93 88 to 97 <0.01  86 76 to 93 <0.01 
* P obtained by comparing the sensitivity or specificity of an emergency department clinician’s assessment with the other diagnostic scales in a series of paired 
comparisons, using a McNemar’s test. Where the number of discordant pairs is <20, I have reported the Exact McNemar’s P † compared to stroke fellow. A 
P<0.01 indicates a statistically significant improvement over ED staff informal diagnosis of ACvD 
ACvD: acute cerebrovascular disease; ED: Emergency department; FAS: face, arm speech tests; ROSIER: recognition of stroke in the ED.  
Whiteley W.N. Blood Markers in Stroke University of Edinburgh 2010 
 
Chapter 3  BBISS: Clinical features and the diagnosis of stroke   99 
 
Table 3.11 Diagnostic performance of different diagnostic approaches for a diagnosis of acute cerebrovascular disease among patients seen by a 
nurse with suspected stroke, compared with ‘gold standard’  
   Sensitivity  Specificity 
 N  % 95% CI P*  % 95% CI P 
ED staff informal diagnosis of definite or probable ACvD 267  73 66 to 79 Reference  56 45 to 66 Reference 
FAS, measured by ED staff 255  81 75 to 86 0.02  36 27 to 48 <0.01 
ROSIER, variables measured by ED staff/stroke fellow 236  81 75 to 87 <0.01  42 31 to 54 0.02 
Logistic regression model designed for nurse use (Hand 2002) 251  96 91 to 98 <0.01  44 33 to 55 0.01 
P obtained by comparing the sensitivity or specificity of an emergency department clinician’s assessment with the other diagnostic scales in a series of 
paired comparisons, using a McNemar’s test. Where the number of discordant pairs is <20, I have reported the Exact McNemar’s P;  
ACvD: acute cerebrovascular disease; ED: Emergency department; FAS: face, arm speech tests; ROSIER: recognition of stroke in the ED.  
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Table 3.12 Missing data 
Variable All  Acute cerebrovascular Mimic 
Fellow collected variables    
Systolic BP  0 0 0 
Diastolic BP 0 0 0 
Temperature 16 (3.9) 15 (5.3) 1 (0.8) 
Well to admission  5 (1.2) 5 (1.2) 0 
Found to admission  5 (1.2) 5 (1.2) 0 
Admission to stroke fellow   6 (1.5) 5 (1.2) 1 (0.3) 
NIHSS  0 0 0 
Sex  0 0 0 
Head trauma  4 (1.0) 3 (1.1) 1 (0.8) 
LOC  7 (1.7) 6 (2.1) 1 (0.8) 
Seizure 7 (1.7) 6 (2.1) 1 (0.8) 
Headache 7 (1.7) 6 (2.1) 1 (0.8) 
Infective symptom 0 0 0 
Cardiac vascular disease 1 (0.2) 0 1 (0.8) 
Peripheral vascular disease 3 (0.7) 2 (0.7) 1 (0.8) 
TIA or stroke 1 (0.2) 0 1 (0.8) 
Heart failure 5 (1.2) 4 (1.4) 1 (0.8) 
AF (prior, during) 0 0 0 
Epilepsy 6 (1.5) 5 (1.8) 1 (0.8) 
Diabetes 0 0 0 
Dementia 3 (0.7) 1 (0.4) 2 (1.7) 
Migraine 7 (1.7) 5 (1.8) 2 (1.6) 
Independent of ADL 0 0 0 
Living alone 0 0 0 
Able to talk 0 0 0 
Orientated to time place & person 0 0 0 
Able to lift arms 0 0 0 
Able to walk without help 0 0 0 
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Variable All  Acute cerebrovascular Mimic 
Antiplatelet 0 0 0 
Warfarin 5 (1.2) 4 (1.4) 1 (0.8) 
Antihypertensive 0 0 0 
Statin 5 (1.2) 4 (1.4) 1 (0.8) 
Current smoker 3 (0.7) 3 (0.1) 0 
Any focal neurological deficit 6 (1.5) 4 (1.4) 2 (1.7) 
Normal pedal pulses 3 (0.7) 2 (0.7) 1 (0.8) 
Heart murmur 5 (1.7) 4 (1.4) 1 (0.8) 
Carotid bruit 1 (0.2) 1 (0.3) 0 
ED collected variables    
Arm weakness   33 (8.1) 27 (9.5) 6 (5.0) 
Facial weakness  31 (7.6) 25 (8.7) 6 (5.0) 
Leg weakness  34 (8.4) 28 (9.8) 6 (5.0) 
Speech disturbance  32 (7.9) 26 (9.1) 6 (5.0) 
Visual disturbance  47 (11.6) 36 (12.6) 11 (9.1) 
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Figure 4 Recruitment to the Blood Biomarkers In Suspected Stroke study.  
Note the constant rate of recruitment throughout the study period (~1 patient/day).  
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Figure 5 Predicted probabilities of a diagnosis of stroke, derived from a logistic regression 
model for stroke registrars.  
The vertical grey line shows the suggested threshold for the use of the model (P=0.90) for a 
high positive predictive value (95%). (Hand 2002). At this threshold, in this cohort, the 
model’s sensitivity for acute cerebrovascular disease is 43% and specificity 86%. 
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Figure 6 Predicted versus observed probability of stroke from a logistic regression model 
designed for stroke registrars in patients with suspected stroke. 
Predictions derived from a logistic regression model for stroke for neurology registrars 
(Hand 2002). Bars indicate 95% confidence intervals and the dotted line represents perfect 
calibration.  
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Figure 7 Receiver operator curve for logistic regression model for use by stroke registrars 
(Hand 2002) applied to BBISS dataset.  
AUROC=0.80 (95% CI: 0.74 to 0.85). The AUROC is a measure of the discrimination of a 
model; 1 indicates perfect discrimination and 0.5 no better discrimination than chance (the 
diagonal line). N=398 
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Figure 8 Predicted versus observed probability of stroke for a logistic regression model 
designed for use by nurses. 
Predicted probabilities derived from a clinical prediction model designed for use by 
emergency department nurses. The dotted line shows perfect calibration 
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Chapter 4.   Blood markers of inflammation, thrombosis, thrombolysis, 
cardiac strain, neural and glial damage and the diagnosis of acute 
cerebrovascular diseases in an emergency department: BBISS, a 
prospective cohort study 
Introduction 
A clinical diagnosis of stroke or TIA (which I will call ‘acute cerebrovascular 
diseases’, ACvD) relies on a few key features: sudden onset of symptoms, a focal 
neurological deficit, and the absence of positive symptoms of stroke mimics such as 
a seizure or loss of consciousness. However, the accuracy of clinical diagnosis made 
by doctors or nurses may depend on their training and expertise in stroke medicine. 
Further tests can improve upon the accuracy of the clinical diagnosis of stroke. Brain 
imaging serves positively to identify brain ischaemia or haemorrhage, and exclude 
the presence of conditions that may mimic stroke in the emergency department such 
as brain tumours or extradural haemorrhage. 
However, brain imaging may take some time to perform, and MR brain imaging – 
probably the most sensitive technique – is not available to many patients as they 
may be too sick or their stroke service may not have rapid access to such a scanner 
(Hand et al. 2005a, Kane et al 2008). Blood markers of various aspects of stroke 
patho-physiology have the potential to improve the clinical diagnosis. 
Some patho-physiological processes may be more common in patients with acute 
cerebrovascular disease than patients with stroke mimics. For example, markers of 
glial and neuronal damage, inflammation and cardiac strain are higher in patients 
with stroke than controls (Dassan, Keir, & Brown 2009, Whiteley, Tseng, & 
Sandercock 2008a). Ideally, the measurement of a single marker of any one of these 
processes would be diagnostic of acute cerebrovascular disease. Alternatively, a 
panel of several markers, assessing markers of several patho-physiological 
processes might be helpful. Panels of markers have been developed for the 
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diagnosis of conditions as diverse as lung cancer and myocardial infarction (Apple 
et al. 2007, Patz, Jr. et al. 2007). A previously developed panel that predicted a 
diagnosis of stroke included markers of cardiac strain (brain natriuretic peptide, 
BNP), inflammation/endothelial activation (matrix metalloproteinase-9, MMP-9), 
glial damage (S100 B) and thrombosis (D-dimer)(Laskowitz et al. 2009f).  
Blood markers therefore have the potential to help to confirm or strengthen a 
clinical diagnosis of acute cerebrovascular disease in patients presenting to the 
emergency department with suspected stroke. 
In this chapter I will seek to: 
• describe the univariate association between acute cerebrovascular disease 
and the plasma or serum concentration of markers of inflammation, 
thrombosis, thrombolysis, cardiac strain, cerebral damage, renal function, 
and glucose,  
• describe the correlation of the plasma or serum concentration of each marker 
with potentially confounding variables such as neurological impairment, 
age, blood pressure, and delay to blood draw, 
• describe the association of the plasma or serum concentration of markers 
with acute cerebrovascular disease after adjustment for those variables, 
• validate a previously published logistic regression model for the diagnosis of 
stroke with four blood markers (Laskowitz et al. 2009e), 
• develop a multiple variable logistic regression model based upon plasma or 
serum levels of blood markers to predict a diagnosis of acute 
cerebrovascular disease and, 
• test whether adding data from any marker positively associated with a 
diagnosis of acute cerebrovascular diseases improves diagnostic 
performance of the clinical opinion of a member of the emergency 
department staff to a clinically useful degree. 
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Methods 
BBISS cohort recruitment 
I have described the process of recruiting the BBISS cohort of patients in detail in the 
preceding chapter. In brief, I recruited all patients presenting to the Western General 
Hospital where an emergency department doctor or nurse suspected TIA or stroke, 
and the patient had been symptomatic for less than 24 hours. Each patient had brain 
imaging, where clinically indicated, or where there was substantial clinical 
uncertainly. A gold standard diagnosis of stroke or TIA was made by a panel of 
experts, including stroke physicians and neuroradiologists with access to the clinical 
findings, relevant imaging, and subsequent clinical course, blinded to the serum or 
plasma marker levels.  
Blood draw 
I drew blood from each patient as soon as possible after assessment into two 2.5 ml 
EDTA tubes, and an 8 ml tube containing clot activator and gel for serum 
separation. I took the samples on water ice to the Wellcome Trust Clinical Research 
Facility (WTRCF) at the Western General Hospital. A technician centrifuged the 
blood at 3000 revolutions per minute for 10 minutes, pipetteted the supernatant 
from each blood tube into two screw-topped tubes, labelled each sample with a 
‘Cryotag’ bar code and transferred them to a -80 0C fridge.  
Nurses from the WTCRF took blood samples from patients at 24 hours after 
symptom onset, when this fell within normal working hours. I personally 
transferred samples in batches to the University of Glasgow for the analysis of 
markers of cardiac strain, inflammation, thrombosis and thrombolysis, and to the 
National Creutzfeld-Jacob Disease Surveillance Unit in Edinburgh for the analysis of 
markers of neuronal and glial damage. 
Sample management 
Bar codes labels marked each sample with a unique identifying number. An Access 
database linked each sample number to the patient identification number, recorded 
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the time and date the sample was drawn and where each sample was to be 
analysed. 
Measurement of blood markers 
Experienced biochemists in academic laboratories measured markers according to 
their standard practice. Dr Ann Rumley and Dr Paul Welsh (Division of 
Cardiovascular and Medical Sciences, Royal Infirmary, University of Glasgow) 
measured markers of inflammation, cardiac strain and thrombosis and Dr Alison 
Green and Mrs. Mary Andrews (National CJD Surveillance Unit, University of 
Edinburgh) measured markers of neuronal and glial damage. Blood markers were 
measured in plasma or serum that had been stored at -80◦C for a maximum of 2 
years. In general, the plasma or serum from the first sample (<24 hours) was 
analysed. Where that sample was unavailable, or there was insufficient plasma or 
serum, the subsequent sample taken at 24 hours after symptom onset was used. All 
markers were measured blind to acute cerebrovascular disease status.  
The coefficient of variation 
One measure of the analytic random variation or imprecision of a test, is the 
coefficient of variation. It is calculated by dividing the standard deviation of repeat 
measures by the mean of all measurements, and it is usually reported as a 
percentage. The advantage of this measure is that, in general, as the mean of 
samples increases so does the standard deviation; the coefficient of variation allows 
comparison of the variability regardless of the mean of samples. Simulation has 
demonstrated that the chance of finding a more than 1.5 fold difference in two 
measurements of the same sample where the coefficient of variation is <10% has a 
probability of <0.001 (Reed, Lynn, & Meade 2002).  
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I list the methods to measure each individual marker below: 
Inflammation 
• Adiponectin (μg/ml): we measured total plasma adiponectin with a 
commercial enzyme-linked immunosorbent assays (ELISA) (R&D Systems). 
The inter-assay coefficients of variation for the assay was < 7%. 
• C-reactive protein (CRP) (mg/l): we measured plasma CRP with high-
sensitivity immunonephelometry (Prospec, Dade Behring Milton Keynes, 
UK) following the manufacturer's reagents and standards. Intra- and inter-
assay coefficients of variation were 4.7% and 8.3%, respectively. 
• Intercellular adhesion molecule-1 (ICAM-1) (ng/ml): we measured plasma 
ICAM-1 with a commercially available ELISA (R&D Systems, Abingdon, 
UK). The inter-assay coefficient of variation was <7%. 
• Interleukin-6 (IL-6) (pg/ml): we assayed serum IL-6 with a high sensitivity 
ELISA (R & D Systems, Abingdon, UK). Intra- and inter-assay coefficients of 
variation were 7.5% and 8.9%, respectively. 
• Tumour necrosis factor-alpha (TNF-α ): (pg/ml): we assayed serum TNF- α with 
a high-sensitivity ELISA (R&D Systems, Abingdon, UK). Intra-assay and 
inter assay coefficients of variation were 8.4% and 12.5%, respectively. 
• Interleukin-10 (IL-10) (pg/ml): we measured serum IL10 with an ELISA assay 
(R&D Systems, Abingdon, UK). The inter-assay coefficient of variation was 
4.5%. 
• Matrix-metalloproteinase-9 (MMP-9) (ng/ml): we measured serum MMP-9 with 
a commercially available sandwich ELISA (R&D Systems, Abingdon, UK). 
Intra-assay and inter assay coefficients variation were 4.4% and 10.4%, 
respectively. 
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• von Willebrand factor (vWF) (IU/dL): we measured serum vWF antigen with 
an ELISA using rabbit antihuman polyclonal antibodies obtained from 
DAKO (High Wycombe, UK). Intra and inter assay coefficient of variation 
were 3.3% and 4.2%, respectively. 
Clotting 
• D-dimer (ng/ml): we measured plasma levels of fibrin D-dimer with a 
commercially available ELISA from Biopool AB, Umea Sweden. The intra 
and inter assay coefficients of variation were 4.7 and 5.2%, respectively. 
• Fibrinogen (g/l): we measured fibrinogen in plasma by imunonephelometry 
(Prospec, Dade Behring Milton Keynes, UK) using the manufacturer’s 
reagents and standards. Intra- and inter-assay coefficients of variation were 
7.5 and 8.9%, respectively. 
Thrombolysis 
• Tissue plasminogen activator (tPA) (ng/mL): we measured plasma levels of 
tissue plasminogen activator (t-PA) antigen with commercially available 
ELISAs from Biopool AB, Umea Sweden. The intra and inter assay 
coefficients of variation were 6.6% and 6.5%, respectively. 
Cardiac Strain 
• N-terminal-pro-brain-natriuretic-peptide (NT pro-BNP) (pg/ml): we measured 
serum levels of NT pro-BNP using the Elecsys 2010 
electrochemiluminescence analyser (Roche Diagnostics, Burgess Hill, UK) 
calibrated using the manufacturer’s reagents. Manufacturer’s controls were 
used with limits of acceptability defined by the manufacturer. Low control 
coefficient of variation was 6.7% and high control coefficient of variation was 
4.9%.  
• Troponin T (ng/ml): we determined serum troponin T using the Elecsys 2010 
electrochemiluminescence analyser (Roche Diagnostics, Burgess Hill, UK) 
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calibrated using the manufacturer’s reagents. Manufacturer’s control was 
used with limits of acceptability defined by the manufacturer. The abnormal 
high (detectable) control coefficient of variation was 2.3%. 
Cerebral damage 
• Tau (pg/ml): we measured tau in serum with a sandwich ELISA using the 
Innotest htau antigen (Innogenetics). The coefficient of variation at 479pg/ml 
was 5.8%. 
• S100 B (pg/ml): we measured S100 B in serum. 96-well microtiter plates were 
coated with 200 μL of 0.05 M carbonate buffer containing monoclonal anti-
S100 B (Affiniti Research Products, Exeter, UK). The plates were washed 
with 0.67 M barbitone buffer containing 5 mM calcium lactate, 0.1% bovine 
serum albumin, and 0.05% Tween and then were blocked with 2% bovine 
serum albumin and washed again. Two-hundred microliters of diluted 
serum (1:1) in 0.67 M barbitone buffer containing 5 mM calcium lactate was 
added in duplicate. After incubation and washing, horseradish-peroxidase-
conjugated polyclonal anti-S100 B (Dako, Copenhagen, Denmark) was used 
as a detecting antibody. The o-phenylenediamine color reaction was stopped 
with 1 M hydrochloric acid, and the absorbances were read at 492 and 405 
nm. The antigen concentration was calculated from an internal standard 
curve ranging from 0 to 250 pg/mL. The coefficient of variation at a 
concentration of 263pg/ml was 11%. 
Other markers 
• Creatinine (μmol/): I used the measurement of serum creatinine made by the 
clinical laboratories at the Western General Hospital. An Ortho Clinical 
Diagnostics Fusion 5.1 measured creatinine with an enzymatic method on 
dry slides. The coefficient of variations at 85 and 480 μmol/L was <1.4%. 
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• Glucose (mmol/l): I used the measurement of glucose in fluoridated serum 
made by the clinical laboratories at the Western General Hospital. An Ortho 
Clinical Diagnostics Fusion 5.1 measured glucose with a glucose 
oxidase/peroxidase on dry slides. The coefficient of variation at 4.3 and 16 
mmol/L was <1.4%. 
Statistical analysis 
Univariate associations between plasma or serum concentration of blood markers 
and acute cerebrovascular disease 
I calculated the association between plasma or serum concentration of blood 
markers and the diagnosis of stroke using a series of univariate logistic regression 
analyses, with a diagnosis of acute cerebrovascular disease as the dependent 
variable, and blood marker marker level the independent variable. For each marker 
I assessed the association as a linear, continuous variable, to maintain power in the 
analysis (Altman & Royston 2006), and presented the results as the ratio of odds of 
acute cerebrovascular disease in the 75th to 25th centile of marker (i.e. (OR per unit 
increase)(75th -25th centile)) to allow comparison between marker distributions.  
Testing the assumption of a linear relationship between serum blood marker 
concentration and log odds of acute cerebrovascular disease 
A logistic regression model assumes a linear association between a continuous 
variable and the log odds of the outcome of interest. However, the relationship may 
not be log-linear, and a transformation of the variable may give a better model fit.. 
There a number of ways of modeling a non-linear relationship. The easiest is with a 
simple transformation of the variable of interest (for example Ln(X), X2, etc.). 
However, simple transformations are limited in the shapes they can take. More 
complex transformations may model relationships better (though with an increased 
risk of overfitting); for example fractional polynomials and restricted cubic splines 
(Steyerberg 2009a). Both complex transformations have their advocates, and it is not 
yet clear which should be preferred for modeling non-linear relationships. As 
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restricted cubic splines can be easily implemented in Stata 10 using the mkspline 
command, I investigated linearity using this transformation, at the default setting of 
three knots (at quantiles 10, 50 and 90%), recommended for smaller datasets (Harrell 
F.E 2001). 
I compared linear and nested restricted cubic splines by calculating the likelihood 
ratio statistic (Equation 6) and its associated probability (from a 2χ distribution with 
4 degrees of freedom) with the lrtest command, which was possible as a linear 
model is nested within the restricted cubic spline model (Dupont 2009). 
Equation 6 Likelihood ratio statistic, 1 degree of freedom. L=likelihood 
( )10
2 2 LL −−=χ  
I investigated the effect of outliers by repeating this process, truncating the 
distribution of the plasma or serum levels of markers at their 5th and 95th centiles. 
Where there was evidence of significant non-linearity I investigated this further by 
plotting the relationships. 
Adjusting for age, neurological impairment, cardiac disease and infection 
The most important confounders of the relationship between plasma or serum 
concentration of blood markers and a diagnosis of stroke are degree of neurological 
impairment and age. I measured the association between plasma or serum blood 
marker levels with NIHSS, age (in years), delay to blood draw (in hours) and 
systolic blood pressure (mmHg) with Spearman’s rank correlation coefficients (and 
associated P-values) using the spearman command in Stata. I did not use a 
parametric test as I expected markers to have a skewed distribution. 
I used the NIHS score as a measure of neurological impairment for this analysis, as 
it had an approximately linear association with the log odds of a diagnosis of acute 
cerebrovascular disease. For the association with cardiac markers (NT pro-BNP and 
troponin T) I made additional adjustments for AF, cardiac failure and previous 
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cardiac vascular disease, and for the association with inflammatory markers I made 
adjustment for ‘symptoms due to infection’. I performed this analysis with 
multivariate logistic regression using the logistic command in Stata, and present 
the odds ratios, their associated 95% confidence intervals and P-values derived from 
Wald tests. 
Validating a published blood marker model 
I assessed the performance of a published predictive model for the diagnosis of 
stroke (Laskowitz et al. 2009d) constructed with blood marker variables. As the 
model was developed to predict an outcome of stroke rather than acute 
cerebrovascular disease, I validated the model with the outcome of ‘all stroke’ as 
well as ‘acute cerebrovascular disease’. The authors constructed a simple logistic 
regression model with the natural logarithm of four markers: S100 B, D-dimer, 
MMP-9 and BNP. I applied the coefficients from the published model to my cohort 
(Equation 7), substituting NT pro-BNP for BNP (the relationship in plasma is 1:1). 
Equation 7 Logit (Stroke) from Laskowitz et al 2009 
Logit (Stroke)=  
-3.51 
+ [0.32 x Ln(BNP)] 
+ [0.13 x Ln(D-dimer)] 
+ [0.3 x Ln(MMP-9)]  
+ [0.05 x Ln(S100 B)] 
I calculated: (a) the predicted probability of stroke, (b) the area under a receiver 
operator curve (AUROC) to predict the diagnosis of both stroke and acute 
cerebrovascular disease and stroke in my cohort (roctab), and (c) applied the 
thresholds reported in the paper for the diagnosis of stroke (Pr<0.39 and Pr>0.64) to 
this cohort to calculate sensitivity and specificity. 
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Generation of predictive models 
This section of the analysis concentrates upon the generation and validation of 
predictive biomarker models for the diagnosis of stroke. I constructed statistical 
models using a number of methods, and compared their performance to one 
another. The methods of model development ranged from those with a high degree 
of flexibility, which potentially had a better fit to the data but at a greater risk of 
poor external validity, to those where the choice of variables was limited by external 
information (from systematic review), where external validity might be higher. 
I generated multivariable logistic regression models with only blood marker 
variables to predict a diagnosis of acute cerebrovascular disease.  
Rather than generating a model with all 19 potential candidate markers, I attempted 
to reduce the number of markers in the final model, because: (a) as a rule of thumb 
there should be more than 10 outcome events per variable, the lower bound for 
reasonable selection of a pre-specified variables; this number may need to be even 
higher (up to 50) when variables are not pre-specified (Harrell F.E, Lee K.L., & Mark 
D.B 1996, Steyerberg 2009b), (b) because a model with all 19 variables would very 
likely over-fit the data and replication in a validation dataset would be unlikely to 
be successful (and so be of little practical use), and (c) a model with all variables 
would be difficult to implement in clinical practice, because of the expense and 
technical difficulty of measuring a large number of proteins simultaneously.  
To restrict the number of variables, I first investigated the number of missing values 
and their distribution for each of the blood markers. Stata deletes any cases missing 
a variable in logistic regression, leading to a complete case analysis. Complete case 
analysis may not only lead to substantial loss of power, and but also selection bias, 
if the number of cases falls substantially in multivariate analysis. I excluded any 
marker with substantial missing data. 
Second, I considered collinearity. I calculated correlation coefficients between each 
marker pair using the Stata command spearman,matrix, keeping only one from a 
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pair when the Spearman’s rank correlation coefficient was >0.8 (Katz 2008b, 
Steyerberg 2009b). 
Third, I constructed a model with those markers that, from previous systematic 
review, were associated with a diagnosis of stroke (Whiteley, Tseng, & Sandercock 
2008b).  
Fourth, I considered only those markers that had associations with acute 
cerebrovascular disease at P<0.1 in univariate analysis, and only those with P>0.1 in 
subsequent multivariate models. Despite the popularity and simplicity of this 
approach, it risked over-fitting data. 
Fifth, I investigated both forward and backward automated variable selection. 
Forward selection procedures select variables and enter them in order of strength of 
association with acute cerebrovascular disease  into the model, continuing to enter 
variables until the fit of the model is no longer improved, at a threshold of 
significance (here, P=0.10). Backward selection procedures begin with a full model, 
and remove the variable with the weakest association with outcome, at a threshold 
of significance (here, P=0.05). I used the Stata command stepwise to implement 
this procedure. However, stepwise selection procedures have a number of 
disadvantages: the selection of variables may be unstable; they may artificially 
inflate estimates of coefficients and P-values, and may give worse predictions than a 
full model (Steyerberg 2009a).  
Sixth, I attempted a more modern approach. Proponents of boosted logistic 
regression (Schonlau 2005) with shrinkage and bagging claim that it generates 
models with improved predictive accuracy, and better generalisability. I 
implemented the boost command in Stata with the following settings: a randomly 
chosen half of the dataset for training and half for validation; all possible 3-way 
interactions between markers; shrinkage set at 0.01, and half the dataset used for 
bagging. 
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Seventh, I examined the standardised Pearson residuals and Pregibon leverage 
statistic from each logistic regression model, and plotted each statistic against the 
predicted probability. I retested model excluding patients who showed a high 
Pearson residual (>2 standard deviation) or undue  leverage (>2*(number of 
independent variables /sample size)) (Katz 2008a). 
Eighth, for each model I considered all two way interactions between variables 
within the model generated with the fitint command. There is a risk of chance 
findings when investigating all two way interactions, so when a two-way 
interaction had P<0.05 in an individual model, I attempted to replicate that 
interaction by creating a logistic regression model with just two variables in the 
whole dataset. Where these remain significant (P<0.01) I report them.  
I then compared the performance of a model developed from variables from 
systematic review, a model developed by univariate selection and a model 
developed by stepwise variable selection. I considered (a) model discrimination 
using the AUROC and its 95% confidence interval. The AUROC ranges from 0.5 to 
1, where 0.5 implies no better discriminative ability that chance and 1, perfect 
discrimination. It can be interpreted as the probability that a randomly chosen 
patient with acute cerebrovascular disease  has a higher predicted probability of 
acute cerebrovascular disease  than a randomly chosen patients without acute 
cerebrovascular disease, and (b) as a measure of calibration, I report the Hosmer-
Lemeshow statistic, which compares the predicted to the observed probability of a 
diagnosis of acute cerebrovascular disease, by dividing the sample into deciles on 
the basis of predicted probability and performing a χ2  test (Stata command estat 
gof). A non-significant result supports a well calibrated model. I also report the 
Cragg-Uhler (Nagelkerke) pseudo R2, which is a measure of explained variance in 
risk (in a similar, though non-equivalent, way to R2 in linear regression models) 
(Stata command fitstat). Whilst pseudo R2 measures should not be used to 
compare models using different estimating equations, they may be useful in 
comparing models using the same data and the same equations (in this case the 
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logistic regression model). Of the number of measures of pseudo R2, Cragg-Uhler’s 
has been  recommended for assessment of prognostic models (Steyerberg 2009a). 
Markers in addition to clinical opinion 
I examined whether any single marker positively associated with a diagnosis of 
stroke, after adjustment for other markers in previous models, added useful 
diagnostic power to the clinical opinion of a member of the emergency department 
staff or the stroke fellow. As some other confounders are easily measured, for 
example age and AF, I forced these into models. I considered the markers that were 
positively, rather than negatively, associated with a diagnosis of acute 
cerebrovascular disease as I felt that ‘acute cerebrovascular disease’ was a more 
stable and less heterogeneous construct than ‘stroke mimic’. First I assessed whether 
the addition of a blood marker significantly improved the log likelihood of a model 
containing only clinical opinion and age (and in addition, for models with NT pro-
BNP, I added AF) with a likelihood ratio test. Second, I added all markers to the 
model. Thirdly, I examined for interactions with time last seen well to admission 
and abnormal brain imaging. 
I used Stata 10 for all statistical analysis. I measured 19 markers. Therefore the 
probability of finding at least one significant result at the p<0.05 level by chance in 
any table of all markers is Pr=0.6. Because of this, I considered a P<0.01 to be 
statistically significant. Even with this more stringent criterion, the probability of at 
least one ‘statistically significant’ result by chance in each table is Pr=0.17; at 
P=0.001, this probability is Pr=0.02. My interpretation of results has, therefore, been 
extremely cautious. All P values are two sided. 
Ethical considerations 
The Multi-centre Ethics Committee for Scotland A gave ethical oversight to the 
study. This committee has responsibility for studies of adults with incapacity in 
Scotland. Approval was also received from the Local research Ethics Committee. A 
grant from ReMIND supported the measurement of serum tau and S100 B.  
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Results 
The median delay to blood draw from symptom onset was 7 hours (interquartile 
range 3 to 19 hours, 5th to 95th centiles 1 to 28 hours). All markers had a positively 
skewed distribution. I have presented their median and interquartile ranges in Table 
4.1 and Table 4.2, though I have not compared statistically these measures of central 
tendency and spread to avoid repeating similar analyses in the following 
paragraphs. 
Linearity of univariate associations of plasma or serum blood marker levels and a 
diagnosis of acute cerebrovascular disease 
In this dataset non-linear, restricted cubic spline models fitted data better than linear 
models for fibrinogen, NT pro-BNP, and S100 B (Table 4.4). After truncation 
(removing the top and bottom 5% of observations), there was no evidence of any 
change in the likelihood ratio statistics between linear and non-linear models, 
indicating that extreme outliers did not explain non-linearity (Table 4.4).  
I plotted predicted against observed probability for NT pro-BNP and S100 B (Figure 
9, Figure 10, Figure 11, Figure 12) and found that a natural logarithm transformation 
of the plasma or serum marker concentration appeared to fit the data as well as a 3-
knot restricted cubic spline at default values. As the logarithmic transform has 
fewer degrees of freedom than a restricted cubic spline model, and appears to 
explain the data well, I used it in subsequent analyses. Linear models of the 
association between marker levels and probability of acute cerebrovascular disease 
underestimated the probability of acute cerebrovascular disease at lower marker 
levels. The relationship between levels of fibrinogen and probability of acute 
cerebrovascular disease was not clear (Figure 13). 
Univariate associations of untransformed blood markers with acute cerebrovascular 
disease diagnosis 
Only tissue plasminogen activator was associated positively with a diagnosis of 
acute cerebrovascular disease (OR 1.6, 75th to 25th centile) (Table 4.3). The positive 
and negative associations between acute cerebrovascular disease and 
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untransformed markers of inflammation, thrombosis, cardiac strain, cerebral 
damage, renal dysfunction or glucose could be explained by chance (P>0.01), though 
there are plausible physiological explanations for the positive association of acute 
cerebrovascular disease  with D-dimer and NT pro-BNP. 
There was no difference in the direction, magnitude or significance of these results 
when considering a diagnosis of all stroke, or ischaemic stroke, versus all other 
diagnoses (including TIA). 
Adjustment of the association between blood markers and potential confounders 
Table 4.5 summarises the relationship between blood markers, age, NIHSS, delay to 
blood draw and blood pressure. All of the markers, except ICAM-1, TNF-α, MMP-9, 
tau and creatinine were positively correlated with severity of neurological 
impairment measured by the NIHSS. All markers, except ICAM, interleukin-10, 
MMP-9, white cell count, tau and glucose, were positively correlated with age. No 
marker was correlated strongly and significantly with the delay to blood draw. 
Most markers were correlated negatively with blood pressure, though this was only 
significant for CRP, IL-6, MMP-9, D-dimer and troponin T. After adjustment, the 
association between adiponectin and mimic strengthened. No marker of any 
physiological process had a positive, strong and statistically significant association 
with a diagnosis of acute cerebrovascular disease after adjustment for neurological 
impairment and age. 
Validation of a multi-marker model for the diagnosis of stroke 
In 355 patients where there was sufficient blood marker data to validate a 
previously published model to predict stroke diagnosis (Laskowitz et al. 2009c), the 
median predicted probability of stroke from the model in patients with stroke was 
Pr=0.83 and in patients without stroke Pr=0.75 (Figure 14). The area under a receiver 
operator curve (AUROC) for discriminating acute cerebrovascular disease from 
mimics was 0.63 (0.57 to 0.69) and stroke from not stroke 0.68 (0.63 to 0.74) (Figure 
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15). This was similar to its performance in the Laskowitz cohort where 
AUROC=0.69.  
I was unable to examine the lower published threshold for the model (P<0.39), as the 
lowest predicted probability from the model in my series was Pr=0.42; this threshold 
therefore had 100% sensitivity, though 0% specificity. The upper threshold (Pr>0.64) 
had a sensitivity of 92% (95% CI: 89 to 95%) and specificity of 18% (95% CI: 13 to 
24%) in my cohort. In the published development cohort, the higher threshold had a 
sensitivity of 27% and specificity of 89%. 
The model was therefore unable reliably to classify patients into those with and 
without stroke, and therefore had poor external validity in my cohort. 
Development of a model for the diagnosis of acute cerebrovascular disease using 
only markers: can a valid model be developed that is better than an emergency 
department nurse or doctor? 
Reducing candidate predictors 
(i) Those with missing values (Table 4.8) 
Values are missing in this dataset because of errors in sample transport, and 
different volumes in each sample available for analysis. These are likely to be 
random errors, and so probably not associated with a significant selection bias. For 
example, though more values were missing for NT pro-BNP for patients with acute 
cerebrovascular disease (7%) than without (3%), there was no significant association 
between missingness of NT pro-BNP and acute cerebrovascular disease (OR=1.75, 
95% CI: 0.16 to 1.46). Therefore I did not reject any marker on the grounds of the 
amount of missing data. I performed subsequent analyses on all available data. 
(ii) Collinearity 
I constructed a Spearman correlation matrix between all 19 variables. No correlation 
coefficient was >0.8. Correlations over 0.5 were: between CRP and fibrinogen, 0.65; 
between IL-6 and D-dimer, 0.61; between IL-6 and vWF 0.55; between IL-6 and CRP 
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0.61 and; between total white cell count and MMP-9, 0.60. Therefore there was no 
justification to reject a marker on the basis of collinearity. 
(iii) Selection by previous described associations 
Of the 19 markers measured in the BBISS cohort, the following have been previously 
found to be positively associated with a diagnosis of ischaemic or haemorrhagic 
stroke or TIA: TNF-α, IL-6, S100 B, NT pro-BNP, vWF, CRP, MMP-9, vWF and D-
dimer (Whiteley, Tseng, & Sandercock 2008c). In a simple logistic regression model 
with plasma or serum concentration of each marker as a linear term, save S100 B 
and NT pro-BNP which were log transformed, only higher levels of NT pro-BNP 
were positively and significantly associated with a diagnosis of acute 
cerebrovascular disease and higher levels of CRP with a diagnosis of mimic after 
adjusting for the levels of all other markers. I could not be certain whether TNF-α, 
MMP-9, IL-6, D-dimer, Ln S100 B and vWF were associated more with a diagnosis 
of acute cerebrovascular disease or mimic in this model.  
(iv) Selection by strength of univariate association 
I considered markers with associations with a P<0.1 in univariate analysis: IL-10, 
vWF, D-dimer, tPA and NT pro-BNP (as its log transform) and S100 B (as its log 
transform). After excluding non-significant variables (P >0.1) in the resulting model 
(D-dimer and vWF), I arrived at the model in Table 4.7. After adjustment for other 
markers, associations between each marker and acute cerebrovascular disease 
remained the same or differed very slightly from those found in unadjusted 
analysis. 
(v) Stepwise selection 
I constructed models using both forward and backwards selection to examine the 
stability of variable selection (Table 4.7). Both forward and backwards selection 
procedures gave the same model. Higher levels of the adiponectin, TNF-α, CRP, IL-
10 and the proportion of neutrophils in the total white cell count predicted mimic 
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rather than ACvD. Higher levels of tPA, Ln NT pro-BNP and Ln S100 B predicted 
acute cerebrovascular disease. After adjustment each association with ACvD 
strengthened, in comparison to unadjusted univariate associations. 
(vi) Boosted logistic regression 
Whilst a boosted model explained variance very well in the training dataset (n=166, 
R2=0.97), it had very little explanatory power in the test dataset (n=166, R2=0.07). The 
following variables explained over 50% of the log likelihood; tPA (19.6%), Ln NT 
pro-BNP (15.6%), fibrinogen (11.2%), IL-10 (8.3%) in the development model. 
Because of its poor external validity even in this dataset, I took analysis of this 
modeling strategy no further. 
(vii) Comparing model performance 
Each model was well calibrated in this dataset (Hosmer Lemeshow χ2 P>0.15). The 
AUROC and Cragg-Uhler R2 for variables derived from my systematic review and 
from univariate selection from the data were similar. Unsurprisingly, a model 
derived from stepwise selection (which was very likely overfitted) had a higher 
AUROC (0.77) and higher Cragg-Uhler R2. 
Note: a model created with only those variables from the Biosite model (Ln NT pro-
BNP, Ln MMP-9, Ln D-dimer and LnS100 B), where the coefficients were allowed to 
vary had an AUROC of 0.67 (95% CI:0.61 to 0.73), Hosmer Lemeshow χ2  357 P=0.38 
and R2 of 0.10.  
 (vii) Residuals and patients with undue leverage 
Model developed with variables from my systematic review: After excluding 71 patients 
with a Pearson residual >2, or a leverage > 0.04, Ln NT pro-BNP was the only 
significant variable (P<0.001) left in the model, though the point estimate of the OR 
for each marker  strengthened. 
Model developed with variables from strength of univariate association: After excluding 30 
patients with a Pearson residual >2, or a leverage > 0.04, each variable remained 
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statistically significant, and the point estimate of the OR for each marker  
strengthened. 
Model developed by stepwise selection: After excluding 81 patients with a Pearson 
residual >2, or a leverage > 0.04, only CRP, Ln NT pro-BNP and tPA remained 
significantly associated with a diagnosis of acute cerebrovascular disease. 
(viii) Interaction 
I fitted all two-way interactions in each model. Because of the number of possible 
interactions in each model, I investigated each significant interaction in the whole 
dataset. Of 12 two-way interactions with P<0.05 in individual models, 3 remained 
significant when tested in the whole dataset: creatinine and tPA (P=0.01), TNF-α and 
IL-10 (P=0.0001) and vWF and D-dimer (P=0.0058). These two-way interactions were 
not pre-specified, subject to non-independence error, and should therefore be 
interpreted with caution. I have not added these interactions to the models.  
(ix) Missing data 
Replacement of missing data for Ln NT pro-BNP with values for the highest quartile 
of Ln NT pro-BNP (7.22) when the diagnosis was acute cerebrovascular disease and 
the lowest quartile (4.72) when the diagnosis was mimic made only a very small 
difference to the performance of the models or the magnitude of associations. 
Does addition of any single blood marker improve upon clinical opinion? 
NT pro-BNP, tPA and Ln S100 B were associated positively and significantly with a 
diagnosis of acute cerebrovascular disease in more than one model. Ln NT pro-BNP 
did not improve the fit of a model containing a member of the emergency 
department staff’s clinical opinion (definite or probable ACvD), age and AF (n=366, 
LR χ2=2.2. P=0.14), nor did Ln S100 B (n=372, LR χ2=3.4. P=0.06), nor did tPA (n=375, 
LR χ2=2.5. P=0.11). Addition of all of these markers to a model containing the clinical 
opinion of an emergency department clinician, age and AF did not significantly 
improve the basic model (n=340, LR χ2=7.1. P=0.07).  
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I examined whether there was evidence of interaction in these models with either 
‘time from when the patient was last seen well’, or whether brain imaging was 
normal. Multiplicative interaction terms with blood levels of blood marker and 
delay to admission or relevant imaging findings did not improve the log likelihood 
of models containing Ln NT pro-BNP, Ln S100 B or tPA (all P>0.15).  
Discussion 
Summary of main findings 
In unadjusted analyses, only tPA and NT pro-BNP (as its natural logarithm 
transform) were associated positively and significantly with a diagnosis of acute 
cerebrovascular disease. After adjustment for severity of neurological impairment 
and age, neither marker was associated with a diagnosis of acute cerebrovascular 
disease. Two markers, IL-10 ( an anti-inflammatory cytokine) and adiponectin (a 
hormone with anti-inflammatory and insulin sensitising effects) were associated 
significantly with a diagnosis of a mimic of acute cerebrovascular disease, an 
association that strengthened after taking account of the severity of neurological 
impairment and age. 
A logistic regression model for the diagnosis of acute cerebrovascular disease with 9 
markers, developed using a data-dependent stepwise technique, had a better 
sensitivity and specificity than an emergency department clinician’s diagnosis of 
probable or definite stroke. However, simpler models (4 variables) and models with 
markers pre-specified by systematic review (8 markers) did not. Neither BNP, nor 
tPA nor S100 B (each associated positively with a diagnosis of acute cerebrovascular 
disease, after adjustment for other markers), improved the model fit of logistic 
regression models which included age, AF and an emergency department clinician’s 
diagnosis of probable or definite acute cerebrovascular disease. It is unlikely any of 
these blood markers would help to improve the accuracy of an emergency 
department clinician’s diagnosis of acute cerebrovascular disease, either measured 
individually or in combination. 
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Study limitations 
Missing data: I did not have a complete data set of all 19 markers for every patient. 
This reduced the power of multivariate analyses, and meant some samples taken 
>24 hours after symptom onset were used in the analysis. The cause of missing data 
was either a problem with transfer of samples to other laboratories for analysis or 
insufficient sample volume. Although of some concern, the analysis do not suggest 
that missing data have led to a material bias in any of the main analysis. 
Measurement variability: The coefficient of variation for the measurement of most 
markers was low, particularly for the measurements made in a clinical laboratory. 
Although the coefficient of variation was small, it will have led to random errors in 
marker measurement and a tendency of the OR to approach 1, though, only to a 
small degree. 
Markers do not track one patho-physiological process: The concept ‘biomarker’ 
implies that the levels of a particular blood marker are strongly correlated with a 
particular patho-physiological process. However, most hormones, cytokines, 
damage markers and other proteins have associations with many biological 
processes; for example the ‘inflammatory’ biomarker, IL-6, not only has effects on 
white cells and other inflammatory cytokines, but also haematopoiesis, liver and 
neuronal regeneration. Which of the many functions of an individual molecule is 
important in a particular clinical situation is often unclear. One solution is to 
investigate the relationship between markers with multivariate linear regression or 
structural equation modelling. However, as the biological meaning of the 
relationships between different markers in physiology is often unclear, these 
complex models may well to lead to confusion rather than real insight. 
Misdiagnosis: A panel of experts, blinded to the results of the marker assessments, 
made the diagnoses after careful consideration of the patient’s clinical course, 
presentation and imaging findings. Despite this, it is possible that they have 
misclassified some patients; for example patients in whom the stroke mimic 
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diagnosis was of ‘functional disorder’ (usually thought to be a condition without 
any major alteration of underlying physiology) in fact had higher levels of tau and 
D-dimer than patients in whom the non-stroke diagnosis was migraine. 
Tau: Serum tau is a marker of axonal damage but it did not rise as expected in 
patients with stroke, nor did it show an association with severity of neurological 
impairment, nor an association with the delay to blood draw since the onset of 
symptoms. This is contrary to a previous, smaller report (Bitsch et al. 2002). 
Although tau is found in neuronal axons, and is believed to be a CNS specific 
protein, its levels were not higher in patients with dementia or minor head injury 
(Ingelson et al. 1999, Kavalci et al. 2007). 
Study strengths 
The study strengths deserve consideration. I recruited a large series of patients and 
made their diagnoses in a uniform way based on all available clinical and 
radiological data. I carefully considered diagnostic categories that would be 
meaningful to clinicians seeing patients very soon after the diagnosis of suspected 
stroke, and specified the main analysis comparisons prior to analysis. The pre-
analysis handling of samples was consisted and performed to a high standard. All 
markers were measured in high throughput research laboratories with extensive 
experience and CPA (UK) Ltd accreditation, or in clinical laboratories with ongoing 
auditing and inspection procedures. Bias was minimised by blinding of the marker 
measurement to clinical diagnosis, and near consecutive recruitment of patients. 
Interpretation 
The markers of inflammation, thrombosis, thrombolysis, cardiac strain, neuronal 
and glial damage measured in this cohort are very unlikely to be useful additions to 
the clinical diagnosis of stroke, either when measured individually or as a panel. As 
most marker levels were strongly correlated with clinical features such as age or 
neurological impairment, which were also associated strongly with a diagnosis of 
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acute cerebrovascular diseases, they are unlikely to be helpful in addition to a 
clinical diagnosis. 
A major challenge in the diagnosis of stroke is both the variety of conditions that 
mimic stroke, and the heterogeneity of stroke itself. It is very difficult to imagine a 
pathophysiological process that is unique to stroke or one of its subtypes and not 
found in a stroke mimic. This is quite unlike the situation for myocardial infarction, 
where there are very few conditions, other than cardiac ischaemia, that cause severe 
acute chest pain and lead to a rise in markers of myocardial necrosis. 
Generalisability 
The results of this study are applicable to situations where the differential diagnosis 
of suspected stroke is similar to this study, and the severity of neurological 
impairment encountered is broad. Where patients are more severely affected, or 
where the range of mimics of acute cerebrovascular disease is narrower, the 
diagnostic performance of blood markers may be better; however the performance 
of clinical assessment is also likely to improve, perhaps by a similar amount. 
Implications for research 
• There are positive associations between markers of thrombolysis and of 
cardiac strain with a diagnosis of acute cerebrovascular disease. 
• Marker levels add very little to clinical features for the diagnosis of acute 
cerebrovascular disease. 
Implications for practice 
• I cannot recommend any marker of inflammation, thrombosis, thrombolysis, 
cardiac strain, neuronal or glial damage measured in this study for the 
diagnosis of acute cerebrovascular disease. 
• I cannot recommend a combination of markers (including one previously 
marketed as the ‘Stroke Triage Panel’) for the diagnosis of acute 
cerebrovascular disease. 
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Table 4.1 Baseline blood marker levels (median, IQR) by diagnostic category 
    ACvD (all)   Most frequent mimics 
Blood marker All      ACvD (all) IS  ICH  TIA Mimic (all) Seizure Sepsis Functional Migraine 
 N=405 N=285 N=230 N=15 N=40 N=120 N=14 N=13 N=12 N=17 
Markers of inflammation           
Adiponectin (µg/ml) 11.65 (11.4) 11.45 (11.2) 11.38 (11.5) 13.95 (11.17) 11.74 (9.73) 11.71 (11.80) 19.27 (15.8) 11.65 (7.30) 8.54 (9.67) 5.61 (6.34) 
CRP (mg/l) 4.02 (7.4) 4.08 (6.68) 4.69 (7.24) 2.22 (11.18) 2.40 (3.39) 3.95 (13.98) 6.17 (12.54) 12.22(27.93) 3.89 (3.99) 2.15 (4.04) 
ICAM (ng/ml) 163 (73) 165 (83) 165 (88) 184 (66) 157 (68) 159 (77) 179 (55) 142 (76) 165 (111) 119.5 (68.5) 
Interleukin-6 (pg/ml) 4.32 (6.71) 4.71 (6.75) 4.83 (6.85) 9.75 (4.42) 2.88 (3.65) 3.74 (7.19) 4.94 (5.10) 8.26 (5.01) 2.73 (1.76) 1.39 (1.2) 
TNF-α (pg/ml) 1.36 (0.53) 1.39 (0.53) 1.39 (0.55) 1.31 (0.42) 1.40 (0.53) 1.32 (0.57) 1.36 (0.81) 1.59 (0.83) 1.28 (0.59) 1.23 (0.33) 
Interleukin-10 (pg/ml) 4.5 (4.4) 4.4 (3.4) 4.4 (3.3) 5.2 (2.2) 4.1 (4.5) 4.6 (6.1) 6.35 (5.3) 10.85 (22.1) 3.65 (4.8) 4.3 (3.55) 
MMP-9 (ng/ml) 916 (811) 900 (807) 854 (781) 1135 (1145) 909 (838) 985 (797) 1114 (815) 1666 (1435) 758 (705) 731.5 (709) 
vWF (IU/dl) 156 (101) 161 (94) 162 (91) 166 (139) 133 (115) 148 (110) 173.5 (88) 229 (140) 102.5 (83) 93 (28) 
White cell count (x10
9
 cell/l) 8.4 (4) 8.7 (3.9) 8.7 (3.9) 9.8 (4.1) 7.4 (4.1) 8.1 (4.1) 6.6 (4.8) 9.6 (7.4) 7.9 (1.25) 7.4(2.9) 
Neutrophil / WCC (mean, SD) 0.72 (0.12) 0.71 (0.17) 0.71 (0.11) 0.86 (0.17) 0.66 (0.21) 0.72 (0.19) 0.71 (0.20) 0.80 (0.11) 0.63 (0.11) 0.64 (0.11) 
Markers of thrombosis           
D-dimer (ng/ml) 198 (324) 229 (355) 251 (381) 161 (416) 148 (168) 144 (249) 270 (256) 321 (414) 134 (257) 61 (85.5) 
Fibrinogen (g/l) 4.78 (1.7) 4.82 (1.62) 4.89 (1.68) 4.95 (1.47) 4.45 (1.2) 4.42 (1.77) 3.86 (1.67) 5.18 (3.06) 4.02 (0.78) 4.28 (0.98) 
Markers of thrombolysis           
tPA (ng/ml) 10.48 (7.0) 11.26 (6.4) 11.29 (3.5) 12.38 (10.1) 10.0 (3.5) 8.7 (6.0) 10.1 (4.2) 10.5 (10.5) 10.0 (9.5) 8.0 (4.5) 
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Table 4.1 continued    ACvD (all)   Most frequent mimics 
Blood marker All     ACvD (all) IS  ICH  TIA Mimic (all) Seizure Sepsis Functional Migraine 
 N=405 N=285 N=230 N=15 N=40 N=120 N=14 N=13 N=12 N=17 
Markers of cardiac strain           
NT pro-BNP (pg/ml) 381 (1252) 515.5 (1635) 701 (1824) 499 (990) 128 (310) 194 (598) 799 (1059) 621.5 (1045) 86 (84) 49 (72) 
Troponin-T>0.01 (n,%)* 52 (14) 39 (15.4) 33 (16.2) 3 (33) 2 (5.3) 13 (11.3) 3 (21.4) 5 (41.7) 0 0 
Markers of cerebral damage           
Tau (pg/ml) 21 (39) 21 (35) 21 (13) 13 (17) 24 (78) 22 (47) 22.5 (44) 15 (83) 50 (314) 18.5 (18) 
S100 B (pg/ml) 60 (59) 63 (72) 59 (72) 109 (119) 63 (56) 55 (43) 55 (73) 77 (35) 50 (69.5) 64 (51) 
Other physiological markers           
Creatinine (µmol/) 83 (36) 84 (36) 86 (36) 66.5 (24) 82 (37) 78 (33) 79 (35) 94 (8) 75 (14) 70 (13) 
Glucose (mmol/l) 5.8 (1.7) 5.8 (1.7) 5.8 (1.6) 6 (5.1) 5.4 (1.6) 5.6 (1.6) 6.1 (1.9) 7.6 (2.8) 5.2 (0.9) 5.1 (1.0) 
* as a proportion of samples with available troponin results. ACvD: acute cerebrovascular disease (probable or definite cerebral ischaemia or intracerebral haemorrhage 
responsible for symptoms at time of clinical assessment) IS: ischaemic stroke; TIA: transient ischaemic attack; ICH: intracerebral haemorrhage. Data for the 2 sub-arachnoid 
haemorrhage patients is included in ICH; Mimic: definitely not, or only possibly responsible for symptoms at time of clinical assessment; data are shown for a subset of the 
most frequent mimics of ACvD
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Table 4.2 Quarters and medians of the distributions of blood markers of inflammation, thrombosis, 
cardiac strain and neuronal and glial damage 
Marker Lower quarter 50
th
 centile (Median) Upper quarter 
Inflammation    
Adiponectin (µg/ml) 1.5 to 6.8 11.6 18.2.5 to 51.2 
CRP (mg/l) 0.163 to 1.79 4.02 9.2 to 289 
ICAM (ng/ml) 72 to 129 163 208 to 445 
Interleukin-6 (pg/ml) 0.12 to 2.04 4.32 8.76 to 15.13 
TNF-α (pg/ml) 0.56 to 1.18 1.36 1.72 to 14.55 
Interleukin-10 (pg/ml) 0.9 to 3.3 4.5 7.7 to 403.5 
MMP-9 (ng/ml) 69 to 580 916 1391 to 3941 
vWF (IU/dl) 27 to 116 156 217 to 479 
White cells (x10
9
 cell/l) 2 to 6.6 8.4 10.6 to 21.6 
Neutrophil / WCC  0.25 to 0.62 0.71 0.80 to 0.97 
Thrombosis    
D-dimer (ng/ml) 11 to 97 198 421 to 2800 
Fibrinogen (g/l) 2.5 to 4.08 4.78 5.78 to 9.95 
Thrombolysis    
tPA (ng/ml) 1.11 to 7.48 10.48 14.49 to 57.4 
Cardiac strain    
BNP (pg/ml) 5 to 112 381 1364 to 28690 
Troponin T (ng/ml)  0.1 to 0.01 0.01 0.01 to 0.699 
Cerebral damage    
Tau (pg/ml) 0 to 12 21 51 to 3000 
S100 B (pg/ml) 0 to 38 60 97 to 2744 
Other markers    
Creatinine (μmol/l) 33 to 67 83 103 to 472 
Glucose (mmol/l) 1.5 to 5.2 5.8 6.9 to 19.9 
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Table 4.3 Univariate associations between marker levels and a diagnosis of acute cerebrovascular 
disease.  




 centile (95% CI) P- value 
Inflammation   
Adiponectin (µg/ml) 0.89 (0.67 to 1.19) 0.447 
CRP (mg/l) 0.97 (0.92 to 1.02) 0.225 
ICAM (ng/ml) 1.15 (0.87 to 1.52) 0.326 
Interleukin-6 (pg/ml) 1.26 (0.88 to 1.82) 0.204 
TNF-α (pg/ml) 0.92 (0.81 to 1.04) 0.172 
Interleukin-10 (pg/ml) 0.97 (0.94 to 0.99) 0.018 
MMP-9 (ng/ml) 0.86 (0.68 to 1.10) 0.234 
vWF (IU/dl) 1.36 (0.96 to 1.93) 0.088 
White cells (x10
9
 cell/l) 1.03 (0.78 to 1.35) 0.828 
Neutrophil / WCC  0.94 (0.68 to 1.29) 0.688 
Thrombosis   
D-dimer (ng/ml) 1.20 (1.02 to 1.42) 0.032 
Fibrinogen (g/l) 1.13 (0.87 to 1.46) 0.374 
Thrombolysis   
tPA (ng/ml) 1.63 (1.20 to 2.21) 0.002 
Cardiac strain   
NT pro-BNP (pg/ml) 1.14 (1.00 to 1.30) 0.045 
NT pro-BNP (Ln Unit) 2.15 (1.52 to 3.04) <0.001 
Troponin T (ng/ml) 1.01 (0.99 to 1.03) 0.492 
Cerebral damage   
Tau (pg/ml) 0.99 (0.97 to 1.01) 0.385 
S100 B (pg/ml) 1.00 (0.97 to 1.03) 0.957 
S100 B (Ln Unit) 1.24 (1.03 to 1.51) 0.027 
Other markers   
Creatinine (μmol/) 1.00 (0.82 to 1.22) 0.973 
Glucose (mmol/l) 1.06 (0.90 to 1.25) 0.504 
The OR is the ratio of odds of acute cerebrovascular disease in the 75th to the 25th centile of plasma or serum marker 
levels assuming a linear relationship between marker level. OR>1 indicates increasing odds of a diagnosis of ACvD 
with increasing marker levels. P-values are derived from Wald tests and determine if the reported OR is 
significantly different from 1.
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Table 4.4 Likelihood ratio test for nested linear versus restricted cubic spline models 
for the prediction of an ACvD diagnosis.  
 Likelihood ratio test, Ho: L linear=L nonlinear 









Inflammation     
Adiponectin  1.16 0.76 1.79 0.62 
CRP 4.28 0.23 4.76 0.19 
ICAM  5.33 0.15 6.27 0.10 
TNF-α 6.21 0.10 0.70 0.87 
Interleukin-6  6.52 0.09 6.48 0.09 
Interleukin-10 4.66 0.20 6.07 0.11 
MMP-9  0.31 0.96 0.03 1.00 
vWF  5.58 0.13 5.13 0.16 
White cells 6.76 0.08 7.52 0.06 
Thrombosis     
D-dimer  6.3 0.10 6.35 0.10 
Fibrinogen 18.1 <0.001 15.78 0.001 
Thrombolysis     
tPA 4.99 0.17 5.73 0.12 
Cardiac strain     
BNP 
 
12.5 0.002 18.4 <0.001 
Troponin T* - - - - 
Cerebral damage     
Tau  0.87 0.26 2.92 0.40 
S100 B  14.98 0.002 8.03 0.04 
Other markers     
Creatinine  5.78 0.12 All within a clinically feasible range 
Glucose 6.08 0.11 All within a clinically feasible range 
Higher χ2 indicate non-linear models fit data better (degrees of freedom =3). Truncation investigates 
the effects of outliers on linear relationships. *Distribution too skewed to allow this analysis  
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Table 4.5 Association of blood markers with potential confounders.  
 Spearman’s rank correlation coefficient, r (P- value) 




Inflammation     
Adiponectin  0.23 (<0.001) 0.32 (<0.001) 0.10 (0.12) 0.03 (0.56) 
CRP  0.26 (<0.001) 0.13 (0.01) 0.06 (0.21) -0.13 (0.01) 
ICAM  0.07 (0.18) 0.03 (0.57) 0.04 (0.41) -0.03 (0.59) 
Interleukin-6  0.40 (<0.001) 0.38  (<0.001) -0.04 (0.48) -0.19  (<0.001) 
TNF-α  0.08 (0.11) 0.20 (<0.001)) 0.05 (0.71) 0.01 (0.92) 
Interleukin-10  0.16(<0.001) 0.12 (0.02) 0.01 (0.90) -0.04 (0.40) 
MMP-9  0.06 (0.24) 0.01 (0.78) 0.06 (0.23) -0.14 (0.006) 
vWF  0.25 (<0.001) 0.33 (<0.001) -0.01 (0.82) -0.11 (0.03) 
White cells  0.22 (<0.001) 0.06 (0.24) 0.11 (0.03) -0.11 (0.02) 
Neutrophil / WCC  0.19 (<0.001) 0.22 (<0.001) 0.12 (0.02) -0.01 (0.85) 
Thrombosis     
D-dimer  0.40 (<0.001) 0.38 (<0.001) -0.04 (0.38) -0.16 (<0.001) 
Fibrinogen  0.22 (<0.001) 0.22 (<0.001) 0.08 (0.10) -0.10 (0.05) 
Thrombolysis     
tPA 0.26 (<0.001) 0.17 (<0.001) -0.03 (0.43) -0.01 (0.71) 
Cardiac strain     
NT pro-BNP 0.44 (<0.001) 0.57 (<0.001) 0.01 (0.77) 0.03 (0.52) 
Troponin T 0.25 (<0.001) 0.23 (<0.001) 0.01 (0.81) -0.13 (0.01) 
Cerebral damage     
Tau 0.05 (0.28) -0.04 (0.50) -0.03 (0.58) -0.06 (0.23) 
S100 B  0.16 (0.002) 0.09 (0.07) -0.05 (0.37) -0.07 (0.19) 
Other markers     
Creatinine  0.06 (0.20) 0.33 (<0.001) -0.07 (0.19) -0.04 (0.40) 
Glucose  0.18 (<0.001) 0.06 (0.23) -0.12 (0.02) 0.09 (0.09) 
Spearman correlation coefficients between plasma or serum marker levels and neurological 
impairment (NIHSS), age, time from last seen well to blood draw and systolic blood pressure. Positive 
correlation coefficients indicate higher marker levels are associated with higher confounder levels; 
negative correlation coefficients that higher levels are associated with lower levels of the confounder. 
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Table 4.6 Adjusted associations between marker levels and acute cerebrovascular disease  
Marker (units) OR, Adjusted for NIHSS & 
age (95% CI) 
P- value OR, with further 
adjustment (95% CI) 
P- 
value 
Inflammation     
Adiponectin (µg/ml) 0.57 (0.41 to 0.81) 0.001 0.54 (0.38 to 0.75) <0.001 
CRP (mg/l) 0.92 (0.86 to 0.98) 0.008 0.93 (0.87 to 0.96) 0.04 
ICAM (ng/ml) 1.11 (0.83 to 1.48) 0.48 1.08 (0.81 to 1.44) 0.60 
Interleukin-6 (pg/ml) 0.65 (0.42 to 0.99) 0.05 0.73 (0.47 to 1.14) 0.17 
TNF-α (pg/ml) 0.77 (0.61 to 0.98) 0.04 0.80 (0.63 to 1.03) 0.08 
Interleukin-10 (pg/ml) 0.94 (0.90 to 0.98) 0.004 0.94 (0.90 to 0.99) 0.01 
MMP-9 (ng/ml) 0.80 (0.62 to 1.04) 0.09 0.84 (0.65 to 1.09) 0.18 
vWF (IU/dl) 0.88 (0.61 to 1.26) 0.48 0.97 (0.67 to 1.40) 0.86 
White cells (x10
9
 cell/l) 0.83 (0.61 to 1.12) 0.23 0.89 (0.65 to 1.22) 0.48 
Neutrophil / WCC  0.69 (0.48 to 0.98) 0.04 0.74 (0.52 to 1.08) 0.11 
Thrombosis     
D-dimer (ng/ml) 1.02 (0.85 to 1.19) 0.98   
Fibrinogen (g/l) 0.91 (0.69 to 1.19) 0.49   
Thrombolysis     
tPA (ng/ml) 1.29 (0.94 to 1.76) 0.11   
Cardiac strain     
Ln BNP (loge unit) 1.26 (0.81 to 1.95) 0.31 1.23 (0.76 to 1.97) 0.40 
Troponin T (ng/ml) n/a n/a   
Cerebral damage     
Tau (pg/ml) 0.99 (0.96 to 1.01) 0.31   
Ln S100 B (loge unit) 1.17 (0.95 to 1.43) 0.14   
Other markers     
Creatinine (μmol/) 0.90 (0.73 to 1.11) 0.31   
Glucose (mmol/l) 1.00 (0.84 to 1.18) 1.00   
Adjustment made for NIHSS and age. Additional adjustment made for prior infection for markers of 
inflammation, and cardiac failure, AF and prior cardiac vascular disease for cardiac strain markers. 
The OR is the ratio of odds of acute cerebrovascular disease in the 75th to the 25th centile of plasma or 
serum marker. OR>1 indicates that higher levels are associated with a diagnosis of ACvD rather than 
mimic. P-values are derived from Wald tests and determine if the reported OR is significantly different 
from 1. 
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Table 4.7 Multivariate models using simple logistic regression models to predict a diagnosis of acute cerebrovascular disease, and measures of model 
performance.  
 Stepwise selection* (n=344)  Univariate selection
†
 (n= 355)  Systematic review
‡
 (n=350)  ↑ marker  associated with mimic Odds Ratio (95% CI) P  Odds Ratio (95% CI) P  Odds Ratio (95% CI) P  
Adiponectin 0.56 (0.38 to 0.83) 0.004        
Neutrophil/total WCC 0.65 (0.42 to 1.00) 0.048        
Creatinine 0.76 (0.59 to 0.97) 0.025        
TNF-α 0.78 (0.62 to 0.98) 0.035     0.86 (0.72 to 1.02) 0.086  
CRP 0.91 (0.86 to 0.98) 0.009     0.90 (0.85 to 1.00) 0.003  
Interleukin 10 0.95 (0.91 to 0.99) 0.019  0.94 (0.90 to 0.97) 0.001     
MMP-9       0.84 (0.63 to 1.11) 0.214  
IL-6       0.82 (0.63 to 1.11) 0.469  ↑ marker associated with ACvD          
Ln NT pro-BNP 4.30 (2.49 to 7.43) <0.001  1.80 (1.23 to 2.64) 0.003  2.69 (1.69 to 4.28) <0.001  
tissue Plasminogen Activator 2.14 (1.40 to 3.28) <0.001  1.83 (1.25 to 2.66) 0.002     
Ln S100 B 1.40 (1.09 to 1.79) 0.008  1.29 (1.03 to 1.62) 0.029  1.26 (1.01 to 1.58) 0.045  
D-dimer       1.09 (0.89 to 1.34) 0.379  
von Willebrand factor       1.29 (0.82 to 2.01) 0.267  
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 Stepwise selection* (n=344)  Univariate selection
†
 (n= 355)  Systematic review
‡
 (n=350)  
Measures of model performance          
AUROC§ (95% CI) 0.77 (0.72 to 0.82)   0.71 (0.65 to 0.77)   0.72 (0.67 to 0.78)   
Hosmer Lemeshow χ2║ (P) 2.3 (0.97)   8.8 (0.36)   3.7 (0.88)   
Cragg-Uhler pseudo R
2¶ 0.26   0.16   0.19   
Comparison with ED clinician**          
Specificity at sensitivity of 77% 70%   53%   50%   
Sensitivity at specificity of 58% 82%   73%   70%   
75th and 25th centiles are given in Table 4.2. Ln NT pro-BNP 75th centile=7.22, 25th centile = 4.72 ; Ln S100 B 75th centile =4.59, 25th centile=3.69. P values are derived from 
Wald tests. 
*Stepwise selection of variables by forward and backward selection of all blood markers, with a threshold of adding a marker to the model of P=0.1 and removal P=0.05 
†Univariate selection of variables adding markers associated with ACvD with a P<0.1 in univariate analysis, and removing those with P>0.05 in multivariate analysis 
‡Variables selected by systematic review of previous literature. 
§AUROC: area under receiver operator curve. A value of 1 indicate perfect discrimination and 0.5 no better discrimination than chance. 
║Hosmer Lemeshow χ2 is a measure of model calibration. Lower χ2 indicate better calibrated model 
¶Cragg-Uhler pseudo R2 is a measure of the is a measure of explained variance in risk due to the model 
** performance of models at the sensitivity and specificity of an emergency department clinician for the diagnosis of probable or definite ACvD 
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Table 4.8 Missing data 
  Missing n, (%)  
Blood markers All (n=405) ACVD (n=285) Mimic (n=120) 
Adiponectin  14 (3.5) 9 (3.2) 5 (4.2) 
CRP 18 (4.4) 10 (3.5) 8 (6.7) 
ICAM 15 (3.7) 10 (3.5) 5 (4.2) 
Interleukin-6  12 (3.0) 9 (3.2) 3 (2.5) 
TNF-α 13 (2.0) 10 (3.5) 3(2.5) 
Interleukin-10 12 (3.0) 9 (3.2) 3 (2.5) 
MMP-9 12 (3.0) 9 (3.2) 3 (2.5) 
vWF 11 (3.0) 8 (2.8) 3 (2.5) 
White cell count 2 (0.5) 2 (0.7) 0 
Neurophil count 4 (1.0) 4 (1.4) 0 
D-dimer 15 (3.7) 10 (3.5) 5 (4.2) 
Fibrinogen 16 (4.0) 9 (3.2) 7 (5.8) 
tPA 15 (3.7) 10 (3.5) 5 (4.2) 
NT pro-BNP 23 (5.7) 19 (6.6) 4 (3.3) 
Troponin T 37 (9.1) 32 (11.2) 5 (4.1) 
Tau 2 (0.5) 1 (0.4) 1 (0.8) 
S100 B  3 (0.7) 1 (0.4) 1 (0.8) 
Creatinine 4 (1.0) 4 (1.4) 0 
Glucose 15 (2.5) 11 (3.9) 4 (3.3) 
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Figure 9 Estimated probability of acute cerebrovascular diseases (ACvD) as a function of serum NT 
pro-BNP, modelled as a linear relationship, a natural logarithm transform and a 3-knot restricted cubic 
spline (RCS). 


























Figure 10 As Figure 9, concentrating on range 0 to 10,000 ng/ml 
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Figure 11  Estimated probabilities of acute cerebrovascular diseases (ACvD) as a function of serum 
S100 B, modelled as a linear relationship, a natural logarithm transform and a 3-knot restricted cubic 
spline (RCS). 


























Figure 12 As Figure 11, concentrating on range 0 to 500ng/ml 
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Figure 13 Estimated probabilities of acute cerebrovascular diseases (ACvD) as a function of 
plasma fibrinogen, modelled as a linear relationship and a 3-knot restricted cubic spline.  
The 95% exact binomial confidence intervals for the observed probability of ACvD are 
shown 
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Figure 14 Predicted probability of stroke from published blood marker model (Laskowitz et 
al. 2009b) in patients with and without a final diagnosis of stroke.  
Plots made using kernel density function (Epanechnikov). 
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Figure 15 Receiver operator curve for a blood marker model (Laskowitz et al. 2009a) to 
predict the diagnosis of acute cerebrovascular disease 
Area under the curve=0.63, 95% CI: 0.57 to 0.69 
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Chapter 5.  Blood markers for the prognosis of ischaemic stroke: a 
systematic review  
Introduction  
The prediction of outcome after ischaemic stroke is important for clinicians, patients 
and researchers. The performance of models based on clinical variables might be 
improved by blood markers of any of the pathological processes in acute ischaemic 
stroke, such as inflammation, haemostasis, neuronal or glial injury and cardiac 
dysfunction. Markers of inflammation and haemostasis have been associated with 
ischaemic stroke and heart attack in prospective cohorts of stroke free people, and it 
is plausible that markers of neuronal, glial and cardiac damage could aid prediction 
of poor outcome after stroke.   To examine the relationship between blood markers 
of ischaemic stroke and outcome after acute ischaemic stroke, I undertook a 
systematic review of the available evidence. 
Methods 
Study identification 
I searched Medline and EMBASE from 1966 to January 2007 for studies in patients 
with acute ischaemic stroke which examined venous blood markers and assessed 
clinical outcome. The search strategy included 13 terms for ischaemic stroke, 4 for 
generic biomarkers and 780 specific biomarker terms. Prognostic studies were 
identified using high sensitivity search terms (Altman 2001a), together with 
common outcome measurements from stroke research (Rankin, NIHSS, Glasgow 
outcome scale). The electronic search strategy is available as an appendix. 
Study inclusion:  
Studies were eligible for inclusion if they: (a) reported results for patients with acute 
ischaemic stroke (not transient ischaemic attack), (b) assayed a venous blood marker 
not routinely measured in ischaemic stroke patients,  (c) drew blood within the first 
week after stroke onset,  (d) measured outcome using death, disability or handicap 
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scales at a week or later after stroke onset. There was no study quality threshold or 
language restriction for inclusion. I considered only papers published in full since 
our resources were limited and abstracts did not contain sufficient detail to permit 
either methodological quality assessment or meta-analysis. I did not include studies 
that examined only the risk of subsequent stroke or MI in patients with stroke or 
risk of stroke in asymptomatic study subjects. 
Data extraction:  
I selected potentially eligible studies and these were reviewed by two colleagues, 
Dr. Anshuman Sengupta and Dr. Wei Li Chong. I extracted data from all relevant 
studies; Dr. Anshuman Sengupta and Dr. Wei Li Chong each re-extracted data from 
half of these and we resolved any disagreements by discussion. Where I identified 
duplicate publication, I included the most informative cohort. I assessed study 
quality using the assay methods and study design sections of the REMARK 
reporting recommendations for prognostic tumour markers (Kyzas, Denaxa-Kyza, 
& Ioannidis 2007, McShane et al. 2005c) (see appendix). To reduce bias in the 
assessment of studies with multiple blood draws and multiple outcomes, I 
prespecified which measures of association we would collect where more than one 
was given. Where more than one biomarker was reported in a single study, we 
recorded data for each biomarker. Where more than one outcome had been reported 
from a single study, I recorded the handicap measure (usually the modified Rankin 
scale).  If the handicap measure had been reported at more than one time point, I 
extracted the measure of effect taken closest to 3 months. Where a single biomarker 
had been measured at multiple time points, I recorded the measure of effect for the 
sample taken soonest after the stroke. To ensure the review was comprehensive, and 
hence reduce the risk of introducing selection bias I aimed to include studies 
irrespective of the method used to measure the association between biomarker and 
outcome. I noted the measure of association with outcome for each biomarker which 
included: odds ratios (OR), hazard ratios (HR), relative risk ratios (RRR), differences 
in mean marker levels between poor and good outcome and correlation coefficients 
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between outcome and marker levels. Where unadjusted and adjusted measures of 
effect were reported, I took the most adjusted measure. After discussion with other 
experts (Prof. Gordon Lowe and Dr. Malcolm MacLeod), biomarkers were classified 
by function and tissue of origin. 
Analysis 
Excel was used to draw plots of measures of effect (OR/HR/RR) and standardised 
differences in means (difference in means / pooled standard deviation) and their 
95% confidence intervals (C.I.), for each biomarker. After review of the data, 
summary estimation was felt to be inappropriate, because of the differences in 
reported marker thresholds and units used in regression analysis. Vote counting of 
statistically significant studies, though superficially appealing,  was rejected as an 
analysis method because of the risk of type 2 error (Hedges LV & Olson 2008). 
Results 
The Medline/EMBASE search identified 6033 publications, and a further 61 were 
identified from reference lists. All abstracts were reviewed, and 232 papers were 
read in full:  82 studies measuring a total of 70 markers were relevant (Table 1, web 
appendix 1). Lists of articles are available on request from the authors. Studies were 
from: China (2), Denmark (4), Estonia (1), Finland (3), France (1), Germany (10), 
Greece (5),  Israel (2), Italy (9),  Malaysia (1), New Zealand (1), Norway (2), Poland 
(2), South Korea (2), Spain (16), Taiwan (2), Turkey (2), UK (12),  US (5). 
Methodological assessment 
Studies were generally small (median sample size 85, interquartile range 49 to 184). 
Few studies reported a sample size calculation (7/82, 9%), reported that the marker 
was measured blind to stroke status (21/82, 26%) or examined an unselected cohort 
of stroke patients (30/82, 37%) ( 
Figure 16). 20 (25%) studies excluded patients with cancer or infection, 9 (11%) 
patients with cancer and 7 (8%) patients with infection. The median number of 
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biomarkers measured per study was 2 (range 1 to 9), markers were sampled at a 
median of one time point (range 1 to 10), and the median number of outcomes 
measured was one (range 1 to 24). Of the 66 studies that performed a regression 
analysis, 10 adjusted for neither age nor stroke severity, 14 for age only, 7 for stroke 
severity only and 35 made adjustment for both. No study reported the additional 
predictive value of models containing one or more markers to validated clinical 
prognostic models or to particular clinical features. Of the 51 studies that developed 
a logistic regression model and reported the numbers of outcome events and 
adjustment variables, 24 did not have sufficient outcome events to develop a reliable 
model (recommended minimum >10 outcomes/variable(Harrell F.E, Lee K.L., & 
Mark D.B 1996)). 
There was marked asymmetry in a funnel plot (OR or HR against the standard error 
of log OR/HR), suggesting small study bias (Figure 17). This may represent 
differences in the methodology of small studies (which may have poorer 
methodology or more severe stroke patients) or publication bias (i.e. small studies 
showing little association between markers and outcome are less likely to be 
published).  
Biomarkers as prognostic factors 
Many markers show an association with poor outcome, whether by difference in 
means, regression coefficients or relative measures of effect (Figure 18 and Figure 
19). Most associations were weak (of 66 reported OR/HR/RR, 37 are less than 3) and 
so could be potentially explained by bias. Larger studies tended to have more 
modest measures of effect, and studies which calculated a threshold (34/64) had 
larger measures of effect. Thresholds were frequently data derived. No one class of 
marker had a stronger association with poor outcome than others, though the effect 
of cardiac markers (troponin or natriuretic pepetides) on outcome was remarkably 
consistent. Within each class of marker, no one marker clearly performed better than 
the rest. Most information was available for the markers fibrinogen and CRP though 
meta-analysis of measures of effect was precluded by differences in reported units 
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and thresholds for both markers, however both seemed to have a weak and positive 
association with poor outcome, consistent across OR, HR, differences in means and 
correlation coefficients.  
Many studies that did not report a significant finding did not report the association 
of marker with outcome numerically; this could lead to bias in the assessment of 
those markers where the majority of studies did not report significant findings. For 
example, it is only for the following markers that the majority of the studies show a 
significant association between marker levels and outcome: adiponectin, brain 
natriuretic peptide (BNP), C-reactive protein (CRP), glial fibrillary acidic protein 
(GFAP), glutamate, homocysteine, insulin like growth factor, intercellular adhesion 
molecule (ICAM), matrix metalloproteinase 9 (MMP-9), platelet activator inhibitor 
(PAI-1), prothrombin fragments, soluble TNF receptors 1, tau, troponin i, troponin t 
and  thrombomodulin. 
Discussion 
Many of the blood markers in this review were associated with poor outcome after 
ischaemic stroke. However, many publications have not established whether these 
markers add information to established clinical variables such as age or stroke 
severity, let alone whether when added to a validated clinical prognostic scale, that 
predictive power increases. Therefore most markers are of uncertain clinical 
significance. 
The association of marker levels with poor outcome after ischaemic stroke are in 
general higher than the association of the same markers with other outcomes, for 
example with the recurrence of vascular disease in patients with prior vascular 
disease. This strong association could be because marker levels in patients soon after 
ischaemic stroke predict: (a) an increased risk of myocardial infarction or stroke 
over and above people with stable vascular disease, (b) markedly reduced brain 
recovery, (c) increased risk of other complications of stroke, or (d) biased studies. 
Recurrence of MI or stroke 
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In patients with minor stroke or TIA, the risk of stroke recurrence is highest in the 
first few weeks after stroke (Coull, Lovett, & Rothwell 2004, Johnston et al. 2000). 
However, in patients with more severe stroke it is difficult to identify stroke 
recurrence. The association between blood markers and poor outcome after stroke 
might arise because of an association with an increased risk of stroke recurrence or 
MI. 
Most blood markers have a modest association with the first development of 
coronary heart disease in population based prospective studies of blood biomarkers. 
The odds ratios for the association with heart disease from meta-analysis are, 
comparing the top third of the distribution to the bottom third: adiponectin OR= 
0.84 (95% C.I. 0.7-1.01); D dimer, OR=1.7 (95% C.I. 1.3-2.2); ICAM 1 OR=1.21 (95% 
C.I. 0.95-1.55); CRP, OR=1.7 (1.8 (95% C.I. 1.6-2.0); fibrinogen, 1.8 (95% C.I. 1.6-2.0); 
BNP, OR between 1.3-5.7 for survival; and ferritin, OR=1 (95% C.I. 0.8-1.3) cut-off 
200 (Danesh et al. 1998a, Danesh et al. 1998b, Danesh et al. 2001, Danesh & Appleby 
1999, Doust et al. 2005, Malik et al. 2001, Sattar et al. 2006).  
In patients with some form of established vascular disease, the association between 
marker levels and incident stroke was less striking, with confidence intervals 
overlapping with those from the prospective cohorts of those asymptomatic at 
baseline: fibrinogen, OR=1.34 (95% CI, 1.13 to 1.60) comparing groups with levels 
above and below the median, and CRP, HR=2.16 (95% CI, 1.32  to 3.53) comparing 
highest to lowest tertiles (Rothwell et al. 2004e, Tanne et al. 2006).  
In stroke free patients with unstable angina, inflammatory and haemostatic markers 
also have a modest association with  recurrence of coronary events: CRP, RR=1.45 
(1.15-1.83) per SD; SAA, RR 1.14 (0.99-1.44) per SD (Haverkate et al. 1997a, 
Haverkate et al. 1997b). 
The associations between D-dimer, fibrinogen, CRP, ferritin, IL6 and SAA and a 
poor outcome after stroke were also modest in studies where no threshold was 
calculated. However many other markers have much larger measures of effect; this 
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could be due to a much stronger association of these markers with MI and stroke 
recurrence than previously recognised, or there is another mechanism responsible 
for their association with poor outcome. 
Stroke recovery 
An association between blood markers and poor outcome could arise because 
markers predict poor brain healing or the development of other stroke 
complications. Inflammatory markers after stroke are associated with poorer 
recovery of brain tissue in experimental stroke (Emsley & Tyrrell 2002); excitatory 
neurotransmitters can increase apoptosis and neuronal and glial death (Kreisel, 
Bezner, & Hennerici 2006) and higher levels of anti-inflammatory markers might 
indicate strengthened intrinsic anti-atherosclerotic mechanisms. Increases in 
neurotrophic or neuroprotective markers may be associated with improved 
neuronal recovery (Denti et al. 2004, Sotgiu et al. 2006). Raised inflammatory 
markers are also associated with other conditions responsible for poor outcome 
such as patients who already have either cancer  or deep venous thrombosis 
(Heikkila, Ebrahim, & Lawlor 2007, Roumen-Klappe et al. 2002).   
Cardiac markers (natriuretic peptides and troponins) show a consistent association 
with poor outcome. As cardioembolic stroke seems to have a poorer outcome than 
other stroke subtypes, a possible explanation could be an association of cardiac 
markers with this stroke subtype (Grau et al. 2001). However, only brain natriuretic 
pepetide  (and not troponin I) has been associated with cardioembolic rather than 
other stroke subtypes (Di Angelantonio et al. 2005, Montaner et al. 2008). Cardiac 
dysfunction simultaneously or shortly before the stroke or pre-existing cardiac 
disease could also account for the association, though an association between 
marker levels and ECG changes was seen in only seen in some studies (Fure, Bruun, 
& Thommessen 2006, Sharma et al. 2006).  
Another potential role of blood biomarkers is to distinguish groups of patients most 
likely to benefit from, or to be harmed by, a particular therapy.  In the context of 
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acute ischaemic stroke, thrombolytic therapy is the most relevant.  Only one 
randomised controlled trial has reported on this, though did not report on the 
presence of a treatment effect x biomarker level interaction for the markers 
measured (MBP, NSE and S100)(Jauch et al. 2006). Several studies, based on groups 
of patients, all of whom had received thrombolytic therapy, reported on markers 
that might predict post-treatment cerebral haemorrhage, but the outcomes reported 
in these papers were largely radiological and none of the studies compared results 
with a non-treated group.  
There are several strong clinical predictors for poor outcome  after stroke, for 
example stroke severity, premorbid disability and age which may themselves be 
strongly associated with marker levels (Counsell et al. 2002e). Many studies of 
stroke prognosis – though by no means all – adjust for these potential confounders. 
However, adjusting for stroke severity is imperfect, and therefore residual 
confounding for stroke severity is likely to account for at least some of the 
association between markers and poor outcome.  
Bias in studies 
Many studies calculated a threshold level of the marker for the prediction of poor 
outcome, although this approach has flaws. Where there is an association between 
marker level and outcome, this is in most cases continuous rather than 
dichotomous. Calculating thresholds in a data dependent fashion (for instance by 
ROC curve analysis) to optimise the prognostic performance of a blood biomarker 
can lead to implausibly large effect sizes. Whilst thresholds or reference intervals 
can be useful in clinical practice, they must be validated by applying the calculated 
marker threshold in a new cohort before being adopted into clinical practice. 
Unfortunately, data-derived thresholds are rarely replicated, and where they are 
replicated, they often are not confirmed (Christensen et al. 2002a). 
The lack of sample size calculations in most studies suggests that the studies were 
performed opportunistically rather than with a careful, prespecified study design.  
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Sample sizes need to be large to allow the detection of the moderate effect sizes that 
can be realistically expected and to overcome the problems of multiple comparisons 
in univariate analysis. Very often this problem is compounded by the measurement 
of biomarkers at multiple time points and the measurement of multiple clinical 
outcomes. Where a logistic regression model is used to analyse study results, 
sample size calculations should aim for at least 10 outcomes per variable to be 
entered in the final model (Harrell F.E, Lee K.L., & Mark D.B 1996). Known 
prognostic variables for poor outcome, such as age, stroke severity and premorbid 
disability should be forced into logistic regression models, as their association with 
poor outcome after stroke is robust. Reliably to assess the addition of a single 
biomarker measured at one time point with one outcome, requires that sufficient 
patients are recruited to ensure that at least 40 people develop the outcome of 
interest (10 each for age, stroke severity, premorbid disability and the biomarker). 
Therefore, in patients with moderate to severe stroke (of whom 40% will have a 
good outcome) the studies should recruit samples of at least 100 patients, assuming 
no loss to follow up. 
Biomarker measurement is subject to both inter- and intra-patient random variation. 
Different batches of the same measurement kit, and of different kits can have 
different performance for the same marker. Very few studies have attempted to 
compare the performance of different kits (Barber et al. 2006) to predict outcome. 
Publication bias probably exists, as the funnel plot showed marked asymmetry, 
though other reasons for larger effect sizes in smaller studies, such as less 
methodological rigour or increased stroke severity and stronger association with 
outcome in smaller studies are also possible.  We have attempted to minimise 
within study reporting bias by reporting both studies where a relative measure of 
effect  (Figure 18) and a difference in means was reported (Figure 19).  
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Limitations of systematic reviews of prognostic variables 
Assessing the quality of prognostic studies is difficult. There is no generally 
accepted scale to assess the quality of reports of prognosis comparable to the 
CONSORT guidelines for randomised controlled trials and the STARD guidelines 
for studies of diagnostic tests. There is a paucity of evidence to support many of the 
suggested measures of quality of prognostic studies, such as well defined inception 
cohorts.  
There is no widely accepted way of correcting for publication bias, and furthermore 
within-study reporting bias becomes a problem when many markers and outcomes 
have been measured. Reports frequently state markers are ‘non significant’ without 
stating an estimate of the measure of effect with its confidence intervals.  Where 
thresholds have been chosen, they usually differ between studies. The interval 
chosen for analysis in multiple logistic regression may be per unit, per log unit or 
per quartile of biomarker. Adjustment in multiple regression analyses may be for 
different variables in different studies. 
Conclusions 
Blood biomarkers may be useful in acute ischaemic stroke, either by suggesting 
possible mechanisms for the aetiology of poor outcome or as part of a clinically 
useful prognostic scale. The reported associations between particular markers and 
outcome may arise because markers predict recurrent stroke or MI, stroke 
complications or new diseases, such as cancer. There is a sufficient risk of bias in the 
studies we assessed that really reliable conclusions cannot be drawn from the 
current literature. 
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Implications for research 
Until there is an international consensus on the ideal components of a prognostic 
study analogous to CONSORT, it would seem reasonable to propose that an ideal 
study should aim to:  
• Recruit a well defined cohort of patients are assembled at an early and 
uniform stage in the disease. 
• Define subsequent treatment (e.g. thrombolysis, stroke unit care).  
• Multiple logistic regression should include known clinical prognostic 
variables (e.g. age and stroke severity) whether or not they reach statistical 
significance in univariate analysis. 
• To be clinically useful, markers should add predictive power to a validated 
clinical model and should be tested in a separate cohort.  
• Although the REMARK guidelines were initially reported for prognostic 
markers of cancer, the recommendations stand for all other fields of 
measurement of prognostic markers, including stroke, and we urge authors 
to read them before designing and reporting their studies (McShane et al. 
2005b). 
• Individual patient data meta-analysis of the best quality studies from this 
review could help to improve the precision of the measures of association 
between blood markers and poor outcome. However, for many markers 
larger, better designed studies are needed before this can be attempted. 
Implications for clinical practice 
• None of the markers measured in this review can be recommended to 
predict the death or disability after acute stroke. 
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Tables 
Table 5.1 Blood markers reported in the systematic review, their putative physiological role in stroke 
and the size and number of studies examining markers and poor outcome in stroke patients. 
Biomarker Hypothesised role 
in ischaemic 
stroke 





Mean study size 
(smallest, 
largest) 
     
Activated Protein C Resistance Haemostasis  1 219 
Adiponectin Anti-inflammatory Adipocytes 1 164 
Alpha 2 antiplasmin Antifibrinolysis Liver 1 63 
Anticardiolipin antibodies Haemostasis B lymphocytes 1 300 
Antithrombin II Anti-clotting Binds at endothelium 1 55 
Atrial natriuretic peptide Cardiac  Atrial myocardium 2 44 (37,51) 
Beta globin DNA Cell damage All cells 1 44 
Beta thromboglobulin Platelet Platelets 2 71 (70,72) 
BDNF Neurotrophic Neurones, renal, retinal 1 50 
Brain natriuretic peptide Cardiac Myocardium 4 107 (51, 175) 
Cortisol Anti-inflammatory/ 
neuronal survival 
Adrenal cortex 4 90 (34,184) 
C-reactive protein Inflammation Liver 14 125 (11,467) 
D-dimer Haemostasis Clot breakdown 8 118 (46, 231) 
Endothelin - 1 Vasoconstrictor Endothelium 2 69 (37, 101) 
Factor VIIc Haemostasis Liver 2 141 (63, 219) 
Factor VIIIC Haemostasis Liver 2 121 (70, 171) 
Factor IXc Haemostasis Liver 1 219 
Factor XIII Haemostasis Liver 1 63 
Ferritin Inflammation Astrocytes/Glia/Liver 4 95 (51,162) 
Fibrinogen Haemostasis Liver 14 156 (22, 469) 
Fibrinopeptide A Haemostasis cleaved from fibrinogen 2 71 (70, 72) 
GABA Neurotransmitter Neurones 2 113 
GFAP Glial protein Glia 1 53 
Glutamate Neurotransmitter Neurones 5 100 (46, 128) 
Glycine Neurotransmitter Neurones 2 121 (113, 128) 
Homocysteine Endothelial 
apoptosis 
?Macrophages 1 75 
Insulin-like growth factor Neuroprotective Most tissues 1 85 
Intercellular adhesion molecule Inflammation Endothelium 2 81.5 (50, 113) 
Interleukin 1 beta Inflammation Endothelium 4 68 (18, 162) 
IL-1 receptor antagonist Anti-inflammatory Lymphocytes/Macrophages 3 102 (41, 162) 
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Biomarker Hypothesised role 
in ischaemic 
stroke 





Mean study size 
(smallest, 
largest) 
     
Interleukin 4 Inflammation CD4 T cells/Macrophages 1 231 
Interleukin 6 Inflammation CD4 T cells/Macrophages 10 101 (11, 231) 
Interleukin 8 Inflammation Endothelium 1 50 
Interleukin 10 Anti-inflammatory Lymphocytes/Macrophages 6 90 (11, 231) 
Iron   1 100 
L-arginine Anti-inflammatory Endothelium 1 113 
LAPa2 Lipid metabolism Vascular smooth muscle 1 467 
Matrix metalloproteinase 2 Inflammation Endothelium 1 49 
Matrix metalloproteinase 9 Inflammation Endothelium 2 50 
Matrix metalloproteinase 1 Inflammation Endothelium 1 50 
MCP Inflammation Endothelium 1 50 
Myelin basic protein Glial damage Glia 1 359 
Neurone specific enolase Neuronal damage Neurone 7 93 (24,359) 
Normetanephrines Sympathetic  Adrenal medulla 1 75 
Nucleosomes Cell damage All cells 1 63 
P selectin Inflammation Platelets 2 73.5 (45,102) 
Plasminogen activator inhibitor Antifibrinolysis Endothelial/liver 3 70 (44, 102) 
Procalcitonin Inflammation ? 1 30 
Protein C Anticlotting Liver 1 55 
Protein S Anticlotting Liver 1 55 
Prothrombin fragments Haemostasis cleaved from prothrombin  2 130 (40, 219) 
Resistin Inflammation Monocytes/lymphocytes 1 211 
S100 beta Glial damage Glia 6 100  (26, 359) 
Selectin Inflammation Endothelium 1 238 
Serum Amyloid A Inflammation Liver 1 203 
sICAM-1  Inflammation Endothelium 1 238 
Soluble TNF alpha receptor 1 Inflammation Vascular smooth muscle  1 43 
Soluble TNF alpha receptor 2 Inflammation Vascular smooth muscle  1 162 
Spermidine Modulate NMDA Neurones 1 16 
Tau Neuronal protein Neurones 1 53 
Thrombin/antiThrombin  Haemostasis Coagulation 3 241 (40,465) 
Thrombomodulin Anticlotting Endothelium 3 445 (359, 510) 
Tissue plasminogen activator Fibrinolysis Endothelium 2 342 (219, 465) 
Troponin I Cardiac myocyte  Cardiac myocyte 4 230 (175, 330) 
Troponin T Cardiac myocyte  Cardiac myocyte 4 209 (172, 279) 
Tumour necrosis factor alpha Inflammation CD4 T cells 8 124 (18, 231) 
Uric Acid Purine catabolism ?all cells 2 2306 (881, 3731) 
VCAM Inflammation Endothelium 1 238 
von Willebrand Factor Haemostasis Endothelium 4 127 (46, 219) 
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Figure 16 Study quality, using questions modified from the REMARK recommendations. 
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Figure 17 Funnel plot of studies of blood markers and poor outcome after stroke.  
Each point represents one estimate of the association between a blood marker and poor 
outcome in one study. The x-axis represents the odds ratio (OR), a measure of the strength of 
the association between markers and poor outcome; OR>1 if higher levels markers are 
positively associated with poor outcome and OR<1 if higher levels of markers are negatively 
associated with poor outcome. The y-axis represents the standard error, a measure of 
precision; the lower the standard error, the more precise the estimate of the OR. Note: there 
are no studies with a low precision that show a negative association between higher levels of 
blood markers and poor outcome, a phenomenon known as ‘small study bias’. 
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Inflammatatory      
C-reactive protein (no threshold) Rallidis 2007   per mg/ml 
+ 
  Elkind 2006   quartiles 
+++ 
  Rallidis 2006   per mg/mL 
+ 
  Muir 1999   per log unit 
+++ 
        
 
C-reactive protein (threshold) Montaner 2006 >0.77 mg/dL 
++ 
  Winbeck 2002 >0.86 mg/dL 
++ 
  Di Napoli 2001 >1.5 mg/dL 
++ 
  Hamidon 2004 >1.5 mg/dL 
+++ 
  Efstathiou 2006     
++ 
        
 
Ferritin Ergeoglu 2002   per µg/L +++ 
  Davalos 1994 >190 µg/L + 
  Davalos 2000 >275 ng/mL 
- 
        
 
Interleukin 6 (no threshold) Blanco 2006   per pg/ml 
+++ 
  Rallidis 2006   per pg/mL 
+ 
  Chamarro 2007   deciles pg/mL 
+ 
        
 
Interleukin 6 (threshold) Vila 2000 >21.5 pg/mL 
+++ 
        
 
Intracellular Adhesion Molecule 1 Wang 2006   per 100ng/ml 
+++ 
  Castellanos 2002 >208 pg/mL 
+ 
        
 
Tumour necrosis factor alpha Castellanos 2002 >14 pg/mL 
+ 
        
 
Resistin Efstathiou 2006   tertiles 
+++ 
        
 
Serum Amyloid A Rallidis 2006   per mg/L 
+ 
        
 
        
 
        
 
Haemostasis       
 
D-dimer (no threshold) Barber 2004   per log unit 
+++ 
  Rallidis 2007   per µg/mL + 
        
 
D-dimer (threshold) Sqizzato 2006 >0.5 µg/mL + 
  Feinberg 1996 >6 log units 
+ 
  Grotta 2001 >10 µg/mL + 
        
 
Fibrinogen Davalos 1997   per 10mg/dL  
+ 
  Wang 2006   per 100 mg/dL 
+++ 
  Rallidis 2007   per 10mg/dL 
+ 
  Turaj 2006 >3.5 g/L 
+++ 
        
 
Anticardiolipin antibodies Tanne 2002 >10 IgG  units 
+ 
        
 
Thrombin antithrombin complexes Tanne 2006   per log ng/mL 
+++ 
        
 
Fibrinopeptide A Landi 1987     
- 
  Feinberg 1996 >2.5 log units 
+ 
        
 
von Willebrand Factor Catto 1997  per IU/ml  
+ 
       
 
       
 
        
 
Glial damage       
 
S100 beta Foerch 2005     
- 
  Jonsson 2001 >0.5 µg/L - 
        
 
        
 
    
 0.1 1 10 100
OR/HR 
Figure 18 Measures of association of venous blood biomarkers and poor outcome.   
95% confidence intervals + = adjustment for age or stroke severity, ++ = adjustment for age and stroke 
severity, +++ = adjustment for age, stroke severity and other factors. 
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0.1 1 10 100
Excitatory Neurotransmitter        
Glutamate Davalos 2000 >200 µmol/L - 
  Castillo 1997 >200 µmol/L - 
  Serena 2001 >200 µmol/L - 
         
Glycine Castillo 1997 >223 pmol/L - 
         
         
         
Cardiac        
Atrial natriuretic peptide Makikallio 2005 >850 pmol/L +++ 
         
Brain natriuretic peptide Sharma 2006 >42 pmol/L +++ 
  Yip 2006 >150 pg/mL + 
  Makikallio 2005 >500 pmol +++ 
         
Troponin I Christensen 2004 >0.1 µg/mL +++ 
  Angelantonio 2005 >0.4 ng/mL ++ 
  Barber 2007 >0.2 µg/mL +++ 
         
Troponin T Fure 2006 >0.04 µg/mL - 
  James 2000 >0.1 µg/mL ++ 
  Jensen 2007 >0.03 µg/mL +++ 
         
         
         
Antiinflammatory        
Adiponectin Efstathiou 2005 <4 µg/L + 
         
Interleukin 10 Vila 2003 <6 pg/mL +++ 
         
Cortisol Davalos 1994 >0.84 nmol/L +++ 
         
         
         
Anticlotting        
Thrombomodulin Olivot 2004   tertiles +++ 
  Tanne 2006   per log ng/mL +++ 
     
       
Miscellaneous      
L-arginine Blanco 2006     +++ 
         
Beta thomboglobulin Feinberg 1996 >3.6 log value - 
         
Insulin-like growth factor Denti 2004   per 20ng/ml +++ 
         
GABA Serena 2001 <240 nmol/L - 
         
Tissue plasminogen activator Tanne 2006   per log ng/mL +++ 
         
Lipoprotein associated phospholipase A2 Elkind 2006   quartiles +++ 
         
Homocysteine Pniewski 2003 >15 µmol/L + 
         
Normetanephrines Chamarro 2007   quartiles + 
         
Uric Acid Chamarro 2002   mg/dL ++ 
  Weir 2003   per 0.1 mmol +++ 
OR/HR
Figure 18 continued 
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-5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10
Standardised difference in means
Inflammatory   
C-reactive protein Kocer 2005 mg/L 
   
Ferritin Davalos 1994 µg/L 
  Ergeoglu 2002 µg/L 
      
      
Interleukin 6 Vila 2000 pg/mL 
      
Matrix Metalloproteinase - 2 Kim 2006 units 
Matrix Metalloproteinase - 9 Kim 2006 units 
      
P selectin Cha 2002 units 
      
Intracellular Adhesion Molecule 1 Wang 2006 ng/ml 
      
      
Tumour necrosis factor alpha Vila 2000 pg/mL 
      
Vascular cell adhesion molecule Wang 2006 ng/mL 
      
Haemostasis     
D-dimer Audebert 2004 mg/L 
  Sqizzato 2006 µg/L 
      
Factor VIIIC Landi 1987 % activity 
      
Fibrinogen Vila 2003 g/L 
  Vila 2000 g/L 
      
  Landi 1987 mg/dL 
  Zuliani 2006 mg/dL 
  Audebert 2004 mg/dL 
  Wang 2006 mg/dL 
  Davalos 1997 mg/dL  
  Davalos 2000 mg/dL 
      
von Willebrand Factor Audebert 2004 %activity 
 Landi 1987 %activity 
      
Excitatory neurotransmitters     
Glutamate Audebert 2004 µmol/L 
  Serena 2001 µmol/L 
  Castillo 1997 µmol/L 
      
Glycine Serena 2001 µmol/L 
  Castillo 1997 µmol/L 
   
Antiinflammatory   
Interleukin 10 Vila 2003 pg/mL 
      
Miscellaneous     
Homocysteine Pniewski 2003 pmol/L 
      
Neurone Specific Enolase  Kim 2006 ng/dL 
      
Plasminogen activator inhibitor Lip 2002 IU/mL 
      
Selectin Wang 2006 ng/mL 
      
Uric Acid Chamarro 2002 mg/dL 
 
 
Figure 19 Standardised differences in means : (mean level in poor outcome - mean 
level in good outcome) /pooled standard deviation, and 95% confidence intervals 
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Chapter 6.  Inflammatory markers and poor outcome after stroke: a 
prospective cohort study and systematic review of interleukin 6 
Introduction 
A non-specific systemic inflammatory response occurs after both ischaemic and 
haemorrhagic stroke, either as part of the process of brain damage or in response to 
complications such as deep venous thrombosis. Several studies have reported that 
higher levels of inflammatory markers such as C-reactive protein (CRP) and 
interleukin 6 (IL-6) are associated with worse outcome after both ischaemic 
(Whiteley et al. 2009a) and haemorrhagic strokes (Castellanos et al. 2005, Castillo et 
al. 2002). However, these studies often had methodological weaknesses, chiefly that 
they were too small, or did not adequately adjust for confounders or assess the 
clinical utility of the measurements.  
The addition of markers of inflammation to validated clinical prognostic models 
might improve the prediction of poor outcome after stroke. There are at least two 
validated models for predicting clinical outcome after stroke; one is based on six 
simple clinical variables which can be applied without specific training (Counsell, 
Dennis, & McDowall 2004c), and the other includes the more complex National 
Institutes of Health Stroke Scale (NIHSS) and age (Konig et al. 2008c). The NIHSS is 
complex, assessing 15 items and requires specific training. 
I therefore aimed to replicate the finding that several markers of the acute phase 
response – CRP, IL- 6, white cell count, fibrinogen or glucose- appear to be 
associated with poor outcome after ischaemic and haemorrhagic stroke. The data 
were available from a large prospective cohort of stroke patients which aimed to 
avoid as many as possible of the methodological weaknesses of the other studies. I 
then wished to assess whether blood biomarkers could improve an existing 
prognostic models in the same cohort 
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IL-6 has shown a particularly strong association with poor outcome after stroke; I 
therefore performed a systematic review of the existing literature to put these 
results in context. 
Methods 
Patients 
The Edinburgh Stroke Study prospectively recruited all consenting patients with 
recent stroke from the emergency department, medical, neurology and occasionally 
other (e.g. surgical)  wards, stroke unit and neurovascular clinics of the Western 
General Hospital, Edinburgh, UK between April 2002 and May 2005 into the 
Edinburgh Stroke Study (Jackson et al. 2008c). Clinicians recorded data at the time 
of assessment using a standardised structured proforma and, in patients who 
consented, drew blood for measurement of inflammatory markers. 
The study definition of a clinically definite stroke was new clinical symptoms or 
signs of a focal disturbance of cerebral function lasting more than 24 hours of a 
vascular origin. Patients with subarachnoid haemorrhage were excluded.  At a 
weekly meeting, stroke physicians, neurologists and neuroradiologists reviewed the 
clinical features of each patient, all brain images and clinical progress. Ischaemic 
stroke was defined as a clinically definite stroke in a patient whose brain imaging 
showed either positive evidence of a relevant ischaemic lesion or was normal and 
excluded intracranial haemorrhage and stroke mimics. Stroke was diagnosed as an 
intracerebral haemorrhage if the patient’s clinical features and brain imaging were 
consistent with acute haemorrhage. The pathological subtype of stroke was defined 
as probably ischaemic in patients with a clinically definite stroke in whom the 
radiological results were equivocal or unavailable, and analysed them together with 
definite ischaemic strokes. A final ischaemic stroke syndrome was assigned 
according to the Oxford Community Stroke Project (OCSP) classification  based on 
the clinical syndrome at the time of maximum deficit modified , where appropriate, 
by the site and size of relevant infarcts on brain imaging (Bamford et al. 1991b). The 
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diagnosis of stroke was made blinded to the measurement of CRP, IL-6 and 
fibrinogen. 
Measurement of clinical variables 
A physician with experience in stroke medicine assessed each patient as soon as 
possible after presentation and recorded risk factors for stroke, current treatment 
and electrocardiogram findings, measured impairment using the National Institutes 
of Health Stroke Scale (NIHSS) and collected variables for a previously validated 
“six simple variables” prognostic model (Brott et al. 1989a, Counsell et al. 2002d) 
(age, prior dependence, able to lift both arms from the bed, able to walk without 
assistance, living alone at the time of the event and orientation in time and person). I 
defined hypertension as a history of treated hypertension; ischaemic heart disease as 
a history of myocardial infarction, angina, coronary artery bypass grafting or 
percutaneous coronary intervention; peripheral artery disease as a history of 
claudication, peripheral artery intervention or definite signs of vascular disease of 
the legs (e.g. absent pedal pulses); cardiac failure as definite signs of heart failure, or 
taking at least two medications for its treatment and independence prior to stroke as 
not requiring assistance for washing, dressing, feeding or toileting. 
Measurement of blood markers 
Clinicians drew blood on the same day as clinical assessment, or for patients 
admitted to hospital, as soon after assessment as possible. A clinical laboratory 
measured total white cell count (Beckman Coulter LH750 analyser) and blood 
glucose (Vitros Chemistry analyser). Blood samples for IL-6, CRP and fibrinogen, 
were transported to the laboratory on water ice, centrifuged to obtain serum and 
EDTA-anticoagulated plasma and stored at -80OC until analysed. CRP and 
fibrinogen in plasma were measured by immunonephelometry (Prospec, Dade 
Behring Milton Keynes, UK) using the manufacturer’s reagents and standards. IL-6 
was assayed by ELISA (R & D Systems, Oxford, UK).  Intra- and inter-assay 
coefficients of variation were 4.7 and 8.3%, 2.6 and 5.3%, and 7.5 and 8.9%, 
respectively. All assays were blind to stroke outcome. 
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Assessment of outcome 
Each patient was sent a validated self completion questionnaire by post at 6 months 
from their stroke onset date, which measured disability with the modified Rankin 
Scale (mRS), a standard tool for examining outcome after stroke. Non-responders 
were sent a repeat questionnaire. Each patient was ‘flagged’ at the General Register 
Office for Scotland who provided information on the date and place of death. The 
cause of death was confirmed by inspection of the relevant medical records. In 
primary analyses, I dichotomised a patient’s outcome into: ‘poor’ if they were 
dependent on others for activities of daily living (mRS scores 3, 4, 5) or dead, and 
‘good’ if they were independent in activities of daily living (mRS 0,1 and 2) 6 
months after stroke onset. In subsidiary analyses, I dichotomised patient outcome at 
6 months into alive or dead. 
Statistical analysis 
Association between marker levels and baseline features 
In a series of bivariate analyses, I compared normally distributed baseline 
characteristic with Student’s t-tests, proportions with χ2 tests and positively skewed 
data with Wilcoxon rank sum tests. For the calculation of Pearson correlation 
coefficients, I logarithmically transformed positively skewed blood marker data to 
obtain a normal distribution. I examined the relationship between biomarker level 
and delay to blood taking using multivariable regression analysis. 
Association between marker levels and outcome: 
I investigated the unadjusted associations between inflammatory marker level and 
outcome with χ2 for trend tests. I built a logistic regression model for the association 
of each inflammatory biomarker with poor or good outcome, with the terms from 
the previously validated six simple variable model added sequentially. I also 
examined logistic regression models for the association between individual 
biomarkers and outcome, adjusting stepwise for NIHSS, age, vascular risk factors, 
sex, and prior independence and living alone (domains not part of the NIHSS). For 
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these analyses, I compared the upper and lower thirds of inflammatory marker 
levels for the entire sample, and modelled the marker levels as linear variables. I 
stratified the analyses by NIHSS, OCSP, delay to blood taking and pathological 
stroke type to look for evidence of effect modification. 
Assessing the contribution of biomarkers to clinical prognostic models 
I assessed the additional contribution of those inflammatory markers that were 
significantly associated with poor outcome after adjustment to previously validated 
six simple variable model (Counsell et al. 2002c).  
First, I assessed whether blood markers improved the goodness of fit of existing 
models using the likelihood ratio statistic. Second, to compare the ability of models 
to discriminate between good and poor outcome, I calculated areas under receiver 
operator curves (AUROC). An AUROC of 1 indicates perfect discrimination and 0.5 
no discrimination. Third, I assessed calibration (whether the average predicted risk 
of poor outcome in subgroups matches that observed in the cohort) with the 
Hosmer Lemeshow χ2 statistic. Fourth, I assessed the ability of the best performing 
model including biomarkers to one without by examining risk stratification tables 
(Janes, Pepe, & Gu 2008). I used the methods of Pencina et al  to calculate net 
reclassification improvement (NRI) (Pencina et al. 2008). NRI is a measure that takes 
into account the correct movement of individuals between categories of predicted 
risk (i.e. the numbers of patients moving correctly or incorrectly between categories) 
to estimate overall improvement. I pre-specified thresholds of <10% and >90% for 
predicted probability of poor outcome as I believe that one would need to be very 
certain of a good or poor outcome before avoiding treatments such as thrombolysis 
or selecting patients for palliative care only.  
All P values reported are 2 sided and I considered P <0.05 statistically significant. I 
performed statistical analyses with Stata (version 10.1, College Station, TX, USA). 
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Systematic review of IL-6  
I searched Medline and EMBASE from 1966 to December 2008 for studies in patients 
with acute stroke that measured IL-6 and assessed clinical outcome. The search 
strategy included 13 terms for ischaemic stroke and 2 for IL-6. Prognostic studies 
were identified using high sensitivity search terms (Altman 2001b), together with 
common outcome measurements from stroke research (Rankin, NIHSS, Glasgow 
outcome scale) (see  MOOSE checklist, appendix). I included studies if they (a) 
reported results for patients with acute stroke (not transient ischaemic attack); (b) 
assayed a venous IL-6 in stroke patients; (c) measured outcome using death, 
disability or handicap scales and (d) reported results in a manner that allowed 
calculation of OR for poor outcome or death per unit increase in marker, to allow 
comparison of measures of association between studies. I extracted data from 
logistic regression models reporting the association between interleukin 6 and poor 
outcome or death after stroke, and the degree of adjustment for age, stroke severity 
and other potential confounders. I performed fixed effects meta-analysis with Stats 
Direct Version 2.7.2. 
I prepared this chapter with reference to the STROBE  guidelines for reports of 
observational epidemiological studies, the REMARK  guidelines for reports of 
prognostic variables and the MOOSE guidelines for the meta-analysis of 
observational studies (McShane et al. 2005a, Stroup et al. 2000, von Elm et al. 2007b). 
Ethics 
This study was conducted according to the principles expressed in the Declaration 
of Helsinki. The study was approved by the Lothian Research Ethics Committee. All 
patients or their guardians provided written informed consent for the collection of 
samples and subsequent analysis. 
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Results 
Baseline characteristics 
Data completeness is summarised in Figure 20. 1408 patients were recruited into the 
main ESS cohort, of whom 844 (60%) had blood drawn for markers of inflammation. 
Of these 785 (93%) had a definite ischaemic stroke, 16 (2%) a probable ischaemic 
stroke and 43 (5%) a haemorrhagic stroke. Those included in this biomarker subset 
were similar to those who were not, in age, sex and the proportions with 
hypertension, peripheral or cardiac vascular disease, diabetes or atrial fibrillation. 
On average, compared to those without biomarker data, patients with biomarker 
data had milder strokes (median NIHSS 1 vs 2 p<0.001, proportion TACS 7.7% vs 
14.7% p=0.001 respectively), as patients admitted to hospital and those with more 
severe symptoms were less likely to be recruited because of practical barriers to 
obtaining and processing research blood samples and obtaining informed consent 
or assent(Jackson et al. 2008b). Included patients were also less likely to have a 
diagnosis of cardiac failure (4.3% vs 8.3% p=0.002). The median delay from stroke to 
blood taking was 13 days (IQR 6 to 22 days). Of those patients who had blood 
drawn for blood markers, 6 month modified Rankin Scale data were available in 
750/844 (89%) and vital status  at 6 months was available in all patients. At 6 
months, of the 844 patients, 59 were dead, and 238 were dead or disabled. Deaths 
were due to the initial or recurrent stroke (35/59, 59%), vascular disease of the heart, 
legs or bowel (9/59, 15%), cardiac failure (5/59, 9%), cancer (5/59, 9%) and bowel 
perforation, chronic obstructive pulmonary disease or pneumonia (5/59, 8%). 
For all markers there was a weak, though statistically significant (p<0.001) negative 
relationship between the natural logarithm of marker and time from stroke onset to 
blood draw. The Pearson correlation coefficients for the relationship between time 
in days and the natural logarithm of each marker were: glucose, r= -0.07; white cell 
count, r= -0.12; fibrinogen, r= -0.12; C-reactive protein, r= -0.14 and interleukin 6, r= -
0.19. In multivariate regression models with time as the independent variable, after 
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adjustment for age and stroke severity measured by NIHSS, these relationships 
were even weaker and not statistically significant. 
Table 6.1 summarises the baseline data for all those patients from whom blood was 
drawn for markers and for those with good and poor outcome at 6 months. Patients 
who died or had poor outcome were older, had more severe strokes, and had more 
ischaemic heart disease, previous strokes or transient ischaemic attacks, diabetes, 
congestive cardiac failure and atrial fibrillation. They were more likely at the time of 
stroke to: live alone, be dependent on others for activities of daily living, be 
disoriented, have arm weakness and be unable to walk. They had higher levels of 
IL-6, CRP, fibrinogen, white cell count and glucose.  
Relation of markers to outcome with and without adjustment for other factors 
There were strong positive associations between marker levels and the odds of poor 
outcome (Figure 21). The risk of poor outcome rose by third of IL-6 distribution (χ2 
trend p<0.001), CRP (χ2 trend p<0.001), fibrinogen (χ2 trend p<0.001), white cell 
count (χ 2 trend p=0.002) and glucose (χ2 trend p=0.001).  The risk of death also rose 
by third of marker (χ2 trend p<0.001 for each marker) (data not shown), though in 
general the association between marker thirds and death was stronger than for poor 
outcome. After adjustment for age, and at the onset of stroke: whether the patient 
lived alone, was independent of activities of daily living, was orientated, able to lift 
their arms or walk, the odds ratios were attenuated for the association with poor 
outcome (IL-6, OR: 3.1, 95% CI 1.9 to 5.0; CRP, OR: 1.9, 95% CI 1.2 to 3.1; fibrinogen 
OR: 1.5, 95% CI: 1.0 to 2.4, white cell count, OR: 2.1, 95% CI: 1.3 to 3.4 and glucose 
OR: 1.3 95%, CI: 0.8 to 2.1 ) and death (data not shown). Adjustment for the 
association between marker levels and poor outcome for NIHSS, age, vascular risk 
factors, sex, and prior independence and living alone, led to only minor changes in 
the magnitude of these odds ratios for the association with poor outcome. After 
additional adjustment for other markers, only the association between IL-6 and poor 
outcome remained independently significant (OR: 2.4 95% CI 1.3 to 4.5). Further 
adjustment of the associations with death was not performed because of the 
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relatively small number of events. There was no material difference in the 
magnitude, direction or significance of the association between IL6, CRP and white 
cell count (data shown for IL6) and outcome after stratifying the analysis by: stroke 
subtype, stroke severity, clinical stroke syndrome or delay to blood taking after 
stroke (Figure 22).  
The crude increase in the odds of death or disability per unit increase in marker 
level, was lowest for CRP and highest for fibrinogen, though the range of the 
fibrinogen (1.2 to 9.6 g/l) was smaller than CRP (0.159 to 263 mg/L). After 
adjustment for the 6 simple variables, the associations between IL6, CRP and white 
cell count remained statistically significant (Table 6.2). 
Does the addition of marker data improve the predictive accuracy of clinical 
predictive models? 
I added data for the markers that were independently associated with poor outcome 
(IL-6, CRP and white cell count) as continuous variables to the previously validated 
six simple variable model (Counsell et al. 2002b) (Table 6.3). Model fit was 
improved significantly after the addition of IL-6 or white cell count, though not 
CRP. Model calibration was adequate after the addition of IL-6, white cell count and 
CRP. However, the AUC improved significantly only after the addition of IL-6 to 
the six simple variable model, though not after the addition of white cell count or 
CRP alone. A model with the six simple variables and all of the inflammatory 
markers was well calibrated, though had a similar AUC to a model with the six 
simple variables and IL-6 alone (p=0.8). As the ‘NIHSS and age’ model was poorly 
calibrated in this cohort (Hosmer-Lemeshow χ2 p=0.01), it was not examined 
further. 
I compared the proportions of patients with predicted high (>90%) and low (<10%) 
risks of poor outcome by the six simple variable model with and without the 
addition of IL-6 (Table 6.4). The addition of IL-6 to the six simple variable model 
increased the proportion of patients in the lowest risk category from 2.5% to 4.4% 
and the proportion in the highest risk category from 2.2 % to 3.0 %, i.e. an extra 2.6% 
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(95% CI: 1.7 to 4.1) were moved from indeterminate (10-90%) to determinate 
categories (>90% or <10%).  The models correctly classified those in the highest risk 
category as having a poor outcome, in 91% (95% CI: 73 to 98) of patients for the 
model including IL-6, and 94% (95% CI: 73 to 99) for model without. The models 
incorrectly classified patients in the lowest risk category in 12% (95% CI: 5 to 27) for 
the model including IL-6 and 16% (95% CI 6 to 38) for the model with the six simple 
variables alone.  The net reclassification improvement after the addition of IL-6 to 
the six simple variable model (5%, p=0.014) was small.  
Systematic review and meta-analysis 
The literature search identified 146 studies. I excluded studies for the following 
reasons: non-systematic reviews (20), the full paper was unobtainable (3), 
participants did not have stroke at baseline (75), blood IL-6 was not measured (12), 
death or disability was not reported (20), reported odds ratios for the association of 
IL-6 above and below a threshold (Castellanos et al. 2008, Vila et al. 2003) (2),  
reported correlation coefficients only (Mazzotta et al. 2004, Smith et al. 2004, Sotgiu 
et al 2006, Waje-Andreassen et al. 2005) (4), reported mean levels in patients with 
good and bad outcome only (Basic, V et al. 2008, Christensen et al. 2002b, Domac et 
al. 2007, Nakase et al. 2008, Shenhar-Tsarfaty et al. 2008) (5) or did not report 
numerical results (Silvestri et al. 2004) (1). I identified 4 relevant studies (Blanco et 
al. 2006, Chamorro et al. 2007, Rallidis et al. 2006, Welsh et al. 2009) (Table 6.5), 
which yielded, for the association between IL-6 and poor outcome 1037 patients, 
and IL-6 and death 1,122 patients. The summary odds ratios are comparable to the 
results of the current study (Figure 23). 
Discussion 
Statement of main findings 
In this large cohort of stroke patients, I found that higher levels of IL-6, CRP and 
white cell count were independently and significantly associated with poor outcome 
and death at six months after stroke. The association was independent of stroke 
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severity, age and risk factors for recurrent stroke, though only IL-6 was independent 
of other markers. The addition of IL-6 to a validated prognostic model increased the 
proportion of patients with predicted probabilities of a poor outcome of >90 or <10% 
by only 2.8%, and the net classification index by 5%. These findings lend support to 
the hypothesis that the inflammatory response is associated with poor outcome after 
stroke. Although the measurement of the inflammatory response assessed with IL-6 
improves prediction of poor outcome, in this cohort the degree was so small that the 
use of these markers in routine practice is unlikely to be helpful to clinicians aiming 
to predict the outcome of their stroke patients, for example by selecting individuals 
for aggressive treatment or palliative care.  
Study limitations and potential biases 
I did not exclude patients with infection even though this is a potential confounding 
factor (infection after stroke is associated both with higher levels of inflammatory 
markers and with poor outcome after stroke independently of other factors) as I 
sought external validity to determine the role of markers in a clinical setting. 
However, the delay between blood draw and stroke did leave time for the 
development of infective or inflammatory complications in some of the more 
severely affected stroke patients, so a rise in inflammatory markers due to infection 
rather than brain damage from the stroke may have been responsible for at least 
part of the observed association. The cohort, consisting of a mixture of outpatients 
and hospital inpatients, contained relatively mild stroke patients, so models 
generated from the whole cohort may not be applicable to cohorts containing only 
patients with severe strokes, as my models may have a ceiling effect at higher stroke 
severities. The study was limited in its ability to recruit more patients with very 
severe strokes chiefly because of the practical barriers to blood taking for research 
purposes out of normal working hours and obtaining informed consent. I 
dichotomised the Oxford Handicap Scale, measured by postal questionnaire, into 
‘independent’ and ‘dependent’. Although crude, this measure has both internal and 
external validity (Lindley et al. 1994). Although analysing each level of the OHS 
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may have added power to the study, this methods increases the complexity of the 
analysis and makes explanation of the results more difficult. 
Blood samples for inflammatory marker levels were only drawn at the time of 
assessment. Although serial measurement might have provided more information, 
even the single measurement available was still strongly associated with outcome. It 
seems unlikely that the additional effort of obtaining serial samples would be 
outweighed by additional predictive power. 
The use of the area under the curve to choose between predictive models is a subject 
of some controversy. The area under the curve analysis is based on rank 
comparison, which may be problematic for populations in whom the risk of an 
event is very low (for example incident stroke in asymptomatic cohorts)(Cook 2007). 
However, as the risk of poor outcome after stroke is high in this cohort (32%), the 
use of the AUC seems reasonable. While in this study IL-6 has an association with 
poor outcome, an extremely strong and independent association needs to be 
demonstrated before a marker usefully improves classification accuracy (Pepe et al. 
2004b). I assessed the additional predictive utility of IL-6 with risk stratification 
tables applying cut points for predicted outcome that are relevant for stroke 
practice, for the treatments that are currently available. Less stringent thresholds of 
risk could be examined, though it is hard to see how they would be useful in 
making decisions about individual patients. I have not demonstrated that IL-6 
improves prediction in this cohort, using my chosen thresholds. My conclusions 
would be strengthened by replication of my findings in a validation dataset. 
The systematic review is limited in scope, as several other studies relevant to the 
association between IL-6 and death or poor outcome reported their results either as 
a comparison of odds of poor outcome above and below optimised cut points or as 
correlation coefficients hence extraction of data per unit increase in marker level 
was not possible. 
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Interpretation 
I have demonstrated that blood markers of the acute inflammatory response, in 
particular IL-6, are associated with death and poor outcome after stroke. The results 
from this study are broadly comparable to other studies of IL-6 and poor outcome 
or death after stroke (Figure 4), which supports the generalisability of the findings.  
The strengths of the current study in comparison to other studies merit 
consideration. It is much larger than previous reports, and has used a measure of 
handicap (the modified Rankin Scale) as well as death to define poor outcome. It has 
used a validated prognostic model to adjust for confounding by stroke severity, age 
and prior dependence and has carefully explored the role of these markers in 
clinical decision making, which though often proposed, has not been examined 
before. 
IL-6 is induced by TNF α and IL-1β, and then leads to the releases of CRP, 
fibrinogen and cell adhesion molecules, though the cellular origin of interleukin 6 
after stroke is not clear. Whether the higher levels of IL-6 are a bystander to, or a 
cause of, poor outcome after stroke is uncertain.  
Evidence in favour of a causal role for inflammation in poor outcome after stroke 
comes from animal studies. A peripheral challenge with either a bacterial endotoxin 
(lipo-polysaccharide) or IL-1β seems to increase the measured volume of brain 
damage after arterial occlusion in a mouse model of stroke. (McColl, Rothwell, & 
Allan 2007). The blockade of IL-1 (which reduces further inflammatory responses) 
reduces the volume of brain damage after arterial occlusion in mice; the results of 
human studies are not yet available. The inhibition of the ingress of neutrophils into 
the brain with antibodies to adhesion molecules (e.g. ICAM) also seems to reduce 
the volume of brain damage in a mouse model. (Muir et al. 2007).  
Evidence against a causal role of inflammation comes from a variety of sources. 
Mice deficient in IL-6 showed similar stroke volume and disability at 24 hours as 
mice with normal IL-6 expression (Clark et al. 2000), suggesting that it may simply 
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be part of the inflammatory response to stroke and not directly pathogenic. The 
association of interleukin-6 with poor outcome has been demonstrated in many 
conditions such as HIV (Kuller et al. 2008), many cancers (Duffy et al. 2008), and the 
occurrence of first episodes of vascular disease including stroke (Danesh et al. 
2008c), making it more plausible that IL-6 is a general marker of disease severity 
rather than part of numerous disease specific pathways to poor outcome.  
Implications for research 
• In this large cohort of stroke patients, blood markers of the acute 
inflammatory response were associated with poor outcome after stroke, 
though only IL-6 showed independent association after adjustment for 
confounding factors including levels of other markers.  
• In this cohort, the addition of IL-6 to a previously validated prognostic 
model added to the prediction of outcome, but by an amount that is unlikely 
to be useful in clinical practice.  
• Whether or not inflammatory markers are useful in prediction of recurrent 
stroke (Welsh et al. 2008a, Woodward et al. 2005f) or other vascular events is 
a separate question, which requires further study. 
Implications for clinical practice 
• The measurement of IL-6, fibrinogen, CRP, white cell count or glucose do 
not give additional predictive power to easily measured clinical variables 
for the prediction of poor outcome after stroke. 
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Tables 












Age – mean (SD) 72 (11) 70 (11) 75 (11) <0.001* 
Male sex  no. (%) 445 (53) 275 (54) 115 (48) 0.169† 
NIHSS§ – median (IQR)
║
 1 (4) 1 (2) 4 (7) <0.001
c
 
Laboratory measurements median median (IQR) median (IQR)  
Interleukin-6 (pg/ml) 4.0 (4.8) 3.3 (3.2) 6.1 (7.5) <0.001‡ 
C-reactive protein  (mg/l)  3.4 (8.1) 2.6 (5.7) 7.1 (18.8) <0.001‡ 
Fibrinogen (g/l)  4.5 (1.6) 4.3 (1.4) 5.0 (1.9) <0.001‡
White cell count (x10
9
/l)¶ 8.0 (3.1) 7.7 (2.9) 8.5 (3.1) <0.001‡
Glucose(mmol/l)
**
 5.6 (1.9) 5.5 (1.7) 6.0 (2.1) 0.0002‡ 
Cholesterol (mmol/l) – mean (SD) 5.2 (1.3) 5.2 (1.2) 5.1 (1.3) 0.189* 
Pathological stroke type No. (%) No. (%) No. (%)  
Definite ischaemic  stroke 785 (93) 484 (95) 215 (90) 0.006† 
Definite haemorrhagic stroke 43 (5) 18 (4) 21 (9)  
Probable ischaemic  stroke 16 (2) 10 (2) 2 (1)  
OCSP ischaemic stroke syndrome     
Total anterior circulation infarction 53 (7) 10 (2) 32 (15) 
Partial anterior circulation infarction 352 (44) 225 (46) 96 (44) 
Lacunar infarction 221 (28) 143 (29) 53 (24) 
Posterior circulation infarction 124 (16) 80 (16) 28 (13) 
Unclassified  51 (6) 36 (7) 8 (4) 
<0.001† 
Six simple variable model ††     
Living alone 324 (38) 327 (36) 105/237 (44) 0.033† 
Independent pre-stroke 799 (95) 502 (98) 209 (88) <0.001† 
Normal verbal Glasgow coma scale 754 (90) 492/509 (97) 185/237 (78) <0.001† 
Able to lift both arms 749 (89) 494/511 (97) 180 (76) <0.001† 
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Able to walk 640 (76) 464/511 (91) 117 (49) <0.001† 
Co-morbidities No. (%) No. (%) No. (%)  
History of hypertension 453 (54) 244 (52) 143 (60) 0.047† 
Prior ischaemic heart disease  234 (28) 125 (24) 86 (36) 0.001† 
History of diabetes  103 (12) 52 (10) 41 (17) 0.006† 
History of peripheral vascular disease  36 (8) 40 (8) 18/235 (8) 0.941† 
History of cardiac failure  40 (5) 11/511 (2) 25/237 (11) <0.001† 
Atrial fibrillation  (previous or current)  162 (19) 73 (14) 69 (29) <0.001† 
Prior stroke or transient ischaemic 262 (31) 144 (28) 86 (36) 0.027† 
Smoker (current or within 1 year)  275/829 (31) 163/508 (32) 73/232 (31) 0.886† 
Good outcome: (mRS =0,1,2) ; Poor outcome: (mRS=3,4,5 or dead)  * t test, †Chi squared test, ‡ Wilcoxon 
rank sum test, §National Institute of Health Stroke Scale,  ║482 good outcome and 224 poor outcome 
strokes, ¶496 good outcome and 233 poor outcome strokes, **471 good outcome and 218 poor outcome 
strokes  ††the sixth variable is age in this model.  
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Table 6.2 The association between marker levels and poor outcome after stroke 
 Odds ratio per unit increase in marker level   (95% CI) 
Markers Unadjusted estimate 
Adjusted for 6 
simple variable Further adjustment
*
 
    
IL6 (pg/ml) 1.14 (1.10 to 1.17) 1.07 (1.03 to 1.11) 1.05 (1.01 to 1.09) 
CRP (mg/L) 1.02 (1.01-1.03) 1.01 (1.00 to 1.01) 1.01 (1.00 to 1.01) 
Fibrinogen (g/l) 1.35 (1.21 to 1.51) 1.12 (0.98 to 1.28) 1.05 (0.90 to 1.21) 
White cell count (x10
9
/l) 1.14 (1.08-1.21) 1.08 (1.01 to 1.16) 1.06 (0.99 to 1.14) 
Glucose (mmol/l) 1.06 (1.00-1.12) 1.04 (0.97 to 1.12) 0.96 (0.87 to 1.05) 
 
* adjusted for NIHSS, age, living alone and prior independence previous diabetes, history of 
cardiovascular disease, history of peripheral vascular disease, history of cardiac failure, history of 
hypertension, current or history of atrial fibrillation 
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1. Six simple variables  Reference Reference 6.2 0.63 0.78 (0.74 to 0.83) Reference 
2. Six simple variables + IL-6  10.9 <0.01 8.0 0.43 0.80 (0.76 to 0.84) <0.01 
3. Six simple variables + CRP  3.4 0.06 6.7 0.57 0.78 (0.75 to 0.82) 0.09 
4. Six simple variables + white cell count 5.62 0.02 3.3 0.91 0.78 (0.74 to 0.82) 0.53 
5. Six simple variables + white cell count + CRP + IL-6 13.39 <0.01 12.0 0.15 0.80 (0.76 to 0.83) 0.01 
Performance of 6 simple variables model (age, living alone, independent of activities of daily living prior to stroke, normal verbal GCS, able to lift arms from bed, able to 
walk) and addition of interleukin-6, C-reactive protein and white cell count as continuous variables. *The likelihood ratio test compares a goodness of fit between models 
with and without biomarker data. p<0.05  indicates that the model with biomarkers gives a significantly better fit of the data. † The Hosmer Lemeshow test compares the 
observed number of people with events to that predicted by the model. p>0.05 indicates that the model is well calibrated ‡AUROC =1 indicates perfect discrimination of a 
model between patients with good and bad outcomes.  p<0.05 indicates that the model containing biomarkers has a significantly higher AUC than one without.
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Table 6.4 Risk stratification tables to assess the clinical significance of added predictive value of IL-6 to the six simple variable model 
 Predicted risk of poor outcome from 6 simple variable model + IL- 6 Total % reclassified 
Predicted risk from 6 simple variable model <10% 10-50% 50-90% >90%  
<10%      
       Patients (n) 14 5 - - - 
       % reclassified - 26 - - 26 
       Observed % poor outcome 14 20 - - - 
10-50%      
       Patients (n) 19 534 4 - - 
       % reclassified 3 - 7 - 4 
       Observed % poor outcome 11 20 75 - - 
50-90%      
       Patients (n) - 4 137 10 - 
       % reclassified - 3 - 7 9 
       Observed % poor outcome - 50 69 90 - 
>90%      
       Patients (n) - - 4 13 - 
       % reclassified - - 23 - 23 
       Observed % poor outcome - - 100 92 - 
Total      
       Patients (n) 33 543 145 23 - 
       Observed % poor outcome 12 20 70 91 - 
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Table 6.5 Table of studies included in the systematic review 
Study 
Stroke 












Covariates in model 






? Yes Yes 70 58 Poor outcome 
3 months 
113 (36) HBP,Age,SBP,Temp, 
Glucose,CSS,Arginine 
Welsh 2009 Clinical 
supported by 
imaging 
IL6, CRP, IL18, 
TNF alpha, D 
dimer 
? Yes Yes 69 53 Poor outcome 
1 month 
219 (94) Age OCSP SSS score CRP 
IL18 TNF 





? No No 74 43 Death 3 
months 
136 (16) NIHSS Infection 
Neutrophils Monocytes 
Normetanephrines 
Rallidis 2006 Positive  
imaging only 
IL6, CRP, Serum 
Amyloid A 
? Yes Yes 54 65 Death in 
hospital 
203 (14) Age Sex BMI HBP 
Cholesterol DM Smoking 
CRP Serum Amyloid A 





Yes Yes Yes 72 53 Poor outcome 
1 month 
844 (238) Lives alone, independent 
prior to stroke, age, able to 
walk, lift arms, talk 
IL6=interleukin 6, IL-18-interleukin 18, TNF=tumour necrosis factor alpha, GABA=gamma-amino-butyric acid, SBP=systolic blood pressure, HBP=high blood pressure, 
CSS=Canadian stroke scale, SSS=Scandinavian stroke scale, NIHSS=National Institutes of Health Stroke Scale, OCSP=Oxfordshire Community Stroke Project classification,  
All studies were prospective, inpatient based studies of patients with ischaemic stroke and drew blood soon after stroke. No study examined unselected admissions of 
patients with stroke 
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Figures 
First stroke in Edinburgh Stroke Study         1408
C-reactive protein measured 844
Interleukin-6 measured 844
Fibrinogen measured 843
White cell count available 817a
Glucose available 771a
Any marker measured 844
Any marker measured and vital status available at 6 months 844
Any marker measured and modified Rankin Scale available at 6 months   750
564 excluded:
No consent for blood draw
Research samples not taken
Median NIHSS 2,  TACS 15%
844 included, with at least one marker 
measured
Median NIHSS 1,  TACS 8%
 
Figure 20 Flowchart of data available in the Edinburgh Stroke Study. 
a Results are incomplete for glucose and white cell count, as for outpatients these results were 
sometimes reported to the general practice rather than the central results database.
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Figure 21 Association between levels of inflammatory marker vs poor outcome (mRS >2 or death) in 
the Edinburgh Stroke Study.  
Expressed as ratio of odds in middle and top thirds of marker distribution, versus the referent lower third. Dotted 
line indicates OR=1 (i.e. same odds as lower third). OR are reported unadjusted and adjusted for six simple 
variables (age, living alone, independent of activities of daily living prior to stroke, normal verbal GCS, able to lift 
arms from bed, able to walk). Tertiles of: IL-6, 2.8 and 5.5 pg/l, CRP: 1.9 and 7.1 mg/l, fibrinogen: 4.1 and 5.1 g/l, 
white cell count: 7.0 and 9.1 x109 cell/l, and glucose: 5.2 and 6.3 mmol/l. 
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Figure 22 Association between upper third and lower third of interleukin 6 by subgroups in the 
Edinburgh Stroke Study.  
Each OR is adjusted for the six simple variables (age, living alone, independent of activities of daily living prior to 
stroke, normal verbal GCS, able to lift arms from bed, able to walk), and the estimate for the whole cohort is given 
by the vertical dashed line. OR of >1 indicates that increased levels of marker are associated with poorer outcome in 
that category of patient. P values are derived from tests for heterogeneity.
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1.07 (1.01 to 1.13)
1.06 (1.0 to 1.14)
1.18 (1.08 to 1.29)
1.15 (1.09 to 1.21)
1.09 (1.01 to 1.26)
1.07 (1.03 to 1.11)
OR for death/poor outcome per 1pg/ml increase 
(95% CI)
Higher levels 
associated with better 
outcome
Higher levels 
associated with worse 
outcome
Summary OR 1.07 (1.04 to 1.10)





Figure 23 Systematic review and meta-analysis of studies of interleukin 6 (IL-6) with available data OR 
for death or poor outcome is presented per unit increase in marker levels.  
Sizes of squares are proportional to the number of patients in each study. Summary estimates are calculated 
by fixed effects meta-analysis. P values show statistical significance of summary estimate of effect and I2 is 
reported as a measure of heterogeneity between studies used to calculate the summary OR.  += adjusted for 
age or stroke severity, ++= adjusted for age and stroke severity, +++= adjusted for age, stroke severity and 
other factors 
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Chapter 7.  Plasma and serum markers of inflammation, thrombolysis, 
thrombosis, cardiac strain, neural and glial damage and poor 
outcome after acute cerebrovascular disease: BBISS, a prospective 
cohort study 
Introduction  
My systematic review of the association between blood biomarkers and the risk of 
poor outcome after stroke (Chapter 5) showed that many of these studies were 
either small, did not adjust for neurological impairment or age, or used optimised 
thresholds which can over-estimate the association between a marker and clinical 
outcome. Although many of these studies proposed that blood markers might 
therefore be useful in predicting poor outcome after stroke, none examined whether 
the addition of a markers to a validated prognostic scores added a useful degree of 
predictive ability. 
Age and clinical measures of neurological impairment, for example inability to 
walk, talk or lift both arms, are strongly associated with poor outcome after stroke. 
These clinical variables may also be associated with higher levels of markers of 
inflammation, thrombolysis, thrombosis, cardiac strain, neural and glial damage, 
confounding any association between the level of blood markers and outcome. To 
assess the potential utility of markers as an aid to predicting prognosis in routine 
clinical practice, appropriate adjustment for these variables is therefore important.  
In chapter 6 I have examined the additional value of CRP, IL-6 and white cell count 
to a validated clinical prognostic model in the ESS cohort, and found that only IL-6 
improved the prediction of poor outcome after stroke, by an amount that was 
unlikely to be clinically important (Whiteley et al. 2009d). However, as blood was 
drawn at variable time after symptom onset (a median of 13 days) post-stroke, 
infection may have been responsible for some of the association in that study, and I 
was unable to make adjustment for symptoms of infection.  
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In this chapter, I will assess in my own BBISS cohort data whether blood markers of 
inflammation, thrombosis, thrombolysis, cardiac strain, cerebral damage add to 
variables in previously validated prognostic models for the prediction of poor 
outcome after stroke (Counsell et al. 2002a, Konig et al. 2008a). 
I will therefore: 
• Assess the univariate association of clinical variables at baseline with: (a) 
disability or death (‘poor outcome’) by 3 months; (b) death by 3 months; and 
(c) complete recovery by 24 hours among patients presenting to an emergency 
department with confirmed acute cerebrovascular disease. 
• In this cohort, calculate the univariate association of 19 serum and plasma 
markers drawn less than 24 hours after stroke or TIA with: (a) poor outcome 
by 3 months; (b) death by 3 months; and (c) complete recovery by 24 hours. 
• Adjustment for stroke severity, age, prior infection and other important 
covariates, to assess the impact on the association of plasma and serum 
markers with: (a) poor outcome by 3 months; (b) death by 3 months; and (c) 
complete recovery by 24 hours. 
• Assess the improvement of the prediction of poor outcome at 3 month after 
stroke or TIA by the addition of serum and plasma markers to prediction 
models based on established clinical variables alone. 
Methods  
Cohort recruitment 
I have described the recruitment of the cohort in detail in chapter 3 and the 
measurement of blood markers in chapter 4. In brief, I recruited patients presenting 
to an emergency department when an emergency department clinician suspected 
stroke or TIA in a symptomatic patient with symptoms of less than 24 hours 
duration. At the baseline assessment I collected measures of neurological 
impairment and co-morbidity. A gold standard diagnosis of confirmed stroke or 
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TIA (‘acute cerebrovascular disease’) was made by a panel of experts after 
considering the presentation, relevant imaging and clinical course of each patient, 
blinded to the results of blood marker levels. I drew blood as soon as patients were 
assessed in the emergency department and then at 24 hours after symptom onset, if 
that fell within normal working hours. Accredited research and clinical laboratories 
measured adiponectin, CRP, ICAM-1, IL-6, MMP-9, TNF-α, vWF, white cell count, 
neutrophil fraction, D-dimer, fibrinogen, tPA, NT pro-BNP, troponin T, tau, S100B, 
creatinine and glucose in serum and plasma blinded to clinical information. 
Follow up 
I followed up each patient at 24 hours and 3 months after symptom onset. At 24 
hours, I spoke to each patient and asked them whether their presenting symptoms 
had resolved completely (yes or no). At 3 months after symptom onset I posted a 
questionnaire to each patient, based upon the Oxford Handicap Scale (Bamford et 
al. 1989a) (Table 7.1). The OHS (a modified Rankin Scale) though intended to 
measure handicap (participation), actually categorises levels according to a mixture 
of a description of symptoms and disability. It does, however, yield grades of 
recovery after stroke that have face validity and are easily understood. 
Conventionally, grades 0-2 describe people who are independent for activities of 
daily living, whereas individuals in grades 3-5 require increasing levels of help from 
other people. 
If a patient failed to return their questionnaire by post, or provided an illegible or 
uninterpretable response, I made a telephone call to them or their carer. I used a 
structured interview to measure the OHS over the telephone (Wilson et al. 2002). I 
ascertained vital status by contacting the patient’s GP at 3 months after onset (as 
normally a general practitioner is informed more quickly of death than the General 
Register Office (Scotland)). For this analysis, I classified patients who were dead or 
OHS 3-5 as poor outcome and OHS 0-2 as good outcome.  
Statistical analysis 
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Association between clinical variables with poor outcome at 3 months, death at 3 
months and recovery within 24 hours 
I assessed the association of baseline clinical variables with poor outcome at 3 
months, death at 3 months and recovery at 24 hours by calculating odds ratios and 
their 95% confidence intervals with simple logistic regression analysis (logistic).  
Linearity of the association between serum and plasma markers with poor 
outcome at 3 months and recovery at 24 hours 
Logistic regression analysis assumes a linear relationship between continuous 
variables and the log-odds of poor outcome. I tested whether the relationship 
between blood markers with poor outcome was a log-linear relationship at 3 months 
and 24 hours. I used likelihood ratio tests to compare models built with a restricted 
cubic spline transformation of blood marker variables with models built with blood 
markers as linear variables. Where relationships were significantly nonlinear, I 
plotted transformations of marker levels against predicted probabilities of poor 
outcome and chose a variable transformation that fitted the data well on inspection. 
I further tested these transformations to ensure linearity with model specification 
link tests (linktest). I used linear logistic regression (logistic) to estimate the 
association between blood markers (transformed where necessary) with poor 
outcome at 3 months and 24 hours after symptom onset. 
Univariate associations between marker levels with poor outcome at 3 months, 
death at 3 months and recovery at 24 hours after symptom onset 
I examined the association between poor outcome at 3 months, death at 3 months 
and recovery at 24 hours with a series of univariate logistic regression analyses, and 
report odds ratios as a measure of association, 95% confidence intervals as a 
measure of uncertainly and the Wald test P values to test the null hypothesis that 
OR = 1. 
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Adjusted associations between marker levels with poor outcome at 3 months, 
death at 3 months and recovery at 24 hours after symptom onset 
I adjusted the association between blood markers and different outcome events 
(poor outcome, death and recovery at 24 hours) for baseline neurological 
impairment, measured using the NIHSS score, and age in a series of multivariable 
logistic regression analysis. I then made further adjustment ofor baseline handicap, 
and in addition for inflammatory markers I made adjustment for previous 
symptoms of infection and for cardiac markers current or previous AF, cardiac 
failure and previous cardiac vascular disease. 
The additional prognostic utility of blood markers to clinical prognostic 
variables, for predicting poor outcome after acute cerebrovascular disease 
I first applied the variables, recorded at baseline, that were part of 2 previously 
described models to my cohort with logistic regression to determine the predicted 
probability of death or dependency. One model incorporated six baseline variables 
(age, prior dependence in activities of daily living, ability to lift both arms from the 
bed, ability to walk without assistance, living alone at the time of the event, and 
orientation in time and person) (Counsell, Dennis, & McDowall 2004b), and the 
other incorporated NIHSS and age (Konig et al. 2008d). I then added each of the 
blood markers that were strongly associated with poor outcome, independent of age 
or NIHSS, (i.e. IL-6 and NT pro-BNP) to each of the clinical models. I allowed the 
coefficients of each variable to vary, rather than applying the coefficients from a 
previous cohort. This gave blood markers and clinical variables a more even chance 
of success in this cohort. I tested all two way interactions (fitint) within each 
model, then to adjust for different sampling times after stroke onset examined for 
interactions between marker levels with time to blood draw. 
I evaluated the added value of each blood markers to models constructed with 
clinical variables alone by measuring goodness of fit, discrimination, model 
calibration and reclassification. 
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Goodness of fit 
(i) I compared the likelihood of nested logistic regression models with and 
without a biomarker variable with the likelihood ratio statistic (lrtest), 
and report the associated P value with reference to the χ2 distribution. 
(ii) I used the fitstat command to calculate Akaike’s information criterion 
(AIC) for nested models with and without blood markers.  
( ) kAIC e 2likelihoodlog*2 +−=  
Where k= degrees of freedom 
AIC measures both fit i.e. -2 Ln (likelihood) and complexity i.e. number 
of degrees of freedom. Of two models, that with the lower AIC is 
generally considered better (McGeechan et al. 2008b).  
Model discrimination 
(iii) I used the predicted probability of poor outcome from each model to 
calculate the area under receiver operator curves (AUROC) (roctab). I 
compared the AUROC with the roccomp command which uses a non-
parametric method (DeLong, DeLong, & Clarke-Pearson 1988). 
Consider a pair of patients, one randomly selected from patients with a 
poor outcome, and the other randomly selected from patients with a 
good outcome. The AUROC can be understood as the probability that 
the patient with a poor outcome has a higher predicted probability (from 
one of the logistic regression models) of poor outcome than a patient 
with a good outcome, with a value of 1 indicating excellent 
discrimination and a value of 0.5 no better discrimination than chance 
(McGeechan et al. 2008a). The calculation of the AUROC is based on 
ranking predicted probabilities of poor outcome, rather than measuring 
the absolute difference. Therefore the contribution to the AUROC of a 
pair of patients with predicted risks 1% apart is the same as a pair with 
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predicted risk 20% apart. It is unlikely that a risk difference of 1% is 
clinically important, though one of 20% may be. 
(iv) The integrated discrimination index (IDI) was developed provide an 
estimate of the mean improvement in predicted probability when 
evaluating the additional value of a new marker (Pencina et al 2008). It 
measures the extent to which a new marker adds a model’s ability to 
improve average sensitivity without sacrificing average specificity. The 
IDI is calculated as follows:  
( ) ( )
goodoriginalpoororiginalgoodnewpoornew
ppppIDI ,,,, −−−=  
Where p is the maximum likelihood estimation of predicted 
probability, new indicates a model with biomarkers, original 
is a model with clinical variables only, poor indicated poor 
outcome and good indicates good outcome. 
As the magnitude of the IDI is often extremely small, a relative, rather 















A simple interpretation of the integrated discrimination improvement is 
that it measures the average difference in predicted outcome between 
patients with good and poor outcome, for a model containing 
biomarkers over a model based upon clinical variables alone.  
Model calibration 
(v) I used the Hosmer-Lemeshow test as a measure of model calibration 
(hl). This test divides the sample into deciles of predicted probability 
and performs a χ2 test, comparing the difference between the observed 
and expected number of patients with poor outcome in each decile. 
Where the χ2 is non-significant, the model may fit the data well and is 
said to be well calibrated. 
Whiteley W.N. Blood Markers in Stroke University of Edinburgh 2010 
 
Chapter 7  BBISS: Blood markers and poor outcome after stroke  195 
I plotted the observed against predicted risks in a series of graphs, to 
visualize where calibration problems might arise.  
Reclassification 
(vi) The most important measure of the utility of a new marker is whether it 
improves the prediction of poor outcome to a clinically important 
degree. One way of measuring this is to determine the number of people 
who, as a result of the information from the new marker, are moved 
correctly between strata of predicted prognosis that are considered 
‘clinically significantly different’. Before calculating measures of 
reclassification, I defined the clinically important threshold as a 
predicted probability of poor outcome of >90%, >50% and >10%, in 
discussion with senior stroke physicians. The measure I chose for 
reclassification was the net reclassification index (Pencina et al 2008). The 
































p ==  (4) 
 The NRI is then calculated from the probabilities (1) to (4): 
( ) ( )( ) ( ) ( )( )goodoutcome|downgoodoutcome|uppooroutcome|downpooroutcome|upNRI =−=−=−== pppp  
The limitation of the NRI are: (a) it depends heavily on the choice of cut-
points, (b) gives equal weight to individuals moving up or down across 
thresholds (c) does not account for patients who move over more than 
one threshold value. 
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(vii) Because of the problems with the NRI, I plotted the predicted risk from 
models with blood markers against the predicted risk of models based 
on clinical variables alone. I gave some measure of reclassification by 
highlighting those patients whose predicted probability of poor outcome 
changed by >10% with the addition of blood markers, and whether the 
change improved or worsened the categorization. 
Statistical significance 
I performed all statistical analysis using Stata 10, StataCorp 2009. Each table, with 19 
markers therefore tests 19 hypotheses. There is a risk of type I error. The Bonferroni 
correction for multiple comparisons becomes overly conservative where more that 5 
hypotheses are tested, so I considered a P value of less than 0.01 (i.e. 0.05/5) to be 
statistically significant. 
Results 
I recruited 285 patients with confirmed acute cerebrovascular disease and obtained 
complete follow up data for all patients for ‘recovery at 24 hours’ and for death at 3 
months. For 283 (99%) patients I had data for handicap at 3 months. I made a 
baseline assessment of patients at a median of 6.2 hours after the onset of their 
symptoms. At 3 months after symptom onset, 88 (31%) patients were dependent on 
others for their activities of daily living and 35 had died (12%). At 24 hours after 
symptom onset, 40 (14%) of patients with acute cerebrovascular disease reported a 
complete recovery.  
The association of clinical features with poor outcome at 3 month, and complete 
recovery by 24 hours 
Neurological impairment: Patients with more severe neurological deficits at 
baseline had an increased risk of poor outcome (Table 7.2) or death at 3 months 
(Table 7.4) and a reduced chance of recovery at 24 hours (Table 7.4) after symptom 
onset. For each 3 point increase in the NIHSS score, there was a doubling of the 
odds of poor outcome (OR=2.00, 95% CI: [1.65 to 2.4]), and an approximately 50% 
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increase in the odds of death (1.58 [1.40 to 1.79]). Figure 24 summarises the non-
linear relationship between NIHSS and recovery at 24 hours. A series of 
dichotomous variables of neurological impairment (orientation to time, place and 
person, the ability to lift the arms from the bed and the ability to walk) were each 
strongly associated with increased odds of poor outcome or death; there were 
negative  relationships of a similar strength with recovery by 24 hours. 
Age: Increasing age increased the odds of poor outcome (Table 7.2) or death ar 3 
months (Table 7.3) in older patients. The odds of poor outcome or death 
approximately doubled for each decade increase in age. The observed reduction in 
the odds of recovery at 24 hours with increasing age was not statistically significant 
(Table 7.4). 
Comorbidities: Atrial fibrillation, discovered either before, or at the time of 
admission to hospital was present in about a quarter of patients, and associated 
with approximately a tripling of the odds of poor outcome (Table 7.2) or death by 3 
months (Table 7.3). Prior cognitive impairment (14% of those with acute 
cerebrovascular disease) was also very strongly associated with poor outcome. The 
associations between poor outcome with AF or cognitive impairment were 
confounded by age and neurological impairment. After adjustment for the NIHSS 
and age, the association with AF (OR=1.47, 95% CI [0.74 to 2.89]) was attenuated and 
no longer statistically significant, though cognitive impairment remained a strong 
predictor (5.40 [1.88 to 15.56]). 
I could not exclude a modest positive (or negative) association between death, poor 
outcome or recovery at 24 hours with history of prior stroke or TIA, MI or angina, 
heart failure or diabetes; for most of these dichotomous variables, the observed 
positive association was weak. 
Haemorrhagic stroke: The number of patients with intracerebral haemorrhage 
(n=13) or subarachnoid haemorrhage (n=2) was small; 8/15 of these haemorrhagic 
strokes had a poor outcome, 6/15 died and none recovered by 24 hours after onset.  
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Ischaemic stroke syndrome: Almost all patients with the clinical syndrome of total 
anterior circulation infarction were dead or dependent at 3 months (40/43, 93%) 
though one 81 year old woman made a remarkable recovery at 24 hours after 
presenting with left hemianopia, moderate hemiparesis and hemi-inattention. Most 
patients with clinical syndrome of lacunar infarction had a good recovery (55/75, 
73%) and only 1 died.  
Brain imaging: The presence of any visible stroke lesion (haemorrhagic or 
ischaemic) on brain imaging was not statistically significantly associated with poor 
outcome or death, though the absence of a lesion was associated with recovery at 24 
hours. 
Reperfusion therapy: Only 7 patients were treated with rtPA (6) or had a neuron-
interventional intra-arterial clot retrieval procedure (1), of whom 5 had a poor 
outcome.  
Physiological variables at baseline: I found no evidence of an association between 
admission systolic or diastolic blood pressure and poor outcome, death or recovery 
at 24 hours. A lower admission temperature was associated with poor outcome at 3 
months, an association that remained robust to adjustment for age, neurological 
impairment and delay to admission (OR=0.52 95% CI [0.31 to 0.87], per oC increase 
in body temperature). 
Linearity of association between serum and plasma markers and outcome at 24 
hours and 3 months 
The relationship between plasma and serum marker levels and poor outcome at 3 
months was approximately linear in univariate analysis for: adiponectin, CRP, 
ICAM-1, TNF-α, IL-10, vWF, white cell count, fibrinogen, tau, creatinine, glucose, 
age and NIHSS (data not shown). Models built with restricted cubic splines of 
serum and plasma markers had a better fit than a linear model for the markers: IL6 
(LR test P=0.049), D-dimer (P=0.002), tPA (P=0.004), NT pro-BNP (P=0.002) and 
S100B (P=0.03). After examining plots of these markers against predicted 
probabilities from restricted cubic spline models, I decided to keep IL-6 and tPA as a 
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linear predictors and used the natural logarithms of S100B, NT pro-BNP and D-
dimer. 
The relationship between plasma and serum marker levels and poor outcome at 24 
hours was approximately linear in univariate analysis for: adiponectin, CRP, ICAM-
1, IL-6, TNF-α, IL-10, white cell count, D-dimer, fibrinogen, tPA, tau, S100B, 
creatinine and age. Models built with restricted cubic splines of untransformed 
serum and plasma markers had a better fit than a linear model for the markers: vWF 
(LR test  P=0.02), NT pro-BNP (P=0.006), glucose (P=0.04) and NIHSS (P<0.0001). 
After examining plots of these markers against predicted probabilities from 
restricted cubic spline models, I decided to keep vWF as a linear predictor and took 
the natural logarithms of NT pro-BNP. I examined a threshold of an NIHSS of 5 to 
predict recovery by the next day (Figure 24).  
Association between markers and poor outcome or death at 3 months and recovery 
at 24 hours 
The pattern seen for most markers, though of differing strength and boundaries of 
uncertainty, was for positive associations with poor outcome and death and 
negative associations with recovery at 24 hours, associations that attenuated after 
adjusting for neurological impairment and age (Figure 25). Because few patients 
died at 3 months or recovered at 24 hours, there is much uncertainty about the 
magnitude of the association between markers levels and these outcomes in this 
cohort. These data are summarized in Table 7.6, Table 7.7 and Table 7.8. 
Inflammatory markers: Higher levels of inflammatory markers were, in general, 
positively associated with increased odds of poor outcome and of death at 3 
months. Associations were slightly stronger with death than with poor outcome, 
though for each individual marker this difference could be explained by chance. Of 
the markers of inflammation, IL-6 had the strongest association with poor outcome 
and death at 3 months, and recovery by 24 hours, associations that attenuated after 
adjusting for neurological impairment and age. Of the other markers, only the 
association between adiponectin and death remained statistically significant (Wald 
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test P=0.007) after making adjustment for age and severity of neurological 
impairment. 
Markers of thrombosis: Higher plasma levels of log-transformed D-dimer were 
positively associated with increased odds of both poor outcome and death alone, 
and reduced odds of recovery at 24 hours. These associations attenuated after 
adjustment for neurological impairment and age for each outcome, and remained 
strong (OR=4.07, 95% CI:[1.96 to 8.44]) only for death. 
Tissue plasminogen activator: Higher levels of tPA were associated with death, an 
association that remained after adjustment for neurological impairment and age. 
After adjustment, no other associations were either strong or statistically significant. 
Cardiac strain: Both a higher blood level of log-transformed NT pro-BNP and a 
detectable troponin T were associated with higher odds of poor outcome or death. 
Only lower levels of NT pro-BNP were associated with recovery at 24 hours after 
symptom onset. Note, however, that troponin T was only present in 52/368 patients, 
and was therefore analysed as a yes/no variable. 
Cerebral damage: Neither S100B nor tau were associated with poor outcome or 
death at 3 months or recovery at 24 hours. 
Creatinine and glucose: After adjustment, only the association between glucose and 
death remained statistically significant. 
The addition of blood markers to variables from clinical prognostic models 
I tested the addition of markers that were significantly associated with poor 
outcome to variables in two clinical models to predict poor outcome at 6 months. 
These markers were interleukin-6 and NT pro-BNP (Table 7.10). The final models 
are shown in Table 7.9. There were no statistically significant two way interactions 
(P>0.05) between marker levels and time to blood draw (when it was forced into the 
final model), stroke severity or age. 
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The six simple variable model and the ‘NIHSS and age’ model were well calibrated 
in this dataset, and showed good discrimination measured by the AUROC. The 
addition of either IL-6 or NT pro-BNP to either of these models based on clinical 
variables led to an improvement in model fit, when measured either by the 
likelihood ratio statistic or Akaike’s information criterion. All the models were well 
calibrated; examples of calibration plots are shown for IL-6 in Figure 27  and Figure 
26. However, the addition of either IL-6 or pro NT-BNP either to a model with six 
simple variables or one based on the NIHSS and age improved the AUROC by a 
very small amount (0.01) which may have been due to chance. There was a small 
integrated discrimination improvement that was a little more for models with IL-6 
than those with pro NT-BNP. A model with interleukin-6 better reclassified 5% of 
patients across clinically relevant borders when compared to a model with six 
simple variables alone, though this may have been due to chance; the addition of IL-
6 to NIHSS and age, and the addition of NT pro-BNP either set of variables slightly 
worsened classification of patients by a small amount that was not statistically 
significant. Figure 28 to Figure 32 confirm the findings from inspection of the 
summary statistics: few patients were reclassified by an amount greater than 10% of 
the predicted probability with the addition of IL-6 or NT pro-BNP; there was no 
clear advantage in accuracy of classification and no patients were reclassified across 




In patients with acute cerebrovascular disease, markers of inflammation, 
thrombosis, thrombolysis, and cardiac strain were associated with an increased risk 
of poor outcome at 3 months. Adjustment for neurological impairment at baseline 
and age substantially attenuated these associations. After adjustment, and with 
correction for multiple comparisons, there was robust evidence of an independent 
and positive association between both NT pro-BNP and IL-6 with poor outcome. 
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However, the results were also compatible with all of the markers (with the 
exception of IL-10 and tau), having a similar, though small, positive association with 
poor outcome.  
There was also good evidence that higher levels of D-dimer, adiponectin, tPA, pro 
NT-BNP, troponin T and glucose were associated with an increased risk of death by 
3 months. None of the markers was associated with an increased chance of recovery 
at 24 hours after symptom onset, after adjusting for neurological impairment and 
age. 
However, despite their strong association with poor outcome, neither IL-6 nor pro 
NT-BNP improved the prediction of poor outcome beyond that of validated 
prognostic models based on clinical variables alone. 
Strengths and weaknesses of the study 
Study power 
The estimates of the odds ratios often had bounds of uncertainty that were 
compatible with a moderately strongly positive or negative association between 
blood markers and poor outcome. It is likely that a larger sample size would have 
reduced this uncertainty. However, for those markers that could have been 
positively or negatively associated with poor outcome, the upper bound of the 
confidence interval was in general no greater than OR=2.5 and the lower bound no 
less that OR=0.5. These only moderate association indicate these markers are 
unlikely to represent clinically useful discriminators (Pepe et al. 2004a). The 
problem of sample size was compounded by missing values for some blood 
markers; though these were missing at random, and so unlikely to lead to an 
important selection bias, they did lead to loss of power in multivariable logistic 
regression analysis. Despite this, the study was larger than most of the previous 
studies of the association between serum or plasma markers and poor outcome after 
stroke (Chapter 5)(Whiteley et al. 2009b). 
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I measured outcome with the Oxford Handicap Scale, an ordinal scale. To increase 
power, I could have analysed the data with ordinal logistic regression analysis, 
rather than dichotomising the OHS into patients who were alive and independent 
and patients who were dead or dependent. However, ordinal logistic regression 
assumes that relationships are parallel with each step on the ordered outcome scale; 
here the relationship between OHS and most markers violated this assumption. 
Case Mix 
The strokes in this study may have been mild in comparison to other studies, 
though they are representative of stroke patients presenting to an emergency 
department. I found no evidence that associations between blood markers and poor 
outcome were different in patients with different levels of neurological impairment: 
two way interactions between stroke severity and marker levels did not 
significantly improve the fit of models to predict poor outcome at 3 months after 
stroke. However, tests for interaction have a relatively lower power, so larger 
studies would be needed to be absolutely certain that the associations between 
blood marker levels and outcome were not different in patients with low and high 
neurological impairment. 
Causality 
This study was designed to obtain empirical evidence on whether blood markers 
have clinical utility as predictive tools, irrespective of the mechanism of the 
association. This study therefore did not aim to elucidate the causal role of 
particular molecules or physiological pathways. Although there are many plausible 
hypotheses for an aetiological role of higher levels of each marker with poor 
outcome after acute cerebrovascular disease, even in a perfect observational study, 
free of the influence of selection or information bias, causality is not the only factor 
that might explain the observed associations.  
First, as I drew blood samples some time after symptom onset, the key processes 
responsible for poor outcome that start within minutes of symptom onset may 
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induce a rise in a particular blood marker level, yet have no relationship to the 
physiological process that the marker purports to measure (e.g. thrombosis and D-
dimer). This ‘reverse causality’ may explain some of the associations between 
marker level and poor outcome. However, I was unable to demonstrate an 
interaction between the observed associations and time to blood draw from 
symptom onset, which might be expected if reverse causality were an important 
explanation. 
Second, the choice of confounding variables used for adjustment can colour the 
interpretation of the adjusted analyses. Here I adjusted univariate associations for 
neurological impairment and age, as these are powerful predictors of poor outcome. 
The adjusted odds ratios are therefore a measure of the effect of markers on poor 
outcome over and above the effect of neurological impairment and age. However, if 
a particular physiological process acted solely through greater neurological 
impairment (hence higher NIHSS) this adjustment would lead to an attenuation of 
an important association.  
Third, many authors assume that there are good markers of particular physiological 
pathways- i.e. ‘biomarkers’. However, as many markers rise with a number of 
different physiological processes – for example the acute inflammatory response 
lead to increased levels of putative markers of both inflammation and thrombosis – 
it is difficult to draw any conclusions about the role of broad categories of markers 
such as ‘inflammation’ or ‘thrombosis’ and poor outcome. 
Measurement of outcome 
I used the Oxfordshire Handicap Scale to measure impairment in this study. There 
have been concerns about the reliability of this scale, usually in face to face 
interview, but also through postal questionnaire. Some patients were followed up 
by telephone and others by post; as it is likely that postal responders were in better 
health than telephone responders, potentially there is a difference in the accuracy of 
measurement of outcome between patients followed up by telephone and those 
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followed up by post. Also, as measurement of disability was made by the patients 
themselves, it was not blinded to the severity of the stroke, though was blind to 
marker levels. However the marker levels and stroke severity are closely related. 
However, as the direction of all association was in the same direction for death as 
well as poor outcome, I believe that these associations are robust. 
Strengths 
This study met almost all the methodological criteria for a reliable study of 
prognosis (Tugwell P & Sackett D 1981): (i) I assembled an inception cohort at an 
early and uniform point in the course of the illness and included subjects with a 
range of disease severities; (ii) I avoided diagnosis access bias, as I made great 
efforts to assess all patients with suspected stroke; (iii) I achieved almost complete 
follow up; (iv) I used objective criteria for determining outcome, which were 
validated and accurate; (iv) I adjusted analyses for other important prognostic 
variables and confounding factors; and (iv) measured markers blinded to outcome 
in established research and clinical laboratories with low coefficients of variation. 
Unanswered questions and future research 
The most remarkable and consistent association in this study was the association 
between levels of the cardiac markers NT pro-BNP and troponin T, even after 
adjusting for prior cardiac disease, heart failure and atrial fibrillation. The reason for 
this association is unclear. Possible explanations are an association between cardiac 
markers and arrhythmia, or with cardiac dysfunction at the time of acute 
cerebrovascular disease, or unmeasured cardiac disease. 
Implications for research 
• The markers NT pro-BNP and IL-6, although they are associated with poor 
outcome, independent of neurological impairment (measured with the 
NIHSS) or age, did not help to improve the prediction of poor outcome.  
• Further research may identify blood markers which do provide clinically 
useful predictive power for ‘poor outcome’. However, it may be more 
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fruitful to explore their role in predicting specific events (e.g. recurrent 
ischaemic stroke or DVT). 
Implication for practice 
• None of the markers measured in this thesis can be recommended for the 
prediction of poor outcome at 3 months after presentation with acute 
cerebrovascular disease. 
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Tables 
 Table 7.1 The Oxford Handicap Scale 
 Handicap level  Description of impact on daily life  Grade  
none  no change  0  
minor symptoms  no interference  1  
minor handicap  some restrictions but able to look 
after self  
2  
moderate handicap  significant restriction; unable to lead 
a totally independent existence 
(requires some assistance)  
3  
moderate-to-severe handicap  unable to live independently but does 
not require constant attention  
4  
severe handicap  totally dependent; requires constant 
attention day and night  
5  
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Table 7.2 The association between baseline clinical features and poor outcome (dead or dependent on other for activities of daily living) at 3 months after presentation 
with acute cerebrovascular disease 
Baseline characteristic   Odds ratio (95% CI) 
 




Poor outcome                 
(n=123)  Poor vs good outcome 
P  
value 
Male sex (n, %) 135 (47.7)  86 (53.8) 49 (39.8)  0.66 (0.44 to 0.99) 0.045 
Age (years) (mean, SD) 74.4 (12.5)  70.6 (12.6) 79.4 (10.4)  1.96 (1.54 to 2.49)* <0.001 
Fellow collected variables  n (%)  n (%) n (%)    
Symptoms of infection 27 (9.5)  11 (6.9) 16 (13.0)  2.03 (0.9 to 4.5) 0.090 
Prior cardiac vascular disease 67 (23.7)  36 (22.5) 31 (25.5)  1.16 (0.67 to 2.01) 0.601 
Prior peripheral vascular disease 16 (5.7)  5 (5.7) 7 (5.7)  1.01 (0.37 to 2.81) 0.978 
Prior TIA or stroke 76 (26.9)  34 (21.3) 42 (34.2)  1.92 (1.12 to 3.27) 0.016 
Prior heart failure 22 (7.9)  8 (5.1) 14 (11.6)  2.45 (0.99 to 6.05) 0.052 
AF (prior or during ED assessment) 74 (26.2)  26 (16.3) 48 (39.0)  3.30 (1.89 to 5.74) <0.001 
Diabetes mellitus 37 (13.0)  20 (12.5) 17 (13.8)  1.12 (0.56 to 2.25) 0.744 
Prior cognitive impairment 39 (13.8)  6 (3.8) 33 (26.8)  9.35 (3.8 to 23.2) <0.001 
Recovery by 24 hours 40 (14.1)  34 (21.3) 6 (4.9)  0.19 (0.08 to 0.47) <0.001 
Simple variables        
Independent prior to admission 246 (86.9)  156 (97.5) 90 (73.2)  0.07 (0.02 to 0.20) <0.001 
Living alone 96 (33.9)  53 (33.1) 43 (35.0)  1.09 (0.66 to 1.78) 0.661 
Orientated to time place & person 208 (73.5)  144 (90.0) 64 (52.0)  0.12 (0.06 to 0.23) <0.001 
Able to lift both arms 180 (63.6)  131 (81.9) 49 (39.8)  0.15 (0.08 to 0.25) <0.001 
Able to walk without help 126 (44.5)  106 (66.3) 20 (16.3)  0.10 (0.06 to 0.18) <0.001 
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Baseline characteristic   Odds ratio (95% CI) 
 




Poor outcome                 
(n=123)  Poor vs good outcome 
P  
value 
Pathological stroke subtype n (%)  n (%) n (%)    
Probably ischaemic 34 (12.0)  27 (16.9) 7 (5.7)  - - 
Definitely ischaemic 234 (82.7)  129 (80.6) 105 (85.4)  - - 
Intracerebral or subarachnoid bleed 15 (5.3)  4 (1.9) 11 (8.1)  3.83 (1.19 to 12.34) 0.024 
OCSP classification, presentation†        
Total anterior circulation infarction 43 (16.0)  3 (1.9) 40 (35.7)  - - 
Partial anterior circulation infarction 114 (42.5)  72 (46.2) 42 (37.5)  - - 
Lacunar infarction 75 (28.0)  55 (35.3) 20 (17.9)  - - 
Posterior circulation infarction 18 (9.0)  18 (11.5) 6 (5.4)  - - 
Unclassifiable clinical syndrome 12 (4.5)  8 (5.1) 4 (3.6)  - - 
Imaging lesion        
Cortical infarction 123 (43.5)  57 (35.6) 66 (53.6)  - - 
Lacunar infarction 40 (14.1)  29 (18.1) 11 (8.9)  - - 
Posterior circulation infarction 21 (7.4)  14 (8.8) 7 (5.7)  - - 
>1 territory infarction 4 (1.4)  0 4 (3.2)  - - 
Intracerebral or subarachnoid bleed 15 (5.3)  4 (2.5) 11 (8.9)  - - 
No visible lesion 74 (26.1)  54 (33.8) 20 (16.2)  - - 
No scan 6 (2.1)  2 (1.3) 4 (3.3)  - - 
Any visible lesion 191 (67.5)  101 (63.1) 90 (73.2)  1.59 (0.95 to 2.67) 0.075 
        
Table 7.2continued        
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Baseline characteristic   Odds ratio (95% CI) 
 




Poor outcome                 
(n=123)  Poor vs good outcome 
P  
value 
Medications n (%)  n (%) n (%)    
Any antiplatelet agent 121 (42.8)  63 (39.4) 58 (47.2)  1.37 (0.85 to 2.21) 0.190 
Warfarin 13 (4.7)  5 (3.1) 8 (6.7)  2.2 (0.70 to 6.90) 0.177 
Antihypertensive 153 (54.1)  84 (52.5) 69 (56.1)  1.16 (0.72 to 1.58) 0.547 
Statin 99 (35.5)  48 (30.2) 51 (42.5)  1.71 (1.04 to 2.81) 0.034 
rtPA (intra-arterial or -venous) 7 (2.5)  1 (0.6) 6 (4.9)  8.15 (0.97 to 68.6) 0.054 
Current smoker 65 (23.2)  40 (25.3) 25 (20.5)  0.76 (0.43 to 1.34) 0.344 
Examination findings        
Normal pedal pulses 133 (47.3)  93 (58.1) 40 (33.1)  0.36 (0.21 to 0.58) <0.001 
Continuous variables  mean (SD)  mean (SD) mean (SD)    
Systolic BP (mmHg) 156 (29.9)  159 (29.3) 153 (30.5)  0.93 (0.86 to 1.01)
‡
 0.080 





C) 36.4 (0.6)  36.5 (0.5) 36.3 (0.7)  0.55 (0.36 to 0.84)
§
 0.005 
Continuous variables  median (IQR)  median (IQR) median (IQR)    
Well to admission (hrs)**  6.3 (13.4)  6.3 (12.2) 6.0 (12.7)  0.98 (0.86 to 1.01)
¶
 0.192 
Found to admission (hrs)**  4.2 (6.2)  5.1 (10.1) 2.7 (4.7)  0.95 (0.92 to 0.99)
¶ 
 0.005 
Admission to stroke fellow (hrs) 0.9 (1.4)  0.9 (1.6) 0.9 (1.4)  1.01 (0.97 to 1.06)
¶
 0.507 
NIHSS  4 (8)  2 (3) 8 (13)  1.26 (1.18 to 1.34)
║
 <0.001 
P values are derived from Wald tests, null hypothesis: OR=1. Prior cardiac vascular diseases are a history of angina, MI or cardiac revascularisation*per decade of age; † 
ischaemic probable and definite acute cerebrovascular disease only; ‡per 10 mmHg; §per 0C rise; ¶per hour increase;║ per unit increase **from last seen well, or when found 
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Table 7.3 The univariate association between baseline clinical variables and death at 3 months in patients with acute cerebrovascular disease 
Baseline characteristic   Odds ratio (95% CI) 
 
All         
(n=285)  
Alive 3 months                 
(n=250) 
Dead 3 months (n=35) 
 Dead vs alive 
P 
value 
Male sex (n, %) 136 (47.7)  125 (50.0) 11 (34.4)  0.46 (0.22 to 0.98) 0.043 
Age (years) (mean, SD) 74.4 (12.4)  73.4 (12.5) 81.8 (1.54)  2.08 (1.40 to 3.09) <0.001 
Fellow collected variables  n (%)  n (%) n (%)    
Symptoms of infection 27 (9.5)  22 (8.8) 5 (14.3)  1.72 (0.61 to 4.90) 0.086 
Prior cardiac vascular disease 67 (23.1)  59 (23.6) 8 (22.9)  0.96 (0.41 to 2022) 0.923 
Prior peripheral vascular disease 17 (6.0)  15 (6.0) 2 (5.9)  0.98 (0.21 to 4.46) 0.974 
Prior TIA or stroke 76 (26.7)  62 (24.8) 14 (40.0)  2.02 (0.97 to 4.21) 0.060 
Prior heart failure 22 (7.8)  17 (6.9) 5 (14.7)  2.33 (0.80 to 6.79) 0.121 
AF (prior or during ED assessment) 86 (30.2)  68 (27.2) 18 (51.4)  2.83 (1.38 to 5.82) 0.005 
Diabetes mellitus 37 (13.0)  29 (11.6) 8 (22.9)  2.26 (0.94 to 5.44) 0.069 
Prior cognitive impairment 39 (13.7)  29 (11.7) 10 (28.6)  3.03 (1.32 to 6.95) 0.009 
Recovery at 24 hours 40 (14.1)  39 (15.6) 1 (2.90)  0.16 (0.02 to 1.20) 0.074 
Simple variables n (%)  n (%) n (%)    
Independent prior to admission 247 (89.7)  225 (90.0) 22 (62.9)  0.19 (0.08 to 0.41) <0.001 
Living alone 96 (33.7)  81 (32.4) 15 (42.9)  1.56 (0.76 to 3.21) 0.223 
Orientated to time place & person 210 (73.7)  200 (80.0) 10 (28.6)  0.10 (0.04 to 0.22) <0.001 
Able to lift both arms 181 (63.5)  174 (69.6) 7 (20.0)  0.11 (0.04 to 0.26) <0.001 
Able to walk without help 127 (44.6)  123 (49.2) 4 (11.4)  0.13 (0.05 to 0.39) <0.001 
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Baseline characteristic   Odds ratio (95% CI) 
 
All         
(n=285)  
Alive 3 months                 
(n=250) 
Dead 3 months (n=35) 
 Dead vs alive 
P 
value 
Pathological stroke subtype n (%)  n (%) n (%)    
Probably ischaemic 34 (11.9)  32 (12.8) 2 (5.7)  - - 
Definitely ischaemic 236 (82.8)  207 (82.8) 29 (82.9)  - - 
Intracerebral or subarachnoid bleed 15 (5.3)  11 (4.4) 6 (17.1)  2.80 (0.84 to 9.34) 0.093 
OCSP classification, presentation†        
Total anterior circulation infarction 43 (15.9)  27 (11.3) 16 (51.6)  - - 
Partial anterior circulation infarction 115 (42.6)  105 (43.9) 10 (32.6)  - - 
Lacunar infarction 75 (27.8)  73 (30.5) 2 (6.5)  - - 
Posterior circulation infarction 25 (9.3)  24 (10.0) 1 (3.2)  - - 
Unclassifiable clinical syndrome 12 (4.4)  10 (4.2) 2 (6.5)  - - 
Imaging lesion        
Cortical infarction 124 (43.5)  101 (40.4) 23 (65.7)  - - 
Lacunar infarction 40 (14.0)  39 (15.6) 1 (2.9)  - - 
Posterior circulation infarction 21 (7.3)  20 (8) 1 (2.9)  - - 
>1 territory 5 (1.8)  5 (2) 0  - - 
Intracerebral or subarachnoid bleed 15 (5.3)  11 (4.4) 4 (11.4)  - - 
No visible lesion 74 (26.0)  69 (27.6) 5 (12.3)  - - 
No scan 6 (2.1)  5 (2.0) 1 (2.9)  - - 
Any visible lesion 193 (67.2)  167 (66.8) 26 (74.3)  1.43 (0.64 to 3.20) 0.377 
Table 7.3 continued        
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Baseline characteristic   Odds ratio (95% CI) 
 
All         
(n=285)  
Alive 3 months                 
(n=250) 
Dead 3 months (n=35) 
 Dead vs alive 
P 
value 
Medications n (%)  n (%) n (%)    
Any antiplatelet agent 121 (42.5)  101 (40.0) 20 (57.1)  1.97 (0.96 to 4.02) 0.064 
Warfarin 13 (4.6)  11 (4.5) 2 (5.9)  1.34 (0.28 to 6.33) 0.711 
Antihypertensive 155 (54.4)  134 (53.6) 21 (60.0)  1.30 (0.63 to 2.67) 0.477 
Statin 99 (35.2)  80 (32.4) 19 (55.9)  2.64 (1.28 to 5.47) 0.009 
rtPA (intra-arterial or -venous) 7 (2.5)  4 (1.6) 3 (8.6)  5.77 (1.23 to 26.93) 0.026 
Current smoker 65 (23.1)  58 (23.5) 7 (20.0)  0.81 (0.34 to 1.96) 0.648 
Examination findings        
Normal pedal pulses 133 (47.0)  123 (49.6) 10 (28.6)  0.41 (0.19 to 0.88) 0.023 
Continuous variables  mean, SD  mean, SD mean, SD    
Systolic BP (mmHg) 157 (30.1)  158.2 (29.5) 146.7 (5.6)  0.87 (0.77 to 0.99) ‡ 0.035 
Diastolic BP (mmHg) 85.9 (17.9)  86.3 (16.9) 83.4 (24.2)  0.91 (0.74 to 1.12) ‡ 0.368 
Temperature (
0
C) 36.4 (0.6)  36.4 (0.56) 36.4 (0.94)  1.06 (0.60 to 1.89) §  0.840 
Continuous variables  median, IQR  median, IQR median, IQR    
Well to admission (hrs)** 6.3 (13.4)  6.85 (14.47) 2.38 (11.18)  0.94 (0.89 to 0.99) ¶ 0.023 
Found to admission (hrs)**  3.8 (6.5)  4.25 (7.25) 2.12 (1.75)  0.91 (0.83 to 0.98) ¶ 0.018 
Admission to stroke fellow (hrs)  0.9 (1.4)  1.04 (1.17) 1.01 (2.28)  1.02 (0.96 to 1.07) ¶ 0.581 
NIHSS  4 (8)  5.6 (5) 15.8 (11)  1.17 (1.11 to 1.22)
 ║
 <0.001 
P values are derived from Wald tests, null hypothesis: OR=1. Prior cardiac vascular diseases are a history of angina, MI or cardiac revascularisation*per decade of age; † ischaemic probable and 
definite acute cerebrovascular disease only; ‡per 10 mmHg; §per 0C rise; ¶per hour increase;║per unit increase **from last seen well, or when found 
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Table 7.4 The univariate association between baseline clinical variables and reported complete recovery of symptoms at 24 hours in patients presenting with acute 
cerebrovascular disease 
Baseline characteristic   Odds ratio (95% CI) 
 
All         
(n=285)  
Recovery 24 hours 
(n=40) 
No recovery 24 hours                 
(n=245)  Recovery vs no recovery 
P  
value 
Male sex (n, %) 136 (47.7)  29 (47.5) 117 (47.8)  0.99 (0.50 to 1.93) 0.976 
Age (years) (mean, SD) 74.4 (12.4)  71.3 (12.6) 74.9 (12.3)  0.80 (0.61 to 1.03)* 0.09 
Fellow collected variables  n, %  n, % n, %    
Prior cardiac vascular disease 67 (23.1)  6 (15.0) 61 (24.9)  0.51 (0.28 to 0.94) 0.031 
Prior peripheral vascular disease 17 (6.0)  0 17 (7.0)  - - 
Prior TIA or stroke 76 (26.7)  9 (22.5) 67 (27.4)  1.37 (0.85 to 2.19) 0.200 
Prior heart failure 22 (7.8)  2 (5.0) 20 (8.3)  0.58 (0.13 to 2.59) 0.477 
AF (prior or during ED) assessment) 74 (26.0)  8 (20.0) 66 (26.9)  0.68 (0.29 to 1.54) 0.356 
Diabetes mellitus 37 (13.0)  3 (7.5) 34 (13.9)  0.50 (0.14 to 1.72) 0.274 
Prior cognitive impairment 39 (13.7)  5 (12.5) 34 (13.9)  0.88 (0.32 to 2.41) 0.807 
Simple variables        
Independent prior to admission 247 (89.7)  37 (82.5) 210 (85.7)  2.05 (0.60 to 7.03) 0.251 
Living alone 96 (33.7)  16 (40) 80 (32.6)  1.38 (0.69 to 2.73) 0.363 
Orientated to time place & person 210 (73.7)  38 (95) 172 (70.2)  8.10 (1.90 to 34.3) 0.005 
Able to lift both arms 181 (63.5)  35 (87.5) 146 (60.0)  4.75 (1.80 to 12.5) 0.002 
Able to walk without help 127 (44.6)  35 (87.5) 92 (37.6)  11.6 (4.40 to 30.8) <0.001 
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Baseline characteristic   Odds ratio (95% CI) 
 
All         
(n=285)  
Recovery 24 hours 
(n=40) 
No recovery 24 hours                 
(n=245)  Recovery vs no recovery 
P  
value 
OCSP classification, presentation†        
Total anterior circulation infarction 43 (15.9)  1 (2.5) 42 (18.3)  - - 
Partial anterior circulation infarction 115 (42.6)  23 (7.5) 92 (40.0)  - - 
Lacunar infarction 75 (27.8)  12 (30.0) 63 (27.4)  - - 
Posterior circulation infarction 25 (9.3)  2 (5.0) 23 (10.0)  - - 
Unclassifiable clinical syndrome 12 (4.4)  2 (5.0) 10 (4.3)  - - 
Imaging lesion        
Cortical infarction 124 (43.5)  7 (17.5) 117 (47.8)  - - 
Lacunar infarction 40 (14.0)  5 (12.5) 35 (14.3)  -  
Posterior circulation infarction 21 (7.3)  1 (2.5) 20 (8.2)  - - 
>1 territory infarction 5 (1.8)  0  5 (2)  - - 
Intracerebral or subarachnoid bleed 15 (5.3)  0 15 (6.1)  - - 
No visible lesion 74 (26.0)  25 (62.5) 49 (20)  - - 
No scan 6 (2.1)  2 (5) 4 (1.6)  - - 
Any visible lesion 205 (50.6)  18 (17.5) 187 (61.9)  0.13 (0.07 to 0.23) <0.001 
Medications        
Any antiplatelet agent 121 (42.5)  14 (35.0) 107 (43.7)  0.69 (0.35 to 1.39) 0.305 
Warfarin 13 (4.6)  2 (5.0) 11 (4.6)  1.10 (0.23 to 5.16) 0.903 
Antihypertensive 155 (54.4)  17 (42.5) 138 (56.3)  0.57 (0.29 to 1.13) 0.106 
Statin 99 (35.2)  8 (20.0) 91 (37.8)  0.41 (0.18 to 0.93) 0.034- 
Table 7.4 continued        
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Baseline characteristic   Odds ratio (95% CI) 
 
All         
(n=285)  
Recovery 24 hours 
(n=40) 
No recovery 24 hours                 
(n=245)  Recovery vs no recovery 
P  
value 
rtPA (intra-arterial or -venous) 7 (2.5)  0 7 (2.9)  n/a  
Current smoker 65 (23.1)  6 (15.0) 59 (24.4)  0.55 (0.22 to 1.37) 0.197 
Examination findings n, %  n, % n, %    
Normal pedal pulses 133 (47.0)  28 (70.0) 105 (43.2)  3.07 (1.49 to 6.31) 0.002 
Continuous variables  mean, SD  mean, SD mean, SD    
Systolic BP (mmHg) 157 (30.1)  158 (32.7) 157 (29.7)  1.01 (0.91 to 1.13) ‡ 0.817 
Diastolic BP (mmHg) 85.9 (17.9)  87.7 (2.7) 85.6 (18.1)  1.06 (0.88 to 1.28) ‡ 0.499 
Temperature (
0
C) 36.4 (0.6)  36.4 (0.5) 36.4 (0.6)  1.09 (0.62 to 1.87) § 0.769 
Continuous variables  median, IQR  median, IQR median, IQR    
Well to admission (hrs)**  6.3 (13.4)  3.0 (6.1) 7.7 (14.4)  0.94 (0.91 to 0.97) ¶ <0.001 
Found to admission (hrs)**  3.8 (6.5)  2.6 (4.1) 4.1 (7.2)  0.97 (0.94 to 1.00) ¶ 0.067 
Admission to stroke fellow (hrs)  0.9 (1.4)  0.8 (1.05) 0.9 (1.5)  0.95 (0.90 to 1.00) ¶ 0.061 
NIHSS  4 (8)  1 (2) 4 (9)  0.78 (0.71 to 0.85) ║ <0.001 
P values are derived from Wald tests, null hypothesis: OR=1. Prior cardiac vascular diseases are a history of angina, MI or cardiac revascularisation*per decade of age; † 
ischaemic probable and definite acute cerebrovascular disease only; ‡per 10 mmHg; §per 0C rise; ¶per hour increase;║ per unit increase**from last seen well, or when found
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Table 7.5 Quarters and medians of the distributions of blood markers of inflammation, thrombosis, 
cardiac strain and neuronal and glial damage in patients with acute cerebrovascular disease. 
Marker Lower quarter 50
th
 centile (Median) Upper quarter 
Inflammation    
Adiponectin (µg/ml) 1.50 to 6.91 11.45 18.16 to 40.66 
CRP (mg/l) 0.16 to 1.89 4.08 8.57 to 289 
ICAM (ng/ml) 72 to 132 165 215 to 413 
Interleukin-6 (pg/ml) 0.62 to 2.14 4.71 8.89 to 14.89 
TNF (pg/ml) 0.78 to 1.18 1.39 1.71 to 6.27 
Interleukin-10 (pg/ml) 0.9 to 3.3 4.4 6.7 to 238.3 
MMP-9 (ng/ml) 69 to 557.5 900 1364 to 3941 
vWF (IU/dl) 27 to 123 161 217 to 479 
White cells (x10
9
 cell/l) 3.7 to 6.8 8.7 10.7 to 21.6 
Neutrophil / WCC  0.25 to 0.63 0.71 0.79 to 0.97 
Thrombosis    
Ln D-dimer (loge unit)* 2.40 to 4.71 5.43 6.14 to 7.93 
Fibrinogen (g/l) 3.2 to 4.2 4.8 5.8 to 9.8 
Thrombolysis    
tPA (ng/ml) 1.11 to 8.34 11.26 14.75 to 57.4 
Cardiac strain    
Ln BNP (loge unit)* 1.61 to 4.95 6.24 7.48 to 10.26 
Troponin T (ng/ml)  0.01 0.01 0.01 to 3.11 
Cerebral damage    
Tau (pg/ml) 0 to 12.5 21 47 to 3000 
Ln S100B (loge unit)* 1.61 to 3.70 4.17 4.74 to 7.93 
Other markers    
Creatinine (μmol/l) 33 to 67 84 103 to 313 
Glucose (mmol/l) 3.7 to 5.2 5.8 6.9 to 19.9 
* variables loge transformed to give a log-linear relationship with outcome in logistic regression 
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Table 7.6 Associations between marker levels and poor outcome at 3 months.  




OR, Adjusted for 











Inflammation       
Adiponectin (µg/ml) 2.54 (1.74 to 3.69) <0.001 1.71 (1.08 to 2.69) 0.022 1.80 (1.13 to 2.92) 0.014 
CRP (mg/l) 1.29 (1.13 to 1.48) <0.001 1.17 (1.01 to 1.35) 0.033 1.16 (1.00 to 1.34) 0.045 
ICAM (ng/ml) 1.09 (0.79 to 1.18) 0.598 1.16 (0.77 to 1.75) 0.468 1.18 (0.78 to 1.79) 0.425 
Interleukin-6 (pg/ml) 5.28 (3.24 to 8.60) <0.001 2.38 (1.36 to 4.16) 0.002 2.21 (1.24 to 3.95) 0.007 
TNF (pg/ml) 1.01 (0.82 to 1.34) 0.673 0.97 (0.72 to 1.31) 0.867 0.90 (0.65 to 1.25) 0.528 
Interleukin-10 (pg/ml) 1.06 (1.00 to 1.12) 0.045 1.00 (0.93 to 1.07) 0.981 1.00 (0.92 to 1.08) 0.945 
MMP-9 (ng/ml) 1.16 (0.87 to 1.54) 0.305 1.20 (0.84 to 1.70) 0.320 1.23 (0.86 to 1.77) 0.253 
vWF (IU/dl) 2.35 (1.63 to 3.40) <0.001 1.63 (1.02 to 2.61) 0.043 1.57 (0.96 to 2.57) 0.072 
White cells (x10
9
 cell/l) 1.93 (1.38 to 2.69) <0.001 1.51 (0.97 to 2.37) 0.070 1.48 (0.93 to 2.35) 0.095 
Neutrophil / WCC  2.07 (1.15 to 2.94) <0.001 1.54 (0.99 to 2.41) 0.057 1.56 (0.98 to 2.49) 0.058 
Thrombosis       
D-dimer (loge unit) 3.32 (2.23 to 1.93) <0.001 1.55 (0.96 to 2.49) 0.070 1.53 (0.95 to 2.48) 0.080 
Fibrinogen (g/l) 1.88 (1.38 to 2.55) <0.001 1.48 (1.05 to 2.12) 0.024 1.76 (1.00 to 3.10) 0.050 
Thrombolysis       
tPA (ng/ml) 1.54 (1.18 to 2.02) 0.002 1.20 (0.88 to 1.63) 0.254 1.24 (0.91 to 1.71) 0.178 
Cardiac strain       
NT pro-BNP (loge unit) 4.98 (3.07 to 8.09) <0.001 2.22 (1.24 to 3.99) 0.007 2.45 (1.25 to 4.80) 0.009 
Troponin T >0.01ng/ml 7.08 (3.10 to 16.2) <0.001 2.94 (1.09 to 8.00) 0.034 2.48 (0.87 to 7.07) 0.089 
Cerebral damage       
Tau (pg/ml) 1.00 (0.98 to 1.03) 0.878 0.99 (0.96 to 1.03) 0.696 0.99 (0.96 to 1.30) 0.597 
S100 b (loge unit) 1.36 (1.06 to 1.73) 0.014 1.24 (0.91 to 1.68) 0.170 1.04 (.91 to 1.71) 0.173 
Other markers       
Creatinine (μmol/) 1.24 (1.22 to 1.61) 0.100 0.96 (0.67 to 1.36) 0.813 0.91 (0.63 to 1.31) 0.596 
Glucose (mmol/l) 1.22 (1.01 to 1.48) 0.040 1.20 (0.95 to 1.51) 0.125 1.19 (0.93 to 1.51) 0.148 
Adjustment made for NIHSS and age* and in addition†, independence of activities of daily living and: 
for markers of inflammation, prior infection and for cardiac strain markers, cardiac failure, AF and 
prior cardiac vascular disease. The OR is the ratio of odds of poor outcome in the 75th to the 25th centile 
of plasma or serum marker. P-values are derived from Wald tests and determine if the reported OR is 
significantly different from 1. 
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Table 7.7 Associations between marker levels and death at 3 months.  




OR, Adjusted for 




OR, with further 
adjustment
†




Inflammation       
Adiponectin (µg/ml) 3.01 (1.91 to 4.81) <0.001 2.22 (1.24 to 3.92) 0.007 2.30 (1.28 to 4.10) 0.005 
CRP (mg/l) 1.12 (1.03 to 1.48) 0.008 1.10 (1.02 to 1.19) 0.012 1.10 (1.02 to 1.19) 0.130 
ICAM (ng/ml) 1.45 (0.93 to 2.27) 0.099 1.85 (1.03 to 3.30) 0.039 1.83 (1.02 to 3.28) 0.043 
Interleukin-6 (pg/ml) 5.00 (2.67 to 9.37) <0.001 2.63 (1.23 to 5.57) 0.013 2.71 (1.24 to 5.90) 0.012 
TNF (pg/ml) 1.06 (0.78 to 1.43) 0.719 1.12 (0.76 to 1.64) 0.562 1.08 (0.73 to 1.59) 0.715 
Interleukin-10 (pg/ml) 1.05 (1.01 to 1.10) 0.024 0.99 (0.95 to 1.04) 0.786 0.99 (0.94 to 1.04) 0.726 
MMP-9 (ng/ml) 1.26 (0.85 to 1.88) 0.243 1.34 (0.84 to 2.19) 0.207 1.37 (0.85 to 2.23) 0.198 
vWF (IU/dl) 2.78 (1.73 to 4.48) <0.001 2.04 (1.40 to 3.64) 0.016 2.07 (1.16 to 3.69) 0.014 
White cells (x10
9
 cell/l) 2.09 (1.35 to 3.24) 0.001 1.30 (0.79 to 2.14) 0.298 1.26 (0.99 to 2.09) 0.374 
Neutrophil / WCC  2.95 (1.64 to 5.31) <0.001 1.88 (1.02 to 3.50) 0.045 1.90 (1.01 to 3.59) 0.047 
Thrombosis       
D-dimer (loge unit) 6.89 (3.70 to 12.8) <0.001 3.94 (1.92 to 8.09) <0.001 4.07 (1.96 to 8.44) <0.001
Fibrinogen (g/l) 3.54 (0.80 to 2.70) 0.212 0.87 (0.39 to 1.91) 0.721 0.84 (0.37 to 1.87) 0.662 
Thrombolysis       
tPA (ng/ml) 1.89 (1.37 to 2.61) <0.001 1.61 (1.16 to 2.13) 0.004 1.57 (1.16 to 2.13) 0.004 
Cardiac strain       
BNP (loge unit) 8.01 (3.71 to 17.3) <0.001 4.29 (1.67 to 11.0) 0.002 5.58 (1.93 to 16.2) 0.002 
Troponin T >0.01ng/ml 17.72 (7.52 to 1.7) <0.001 9.09 (3.44 to 24.0) <0.001 8.48 (3.14 to 22.9) <0.001 
Cerebral damage       
Tau (pg/ml) 0.95 (0.86 to 1.06) 0.371 0.95 (0.85 to 1.07) 0.395 0.95 (0.86 to 1.06) 0.395 
S100B (loge unit) 1.35 (0.98 to 1.86) 0.068 1.14 (0.78 to 1.67) 0.146 1.17 (0.80 to 1.71) 0.422 
Other markers       
Creatinine (μmol/) 1.60 (1.16 to 2.20) 0.004 1.24 (0.95 to 1.62) 0.115 1.39 (0.94 to 2.05) 0.103 
Glucose (mmol/l) 1.50 (1.21 to 1.87) <0.001 1.69 (0.98 to 1.58) 0.074 1.50 (1.15 to 1.97) 0.003 
Adjustment made for NIHSS and age* and in addition† independence of activities of daily living and: 
prior infection for markers of inflammation, and cardiac failure, AF and prior cardiac vascular disease 
for cardiac strain markers. The OR is the ratio of odds of death in the 75th to the 25th centile of plasma or 
serum marker. P-values are derived from Wald tests and determine if the reported OR is significantly 
different from 1 
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Table 7.8 Associations between marker levels and recovery by 24 hours. 




OR, Adjusted for 











Inflammation       
Adiponectin (µg/ml) 0.83 (0.51 to 1.34) 0.439 1.24 (0.71 to 2.17) 0.77 1.23 (0.70 to 2.17) 0.469 
CRP (mg/l) 0.65 (0.44 to 0.96) 0.031 0.82 (0.59 to 1.14) 0.235 0.81 (0.57 to 1.13) 0.206 
ICAM (ng/ml) 0.81 (0.50 to 1.30) 0.381 0.82 (0.50 to 1.35) 0.435 0.82 (0.50 to 1.35) 0.437 
Interleukin-6 (pg/ml) 0.32 (0.15 to 0.67) 0.002 0.77 (0.35 to 1.69) 0.513 0.76 (0.33 to 1.75) 0.523 
TNF (pg/ml) 0.81 (0.56 to 1.18) 0.277 0.86 (0.60 to 1.22) 0.387 0.82 (0.58 to 1.16) 0.266 
Interleukin-10 (pg/ml) 1.01 (0.96 to 1.06) 0.716 1.12 (1.00 to 1.25) 0.061 1.13 (1.02 to 1.26) 0.023 
MMP-9 (ng/ml) 1.08 (0.73 to 1.59) 0.701 1.18 (0.75 to 1.84) 0.476 1.20 (0.76 to 1.90) 0.422 
vWF (IU/dl) 0.65 (0.39 to 1.08) 0.094 0.95 (0.56 to 1.61) 0.853 0.97 (0.57 to 1.68) 0.926 
White cells (x10
9
 cell/l) 0.50 (0.29 to 0.84) 0.008 0.67 (0.38 to 1.19) 0.169 0.67 (0.37 to 1.21) 0.185 
Neutrophil / WCC  0.60 (0.39 to 0.94) 0.026 0.81 (0.49 to 1.34) 0.418 0.84 (0.50 to 1.41) 0.510 
Thrombosis       
D-dimer (ng/ml) 0.31 (0.14 to 0.68) 0.004 0.61 (0.32 to 1.16) 0.128 0.63 (0.34 to 1.18) 0.151 
Fibrinogen (g/l) 0.65 (0.41 to 1.04) 0.073 0.90 (0.55 to 1.49) 0.694 0.84 (0.38 to 1.87) 0.668 
Thrombolysis       
tPA (ng/ml) 0.73 (0.48 to 1.11) 0.141 1.01 (0.62 to 1.65) 0.960 1.01 (0.93 to 1.65) 0.967 
Cardiac strain       
NT pro-BNP (loge unit) 0.22 (0.12 to 0.42) <0.001 0.39 (0.18 to 0.84) 0.017 0.24 (0.09 to 0.64) 0.004 
Troponin T >0.01ng/ml 0.27 (0.06 to 1.15) 0.078 0.60 (0.11 to 3.20) 0.548 0.52 (0.09 to 2.99) 0.464 
Cerebral damage       
Tau (pg/ml) 0.99 (0.95 to 1.04) 0.802 1.00 (0.95 to 1.05) 0.966 1.00 (0.96 to 1.05) 0.962 
S100 B (loge unit) 0.90 (0.64 to 1.27) 0.550 1.02 (0.70 to 1.48) 0.908 1.02 (0.70 to 1.48) 0.914 
Other markers       
Creatinine (μmol/) 0.81 (0.53 to 1.24) 0.323 0.92 (0.55 to 1.55) 0.752 0.90 (0.53 to 1.53) 0.707 
Glucose (mmol/l) 0.81 (0.58 to 1.15) 0.247 0.93 (0.94 to 1.04) 0.724 0.93 (0.68 to 7.25) 0.657 
Adjustment made for NIHSS and age*, and in addition† activities of daily living, and prior infection for 
markers of inflammation, and cardiac failure, AF and prior cardiac vascular disease for cardiac strain 
markers. The OR is the ratio of odds of recovery at 24 hours in the 75th to the 25th centile of plasma or 
serum marker. P-values are derived from Wald tests and determine if the reported OR is significantly 
different from 1
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Table 7.9 Predictive logistic regression models to predict poor outcome at 3 months after presenting with acute cerebrovascular disease  
Variables 6 simple variables NT pro-BNP            
+ 6 simple 
variables 
IL-6                          
+ 6 simple 
variables 
 NIHSS + age NT pro-BNP             
+ NIHSS + age 
IL-6                          
+ NIHSS + age 
Lives alone 0.83 (0.42 to 1.65) 0.78 (0.40 to 1.57) 0.78 (0.39 to 1.57)     
Orientated to time place & person 0.33 (0.15 to 0.75) 0.40 (0.17 to 0.90) 0.36 (0.16 to 0.82)     
Able to lift arms 0.50 (0.24 to 1.03) 0.56 (0.26 to 1.16) 0.61 (0.29 to 1.28)     
Able to walk 0.20 (0.10 to 0.39) 0.23 (0.11 to 0.46) 0.24 (0.11 to 0.49)     
Independent of ADL 0.21 (0.05 to 0.84) 0.21 (0.05 to 0.84) 0.22 (0.05 to 0.92)     
Age* 1.05 (1.01 to 1.08) 1.03 (0.99 to 1.06) 1.04 (1.00 to 1.07)  1.07 (1.03 to 1.10) 1.05 (1.02 to 1.08) 1.06 (1.03 to 1.09) 
NT pro-BNP
†
  2.12 (1.14 to 3.92)    2.22 (1.24 to 3.99)  
IL-6
†
   2.15 (1.23 to 3.82)    2.38 (1.36 to 4.16) 
NIHSS
‡
     1.24 (1.16 to 1.32) 1.21 (1.13 to 1.30) 1.20 (1.12 to 1.28) 
        
Constant -0.17 -1.05 -0.81  -6.44 -6.92 -6.45 
*per year; †75th to 25 centile; ‡per unit increase;  
Odds ratios and 95% confidence intervals for variables in each model. Odds ratios for each variable from each logistic regression model (i.e. eβ ).  
The constant terms come from the underlying logistic regression model of the form: logit (poor outcome)= βa.a + βb.b + constant 
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Table 7.10 Performance of models to predict poor outcome in patients with acute cerebrovascular disease 3 months. 





















6 simple variable model Reference 260.3  0.86 (0.72 to 0.91) Reference Reference 0.90 Reference 
6 simple variable model + IL-6 <0.01 255.0  0.87 (0.83 to 0.90) 0.02 (0.01 to 0.04) 6% 0.12 +5% (p=0.32) 
6 simple variable model + NT pro-BNP 0.016 256.5  0.87 (0.83 to 0.91) 0.01 (0.00 to 0.02) 2% 0.51 -3% (p=0.56) 
         
NIHSS + age Reference 261.9  0.84 (0.79 to 0.88) Reference Reference 0.76 Reference 
NIHSS + age + IL6 <0.01 255.0  0.85 (0.81 to 0.89) 0.02 (0.00 to 0.04) 6% 0.12 -4% (p=0.35) 
NIHSS + age + BNP 0.01 256.4  0.85 (0.82 to 0.89) 0.01 (-0.01 to 0.02) 1% 0.99 -4% (p=0.40) 
         
χ2 tests with: *1 degree of freedom † 8 degrees of freedom 
Likelihood ratio statistic compares the goodness of fit between nested models; a significantly better model has a better fit to the data 
AUROC =1 indicates perfect discrimination of a model and AUROC=0.5 indicates no better discrimination than chance 
IDI: the difference between models with and without markers, of the difference in mean predicted probabilities of poor outcome for those with a good and those with a poor outcome 
Hosmer Lemeshow statistic: compares the predicted to observed number of events in deciles of predicted probabilities. A higher P value indicate a better calibrated model. 
Net reclassification improvement: the difference in correct and clinically useful classifications between models with and without biomarkers, at thresholds of predicted probability of poor 
outcome of 0.1, 0.5 and 0.9 . Positive values indicate better prediction with the addition of a marker, negative values indicate worse prediction. 
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Table 7.11 Missing Data 
Variable All Poor outcome Good outcome 
 (n=283) (n=123) (n=160) 
    
Systolic BP  0 0 0 
Diastolic BP 0 0 0 
Temperature 15 (5.3) 6 (4.9) 9 (5.6) 
Well to admission  5 (1.8) 2 (1.6) 3 (1.9) 
Found to admission  5 (1.8) 2 (1.6) 3 (1.9) 
Admission to stroke fellow   5 (1.8) 2 (1.6) 3 (1.9) 
NIHSS  0 0 0 
Sex  0 0 0 
Headache 6 (2.1) 3 (2.4) 3 (1.9) 
Infective symptom 0 0 0 
Cardiac vascular disease 0 0 0 
Peripheral vascular disease 2 (0.7) 1 (0.8) 1(0.6) 
TIA or stroke 0 0 0 
Heart failure 4 (1.4) 2 (1.6) 2 (1.3) 
AF (prior, during) 0 0 0 
Diabetes 0 0 0 
Dementia 0 0 0 
Migraine 5 (1.8) 3 (2.4) 2 (1.3) 
Independent of ADL 0 0 0 
Living alone 0 0 0 
Able to talk 0 0 0 
Orientated time place & 0 0 0 
Able to lift arms 0 0 0 
Able to walk without help 0 0 0 
Antiplatelet 0 0 0 
Warfarin 4 (1) 3 (2.4) 1 (0.6) 
Antihypertensive 0 0 0 
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Variable All Poor outcome Good outcome 
 (n=283) (n=123) (n=160) 
Statin 4 (1) 3 (2.4) 1 (0.6) 
Current smoker 3 (1.1) 1 (0.8) 2 (1.3) 
Normal pedal pulses 2 (0.7) 2 (1.6) 0 
Blood markers    
Adiponectin  9 (3.1) 4 (3.2) 5 (3.1) 
CRP  10 (3.5) 5 (4.1) 5 (3.1) 
ICAM  10 (3.5) 4 (3.2) 6 (3.8) 
Interleukin-6  9 (3.1) 3 (2.4) 6 (3.8) 
TNF  10 (3.5) 4 (3.2) 6 (3.8) 
Interleukin-10  4 (1.4) 3 (2.4) 1 (0.6) 
MMP-9  4 (1.4) 3 (2.4) 1 (0.6) 
vWF  3 (1.1) 2 (1.6) 1 (0.6) 
White cells  2 (0.7) 1 (0.8) 1 (0.6) 
Neutrophil / WCC  4 (1.4) 2 (1.6) 2 (1.2) 
D-dimer  10 (3.5) 4 (3.2) 6 (3.8) 
Fibrinogen  9 (3.1) 4 (3.2) 5 (3.1) 
tPA  10 (3.5) 4 (3.2) 6 (3.8) 
NT pro-BNP  19 (6.7) 6 (4.9) 13 (8.1) 
Troponin T  15 (5.3) 0 15 (9.4) 
Tau  1 (0.4) 0 1 (0.6) 
S100 B  2 (0.7) 0 2 (1.2) 
Creatinine  4 (1.4) 2 (1.6) 2 v 
Glucose 11 (3.9) 5 (4.1) 6 (3.8) 
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Figure 24 Relationship between NIHSS, a marker of neurological impairment, and the 
proportion of patients reporting complete recovery by 24 hours. 
40/285 patients with acute cerebrovascular disease made a complete recovery. The plot had a 
similar form for patients seen <6 hours after symptom onset. 
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Figure 25 Association between blood markers levels and poor outcome at 3 months after acute 
cerebrovascular disease. 
Adjustment made for NIHSS and age. Ratio of odds between the 75th and 25th centiles of a marker’s 
distribution with 95% confidence intervals. The vertical dotted line indicates OR=1, i.e. no association 
between marker levels and poor outcome 
Whiteley W.N. Blood Markers in Stroke University of Edinburgh 2010 
 



























Figure 26 Plot of the observed risk of poor outcome in each decile of 
predicted risk calculated from a model with only the six simple variables.  
 


















Figure 27 Plot of the observed risk of poor outcome in each decile of 
predicted risk calculated from a model with interleukin 6 in addition to the 
six simple variables.  
The dotted straight line indicates a perfectly calibrated model 
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0 .2 .4 .6 .8 1
Pr(pooroutcome), 6 simple variables alone
Predicted probability >10 % better with biomarker model
Predicted probability >10% worse with biomarker model
Difference between models <10%
Figure 28 The predicted probability of poor outcome at 3 months after presentation with 
acute cerebrovascular disease using interleukin-6 in addition to the six simple variable 
model against the predicted probability of poor outcome with the six simple variable model 
alone. 
 Coloured markers indicate those patients in whom the predicted probability of poor 
outcome from the 2 models differs by 10% or more. Dotted lines indicate predicted 
probability of poor outcome of 0.1 and 0.9. Markers coloured red indicate the model with 
interleukin 6 gave a worse prediction of poor outcome compared to the observed outcome 
than the six simple variable model alone (n(poor outcome)=11, n(good outcome)=6); markers 
coloured green indicate that the model with interleukin-6 gave a better prediction than the 
six simple variable model alone (n(poor outcome)=12, n(good outcome)=21 ). N=274. 
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0 .2 .4 .6 .8 1
Pr(pooroutcome), NIHSS + age
Predicted probability >10 % better with biomarker model
Predicted probability >10% worse with biomarker model
Difference between models <10%
Figure 29 The predicted probability of poor outcome at 3 months after presentation with 
acute cerebrovascular disease using interleukin-6 in addition to NIHSS + age against the 
predicted probability of poor outcome with NIHSS + age alone 
Coloured markers indicate those patients in whom the predicted probability of poor 
outcome from the 2 models differs by 10% or more. Dotted lines indicate predicted 
probability of poor outcome of 0.1 and 0.9. Markers coloured red indicate the model with 
interleukin 6 gave a worse prediction of poor outcome compared to the observed outcome 
than NIHSS + age alone (n(poor outcome)=13, n(good outcome)=3); markers coloured green 
indicate that the model with interleukin-6 gave a better prediction than the six simple 
variable model alone (n(poor outcome)=15, n(good outcome)=15 ). N=274. 
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0 .2 .4 .6 .8 1
Pr(pooroutcome), 6 simple variables alone
Predicted probability >10% better with a biomarker model
Predicted probability > 10% worse with a biomarker model
Difference between models <10%
Figure 30 The predicted probability of poor outcome at 3 months after presentation with 
acute cerebrovascular disease using NT pro-BNP in addition to the six simple variables 
against the predicted probability of poor outcome with 6 simple variables alone. 
Coloured markers indicate those patients in whom the predicted probability of poor 
outcome from the 2 models differs by 10% or more. Dotted lines indicate predicted 
probability of poor outcome of 0.1 and 0.9. Markers coloured red indicate the model with NT 
pro-BNP gave a worse prediction of poor outcome compared to the observed outcome than 
the 6 simple variables alone (n(poor outcome)=5, n(good outcome)=7); markers coloured 
green indicate that the model with NT pro-BNP gave a better prediction than the six simple 
variable model alone (n(poor outcome)=8, n(good outcome)=9 ). N=274. 
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0 .2 .4 .6 .8 1
Pr(pooroutcome), NIHSS & age
Predicted probability >10% better with a biomarker model
Predicted probability > 10% worse with a biomarker model
Difference between models <10%
Figure 31 The predicted probability of poor outcome at 3 months after presentation with 
acute cerebrovascular disease using NT pro-BNP in addition to NIHSS + age against the 
predicted probability of poor outcome with NIHSS + age alone.  
Coloured markers indicate those patients in whom the predicted probability of poor 
outcome from the 2 models differs by 10% or more. Dotted lines indicate predicted 
probability of poor outcome of 0.1 and 0.9. Markers coloured red indicate the model with NT 
pro-BNP gave a worse prediction of poor outcome compared to the observed outcome than 
the NIHSS + age (n(poor outcome)=5, n(good outcome)=9); markers coloured green indicate 
that the model with NT pro-BNP gave a better prediction than the six simple variable model 
alone (n(poor outcome)=13, n(good outcome)=14 ). N=274. 
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0 .2 .4 .6 .8 1
Pr(pooroutcome) NIHSS and age
Predicted probability >10 % better with 6 simple variables
Predicted probability >10% worse with 6 simple variables
Difference < 10% between models
Figure 32 The predicted probability of poor outcome at 3 months after presentation with 
acute cerebrovascular disease using the 6 simple variables model against the predicted 
probability of poor outcome with NIHSS + age.  
Coloured markers indicate those patients in whom the predicted probability of poor 
outcome from the 2 models differs by 10% or more. Dotted lines indicate predicted 
probability of poor outcome of 0.1 and 0.9. Markers coloured red indicate the 6 simple 
variable model gave a worse prediction of poor outcome compared to the observed outcome 
than NIHSS + age (n(poor outcome)=36, n(good outcome)=37); markers coloured green 
indicate that the model with 6 simple variables gave a better prediction than the NIHSS and 
age model (n(poor outcome)=36, n(good outcome)=47 ). N=405. 
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Chapter 8.  The association of circulating inflammatory markers with 
recurrent vascular events after stroke: ESS, a prospective cohort 
study 
Introduction 
Circulating levels of inflammatory markers may be elevated soon after stroke. In 
prospective studies of patients with prior stroke or transient ischaemic attack (TIA), 
increased levels of markers of acute inflammation – C-reactive protein (CRP) (Di 
Napoli et al. 2005, Woodward et al. 2005e), interleukin -6 (IL-6) (Welsh et al. 2008b), 
fibrinogen (Rothwell et al. 2004b, Woodward et al. 2005d) and white cell count 
(Grau et al. 2004) – were associated with an increased subsequent incidence of 
recurrent stroke and myocardial infarction (MI). These inflammatory markers are 
also associated with the risk of death or disability at 3 months after stroke (Whiteley 
et al. 2009c). IL-6 is a messenger cytokine that is proximal to CRP in the 
inflammatory process. It stimulates the production of acute phase reactants by the 
liver, and may have a stronger association than CRP with the risk of recurrent 
stroke (Welsh et al. 2008c).  
If high levels of acute-phase markers in the early stages of stroke appear to 
contribute to the risk of recurrent vascular events (Danesh & Pepys 2009), I 
hypothesised that the  associations with recurrent events may differ among different 
stroke subtypes. If inflammatory markers have a causal role in further vascular 
events after a stroke, I hypothesised the association between inflammatory markers 
with recurrent vascular events to be stronger than with other, non-vascular 
outcomes. 
In a prospective cohort of patients with recent stroke I aimed to: (1) estimate the 
association between levels of circulating inflammatory markers and the incidence of 
‘recurrent vascular events’ (recurrent stroke, MI and vascular death), and (2) 
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compare the strength of the association between the risk of death from vascular and 
non-vascular causes. 
Methods 
The Edinburgh Stroke Study was a prospective, hospital based cohort study of 
patients with stroke followed up for recurrent stroke, MI and death. In brief, 
consenting stroke patients presenting to the Western General Hospital were 
recruited in Edinburgh between April 2002 and May 2006. A clinical assessment was 
made at baseline and blood was drawn at the same time from consenting patients 
for markers of inflammation (CRP, IL-6, fibrinogen and white cell count and 
glucose). The Lothian Research Ethics Committee reviewed the project. 
Definition of stroke  
I defined a clinically definite stroke as new focal disturbance of cerebral function 
lasting more than 24 hours of a vascular origin. I excluded patients with 
subarachnoid haemorrhage. I defined an ischaemic stroke as a clinically definite 
stroke in a patient in whom brain imaging showed either a relevant ischaemic lesion 
or was normal and excluded both intracranial haemorrhage and stroke mimics. I 
defined the pathological type of stroke as probably ischaemic in patients with a 
clinically definite stroke in whom the radiological results were equivocal or 
unavailable, and analysed them together with definite ischaemic strokes. I assigned 
a final ischaemic stroke syndrome according to the Oxford Community Stroke 
Project (OCSP) classification (Bamford et al. 1991a) based on the clinical syndrome 
at the time of maximum deficit, modified if necessary by the site and size of relevant 
infarcts on brain imaging (Mead et al. 2000). I used an algorithm based on a 
modified TOAST classification (Adams, Jr. et al. 1993) to assign aetiological stroke 
subtypes. The diagnosis of stroke and stroke subtypes was made blind to marker 
levels. 
Assessment of outcome 
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Patients were followed from their index stroke to the end of the study or to death, 
whichever occurred first. A recurrent stroke was defined as new focal disturbance of 
cerebral function lasting more than 24 hours of a vascular origin, occurring after a 
period of at least 24 hours of neurological stability from the index stroke, and after 
exclusion of other causes of the symptoms. MI was diagnosed either in patients with 
at least two of: chest pain, a rise in cardiac enzymes and ECG changes of MI, or in 
patients who died with autopsy evidence of acute MI or cases of sudden death with 
no alternative explanation. Where possible, the study team assessed patients with a 
suspected recurrent stroke. In the remainder, results of brain imaging and medical 
records were reviewed. I defined ‘other vascular death’ as deaths due to vascular 
diseases other than stroke or MI, e.g. ruptured abdominal aortic aneurysm, 
ischaemic limb, ischaemic bowel or cardiac failure. I classified deaths due to the 
qualifying stroke (which were often due to pneumonia) or gastrointestinal 
haemorrhage as non-vascular. I defined the outcome cluster as recurrent vascular 
events: ‘recurrent fatal or non-fatal stroke, subsequent fatal or non-fatal MI or other 
vascular death’. Infections or other complications between stroke onset and the 
measurement of vascular outcome or death were not routinely recorded. 
Patients were followed for up to four years with multiple overlapping methods. To 
ascertain new events occurring during follow up, we: wrote to general practitioners; 
invited clinicians to notify us ; gave patients a study contact card; mailed 
questionnaires to patients at 6 months and annually afterwards; and flagged 
patients with the General Register Office for Scotland to notify us of deaths. When a 
patient died, all medical records were reviewed to verify the cause of death. At the 
end of the follow up, patients’ general practitioners were contacted and an 
Edinburgh wide stroke audit system was reviewed, which aimed to record all stroke 
admissions in the city.  
Measurement of blood markers 
The NHS clinical laboratory measured total white cell count (Beckman Coulter 
LH750 analyser) and blood glucose (Vitros Chemistry analyser). CRP and fibrinogen 
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were measured in plasma by immunonephelometry (Prospec, Dade Behring Milton 
Keynes, UK) using the manufacturer’s reagents and standards. IL-6 was assayed by 
ELISA (R & D Systems, Oxford, UK). Intra- and inter-assay coefficients of variation 
were for CRP 4.7 and 8.3%, for fibrinogen 2.6 and for IL-6 5.3%, and 7.5 and 8.9%. 
All assays were performed blind to stroke outcome. 
Statistical analysis 
I used Stata version 10 (Statcorp 2007) for analysis and prepared the chapter with 
reference to the STROBE (von Elm et al. 2007a) guidelines for the reporting of 
observational studies.  
I measured time to first recurrent stroke, MI or vascular death and censored patients 
at the end of follow up or non-vascular death. I compared the baseline 
characteristics of patients who experienced a stroke, MI or vascular death with those 
who did not in a number of univariable Cox regression analyses. I examined the 
relationships between inflammatory markers with correlation coefficients, and used 
linear regression (after loge transformation of markers) to examine the relationship 
of markers with delay to blood draw. I used Kaplan Meier survival curves to 
compare event free survival between groups of patients defined by thirds of 
inflammatory biomarkers and compared curves with log rank trend tests. I used 
Cox regression analysis to calculate unadjusted hazard ratios (HR) and 95% 
confidence intervals (CI) per unit increase in marker levels. I built a multivariate 
Cox regression model to adjust for confounders, adding variables sequentially that 
were associated with recurrent stroke, MI or vascular death in univariable analysis 
and had data completeness of over 95%, keeping those variables that significantly 
improved the fit of the model (p<0·05). To test the improvement of the model by 
adding each variable, I used likelihood ratio tests. 
When the model was complete, I tested the proportional hazards assumption in the 
final model by plotting and testing Schoenfield residuals and time dependent 
covariates. To evaluate goodness of fit, I plotted Nelson-Aalen cumulative hazard 
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functions against Cox Snell residuals. I looked for first order interactions of 
inflammatory biomarker levels with other variables in the final model by adding 
multiplicative terms, performed sensitivity analysis for patients seen as inpatients 
and as outpatients, and examined the association between inflammatory markers 
and stroke, other markers, MI or vascular death by stroke subtype with the 
modified TOAST classification.  
I assessed the change in discrimination after the addition of interleukin 6 to a model 
containing only clinical variables by calculating Harrell’s c-statistic for models with 
and without biomarkers. The c-statistic is analogous to the area under a receiver 
operator curve for Cox regression models; a vale of 0.5 indicates no better 
discrimination than chance and a value of 1.0 perfect discrimination. 
I replicated the analysis measuring time to death only, censoring at the end of the 
study. To adjust models examining the risk of death, I used previously validated 
covariates (Counsell, Dennis, & McDowall 2004a). I also plotted, by thirds of marker 
levels, the competing risks of vascular deaths, death due to the initial stroke and 
death due to other causes using the ‘stcompet’ command (Coviello 2004), which 
calculates the cumulative incidence of each outcome. 
Results 
Baseline characteristics 
877 of 1408 patients in the Edinburgh Stroke Study (62%), gave consent and had 
blood drawn for markers of inflammation. Of these 817 (93%) had a definite 
ischaemic stroke, 17 (2%) a probable ischaemic stroke and 43 (5%) a haemorrhagic 
stroke. Of those patients who had blood drawn for blood markers, no patient was 
lost to follow up for the outcomes of death, recurrent stroke or myocardial 
infarction. Patients were first assessed at a median of 10 days (IQR 3 to 21 days) 
after onset and blood drawn at a median of 0 days (IQR 0 to 3 days) after 
assessment. The delay to assessment was longer for patients seen in an out-patient 
clinic (median 19 days) than in the in-patient stroke unit (median 2 days). During 
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the 1866 person years of follow up time (mean 2.12 years), 106 recurrent strokes (92 
ischaemic, 5 haemorrhagic and 9 of uncertain type) and 34 myocardial infarctions 
occurred. There was a total of 184 deaths: 113 from vascular causes (63 strokes, 35 
from cardiac causes, and death from bowel ischaemia, vascular dementia and 
presumed vascular renal failure) and 64 from other causes (33 cancers, 13 chest 
infections, 6 from COPD and the rest pancreatitis, bowel perforation, hip fracture, 
and extra-pulmonary sepsis). 
At the time of the clinical assessment of the index stroke, the median IL-6 was 4·0 
(interquartile range [IQR] 2.4 to 7.2) pg/l, median CRP 3.5 (IQR 1.4 to 9.7) mg/l, 
median fibrinogen 4.5 (IQR 3.8 to 5.4) g/l, median white cell count 8 (IQR 6.6 to 9.7) 
x109/l and median glucose 5.6 (IQR 5 to 6.8) mmol/l. The correlation coefficients 
were, between IL-6 and: CRP 0.59, fibrinogen 0.48, glucose 0.06 and white cell count 
0.25. Although the blood level of each marker fell with increasing delay to blood 
draw after stroke, these association between markers attenuated and became 
statistically insignificant, after adjusting for the level of baseline neurological 
impairment and age. 
Circulating inflammatory markers and recurrent stroke, MI and vascular death 
There was a significant increase in the risk of recurrent vascular events for patients 
who: were older; or had a history of AF, heart failure or previous peripheral 
vascular disease, coronary heart disease or stroke (Table 8.1).  
The log hazard of stroke, MI or vascular death rose with each third of IL-6 and CRP, 
though not by thirds of glucose, fibrinogen or white cell count. In unadjusted 
Kaplan-Meier survival analyses, patients survived free of recurrent vascular events 
for a shorter time in the highest third of IL-6 (log rank trend χ2=13.22 p=0.0003) 
(Figure 33) and CRP (log rank trend χ2=13.9 p=0.0002). This relationship did not reach 
statistical significance for fibrinogen (log rank trend χ2=2.84 p=0.0921), glucose (log 
rank trend χ2=1.07 p=0.3003) or white cell count (log rank trend χ2=3.09 p=0.0787). 
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However, as a linear model fitted the data well for each marker, we modelled each 
marker as a linear variable. 
Table 8.2 shows the association between circulating inflammatory markers and 
recurrent vascular events. In univariate analyses, all markers except glucose were 
significantly associated with recurrent vascular events. The relative hazard of 
recurrent vascular events for an increase of 1 pg/ml of IL-6 was 1.07 (95% CI: 1.04 to 
1.10) per pg/ml. The unadjusted associations between IL-6 and recurrent fatal or 
non-fatal stroke alone (HR 1.04 95% CI 1.00 to 1.08 per pg/ml) were weaker though 
the HRs for the association with a one unit increase of CRP, fibrinogen, white cell 
count and glucose were not significantly different from 1. The unadjusted 
association between IL-6 and fatal or non-fatal MI alone (HR 1.09 95% CI:1.03 to 
1.15) was stronger than for recurrent stroke alone. 
I adjusted for the following confounders in the final model: age, prior stroke or TIA 
or ischaemic heart disease, current or prior AF and cardiac failure. Adding markers 
of stroke severity (i.e. ability to walk or lift arms off bed), blood pressure at 
assessment, diabetes, carotid stenosis or smoking did not significantly improve 
models containing a single inflammatory marker. After adjustment, there was still a 
significant association between recurrent vascular events and increasing levels of IL-
6, CRP and fibrinogen (Table 8.2). In this cohort, those patients with highest blood 
levels (75th centile) of interleukin 6 had a 1.33 fold increase in the incidence of 
recurrent vascular events compared with those with the lowest levels (25th centile). 
A similar relative increase in incidence was seen for fibrinogen (HR 1.20), and less 
for C-reactive protein (HR 1.06).  
I added markers sequentially, in order of the strength of their association with 
recurrent vascular events, to a model containing only clinical variables (age, prior 
stroke or TIA or heart disease, current or prior AF or cardiac failure). Addition of IL-
6 significantly improved the model (likelihood ratio (LR) test χ2=14.0, p<0.001), 
though further addition of CRP (LR test χ2=0.3, p=0.56), fibrinogen (LR test χ2=0.2, 
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p=0.68), white cell count (LR test χ2=0.7, p=0.40), or glucose (LR test χ2=1.3, p=0.25) 
did not make further improvement, probably as the markers were correlated. After 
adjustment for all markers, only the association between IL-6 and recurrent vascular 
events remained statistically significant. The final model with units of IL-6 fulfilled 
the proportional hazards assumption and fitted the data well. 
A model with only clinical variables (age, prior TIA, MI or stroke and AF) had a 
Harrell’s C statistic of 0.62; when I added interleukin-6 to this model, the Harrell’s C 
statistic increased by a small amount, to 0.64. 
First order interactions  
There was significant heterogeneity in the association between IL-6 and recurrent 
vascular events by the subtype of ischaemic stroke at baseline (Figure 34), driven 
largely by unclassified strokes. Multiplicative interaction terms between stroke 
subtype (small vessel stroke versus all others (with a modified TOAST algorithm 
and the OCSP classification)), delay to blood taking after stroke, age, ability to walk 
and level of interleukin 6 did not make important changes to the association 
between IL-6 and recurrent vascular events (and none significantly improved the fit 
of the final Cox proportional hazards model). There were no significant two way 
interactions between other blood markers and IL-6. The strength of the association 
between inflammatory markers and recurrent vascular events was consistent 
between clinic patients and in-patients (Table 8.4). 
Circulating inflammatory markers and death 
All markers were significantly associated with an increased risk of death (Table 8.3). 
After adjustment for factors which are known reliably to influence survival after the 
index stroke (age, being able to walk or talk, independence of daily activities prior 
to stroke, being able to lift arms from the bed), these associations remained 
statistically significant though attenuated. IL-6, CRP, fibrinogen and glucose were 
more strongly associated with death than with recurrent vascular events, though 
white cell count was less strongly associated. After additional adjustment for all 
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other markers, only the associations of IL-6 and fibrinogen with death remained 
statistically significant. The association between higher levels of IL-6, CRP and 
fibrinogen and an increased incidence of death was consistent for each of the 
separate causes of death (vascular deaths, deaths due to the initial stroke and deaths 
due to other causes)(Figure 35, data for CRP and fibrinogen not shown). Where the 
cause of death was the qualifying stroke, patients in the top third of the IL-6 
distribution had the shortest survival time. 
Discussion 
In this study of inpatients assessed soon after onset and a group of outpatients with 
milder strokes seen after a short interval, higher levels of IL-6, CRP and fibrinogen 
were associated with a higher incidence of recurrent stroke, MI or vascular death, 
independent of atrial fibrillation, prior vascular events and age. In addition, higher 
levels of each inflammatory marker were associated with a higher incidence of 
death from all causes, an association that was stronger than for all vascular events. 
The associations with recurrent stroke alone were weaker: it was weak but 
statistically significant for IL6, and did not reach statistical significance in this cohort 
for the other markers. 
Somewhat unexpectedly I found no consistent evidence of different strengths of 
association between higher baseline levels of IL-6 with different ischaemic stroke 
subtypes, strokes of different severity or different times from stroke onset to blood 
draw. Stroke patients had qualitatively similar associations between IL-6, CRP and 
fibrinogen and deaths from vascular and from non vascular causes. However, there 
was a suggestion that early deaths from the index stroke might be more strongly 
associated with higher levels of inflammation. 
Strengths and limitations 
This study had a number of methodological strengths: several overlapping methods 
were used to ensure all recurrent vascular events were detected; vital status was 
determined at the end of the follow up period for all of the cohort; data on all 
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suspected outcome events were checked by the study clinicians, either directly or by 
review of the medical and imaging records. The majority of patients with recurrent 
strokes underwent brain imaging (93%), in contrast to previous studies, which had 
limited access to brain imaging. 
Not all patients had blood drawn for inflammatory markers. The most common 
reasons for not drawing blood were: the patient did not consent and practical 
constraints in inpatients, chiefly the working hours of research laboratories handling 
the samples. Patients without blood samples tended to have more severe strokes 
though were otherwise similar; there was no evidence of an interaction between 
stroke severity and the association of inflammatory markers and recurrent vascular 
events or death. 
The number of patients with haemorrhagic strokes was too small reliably to explore 
interactions between haemorrhagic versus ischaemic strokes, or between 
inflammatory markers and the risk of occlusive vascular outcomes, though no 
trends were observed (Welsh et al. 2008d, Woodward et al. 2005c). With only a 
single sample of blood I could not correct my analyses for regression dilution bias 
(Danesh et al. 2008b).  
Blood was drawn as soon as possible after assessment (median 2 days among 
patient admitted to hospital); hence levels of IL-6 and CRP were higher than in 
previous studies, which may in some cases have been due to stroke complications 
such a pneumonia or deep vein thrombosis As I were unable to adjust for these in 
our analysis, the observed association may have been due to confounding by these 
complications. However, in the 60% of patients seen as an outpatient, who had 
milder strokes, and probably fewer infections or other complications the median 
time to blood draw was 19 days. Despite this, I was unable to demonstrate effect 
modification by the time to blood draw after stroke on the association between 
either IL-6 or CRP and recurrent vascular events. It is possible that among patients 
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in whom the initial assessment was delayed, some early recurrent strokes may have 
been overlooked. 
I did not confirm my hypothesis that large vessel stroke subtype at baseline would 
have had a stronger association between marker levels and the risk of subsequent 
vascular events. However, a relatively large number of strokes were unclassified by 
the TOAST classification, so I cannot exclude the possibility that an association 
exists.  
I used a competing risks survival analysis to examine the association of IL-6, 
fibrinogen and CRP with of the three main causes of death; vascular, non-vascular 
and deaths due to the initial stroke. It is possible that there was some 
misclassification of the cause of death, particularly for deaths occurring soon after 
stroke when accurate attribution of the cause of death is difficult, even if autopsy is 
performed. 
The epidemiological association between inflammatory markers and recurrent 
vascular events appears consistent and strong, and similar for IL-6 and CRP, though 
a somewhat weaker for fibrinogen. However, the clinical utility of adding 
inflammatory markers to a clinical predictive model is not determined only by 
independence in multivariate models. The small increase in the c-statistic for a 
model containing IL-6 makes it unlikely that it will add clinically useful prediction 
to prediction based on variables that do not require blood draw. 
Interpretation 
It is unlikely that CRP or IL-6 has a causal role in the generation of recurrent 
vascular events after stroke, and more likely that the observed association reflects an 
inflammatory response either to atherosclerosis or to its risk factors, or to an as yet 
unidentified trigger. In support of this, studies that have examined functional CRP 
and IL-6 polymorphisms (which produce differences in baseline CRP or IL-6 levels) 
found no increased risk of stroke (Ladenvall et al. 2006) or other occlusive vascular 
Whiteley W.N. Blood Markers in Stroke University of Edinburgh 2010 
 
Chapter 8 ESS: Blood markers of inflammation and recurrent vascular events     244 
events (Elliott et al. 2009, Walston et al. 2007, Zacho et al. 2008) with different 
polymorphisms.  
Generalisability 
IL-6 is a key pro-inflammatory cytokine that up-regulates circulating downstream 
inflammatory markers including CRP, fibrinogen and white cell count. My finding 
that IL-6 showed the strongest association with recurrent vascular events and with 
death in this cohort of stroke patients, is consistent with recent reports from 
population-based prospective studies (Danesh et al. 2008a, Patterson et al.).  
Most other studies in patients with acute cerebrovascular diseases found lower 
levels of inflammatory markers than ours, perhaps because of greater delay between 
blood draw and stroke (delay to blood draw in these studies was between 12 hours 
and 30 days). My estimates of the association between: (i) CRP, IL-6, fibrinogen and 
recurrent stroke (Campbell et al. 2006b, Elkind et al. 2006a, Woodward et al. 2005b), 
and (ii) CRP, fibrinogen and death (Di Napoli, Papa, & Bocola 2001a, Elkind et al. 
2006b) are consistent with previous studies (Table 8.5). Increasing fibrinogen 
predicted both recurrent ischaemic stroke and myocardial infarction in an analysis 
of pooled data (Rothwell et al. 2004c) though the association with all death or non-
vascular death was not consistent across studies (Di Napoli, Papa, & Bocola 2001b, 
Rallidis et al. 2008, Rothwell et al. 2004d). 
Conclusion 
I have demonstrated an association between higher levels of IL-6, CRP and 
fibrinogen and increased incidence of occlusive vascular events in patients after 
stroke. The association between IL-6, CRP and fibrinogen and fatal vascular and 
non-vascular events after stroke seems similar. 
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Tables  
Table 8.1 Baseline characteristics of stroke patients. 
 Total Recurrent 





Univariate HR  
(95% CI) 
Number 877 159 718  
Demographic     
Age, years(mean, SD) 71.4 (12.0) 73.6 (10.7) 70.9 (12.2) 1.02 (1.00 – 1.04)
†
 
Male sex, N (%) 463 (52.8) 80 (50.3) 383 (53.3) 0.9 (0.6 to 1.2) 
Laboratory results Median (IQR) Median (IQR) Median (IQR)  
Interleukin-6 (pg/ml) 4.0 (2.4-7.2) 4.8 (2.8-9.1)  3.8 (2.3-6.6)  
CRP (mg/L) 3.5 (1.4-9.7) 5.9 (1.9-15.5) 3.3 (1.2-8.8)  
Fibrinogen (g/L) 4.5 (3.8-5.4) 5.7 (3.9-5.7) 4.4 (3.8-5.4)  
White cell count (x10
9
/l) 8 (6.6-9.7) 8.4 (6.7-9.7) 7.9 (6.6-9.7)  
Glucose (mmol) 5.6 (5-6.8) 5.7 (4.9-7.2) 5.6 (5-6.7)  
Cholesterol (mmol/l) 5.1 (4.4-6.0) 4.9 (4.3-5) 5.1 (4.4-6)  
Pathological type, index stroke N (%) N (%) N (%)  
Definite ischaemic  817 (93.2) 149 (93.7) 668 (93.0) 1.1 (0.6 to 2.1)
‡
 
Definite haemorrhagic  43 (4.9) 9 (5.7) 34 (4.7) 1.2 (0.6 to 2.4)
 ‡
 
Subtype unknown  17 (1.9) 1 (0.6) 16 (2.2) 0.3 (0.1 to 1.9)
 ‡
 
Clinical stroke syndrome of index 
stroke (OCSP*)  
    
TACI 57 (6.8) 10 (6.3) 53 (7.4) 1.2 (0.6 to 2.2)
 §
 
PACI  376 (45.1) 81 (50.9) 308 (42.9) 1.1 (0.8 to 1.6)
 §
 
LACI  228 (27.3) 38 (23.9) 200 (27.9) 0.8 (0.5 to 1.1)
 §
 
POCI  131 (15.7) 22 (13.8) 121 (16.9) 0.8 (0.5 to 1.3)
 §
 
Uncertain subtype  42 (5.0) 8 (5.0) 36 (5.0) 0.9 (0.5 to 1.9)
 §
 
Severity of index stroke     
Can’t walk, can’t lift arms  91 (10.4) 12 (7.6) 79 (11.0) 0.9 (0.5 to 1.5) 
Can’t walk, can lift arms  119 (13.6) 31 (19.5) 88 (12.3) 1.6 (1.1 to 2.4) 
Can walk  664 (76.0) 115 (72.9) 549 (76.7) 0.7 (0.5 to 1.0) 
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Table 8.1 continued Total Recurrent 




Univariate HR  
(95% CI) 
Cardioembolic  117 (13.3) 28 (17.6) 89 (12.4) 1.2 (0.8 to 2.0)
 ║
 
Large vessel disease  72 (8.2) 12 (7.6) 60 (8.4) 1.0 (0.7 to 1.6)
 ║
 
Mixed aetiology  58 (6.6) 16 (7.6) 42 (5.9) 1.8 (1.2 to 2.7)
 ║
 
Small vessel disease  178 (20.3) 24 (15.1) 154 (21.5) 0.8 (0.6 to 1.2)
 ║
 
Unclassified after complete 
investigation  
355 (40.5) 65 (40.9) 290 (40.4) 0.9 (0.7 to 1.3)
 ║ 
 
Unclassified after incomplete 
investigation  
40 (15.8) 14 (8.8) 83 (11.6) 0.8 (0.5 to 1.5)
 ║
 
Risk factors     
History of TIA 143 (16.3) 29 (18.2) 114 (15.9) 1.1 (0.8 to 1.7) 
History of stroke  166 (18.9) 41 (25.8) 125 (17.4) 1.5 (1.1 to 2.2) 
History of ischaemic heart disease 242 (27.6) 62 (39.0) 180 (25.1) 1.9 (1.4 to 2.6) 
History of PVD 69 (7.9) 22 (13.9) 47 (6.6) 2.0 (1.3 to 3.2) 
Ipsilat. carotid stenosis >70  97 (12.5) 21 (14.9) 76 (12.0) 1.2 (0.8 to 2.0) 
Ever AF  168 (20.3) 42 (26.4) 126 (17.6) 1.7 (1.3 to 2.5) 
Prior treated hypertension  467 (53.3) 96 (60.4) 371 (51.7) 1.4  (1.0 to 1.9) 
Diabetes  110 (12.5) 26 (16.4) 84 (11.7) 1.4 (0.9 to 2.2) 
Ever smoker  602 (69.8) 113 (71.1) 489 (69.5) 1.1 (0.8 to 1.5) 
Heart failure  40 (4.58) 14 (8.7) 26 (3.6) 2.8 (1.6 to 4.8) 
Any antiplatelet at baseline  369 (46.1) 11 (6.9) 33 (4.6) 1.7 (0.9 to 3.1) 
Warfarin at baseline  43 (4.9) 32 (4.5) 11 (6.9) 1.5 (0.8 to 2.7) 
Systolic BP (Mean, No.observations) 147.2 (874) 147.3 (159) 147.2 (715) 1.00 (0.99 to 1.01)
 †
 
Diastolic BP (Mean, No. observations) 80.0 (874) 80.1 (159) 80.0 (715) 1.00 (0.99 to 1.01)
 †
 
Footnote.  *OCSP=Oxfordshire Community Stroke Project Classification (ischaemic and probable), 
TACS=total anterior circulation stroke, PACS=partial anterior circulation stroke, LACS=lacunar stroke, 
POCS=posterior circulation stroke. † per unit increase ‡ versus other pathological types §versus all others in 
OCSP classification ║ versus all others in TOAST classification.
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Table 8.2 The association between marker level and recurrent stroke, MI or vascular death, assuming a linear association between marker level and log hazards 





 Unadjusted  Adjusted
†







Interleukin-6 (pg/ml) 1.07 (1.04 to 1.10) 1.06 (1.03 to 1.09) 1.05 (1.01 to 1.09) 1.33 (1.15 to 1.53) 
C-reactive protein (mg/l) 1.01 (1.00 to 1.01) 1.01 (1.00 to 1.01) 1.00 (1.00 to 1.03) 1.06 (1.02 to 1.09) 
Fibrinogen (g/l) 1.16 (1.05 to 1.28) 1.12 (1.01 to 1.25) 1.02 (0.97 to 1.17) 1.20 (1.01 to 1.43) 
White cell count (x10
9
/l) 1.06 (1.02 to 1.10) 1.05 (1.00 to 1.11) 1.03 (0.97 to 1.09) 1.17 (0.98 to 1.38) 
Glucose (mmol/l) 1.04 (0.99 to 1.09) 1.03 (0.98 to 1.08) 1.02 (0.97 to 1.08) 1.06 (0.97 to 1.15) 
 
Footnote * HR per unit increase in marker (99th centile-1st centile level of marker).25th and 75th  percentile respectively for: IL6 2.39 and 7.22 pg/ml; CRP 1.39 and 9.65 mg/l; 
fibrinogen 3.81 and 5.41 g/l; white cell count 6.6  and 9.7 x109/l; glucose 5.0 and 6.8 mmol/l. †Adjusted for confounders: age, cardiac failure, atrial fibrillation (current or past), or prior 
stroke, TIA, peripheral vascular disease or MI. ‡ adjusted for all confounder in previous column, and other markers. 
Whiteley W.N. Blood Markers in Stroke University of Edinburgh 2010 
 
 248
 Table 8.3 The association between marker level and any death, assuming a linear association between marker level and log hazards 





 Unadjusted  Adjusted
†







Interleukin-6 (pg/ml) 1.13 (1.10 to 1.15) 1.10 (1.07 to 1.12) 1.07 (1.04 to 1.12) 1.56 (1.37 to 1.77) 
C-reactive protein (mg/l) 1.01 (1.00 to 1.01) 1.01 (1.00 to 1.01) 1.00 (1.00 to 1.81) 1.08 (1.04 to 1.11) 
Fibrinogen (g/l) 1.37 (1.26 to 1.49) 1.26 (1.14 to 1.40) 1.14 (1.01 to 1.28) 1.45 (1.24 to 1.72) 
White cell count (x10
9
/l) 1.07 (1.02 to 1.12) 1.05 (1.00 to 1.11) 1.03 (0.97 to 1.09) 1.17 (1.00 to 1.37) 
Glucose (mmol/l) 1.95 (1.02 to 1.10) 1.06 (1.02 to 1.11) 1.04 (0.99 to 1.09) 1.12 (1.03 to 1.21) 
 
Footnote * HR per unit increase in marker (75th centile-25th centile level of marker).25th and 75th  percentile respectively for: IL6 2.39 and 7.22 pg/ml; CRP 1.39 and 9.65 mg/l; fibrinogen 3.81 and 5.41 
g/l; white cell count 6.6  and 9.7 x109/l; glucose 5.0 and 6.8 mmol/l. †Adjusted for confounders: age, ability to walk, living alone, independent prior to stroke, orientated to place time 
and person, able to lift arms from bed. ‡ adjusted for all confounder in previous column, and other markers 
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Table 8.4 Association between inflammatory markers and recurrent stroke, MI or vascular death, adjusted for age, cardiac failure, AF and previous occlusive vascular disease and 
reported separately for patients seen as an inpatient and patients seen as an outpatient. 
 Inpatient  Outpatient 








 centile) P 
      
Interleukin-6 1.41 (1.03 to 1.11) 0.001  1.27 (0.96 to 1.71) 0.097 
C-reactive protein 1.03 (1.01 to 1.06) 0.018  1.05 (0.98 to 1.23) 0.173 
Fibrinogen 1.10 (0.95 to 1.28) 0.191  1.14 (0.95 to 1.37) 0.157 
White cell count 1.16 (0.98 to 1.34) 0.079  1.03 (0.86 to 1.24) 0.755 
Glucose 1.09 (1.03 to 1.16) 0.004  0.98 (0.90 to 1.07) 0.668 
25th and 75th  percentile respectively for: IL6 2.39 and 7.22 pg/ml; CRP 1.39 and 9.65 mg/l; fibrinogen 3.81 and 5.41 g/l; white cell count 6.6 and 9.7 x109/l; glucose 5.0 and 6.8 mmol/l 
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Table 8.5.Thresholds from other studies of stroke recurrence and inflammatory markers applied to the Edinburgh Stroke Study (ESS), using the same analytical technique. 
Study Marker Thresholds Outcome Reported association Association when threshold applied 
to ESS 
      
(Woodward et al. 2005a) CRP mg/L 1.14, 3.34 Recurrent stroke OR: 1.26 (0.98 to 1.61)* 1.18 (0.69 to 2.13)
║
 
 Fibrinogen g/L 3.32, 4.04 Recurrent stroke OR: 1.24 (0.97 to 1.59)* 0.97 (0.47 to 1.98)
 ║
 
(Welsh et al. 2008e) IL-6 pg/ml 1.70, 2.94 Recurrent stroke OR: 1.31 (1.01 to 1.69)* 1.35 (0.61 to 2.97)
 ║
 
(Di Napoli, Papa, & 
Bocola 2001c) 
CRP mg/L 5, 33 Death or any vascular event HR: 2.89 (1.58 to 5.29)
†
 1.77 (1.41 to 2.21)** 
 Fibrinogen g/L 3.78, 6.17 Death or any vascular event HR: 2.08 (1.19 to 3.62)
†
 1.85 (1.41 to 2.42) ** 
(Rallidis et al 2008) CRP mg/l Per 1mg/l Death by hospital discharge OR: 1.20 (1.09 to 1.30)
 ‡
 1.01 (1.01 to 1.02) **
††
 
 Fibrinogen  Per 0.1 g/L Death by hospital discharge OR: 1.18 (1.08 to 1.30)
 ‡
 1.02 (1.00 to 1.04) ** 
(Elkind et al. 2006c) CRP mg/L 4.2, 10.3, 31.1 Recurrent vascular event HR: 1.86 (1.13 to 3.08)
§
 1.91 (1.15 to 3.18)
 ║
 
 CRP mg/L 4.2, 10.3, 31.1 Death HR: 4.50 (2.83 to 7.15)
§
 3.21 (2.04 to 5.05) ** 
(Campbell et al. 2006a) CRP mg/L 0.8, 1.8, 4.4. 92.1 Recurrent ischaemic stroke OR: 1.00 (0.63 to 1.58)
 §
 1.55 (0.14 to 3.30)
 ║
 
*Top versus bottom third, adjusted; †per third, unadjusted; ‡adjusted; § top to bottom quarter adjusted ║ adjusted for age, AF, prior TIA, stroke or MI and cardiac failure; ** adjusted for age, ability to walk, 
living alone, independent prior to stroke, orientated to place time and person, able to lift arms from bed†† death within first year only 
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Figure 33 Unadjusted Kaplan Meier survival curve and life table, for survival free from recurrent stroke, myocardial infarction or vascular death by third of interleukin 6 
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Figure 34 Hazard ratio per pg/ml increase in interleukin-6 for the occurrence of recurrent stroke, 
myocardial infarction and vascular death, for different baseline subtypes of ischaemic stroke.  
Adjusted for age, AF, prior TIA, stroke or MI and cardiac failure. Stroke classified by the Trial of Org 
10172 in Acute Stroke Treatment algorithm and the OCSP classification. P value is derived from a χ2 
test of heterogeneity. Each square is placed at the point estimate, and the size of the square is 
proportional to the number of strokes in that category. Horizontal lines mark 95% confidence intervals
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Figure 35 Unadjusted cumulative incidence curves of (a) death from recurrent stroke, MI or other 
vascular causes, (b) death from the initial stroke or (c) non-vascular death, by thirds of interleukin 6, 















Whiteley W.N. Blood Markers in Stroke University of Edinburgh 2010 
 
Chapter 9  Discussion 254 
Chapter 9.  Discussion 
Implications for clinical practice 
I have studied the clinical utility of blood biomarkers that are easily available to 
clinical researchers. In chapter 2, I posed a number of clinical questions that could 
be addressed with the use of blood biomarkers: 
Do blood markers identify patients with ischaemic or haemorrhagic stroke (‘acute 
cerebrovascular disease’) in a group of patients in whom stroke is suspected by a member of 
the emergency team? 
A member of the emergency department team might use a blood marker that could 
identify patients with acute cerebrovascular diseases quickly and simply to aid a 
decision whether or not to admit a patient to a stroke service or prioritise them for 
urgent brain imaging. This could reduce the delay to time-dependent treatments.  
However, I found that - in patients presenting with suspected stroke - none of the 
markers of inflammation, thrombosis, thrombolysis, cardiac strain or cerebral 
damage that I measured were likely to improve the clinical diagnosis of acute 
cerebrovascular disease. I have answered this question satisfactorily in the thesis 
though subject to the constraints in the recruitment of the cohort (see below). There 
was no evidence that blood markers could identify patients with acute 
cerebrovascular disease amongst those patients in whom a member of the 
emergency department was substantially uncertain about the diagnosis of stroke 
(i.e. excluding those with definite stroke).  
Do blood markers identify patients with ischaemic stroke amongst patients in whom a stroke 
physician suspects stroke, though the initial imaging is normal? 
An emergency department doctor might want positive reassurance that the patient 
in front of him has had an ischaemic stroke, when the initial CT imaging appears to 
be normal. Were the diagnosis of positive diagnosis of ischaemic stroke made more 
easily in patients with normal CT brain scans, then thrombolysis or other important 
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acute treatments for stroke might be delivered more frequently by non-experts, 
improving access to treatments for those remote from larger hospitals. 
In this study, the use of blood markers did not improve the identification of patients 
with ischaemic stroke amongst those with a normal scan over and above simple 
clinical measurements.  
Does this patient with a clinical diagnosis of definite stroke have either a haemorrhagic or 
ischaemic stroke? 
If patients with ischaemic stroke could be distinguished from patients with 
haemorrhagic stroke without the use of a CT scan (for example in an ambulance or 
an emergency department triage) then important acute treatments, such as 
intravenous thrombolysis, could be given more rapidly. I have not been able to 
address this important question in this thesis, as the study recruited too few patients 
with intracranial haemorrhage, and hence any analysis underpowered. The ideal 
design for such a study would be to recruit a large number of patients very early 
after the onset of their symptoms  in whom the ‘first responder’ had made a firm 
diagnosis of stroke, and then see whether blood markers could identify either those 
with intracranial haemorrhage, or those with cerebral ischaemia from the remaining 
patients. 
What is the prognosis of the patient with stroke, in the shorter or the longer term? 
In my view, no laboratory measurement of a blood marker of inflammation, 
thrombosis, thrombolysis, cardiac strain or cerebral damage is likely to improve the 
prediction of poor outcome after acute cerebrovascular disease over and above the 
simple bedside measurement of neurological impairment and age. The data from 
this thesis suggests that for patients presenting with acute cerebrovascular disease 
the currently available markers have limited or no clinical utility. 
Therefore, none of the markers measured in this project can be recommended for 
use in clinical practice for the diagnosis or prediction of poor outcome after stroke. 
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Limitations of the study 
The study had a number of limitations, which may give opportunities for further 
research.  
Selection bias 
Despite intensive efforts, I only managed to recruit about one half of patients 
presenting to hospital with ischaemic stroke within the first day of their symptoms, 
and fewer patients with transient ischaemic attack. . The routinely collected data 
from the Scottish Stroke Care Audit (collected on stroke patients only) reveals that 
the severity and age of stroke patients in the current study are similar to the patients 
who I failed to recruit. There is no routinely collected data available on patients with 
TIA, or patients with stroke mimics.   
Therefore, I believe that the patients within the study were broadly representative of 
those presenting to hospital with suspected stroke. These patients have, in general, 
milder symptoms than those who are studied within acute stroke treatment trials 
and those who are admitted to stroke units. However, the patients that I recruited 
were comparable in age and level of neurological impairment to studies recruiting 
patients in emergency departments with suspected stroke.(Chalela et al 2007, Hand 
et al. 2006d)  
I did not recruit out of hours or at weekends, and during my holidays there was a 
reduction in the intensity of recruitment as other stroke fellows were recruiting 
patients to other studies concurrently. The second reason for failure to recruit 
patients to the study was incapacity on behalf of the patient and absence of a 
welfare guardian. As I not collect a log of patients not recruited to the trial, I could 
not study this issue systematically, though clearly it is important source of bias as 
those patients unable to consent differ from those who do in important, and often 
unpredictable ways. (Al-Shahi, Vousden, & Warlow 2005) 
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Selection of blood markers 
The selection of the best candidate markers for the diagnosis of prediction of 
outcome in stroke from amongst the vast array of possible markers is difficult. There 
are a number of competing approaches.  
The first approach could be termed ‘biological plausibility’. Here, a marker might be 
selected because of its theoretical association with stroke pathophysiology, or the 
presumptive kinetics of marker release after stroke onset, usually based on animal 
studies. There are many narrative reviews which have taken this approach. 
(Beaudeux 2009, Foerch et al. 2009). However, the basis of the theoretical 
associations may not be sound: they are highly dependent on the existing findings 
in the published literature, which are as prone to publication and other biases as the 
clinical literature.  
Second, proteomic methods might be used to discover new proteins in serum of 
patients with stroke. In essence these methods compare the protein profile, 
measured usually as a mass/charge spectrum, of serum or CSF of patients with 
stroke (or one of its subtypes) to patients without stroke. These studies have 
identified a number of proteins, though there has yet to be a large scale 
reproduction of their work.(Allard et al 2007, Allard et al 2005i, Allard et al. 2005a, 
Allard et al. 2004g). Despite the novelty of proteomic methods, and the exciting 
potential for the discovery of new proteins, current laboratory and statistical 
methods limit the usefulness of the technique. First, even after depleting the most 
abundant proteins from serum (for example albumin and immunoglobulins), the 
proteins with the lowest concentrations, which might be the most tissue specific, are 
hard to identify. For example, studies of serum taken soon after myocardial 
infarction have not identified troponin as potential candidate markers, but instead 
rather more common, non-specific markers of inflammation and proteins that have 
subsequently been shown to be storage artifacts.(Marshall et al. 2003) Second, the 
challenge of identifying an important protein from amongst hundreds (or even 
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thousands) of others – particularly where differences may be quantitative rather 
than qualitative – is so difficult as not to be tractable to modern statistical methods. 
My approach was to select blood markers for this study by two systematic reviews 
of the existing literature. This approach has a number of advantages. By reviewing 
the entirety of the medical literature, it ensures that no potential candidate markers 
are ignored. It ensures an unbiased selection of markers, not dependent on any pre-
existing prejudices of the study authors. It also ensures that those markers chosen 
can be measured, and does not rely on the development of new technology or 
statistical methods. However, this method, which identifies a number of different 
biomarkers studies in different patient populations does not directly compare the 
expected comparative strength of association between markers and outcomes of 
interest. This is the reason for the current study. 
Of course, the relationship between the levels of blood markers and either the 
diagnosis of stroke or the prediction of outcome after stroke is complex. My 
approach in this study has been to examine the role of blood markers in prediction 
of either outcome after stroke or diagnosis of stroke, and not the causal role of 
particular biological processes in stroke. The study has therefore measured the effect 
of adding each marker to a clinical assessment in improving prediction rather than 
whether a marker has a causal role in stroke pathogenesis. In other settings, causal 
variables may be weak predictors. 
Difficulties of blood marker measurement 
For large scale studies examining the causal relationship between marker levels and 
particular outcomes, it is important to measure the level of blood markers in each 
individual that most truly reflects the activity of physiological process that the 
biomarker purports to measure. For example, many important biomarkers are 
altered by time of day, and timing of blood draw in relation to food or symptom 
onset. These can lead to important – sometimes several-fold – differences in the 
concentration of blood marker levels. However, the aim of this study was to try to 
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determine whether blood markers might be useful in clinical practice. Those 
markers which change rapidly with minor differences in physiological state or time 
of day are unlikely to be blood markers which make their way into clinical practice.  
However, whereas this biological variability is to be welcomed, it is important that 
the sample collection and storage is as homogenous as possible. I achieved this in 
this study by rapid freezing of each sample very soon after each blood sample was 
taken. All the procedures were done in the same research laboratory by staff 
experienced in the preparation and measurement of samples for blood markers. 
Use of other medications 
The levels of CRP and other inflammatory markers are reduced clearly by 
rosuvastatin. (Ridker et al. 2009). However, in this study the additional confounding 
due to statin prescription of the relationship between poor outcome after stroke, 
over and above neurological impairment and age, was small and not statistically 
significant. 
Implications for research 
The search for a blood marker for the diagnosis of stroke, or any of its subtypes has 
many theoretical and practical difficulties. First, it is difficult to imagine a 
physiological process that is unique to any one subtype of stroke that could not be 
found in a stroke mimic. Second, as the release into blood of brain proteins is 
slowed by the blood brain barrier, venous blood levels will not rise early after 
symptom onset, when their measurement might be most clinically useful. 
It is unlikely that other markers of the physiological processes of inflammation, 
thrombosis, thrombolysis, or cardiac strain will be useful in stroke diagnosis, unless 
markers are discovered that are unique to stroke. There may be brain proteins or 
other molecules that are released from damaged brain and are able to pass to pass 
rapidly through a damaged blood brain barrier (for example very small, or 
uncharged molecules) though again these may not unique to acute ischaemic  
stroke, or one of its pathological subtypes.  
Whiteley W.N. Blood Markers in Stroke University of Edinburgh 2010 
 
Chapter 9  Discussion 260 
I have not examined structural proteins that form the tight junctions of the blood 
brain barrier – for example cadherins, occludins and junctional adhesion molecules 
– which may be unique to brain, and might be released rapidly after damage to the 
luminal side of the blood brain barrier after arterial occlusion by thrombus, rather 
than other pathologies. These proteins are worthy of further study, when they can 
be measured easily in serum or plasma. 
The main challenge facing a blood test for the prediction of poor outcome after 
stroke is that easily measured clinical variables, particularly neurological 
impairment and age, are so strongly associated with poor outcome. As most 
physiological markers that rise after stroke are associated with one or both of these 
variables, markers will probably add no more than a small improvement in 
prediction to clinical examination. 
One potential use for a blood marker of a physiological process is targeting 
particular treatment on those patients most likely to benefit from them. The most 
plausible blood marker candidates are those that reflect the mechanism of action of 
treatments – for example markers of endogenous thrombolysis (e.g. tPA) or clot 
burden (D-dimer) in acute ischaemic stroke patients treated. High or low levels of 
such markers could describe groups of patients who might stand to gain benefit 
from, or be harmed by, particular interventions. Reliably to identify these patients 
would need: (i) two groups of patients, one randomly allocated to receive the 
treatment and the other to avoid treatment, (ii) the measurement of blood marker 
levels and potentially confounding baseline variables before treatment in all 
patients, (iii) a sufficiently large sample size to assess the interaction between blood 
marker level and treatment benefit, and (iv) the validation of thresholds calculated 
for decision making in other, potentially larger studies. However, blood markers to 
aid treatment decision making are often suggested after a treatment is already used 
routinely in clinical practice, when the allocation of patients to a control group 
would be difficult to justify. As a trial to assess of the role of blood markers in 
making treatment decisions needs a larger sample size than a trial simply to identify 
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treatment effects, blood markers are not usually evaluated in the early large-scale 
studies of a new treatment. The additional complexity of study design and 
increased sample size mean these studies are very expensive to perform. For 
pharmaceutical companies, the additional cost of biomarker evaluation might not be 
economic: even were a trial to show an effective biomarker based approach, a 
targeted treatment is used (therefore sold) less frequently. The only successful 
commercial model is probably where the company owns of both the revenue from 
sale of the blood marker and the drug itself. For example, Roche owns patents for 
both trastuzumab (herceptin) and the fluorescent in-situ hybridisation test for 
HER/neu in breast cancer tissue, which identifies the patients most likely to benefit.  
Future directions 
The prediction of poor outcome and other potentially predictable events (recurrent 
stroke, MI, DVT, PE, infection) after stroke is of great interest to clinicians and 
patients. Senior clinicians often use a clinical assessment of prognosis to inform 
decisions about acute drug treatments or other interventions, the timing of long 
term placement and suitability for rehabilitation. As a clinician’s predictions have a 
potentially large impact on treatment, improvement and standardisation of 
prediction might improve patient outcomes.  
Clinical predictions are likely based on: experience; a doctor’s ability; and the type 
of outcome they are trying to predict. Outcomes that might be predicted more 
accurately are those that are frequent, for which a clinician can build experience 
quickly and have the prediction confirmed by experience, and those which occur 
soon after stroke, when a clinician would link outcomes with baseline clinical 
variables. 
The work of this thesis has led me to propose a study to improve the prediction of 
thrombotic and haemorrhagic events after stroke: to build and validate better 
models; to examine the interaction between predicted outcome and treatment effect 
of antiplatelets, heparin and thrombolysis; and to implement the prediction from 
predictive models in clinical practice (see final appendix). 
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Appendix 1.  Search Strategy 
MEDLINE Search Strategy 
1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or exp brain 
ischemia/ or carotid artery diseases/ or carotid artery thrombosis/ or carotid 
stenosis/ or cerebrovascular accident/ or exp brain infarction/ or exp hypoxia-
ischemia, brain/ or exp intracranial arterial diseases/ or exp "intracranial embolism 
and thrombosis"/ 
2. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or 
intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or 
anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or 
hypoxi$)).tw. 
3. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or 
attack$)).tw. 
4. 1 or 2 or 3 
5. exp biological markers/ 
6. biomarker$.tw. 
7. ((biochemical or clinical or immun$ or laboratory or biologic$ or serum or 
surrogate or viral) adj6 marker$).tw. 
8. ((blood or plasma) adj6 marker$).tw. 
9. 5 or 6 or 7 or 8 
10. Fructose-Bisphosphate Aldolase/ or activins/ or inhibin-beta subunits/ or 
Inhibins/ or Adiponectin/ or Antiplasmin/ or alpha-Macroglobulins/ or alpha 1-
antichymotrypsin/ or alpha 1-antitrypsin/ or Orosomucoid/ or Peptidyl-Dipeptidase 
A/ or Fibroblast Growth Factor 2/ or angiotensins/ or angiotensin i/ or angiotensin ii/ 
or angiotensin iii/ or Antithrombin III/ or apolipoproteins/ or apolipoproteins a/ or 
apolipoprotein a-i/ or apolipoprotein a-ii/ or apolipoproteins b/ or apolipoprotein b-
48/ or apolipoprotein b-100/ or apolipoproteins c/ or apolipoprotein c-i/ or 
apolipoprotein c-ii/ or apolipoproteins d/ or apolipoproteins e/ or apolipoprotein e2/ 
or apolipoprotein e3/ or apolipoprotein e4/ or beta 2-Glycoprotein I/ or Natriuretic 
Peptide, Brain/ or Brain-Derived Neurotrophic Factor/ or caspases, effector/ or 
caspase 3/ or caspase 6/ or caspase 7/ or caspase 14/ or Cathepsin B/ or antigens, 
cd40/ or cd40 ligand/ or Ceruloplasmin/ or Chitinase/ or Cholesterol Ester Transfer 
Proteins/ or Chromogranin A/ or Clusterin/ or Fibronectins/ or Chimerin Proteins/ 
or Chimerin 1/ or complement system proteins/ or anaphylatoxins/ or complement 
activating enzymes/ or complement c1/ or complement c2/ or complement c3/ or 
complement c4/ or complement c5/ or complement c6/ or complement c7/ or 
complement c8/ or complement c9/ or complement factor b/ or complement 
inactivator proteins/ or complement membrane attack complex/ or properdin/ or C-
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Reactive Protein/ or Fibrin Fibrinogen Degradation Products/ or phosphopyruvate 
hydratase/ or tau-crystallins/ or cell adhesion molecules/ or antigens, cd22/ or 
antigens, cd24/ or antigens, cd31/ or antigens, cd146/ or antigens, cd164/ or 
cadherins/ or carcinoembryonic antigen/ or cd4 immunoadhesins/ or cell adhesion 
molecules, neuronal/ or integrin alpha beta2/ or intercellular adhesion molecule-1/ 
or receptors, lymphocyte homing/ or selectins/ or vascular cell adhesion molecule-1/ 
or endothelins/ or endothelin-1/ or endothelin-2/ or endothelin-3/ or Erythropoietin/ 
or E-Selectin/ or Factor XI/ or Factor IX/ or Factor XII/ or Factor V/ or Factor VII/ or 
Factor VIII/ or Factor X/ or Factor XIIa/ or exp Interleukins/ or exp Fibrinogen/ or 
Antigens, CD95/ or exp Ferritins/ or fibrinopeptide a/ or fibrinopeptide b/ or exp 
Fibronectins/ or exp Follistatin-Related Proteins/ or exp Follistatin/ or exp Fatty 
Acids, Nonesterified/ or exp Glial Fibrillary Acidic Protein/ or exp Glutathione 
Transferase/ or Granulocyte-Macrophage Colony-Stimulating Factor/ or exp 
Selectins/ or Platelet Glycoprotein GPIIb-IIIa Complex/ or growth hormone/ or 
human growth hormone/ or exp Haptoglobins/ or Hemopexin/ or Heparin Cofactor 
II/ or exp Intercellular Adhesion Molecule-1/ or exp Immunoglobulin G/ or 
Laminin/ or Leptin/ or Macrophage Colony-Stimulating Factor/ or 
Malondialdehyde/ or exp matrix metalloproteinases, secreted/ or exp Monocyte 
Chemoattractant Proteins/ or Myelin Basic Proteins/ or Peroxidase/ or exp S100 
Proteins/ or Neurotrophin 3/ or 9 Nitric Oxide/ or Nucleoside-Diphosphate Kinase/ 
or Aryldialkylphosphatase/ or Phosphoglycerate Mutase/ or Pregnancy-Associated 
Plasma Protein-A/ or Plasminogen Activator Inhibitor 1/ or Plasminogen/ or 
Plasminogen Activator Inhibitor 2/ or Platelet Activating Factor/ or Antigens, CD31/ 
or Platelet-Derived Growth Factor/ or Platelet Factor 4/ or Protein C/ or Protein S/ or 
Prothrombin/ or Resistin/ or Plasminogen Inactivators/ or Platelet Activation/ or tau 
Proteins/ or Thrombin/ or Thrombomodulin/ or Thromboplastin/ or TUMOR 
NECROSIS FACTOR-ALPHA/ or Transforming Growth Factor beta/ or Vascular 
Endothelial Growth Factor A/ or Vitronectin/ or von Willebrand Factor/ 
11. (Aldolase A or aldolase b or aldolase c or fructose bisphosphonate aldolase or 
activin$ or inhibin$ or adiponectin or adipocyte specific secretory protein or 
gelatine binding protein or adipocyte complement related protein or alpha 2 
antiplasmin or Alpha-2-antiplasmin precursor or Alpha-2-AP or Alpha-2-PI or 
Alpha-2-plasmin inhibitor or pigment epithelium derived factor or plasmin 
inhibitor alpha 2 or alpha-macroglobulin$ or alpha 2M or antichymotrypsin or 
alpha 1-antichymotrypsin or alpha 1-antitrypsin or Seromucoid or serum 
sialomucin or alpha 1-acid glycoprotein or alpha 1-acid seromucoid or a 1-acid 
seromucoid or acid alpha 1-glycoprotein or alpha 1 -acid glycoprotein or alpha 1-
acid glycoprotein acute phase or alpha 1-glycoprotein acid or angiotensin 
converting enzyme or cd143 or cd143 or kininase ii or angiotensin i-converting 
enzyme or carboxycathepsin or dipeptidyl peptidase a or kininase a or ACE or 
kininase 2 or Dipeptidyl carboxypeptidase I or basic fibroblast growth factor or 
fibroblast growth factor, basic or hbgf-2 or cartilage-derived growth factor or class ii 
heparin-binding growth factor or fgf-2 or fgf2 or fibroblast growth factor-2 or 
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heparin-binding growth factor class ii or prostate epithelial cell growth factor or 
prostatropin or Fibroblast Growth Factor 2 or heparin-binding growth factor 2 or 
angiotensin$ or antithrombin ii or heparin cofactor i or at iii or antithrombin iii, 
human plasma or antithrombin iii-alpha or atenativ or baxter brand of antithrombin 
or bayer brand of antithrombin or factor xa inhibitor or grifols brand of 
antithrombin or heparin co-factor i or pharmacia brand of antithrombin or 
thrombate iii or antithrombin 3 or antithrombin-3 or antithrombin iii or 
apolipoprotein$ or beta 2 glycoprotein$ or beta 2-Glycoprotein I or brain natriuretic 
peptide or nesiritide or b-type natriuretic peptide or bnp gene product or bnp-32 or 
brain natriuretic peptide-32 or natrecor or natriuretic factor-32 or natriuretic peptide 
type-b or type-b natriuretic peptide or ventricular natriuretic peptide, b-type or 
Brain-Derived Neurotrophic Factor or casp3 or apopain or caspase-3 or pro-caspase-
3 or procaspase-3 or caspase 3 or cathepsin b-like activity or cathepsin b-like 
proteinase or cathepsin b1 or cathepsin b or amyloid precursor protein secretase or 
endoglin$ or CD105 or cd40 or Bp50 or caeruloplasmin or caeruloplasmin or 
ferroxidase or ceruloplasmin ferroxidase or ceruloplasmin oxidase or ferroxidase i 
or alpha 2 -ceruloplasmin or endochitinase or chitinase$ or chitotriosidase or 
cholesterol ester transport protein or cetp or cholesteryl ester exchange protein or 
cholesteryl ester transfer protein or parathyroid secretory protein or secretory 
protein i, parathyroid gland or Chromogranin A or pancreastatin or parastatin or 
Pituitary secretory protein I or vasostatin or apoj protein or apolipoprotein j or 
complement lysis inhibitor or complement-associated protein sp-40,40 or ionizing 
radiation-induced protein-8 or mac393 antigen or sgp-2 protein or sp 40,40 protein 
or sulfated glycoprotein 2 or sulfated glycoprotein-2 or trpm-2 protein or 
testosterone-repressed prostate message-2 protein or x-ray-inducible protein 8 or 
xip8 protein or aging-associated protein 4 or Complement cytolysis inhibitor or 
clusterin or cold-insoluble globulins or lets proteins or fibronectin or opsonic 
glycoprotein or opsonic alpha 2 sb glycoprotein or alpha 2-surface binding 
glycoprotein or c-fibronectin or c fibronectin or cellular fibronectin or alpha-1 
chimerin or alpha-2 chimerin or alpha-chimerin or arhgap2 protein or n-chimerin or 
rhogap2 protein or chimaerin 1 or alpha-1 chimaerin or alpha-2 chimaerin or alpha-
chimaerin or alpha1-chimaerin or n-chimaerin or chimerin or chimerin$ or collagen 
synthesis byproduct or complement or c reactive protein or c-reactive protein or 
CRP or antithrombin vi or fibrin degradation products or fibrin fibrinogen split 
products or Fibrin Fibrinogen Degradation Products or D-dimer or D dimer or 
enolase or neuron-specific enolase or 2-phospho-d-glycerate hydrolase or cobalt 
enolase or nervous system-specific enolase or non-neuronal enolase or alpha, alpha-
enolase or beta-enolase or gamma, gamma-enolase or Phosphopyruvate Hydratase 
or Neuron specific enolase or Neurone specific enolase or Neurone-specific enolase 
or endothelial protein c receptor or endothelial cell protein c receptor or protein c 
receptor or centrocyclin or CD201 antigen or antigens, cd106 or cd106 antigens or 
vcam-1 or cd106 antigen or incam-110 or inducible cell adhesion molecule 110 or 
vascular cell adhesion molecule or big endothelin or big endothelin-1 or et-1 
endothelin-1 or endothelin type 1 or endothelin, big or preproendothelin or 
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preproendothelin-1 or proendothelin 1-38 or proendothelin-1 precursor or 
Erythropoietin or antigens, cd62e or cd62e antigens or e selectin or elam-1 or 
endothelial leukocyte adhesion molecule-1 or lecam-2 or cd62e antigen or 
endothelial leukocyte adhesion molecule 1 or e-selectin or selectin e or 
autoprothrombin ii or christmas factor or coagulation factor ix or ptc or plasma 
thromboplastin component or blood coagulation factor ix or factor ix complex or 
factor ix fraction or coagulation factor xi or plasma thromboplastin antecedent or 
blood coagulation factor xi or coagulation factor xii or hageman factor or blood 
coagulation factor xii or coagulation factor v or proaccelerin or ac globulin or blood 
coagulation factor v or factor pi or factor v or factor ix or factor xii or factor xi or 
coagulation factor vii or proconvertin or stable factor or blood coagulation factor vii 
or factor vii or antihemophilic factor or coagulation factor viii or factor viii clotting 
antigen or factor viii coagulant antigen or factor viii procoagulant activity or 
thromboplastinogen or blood coagulation factor viii or f viii-c or factor viii-heavy 
chain or factor viiic or hemofil or hemofil hm or hemofil m or hemophil or humate-p 
or hyate-c or hyatt-c or monoclate or factor viii or autoprothrombin iii or 
coagulation factor x or stuart factor or stuart-prower factor or blood coagulation 
factor x or stuart prower factor or factor vii activating protease or coagulation factor 
xiia or factor xii, activated or activated factor xii or blood coagulation factor xii, 
activated or hageman-factor fragments or prekallikrein activator or factor xiia or 
interleukin or fibrinogen or coagulation factor i or factor i or blood coagulation 
factor i or gamma-fibrinogen or apo-1 antigen or apoptosis antigen 1 or cd95 
antigens or receptors, fas or tumor necrosis factor receptor superfamily, member 6 
or fas antigens or fas receptors or cd95 antigen or tnfrsf6 receptor or fas antigen or 
fas receptor or basic isoferritin or ferritin or isoferritin or isoferritin, basic or 
fibrinopeptide or cold-insoluble globulins or lets proteins or fibronectin or opsonic 
glycoprotein or opsonic alpha 2 sb glycoprotein or alpha 2-surface binding 
glycoprotein or activin-binding protein or follistatin or fatty acids, free or free fatty 
acids or nefa or glial fibrillary acidic protein or GFAP or glial intermediate filament 
protein or astroprotein or gfa-protein or glial fibrillary acid protein or glutathione s-
alkyltransferase or glutathione s-aryltransferase or glutathione s-epoxidetransferase 
or ligandins or s-hydroxyalkyl glutathione lyase or glutathione organic nitrate ester 
reductase or glutathione s-transferase or glutathione s-transferase 3 or glutathione s-
transferase a or glutathione s-transferase b or glutathione s-transferase c or 
glutathione s-transferase iii or glutathione s-transferase p or glutathione transferase 
e or glutathione transferase mu or glutathione transferases or heme transfer protein 
or ligandin or b-glutathione-s-transferase or csf-gm or colony-stimulating factor, 
granulocyte-macrophage or gm-csf or histamine-producing cell-stimulating factor 
or csf-2 or tc-gm-csf or tumor-cell human gm colony-stimulating factor or 
granulocyte macrophage colony stimulating factor or antigens, cd62p or cd62p 
antigens or gmp-140 or lecam-3 or p selectin or platelet alpha-granule membrane 
protein or cd62p antigen or padgem or antigens, cd62l or cd62l antigens or lecam-1 
or cd62l antigen or l selectin or lam-1 or leu-8 antigen or leukocyte adhesion 
molecule, lam-1 or mel-14 antigen or tq1 antigen or antigens, cd62e or cd62e 
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antigens or e selectin or elam-1v or endothelial leukocyte adhesion molecule-1 or 
lecam-2 or cd62e antigen or endothelial leukocyte adhesion molecule 1 or gp130 or 
sgp130 or interleukin 11 receptor or gpiib-iiia receptors or integrin alphaiibbeta3 or 
glycoproteins iib-iiia or integrin alpha-iib beta-3 or pituitary growth hormone or 
somatotropin or growth hormone, pituitary or haptoglobin or haemopexin or 
hemopexin or heparin co-factor ii or antigens, cd54 or cd54 antigens or icam-1 or 
cd54 antigen or intercellular adhesion molecule 1 or gamma globulin, 7s or igg or 
allerglobuline or igg t or igg1 or igg2 or igg2a or igg2b or igg3 or igg4 or 
immunoglobulin gt or polyglobin or immunoglobulin g or insulin or ischaemia 
modified albumin or merosin or glycoprotein gp-2 or laminin m or laminin m chain 
or laminin or leptin or ob protein or obese protein or ob gene product or obese gene 
product or lipoprotein associated phospholipase or lipoprotein lipase or csf-1 or csf-
m or colony-stimulating factor 1 or colony-stimulating factor, macrophage or m-csf 
or macrophage colony stimulating factor or malonaldehyde or propanedial or 
malonylaldehyde or malonyldialdehyde or sodium malondialdehyde or 
Malondialdehyde or interstitial collagenase or mmp-1 metalloproteinase or mmp1 
metalloproteinase or matrix metalloproteinase-1 or pro-matrix metalloproteinase-1 
or promatrixmetalloproteinase-1 or prommp-1 or matrix metalloproteinase 1 or 
gelatinase a or 72-kda gelatinase or 72-kda type iv collagenase or mmp-2 
metalloproteinase or mmp2 metalloproteinase or matrix metalloproteinase-2 or 
matrix metalloproteinase 2 or stromelysin 1 or transin or mmp-3 metalloproteinase 
or mmp3 metalloproteinase or stromelysin or matrix metalloproteinase 3 or 
gelatinase b or 92-kda gelatinase or 92-kda type iv collagenase or mmp-9 
metalloproteinase or mmp9 metalloproteinase or matrix metalloproteinase-9 or 
matrix metalloproteinase 9 or metallopeptidase 9 or monocyte chemoattractant 
protein-1 or myelin basic protein or encephalitogenic basic proteins or basic protein, 
encephalitogenic or basic proteins, encephalitogenic or encephalitogenic basic 
protein or neuritogenic protein or protein, encephalitogenic basic or proteins, 
encephalitogenic basic or myeloperoxidase or hemi-myeloperoxidase or Peroxidase 
or antigen s 100 or nerve tissue protein s 100 or s-100 protein or s100 protein family 
or s 100 or ngf-2 or nerve growth factor 2 or neurotrophin 3 or neutrophil gelatinase 
associated lipocalin or neutrophil protease 4 or deoxynucleoside diphosphate 
kinases or gdp kinase or nucleoside diphosphokinases or nucleoside-diphosphate 
kinases or oxidised ldl or osteoprotogerin or aryl-dialkyl phosphatase or 
arylalkylphosphatase or homocysteine thiolactone hydrolase or opa anhydrase or 
oph enzyme or organophosphorus acid anhydrase or organophosphorus acid 
anhydrolase or organophosphorus acid hydrolase or organophosphorus hydrolase 
or paraoxonase or paraoxonase-1 or paraoxonase-2 or glycerate 3-2 -phosphomutase 
or phosphoglyceromutase or phosphoglycerate phosphomutase or 
phosphoglycerate mutase or papp-a or igfbp-4 metalloproteinase or igfbp-4 protease 
or igfbp-4-specific proteinase or insulin-like growth factor-dependent igf binding 
protein-4 protease or insulin-like-growth factor binding protein-4 protease or papp-
alpha or pregnancy associated alpha plasma protein or pregnancy-associated alpha-
plasma protein or pregnancy associated plasma protein a or profibrinolysin or glu-
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plasminogen or glutamic acid 1-plasminogen or glutamyl plasminogen or agepc or 
acetyl glyceryl ether phosphorylcholine or paf-acether or phosphorylcholine, acetyl 
glyceryl ether or 1-alkyl-2-acetyl-sn-glycerophosphocholine or platelet aggregating 
factor or platelet aggregation enhancing factor or platelet-activating substance or 
thrombocyte aggregating activity or platelet activating factor or cd31 antigens or 
pecam-1 or platelet endothelial cell adhesion molecule-1 or cd31 antigen or platelet 
derived microvesicles or platelet derived growth factor or antiheparin factor or pf 4 
or heparin neutralizing protein or pf4 or gamma-thromboglobulin or prorenin or 
Protein C or Protein S or Protein Z or coagulation factor ii or factor ii or blood 
coagulation factor ii or differentiation reversal factor or prothrombin or adipocyte 
cysteine-rich secreted protein fizz3 or resistin or receptor of AGE or RAGE or 
receptor of advanced glycation end products or secretagogin or plasminogen 
activator inhibitors or bae-pai or endothelial plasminogen activator inhibitors or 
placental plasminogen activator inhibitors or plasminogen activator inhibitors, 
endothelial or plasminogen activator inhibitors, placental or platelet activation or 
PARK 7 or SCD40L or Tau or thrombase or thrombinar or thrombostat or alpha-
thrombin or beta,gamma-thrombin or beta-thrombin or gamma-thrombin or 
thrombin or thrombin-antithrombin complex or Thrombomodulin or antigens, 
cd142 or cd142 antigens or coagulation factor iii or factor iii or tissue factor or tissue 
thromboplastin or blood coagulation factor iii or coagulin or glomerular 
procoagulant activity or prothrombinase or tissue factor procoagulant or 
urothromboplastin or thromboplastin or tissue factor pathway inhibitor or tissue 
inhibitor of metalloproteinase or cachectin or tnf-alpha or tumor necrosis factor 
ligand superfamily member 2 or cachectin-tumor necrosis factor or tnf superfamily, 
member 2 or tumor necrosis factor or bone-derived transforming growth factor or 
platelet transforming growth factor or tgf-beta or milk growth factor or tgfbeta or 
Transforming Growth Factor beta or ubiquitin fusion degradation protein 1 or 
Vascular Endothelial Growth Factor A or vascular endothelial growth factor or 
vascular endothelial growth factor-a or gd-vegf or glioma-derived vascular 
endothelial cell growth factor or vegf or vegf-a or vascular permeability factor or 
vasculotropin or vitronectin or factor viii-related antigen or f viii-vwf or factor viiir-
ag or factor viiir-rco or plasma factor viii complex or ristocetin cofactor or ristocetin-
willebrand factor or vwf ag or von willebrand factor type iib or von willebrand 
protein or von Willebrand Factor).tw. 
12. 10 or 11 
13. (12 and 4) not (4 and 9) 
14. (alzheimer$ or coronary or fibrillation or cardiac or cardio$ or cadasil or diabetes 
or tumour or tumor or trauma$ or angina or dement$ or child$ or pediatr$ or 
paediatr$ or newborn$).ti. 
15. 14 and stroke.ti. 
16. 14 not 15 
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17. 13 not 16 
18. limit 17 to humans 
EMBASE Search Strategy 
1. cerebral artery disease/ or cerebrovascular accident/ or stroke/ or vertebrobasilar 
insufficiency/ or wallenberg syndrome/ or exp brain infarction/ or exp brain 
ischemia/ or exp occlusive cerebrovascular disease/ or cerbrovascular disease/ or 
exp carotid artery diseases/ 
2. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or 
intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or 
anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or 
hypoxi$)).tw. 
3. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or 
attack$)).tw. 
4. 1 or 2 or 3 
5. disease Marker/ or biochemical marker/ or biological marker/ or molecular 
marker/ or marker/ 
6. biomarker$.tw. 
7. ((biochemical or clinical or immun$ or laboratory or biologic$ or serum or 
surrogate or viral) adj6 marker$).tw. 
8. ((blood or plasma) adj6 marker$).tw. 
9. (Aldolase A or aldolase b or aldolase c or fructose bisphosphonate aldolase or 
activin$ or inhibin$ or adiponectin or adipocyte specific secretory protein or 
gelatine binding protein or adipocyte complement related protein or alpha 2 
antiplasmin or Alpha-2-antiplasmin precursor or Alpha-2-AP or Alpha-2-PI or 
Alpha-2-plasmin inhibitor or pigment epithelium derived factor or plasmin 
inhibitor alpha 2 or alpha-macroglobulin$ or alpha 2M or antichymotrypsin or 
alpha 1-antichymotrypsin or alpha 1-antitrypsin or Seromucoid or serum 
sialomucin or alpha 1-acid glycoprotein or alpha 1-acid seromucoid or a 1-acid 
seromucoid or acid alpha 1-glycoprotein or alpha 1 -acid glycoprotein or alpha 1-
acid glycoprotein acute phase or alpha 1-glycoprotein acid or angiotensin 
converting enzyme or cd143 or cd143 or kininase ii or angiotensin i-converting 
enzyme or carboxycathepsin or dipeptidyl peptidase a or kininase a or ACE or 
kininase 2 or Dipeptidyl carboxypeptidase I or basic fibroblast growth factor or 
fibroblast growth factor, basic or hbgf-2 or cartilage-derived growth factor or class ii 
heparin-binding growth factor or fgf-2 or fgf2 or fibroblast growth factor-2 or 
heparin-binding growth factor class ii or prostate epithelial cell growth factor or 
prostatropin or Fibroblast Growth Factor 2 or heparin-binding growth factor 2 or 
angiotensin$ or antithrombin ii or heparin cofactor i or at iii or antithrombin iii, 
human plasma or antithrombin iii-alpha or atenativ or baxter brand of antithrombin 
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or bayer brand of antithrombin or factor xa inhibitor or grifols brand of 
antithrombin or heparin co-factor i or pharmacia brand of antithrombin or 
thrombate iii or antithrombin 3 or antithrombin-3 or antithrombin iii or 
apolipoprotein$ or beta 2 glycoprotein$ or beta 2-Glycoprotein I or brain natriuretic 
peptide or nesiritide or b-type natriuretic peptide or bnp gene product or bnp-32 or 
brain natriuretic peptide-32 or natrecor or natriuretic factor-32 or natriuretic peptide 
type-b or type-b natriuretic peptide or ventricular natriuretic peptide, b-type or 
Brain-Derived Neurotrophic Factor or casp3 or apopain or caspase-3 or pro-caspase-
3 or procaspase-3 or caspase 3 or cathepsin b-like activity or cathepsin b-like 
proteinase or cathepsin b1 or cathepsin b or amyloid precursor protein secretase or 
endoglin$ or CD105 or cd40 or Bp50 or caeruloplasmin or caeruloplasmin or 
ferroxidase or ceruloplasmin ferroxidase or ceruloplasmin oxidase or ferroxidase i 
or alpha 2 -ceruloplasmin or endochitinase or chitinase$ or chitotriosidase or 
cholesterol ester transport protein or cetp or cholesteryl ester exchange protein or 
cholesteryl ester transfer protein or parathyroid secretory protein or secretory 
protein i, parathyroid gland or Chromogranin A or pancreastatin or parastatin or 
Pituitary secretory protein I or vasostatin or apoj protein or apolipoprotein j or 
complement lysis inhibitor or complement-associated protein sp-40,40 or ionizing 
radiation-induced protein-8 or mac393 antigen or sgp-2 protein or sp 40,40 protein 
or sulfated glycoprotein 2 or sulfated glycoprotein-2 or trpm-2 protein or 
testosterone-repressed prostate message-2 protein or x-ray-inducible protein 8 or 
xip8 protein or aging-associated protein 4 or Complement cytolysis inhibitor or 
clusterin or cold-insoluble globulins or lets proteins or fibronectin or opsonic 
glycoprotein or opsonic alpha 2 sb glycoprotein or alpha 2-surface binding 
glycoprotein or c-fibronectin or c fibronectin or cellular fibronectin or alpha-1 
chimerin or alpha-2 chimerin or alpha-chimerin or arhgap2 protein or n-chimerin or 
rhogap2 protein or chimaerin 1 or alpha-1 chimaerin or alpha-2 chimaerin or alpha-
chimaerin or alpha1-chimaerin or n-chimaerin or chimerin or chimerin$ or collagen 
synthesis byproduct or complement or c reactive protein or c-reactive protein or 
CRP or antithrombin vi or fibrin degradation products or fibrin fibrinogen split 
products or Fibrin Fibrinogen Degradation Products or D-dimer or D dimer or 
enolase or neuron-specific enolase or 2-phospho-d-glycerate hydrolase or cobalt 
enolase or nervous system-specific enolase or non-neuronal enolase or alpha, alpha-
enolase or beta-enolase or gamma, gamma-enolase or Phosphopyruvate Hydratase 
or Neuron specific enolase or Neurone specific enolase or Neurone-specific enolase 
or endothelial protein c receptor or endothelial cell protein c receptor or protein c 
receptor or centrocyclin or CD201 antigen or antigens, cd106 or cd106 antigens or 
vcam-1 or cd106 antigen or incam-110 or inducible cell adhesion molecule 110 or 
vascular cell adhesion molecule or big endothelin or big endothelin-1 or et-1 
endothelin-1 or endothelin type 1 or endothelin, big or preproendothelin or 
preproendothelin-1 or proendothelin 1-38 or proendothelin-1 precursor or 
Erythropoietin or antigens, cd62e or cd62e antigens or e selectin or elam-1 or 
endothelial leukocyte adhesion molecule-1 or lecam-2 or cd62e antigen or 
endothelial leukocyte adhesion molecule 1 or e-selectin or selectin e or 
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autoprothrombin ii or christmas factor or coagulation factor ix or ptc or plasma 
thromboplastin component or blood coagulation factor ix or factor ix complex or 
factor ix fraction or coagulation factor xi or plasma thromboplastin antecedent or 
blood coagulation factor xi or coagulation factor xii or hageman factor or blood 
coagulation factor xii or coagulation factor v or proaccelerin or ac globulin or blood 
coagulation factor v or factor pi or factor v or factor ix or factor xii or factor xi or 
coagulation factor vii or proconvertin or stable factor or blood coagulation factor vii 
or factor vii or antihemophilic factor or coagulation factor viii or factor viii clotting 
antigen or factor viii coagulant antigen or factor viii procoagulant activity or 
thromboplastinogen or blood coagulation factor viii or f viii-c or factor viii-heavy 
chain or factor viiic or hemofil or hemofil hm or hemofil m or hemophil or humate-p 
or hyate-c or hyatt-c or monoclate or factor viii or autoprothrombin iii or 
coagulation factor x or stuart factor or stuart-prower factor or blood coagulation 
factor x or stuart prower factor or factor vii activating protease or coagulation factor 
xiia or factor xii, activated or activated factor xii or blood coagulation factor xii, 
activated or hageman-factor fragments or prekallikrein activator or factor xiia or 
interleukin or fibrinogen or coagulation factor i or factor i or blood coagulation 
factor i or gamma-fibrinogen or apo-1 antigen or apoptosis antigen 1 or cd95 
antigens or receptors, fas or tumor necrosis factor receptor superfamily, member 6 
or fas antigens or fas receptors or cd95 antigen or tnfrsf6 receptor or fas antigen or 
fas receptor or basic isoferritin or ferritin or isoferritin or isoferritin, basic or 
fibrinopeptide or cold-insoluble globulins or lets proteins or fibronectin or opsonic 
glycoprotein or opsonic alpha 2 sb glycoprotein or alpha 2-surface binding 
glycoprotein or activin-binding protein or follistatin or fatty acids, free or free fatty 
acids or nefa or glial fibrillary acidic protein or GFAP or glial intermediate filament 
protein or astroprotein or gfa-protein or glial fibrillary acid protein or glutathione s-
alkyltransferase or glutathione s-aryltransferase or glutathione s-epoxidetransferase 
or ligandins or s-hydroxyalkyl glutathione lyase or glutathione organic nitrate ester 
reductase or glutathione s-transferase or glutathione s-transferase 3 or glutathione s-
transferase a or glutathione s-transferase b or glutathione s-transferase c or 
glutathione s-transferase iii or glutathione s-transferase p or glutathione transferase 
e or glutathione transferase mu or glutathione transferases or heme transfer protein 
or ligandin or b-glutathione-s-transferase or csf-gm or colony-stimulating factor, 
granulocyte-macrophage or gm-csf or histamine-producing cell-stimulating factor 
or csf-2 or tc-gm-csf or tumor-cell human gm colony-stimulating factor or 
granulocyte macrophage colony stimulating factor or antigens, cd62p or cd62p 
antigens or gmp-140 or lecam-3 or p selectin or platelet alpha-granule membrane 
protein or cd62p antigen or padgem or antigens, cd62l or cd62l antigens or lecam-1 
or cd62l antigen or l selectin or lam-1 or leu-8 antigen or leukocyte adhesion 
molecule, lam-1 or mel-14 antigen or tq1 antigen or antigens, cd62e or cd62e 
antigens or e selectin or elam-1v or endothelial leukocyte adhesion molecule-1 or 
lecam-2 or cd62e antigen or endothelial leukocyte adhesion molecule 1 or gp130 or 
sgp130 or interleukin 11 receptor or gpiib-iiia receptors or integrin alphaiibbeta3 or 
glycoproteins iib-iiia or integrin alpha-iib beta-3 or pituitary growth hormone or 
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somatotropin or growth hormone, pituitary or haptoglobin or haemopexin or 
hemopexin or heparin co-factor ii or antigens, cd54 or cd54 antigens or icam-1 or 
cd54 antigen or intercellular adhesion molecule 1 or gamma globulin, 7s or igg or 
allerglobuline or igg t or igg1 or igg2 or igg2a or igg2b or igg3 or igg4 or 
immunoglobulin gt or polyglobin or immunoglobulin g or insulin or ischaemia 
modified albumin or merosin or glycoprotein gp-2 or laminin m or laminin m chain 
or laminin or leptin or ob protein or obese protein or ob gene product or obese gene 
product or lipoprotein associated phospholipase or lipoprotein lipase or csf-1 or csf-
m or colony-stimulating factor 1 or colony-stimulating factor, macrophage or m-csf 
or macrophage colony stimulating factor or malonaldehyde or propanedial or 
malonylaldehyde or malonyldialdehyde or sodium malondialdehyde or 
Malondialdehyde or interstitial collagenase or mmp-1 metalloproteinase or mmp1 
metalloproteinase or matrix metalloproteinase-1 or pro-matrix metalloproteinase-1 
or promatrixmetalloproteinase-1 or prommp-1 or matrix metalloproteinase 1 or 
gelatinase a or 72-kda gelatinase or 72-kda type iv collagenase or mmp-2 
metalloproteinase or mmp2 metalloproteinase or matrix metalloproteinase-2 or 
matrix metalloproteinase 2 or stromelysin 1 or transin or mmp-3 metalloproteinase 
or mmp3 metalloproteinase or stromelysin or matrix metalloproteinase 3 or 
gelatinase b or 92-kda gelatinase or 92-kda type iv collagenase or mmp-9 
metalloproteinase or mmp9 metalloproteinase or matrix metalloproteinase-9 or 
matrix metalloproteinase 9 or metallopeptidase 9 or monocyte chemoattractant 
protein-1 or myelin basic protein or encephalitogenic basic proteins or basic protein, 
encephalitogenic or basic proteins, encephalitogenic or encephalitogenic basic 
protein or neuritogenic protein or protein, encephalitogenic basic or proteins, 
encephalitogenic basic or myeloperoxidase or hemi-myeloperoxidase or Peroxidase 
or antigen s 100 or nerve tissue protein s 100 or s-100 protein or s100 protein family 
or s 100 or ngf-2 or nerve growth factor 2 or neurotrophin 3 or neutrophil gelatinase 
associated lipocalin or neutrophil protease 4 or deoxynucleoside diphosphate 
kinases or gdp kinase or nucleoside diphosphokinases or nucleoside-diphosphate 
kinases or oxidised ldl or osteoprotogerin or aryl-dialkyl phosphatase or 
arylalkylphosphatase or homocysteine thiolactone hydrolase or opa anhydrase or 
oph enzyme or organophosphorus acid anhydrase or organophosphorus acid 
anhydrolase or organophosphorus acid hydrolase or organophosphorus hydrolase 
or paraoxonase or paraoxonase-1 or paraoxonase-2 or glycerate 3-2 -phosphomutase 
or phosphoglyceromutase or phosphoglycerate phosphomutase or 
phosphoglycerate mutase or papp-a or igfbp-4 metalloproteinase or igfbp-4 protease 
or igfbp-4-specific proteinase or insulin-like growth factor-dependent igf binding 
protein-4 protease or insulin-like-growth factor binding protein-4 protease or papp-
alpha or pregnancy associated alpha plasma protein or pregnancy-associated alpha-
plasma protein or pregnancy associated plasma protein a or profibrinolysin or glu-
plasminogen or glutamic acid 1-plasminogen or glutamyl plasminogen or agepc or 
acetyl glyceryl ether phosphorylcholine or paf-acether or phosphorylcholine, acetyl 
glyceryl ether or 1-alkyl-2-acetyl-sn-glycerophosphocholine or platelet aggregating 
factor or platelet aggregation enhancing factor or platelet-activating substance or 
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thrombocyte aggregating activity or platelet activating factor or cd31 antigens or 
pecam-1 or platelet endothelial cell adhesion molecule-1 or cd31 antigen or platelet 
derived microvesicles or platelet derived growth factor or antiheparin factor or pf 4 
or heparin neutralizing protein or pf4 or gamma-thromboglobulin or prorenin or 
Protein C or Protein S or Protein Z or coagulation factor ii or factor ii or blood 
coagulation factor ii or differentiation reversal factor or prothrombin or adipocyte 
cysteine-rich secreted protein fizz3 or resistin or receptor of AGE or RAGE or 
receptor of advanced glycation end products or secretagogin or plasminogen 
activator inhibitors or bae-pai or endothelial plasminogen activator inhibitors or 
placental plasminogen activator inhibitors or plasminogen activator inhibitors, 
endothelial or plasminogen activator inhibitors, placental or platelet activation or 
PARK 7 or SCD40L or Tau or thrombase or thrombinar or thrombostat or alpha-
thrombin or beta,gamma-thrombin or beta-thrombin or gamma-thrombin or 
thrombin or thrombin-antithrombin complex or Thrombomodulin or antigens, 
cd142 or cd142 antigens or coagulation factor iii or factor iii or tissue factor or tissue 
thromboplastin or blood coagulation factor iii or coagulin or glomerular 
procoagulant activity or prothrombinase or tissue factor procoagulant or 
urothromboplastin or thromboplastin or tissue factor pathway inhibitor or tissue 
inhibitor of metalloproteinase or cachectin or tnf-alpha or tumor necrosis factor 
ligand superfamily member 2 or cachectin-tumor necrosis factor or tnf superfamily, 
member 2 or tumor necrosis factor or bone-derived transforming growth factor or 
platelet transforming growth factor or tgf-beta or milk growth factor or tgfbeta or 
Transforming Growth Factor beta or ubiquitin fusion degradation protein 1 or 
Vascular Endothelial Growth Factor A or vascular endothelial growth factor or 
vascular endothelial growth factor-a or gd-vegf or glioma-derived vascular 
endothelial cell growth factor or vegf or vegf-a or vascular permeability factor or 
vasculotropin or vitronectin or factor viii-related antigen or f viii-vwf or factor viiir-
ag or factor viiir-rco or plasma factor viii complex or ristocetin cofactor or ristocetin-
willebrand factor or vwf ag or von willebrand factor type iib or von willebrand 
protein or von Willebrand Factor).tw. 
10. Fructose Bisphosphate Aldolase/ or ACTIVIN A/ or ACTIVIN/ or INHIBIN A/ or 
INHIBIN/ or INHIBIN B/ or ADIPONECTIN/ or ANTIPLASMIN/ or ALPHA 2 
ANTIPLASMIN/ or Alpha 2 Macroglobulin/ or Chymotrypsin A/ or Alpha 1 
Antitrypsin/ or OROSOMUCOID/ or Dipeptidyl Carboxypeptidase/ or Fibroblast 
Growth Factor 2/ or ANGIOTENSIN I/ or ANGIOTENSIN/ or ANGIOTENSIN 
BLOOD LEVEL/ or ANGIOTENSIN II/ or Antithrombin III/ or exp Apolipoprotein/ 
or Beta2 Glycoprotein 1/ or exp Brain Natriuretic Peptide/ or Brain Derived 
Neurotrophic Factor/ or exp CASPASE/ or Cathepsin B/ or CD40 LIGAND/ or CD40 
ANTIGEN/ or exp CERULOPLASMIN BLOOD LEVEL/ or exp CERULOPLASMIN/ 
or CHITINASE/ or Cholesterol Ester Transfer Protein/ or Chromogranin A/ or exp 
CLUSTERIN/ or Fibronectin/ or Chimerin/ or exp COMPLEMENT/ or 
COMPLEMENT BLOOD LEVEL/ or Anaphylatoxin/ or PROPERDIN/ or C Reactive 
Protein/ or Fibrin Degradation Product/ or Enolase/ or TAU PROTEIN/ or Cell 
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Adhesion Molecule/ or Cd22 Antigen/ or Cd24 Antigen/ or Cd31 Antigen/ or 
antigens, cd164/ or Cadherin/ or Carcinoembryonic Antigen/ or Cd4 
Immunoglobulin/ or Nerve Cell Adhesion Molecule/ or Integrin/ or Intercellular 
Adhesion Molecule 1/ or Homing Receptor/ or Selectin/ or Vascular Cell Adhesion 
Molecule 1/ or ENDOTHELIN 2/ or BIG ENDOTHELIN 2/ or ENDOTHELIN 1/ or 
BIG ENDOTHELIN 1/ or ENDOTHELIN 3/ or ENDOTHELIN/ or 
ERYTHROPOIETIN/ or P SELECTIN GLYCOPROTEIN LIGAND 1/ or L 
SELECTIN/ or SELECTIN/ or exp Blood Clotting Factor/ or exp Cytokine/ or exp 
Fibrinogen/ or Antigens, CD95/ or exp Ferritin/ or fibrinopeptide a/ or 
fibrinopeptide b/ or exp Fibronectins/ or exp Follistatin-Related Proteins/ or exp 
Follistatin/ or exp Fatty Acids, Nonesterified/ or exp Glial Fibrillary Acidic Protein/ 
or exp Glutathione Transferase/ or Granulocyte-Macrophage Colony-Stimulating 
Factor/ or exp Selectins/ or Platelet Glycoprotein GPIIb-IIIa Complex/ or growth 
hormone/ or human growth hormone/ or exp Haptoglobins/ or Hemopexin/ or 
Heparin Cofactor II/ or exp Intercellular Adhesion Molecule-1/ or exp 
Immunoglobulin G/ or Laminin/ or Leptin/ or Macrophage Colony-Stimulating 
Factor/ or Malondialdehyde/ or exp Matrix Metalloproteinase/ or exp Monocyte 
Chemoattractant Proteins/ or Myelin Basic Proteins/ or Peroxidase/ or exp S100 
Proteins/ or Neurotrophin 3/ or 9 Nitric Oxide/ or Nucleoside-Diphosphate Kinase/ 
or Aryldialkylphosphatase/ or Phosphoglycerate Mutase/ or Pregnancy-Associated 
Plasma Protein-A/ or Plasminogen Activator Inhibitor 1/ or Plasminogen/ or 
Plasminogen Activator Inhibitor 2/ or Platelet Activating Factor/ or Antigens, CD31/ 
or Platelet-Derived Growth Factor/ or Platelet Factor 4/ or Protein C/ or Protein S/ or 
Prothrombin/ or Resistin/ or Plasminogen Inactivators/ or Platelet Activation/ or tau 
Proteins/ or Thrombin/ or Thrombomodulin/ or Thromboplastin/ or TUMOR 
NECROSIS FACTOR-ALPHA/ or Transforming Growth Factor beta/ or Vascular 
Endothelial Growth Factor A/ or Vitronectin/ or von Willebrand Factor/ or Tissue 
Plasminogen Activator/ec [Endogenous Compound] 
11. 5 or 6 or 7 or 8 or 9 or 10 
12. 4 and 11 
13. (alzheimer$ or coronary or fibrillation or cardiac or cardio$ or cadasil or diabetes 
or tumour ot tumor or trauma$ or angina or dement$ or child$ or pediatr$ or 
paediatr$ or newborn$).m_titl. 
14. stroke.m_titl. 
15. 13 not 14 
16. 12 not 15 
17. limit 16 to human 
18. (diagnos$ or sensitivity or specificity or odds ratio or likelihood ratio or LR).tw. 
19. 17 and 18
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Appendix 2.  Modified QUADAS questionnaire: systematic 
review of blood markers for the diagnosis of stroke 
1. Is the reference standard likely to correctly classify the target condition? 
Yes:  Expert clinical opinion supported by neuroimaging. 
No: No imaging, no expert opinion on stroke diagnosis. 
2. Did patients receive the same reference standard regardless of the index test 
result? 
Yes: All patients had reference standard. If ‘normal controls’ recruited, some 
description of how stroke was excluded in the ‘normal’ cohort is necessary. 
No: Some patients who had the biomarker test did not have a sensible reference 
standard (i.e. expert clinical opinion + imaging) 
3. Was the reference standard independent of the index test? 
Yes: The biomarker status was not used to make a diagnosis of stroke 
No: The biomarker status could be used to make a diagnosis of stroke 
4. Were the index test results interpreted without knowledge of the results of the 
reference standard? 
Yes: The report mention that assessors of biomarker status are blinded to stroke 
status 
No: If the report states that the assessor of biomarker status had knowledge of 
stroke staus. 
5. Were the reference standard results interpreted without knowledge of the 
results of the index test. 
Yes: Either the report mentions the diagnosis was collected before the blood marker 
was measured, or there is mention of blinding 
No: The reporter of the diagnostic study (expert or radiologist) has access to 
biomarker status 
6. Were withdrawals from the study explained? 
Yes: all patients who enter the study complete it, or there is explanation of why 
some patients do not make it to analysis 
No: Patients missing from final analysis without explanation 
7. Was a cut-off established before the study was started? 
Yes: A cut off was taken either from the literature, or in a clearly defined pilot study 
prior to the analysis of the main data. 
No: Not true
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Name of Assessor _________________________ 
 
Profession:   Nurse  
 
   Doctor   
 
Year qualified:   _________________________ 
       
Face weak?              Y N  
     
Arm weak?  Y N  
     
Leg weak?  Y N  
     
Speech abnormal? Y N 
     












DoB ____/____/________   
 
TELEPHONE NUMBER    














Symptom onset (date/time) ____:____   ___/___/_______ 
 
IF no history of onset (e.g. during sleep) 
 
Last seen well   ____:____   ___/___/_______ 
 
Found unwell   ____:____   ___/___/_______ 
 
 
Time of last meal   ____:____   ___/___/_______ 
      
Time of first assessment ____:____   ___/___/_______   
      
Time of ARU arrival  ____:____   ___/___/_______ 
      
Time of first ARU observations ____:____   ___/___/_______ 
      
Time of fellow assessment ____:____   ___/___/_______ 
      







   
 
 Probable 
 (stroke most likely  
 of a number of possibilities) 
 
 Possible 
 (stroke not most likely  
 of a number of possibilities) 
 
 By whom?  




ED   
 


























































     YES NO UNSURE 
Focal brain deficit           
Head injury          
Loss of consciousness at onset        
Seizure at onset         focal onset? Y  N   Unsure  
History suggestive of infection         which? ___________________ 
Headache at onset          describe __________________ 





     YES NO UNSURE 
MI/Angina            last symptomatic? __ /___/____ 
Heart failure (clinical or echo diagnosis)       
Peripheral vascular (symptoms or operation)       
Renal impairment (previous diagnosis)        
Migraine            with aura?   Y  N   Unsure  
Epilepsy            focal onset? Y  N    Unsure  
AF (permanent or PAF)         
Stroke or TIA            last event? __ /___/____ 
Diabetes          





  YES NO 
Aspirin    
Clopidigrel   
Dipyridamole   
Warfarin   
ACE inhibitor   
Beta blocker   











Current Smoker?   
Y  Never  No < 1 yr   
No > 1 yr  
SOCIAL HISTORY 
    YES NO UNSURE 
Independent of ADLS        
Living alone         
 
OHS – BEFORE EVENT 
0. No symptoms at all     
 
1. Minor symptoms     
despite symptoms able to carry out all usual duties and activities  
2. Minor handicap    
unable to carry out previous activities: able to look after own affairs without 
assistance  
3. Moderate handicap    
requiring some help but able to walk without assistance     
4. Moderately severe handicap   
unable to walk without assistance, attends to bodily needs without assistance  
5. Severe handicap    
bedridden, incontinent requiring constant nursing care and attention day and night 
 
CIRCLE ONE 
hemiparesis,  dysphagia, aphasia, 
hemisensory loss, hemianopia or 
ataxia, facial or hand weakness 
NOT 
isolated dysarthria, diplopia or 
vertigo 
 
Whiteley W.N. Blood Markers in Stroke University of Edinburgh 2010 
 
Appendices 314 
NIH Stroke Scale (Please circle the most appropriate response for each section. See supplementary notes attached. If 
untestable please state reason. Add the scores for each item to get the total, and do not count untestable items) 








Alert – keenly responsive 
Drowsy – arousable by minor stimulation to obey, answer, or respond 
Stuporous – requires repeated stimulation to attend, or is obtunded and requires strong or painful stimulation to make 
movements (not stereotyped) 






Answers both correctly 







Obeys both correctly 
Obeys one correctly 
Incorrect 





Partial gaze palsy – gaze is abnormal in one or both eyes, no forced deviation/total gaze paresis  
Forced deviation – or total gaze paresis not overcome by oculocephalic maneouvre 





No visual loss 
Partial hemianopia or visual inattention 
Complete hemianopia 
Bilateral hemianopia – including cortical blindness 






Minor -  flattened nasolabial fold, asymmetry on smiling 
Partial – total or near total paralysis of lower face 
Complete -  absent facial movement in upper and lower face on one or both sides 








No drift – holds limb at 90 degrees for full 10 seconds 
Drift -  drifts down but does not hit bed 
Some effort against gravity 
No effort against gravity 
No movement 
Untestable (only for amputation or shoulder joint fusion – please state which) 








No drift – holds limb at 90 degrees for full 10 seconds 
Drift -  drifts down but does not hit bed 
Some effort against gravity 
No effort against gravity 
No movement 
Untestable (only for amputation or shoulder joint fusion – please state which) 








No drift – holds limb at 45 degrees for full 5 seconds 
Drift -  drifts down but does not hit bed 
Some effort against gravity 
No effort against gravity 
No movement 
Untestable (only for amputation or hip joint fusion – please state which) 








No drift – holds limb at 45 degrees for full 5 seconds 
Drift -  drifts down but does not hit bed 
Some effort against gravity 
No effort against gravity 
No movement 
Untestable (only for amputation or hip joint fusion – please state which) 






Present in 1 limb 
Present in 2 or more limbs 






Partial loss - patient feels pinprick is less sharp or is dull on affected side 










Mild to moderate dysphasia - obvious loss of fluency or comprehension, without significant limitation in ideas expressed or 
form of expression. Conversation about provided material difficult or impossible but examiner can identify items from patient's 
response. 
Severe dysphasia - all communication is through fragmentary expression; great need for inference, questioning, and guessing 
by the listener who carries burden of communication. Examiner cannot identify items provided from patient response. 







Mild to moderate dysarthria - patient slurs some words, can be understood with some difficulty. 
Unintelligible or worse - speech is so slurred as to be unintelligible (absence of or out of proportion to dysphasia) or is 
mute/anarthric 







Partial neglect - Visual, tactile, auditory, spatial, or personal inattention or extinction to bilateral simultaneous stimulation in one 
of the sensory modalities 
Complete neglect - Profound hemi-inattention (e.g. does not recognise own hand or orients to only one side of space) or 
hemi-inattention to more than one sensary modality (e.g. visual + tactile). 
 
 
Patient is asked to close & open eyes, grip & release normal hand 
Patient is asked to state the month & his/her age. No credit for partly correct 
answers. 
























































Temperature   __________________ 
 
Blood pressure   _________/_________mmHg 
 
Pulse    __________________ 
 
Blood sugar   __________________mmol 
 
    YES NO UNSURE                YES           NO      UNSURE 
  
AF on ECG            Hoover’s                      
Heart murmur            Yawning                       
≥ 1 absent peripheral pulse       
Movement disorder        
Mirror movements        
Able to talk         
Walks without help        
Lifts arms from bed        
Orientated (time, place, person)       
    L R    none 
Carotid bruit         
 
Other findings: 
DIAGNOSIS – STROKE FELLOW 
 
Cerebral ischaemia: 
   Definite IF  ANY: Hemisphere    L  R  Unsure 
   Probable 
   Possible     TACS   hemiparesis + hemianopia + higher cerebral  
        dysfunction (HCD: aphasia or inattention) 
       PACS 2 of: motor/sensory, hemianopia or HCD; monoparesis, 
        new HCD alone 
       POCS CN with contralateral motor/sensory, bilateral  
        motor/sensory, EOM disorder, ataxia + no long tract 
        signs, isolated hemianopia 
       LACS no visual field or HCD: involves 2 of 3 of face, arm and 
        leg – not hand alone: Pure motor, pure sensory, ataxic 
        hemiparesis,sensorimotor 
       Unsure  
 
Not Stroke    IF YES: Diagnosis ____________________ 
 
Presenting symptom   ___________________________________ 
Immediate management: 
 
IV rtPA  IA rtPA  Clot extraction  IST3   Not eligible  
 


























































Scan Time  _____:_____   Scan Date ____/_____/_______ MR  CT  
 
Relevant Brain lesion side  Left  Right  Both  None visible   
 
Relevant Lesion type   Ischaemic    Haemorrhage  None visible   
 
Lesion location  Lacunar       Cortical               Posterior Fossa              
(underline symptomatic lesion) 
 
Other diagnosis _______________________________________________________________ 
CAROTID IMAGING 
 
ICA stenosis left  ___________%  Irregularity   Yes   No  
 








     
                                                             Definite         Probable  Possible 
Cerebral ischaemia           
Cerebral haemorrhage           
Not stroke ___________________         
 
Cause:   Cardioembolic Cortical, b’stem or c’bellar, at least one cardiac source identified, TIA in>1 vascular territory 
  Large artery Cortical, b’stem or c’bellar, vessel >50% stenosis, no cardiac source, TIA in same territory, 
    carotid bruit, loss of  pulses, CT /MR lesion >1.5cm, intermittent claudication, 
  Small-vessel lacunar syndrome, no vessel >50% stenosis, no cardiac source NIDDM, HBP, lesion<1.5cm 
    MR/CT, normal carotid and heart 
  Other aetiology       _____________________ 




SHORT TERM OUTCOMES     YES NO  UNSURE 
Post thrombolysis:  symptomatic haemorrhage         
   non-symptomatic haemorrhage        
Resolved by 24 hours            
 
ECHO   TTE  TTE + contrast  TOE 
LA atrial size  _____________cm   LV function Good  
Valve Lesion Aortic  Mitral     Moderate  
PFO  Yes     No         Poor 
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Appendix 4.  Patient Consent Form 
 
 Blood Biomarkers in Suspected Stroke v3 22/1/7 
  
Department of Clinical Neurosciences 
Western General Hospital  
 
 
Study of Blood Tests to Improve the Diagnosis of Suspected Stroke 
 




                (please tick) 
      
The study has been explained to me and I have read the  
information leaflet about it.  I have had time to consider  
the study and have had all my questions answered.  
   
I give my consent for my usual general practitioner and consultant   
to be contacted about the study and for follow up,  
for my medical records to be examined, and for the information  
collected in this study to be linked to other NHS information on my 
health care held confidentially by NHS Scotland.      
        
I give my consent for up to 3 samples of my blood  
to be taken and tested for markers of acute stroke and  
stored for developing new tests and in future studies. 
 
 
I give my consent to be contacted in the future  
about my health and to be invited to attend for follow-up  
assessments        
 
 
I understand that I am free to withdraw at any time from any part of the study, without 







Place patient sticker here 
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Appendix 5 Relative assent form 
 
 Blood Biomarkers in Suspected Stroke v2 4/1/7 
  
Department of Clinical Neurosciences 
Western General Hospital  
 
 
Study of Blood Tests to Improve the Diagnosis of Suspected Stroke 
 
RELATIVE/WELFARE GUARDIAN’S ASSENT FORM 
 
YES NO 
                (please tick) 
      
The study has been explained to me and I have read the  
information leaflet about it.  I have had time to consider  
the study and have had all my questions answered.  
   
I give my assent for my usual general practitioner  
and consultant to be contacted about the study and for follow up, 
for their medical records to be examined, and for the information  
collected in this study to be linked to other NHS information  
on their health care held confidentially by NHS Scotland.      
        
I give my assent for up to 3 samples of  blood  
to be taken and tested for markers of acute stroke and  
stored for developing new tests and in future studies. 
 
 
I give my assent to   
be contacted in the  future about their health, and to be                                                      
invited to attend for follow-up assessments  
 
 
I understand that my relative is free to withdraw at any time from any part of the 
study, without giving a reason, and without it adversely affecting their future medical 
care. If I am not appointed as welfare guardian, I confirm I am the nearest relative 








Place patient sticker here 
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Appendix 5.  Patient short information leaflet  
 
Blood Biomarkers in Suspected Stroke v4 26/2/7 
 
Department of Clinical Neurosciences 
Western General Hospital  
 
PATIENT SUMMARY INFORMATION SHEET 
 
Study of Blood Tests to Improve the Diagnosis of Suspected Stroke 
 
You have come to hospital with a suspected stroke. We are trying to find 
out if a new blood test helps to make the right diagnosis for people with 
symptoms like yours. We are therefore asking if you can help with this 
study. 
 
We will take up to three blood samples over the next 24 hours from a 
vein in the arm in the same way as the other blood tests you had on 
arriving in hospital. Your care in the hospital will not be affected by the 
results of this blood test.  
 
The research team will discuss your diagnosis with the doctors looking 
after you. We will look at the tests and brain scans done as part of your 
routine clinical care.  We will see how well the diagnosis made by the 
blood test matches the correct diagnosis.  
 
The blood taken will be stored in the Wellcome Trust Clinical Research 
Facility at the Western General Hospital. It will be used by researchers in 
the University of Edinburgh and the University of Glasgow to assess new 
blood tests for stroke. We will not be able to give you the results of the 
blood test. 
 
We would like to contact you in 3 months time and between 6 and 18 
months to see how you are recovering from your illness. We will usually 
do this by sending you a questionnaire by post after contacting your GP
with a telephone reminder should there be no response.  
 
You do not have to take part in this study. If you do not wish to take part,
your care will not be affected in any way. If you withdraw from the study, 
we will destroy all your identifiable samples, but we will need to use the 
data collected up to your withdrawal. 
 
If you like, you can discuss whether to take part in the research with one 
of the doctors in the department who is not involved in the research. Her
name is Dr Sarah Keir. She is a Consultant Stroke Physician at the 
Western General Hospital. Please ask us if you wish to speak to her, or 
she can be contacted by telephone on 0131-5371000. 
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Appendix 6.  Patient long information leaflet  
 
Investigation of Blood Biomarkers in Suspected Stroke 
 
Department of Clinical Neurosciences 
Western General Hospital  
PATIENT DETAILED INFORMATION SHEET 
Study of Blood Tests to Improve the Diagnosis of Suspected Stroke 
 
We are inviting you to take part in a research study.  Before you decide it is important 
for you to understand why the research is being done and what it will involve.  Please 
take time to read the following information carefully. Talk to others about the study if you 
wish. Ask us if there is anything that is not clear or if you would like more information.   
 
What is the purpose of the study? 
 
We are trying to find a better way to make a correct diagnosis when people arrive at 
hospital with suspected stroke. We are investigating how well a new blood test makes 
the diagnosis of stroke. We will also see if blood tests help to predict how well people 
recover after a stroke. 
 
Why have I been chosen? 
 
You have been chosen to take part in this study as one of your doctors or nurses 
suspects you may have had a stroke. 
 
Do I have to take part? 
 
No.  It is up to you to decide whether or not to take part.  If you do, you will be given this 
information sheet to keep and be asked to sign a consent form. You are still free to 
withdraw at any time and without giving a reason.  A decision to withdraw at any time, or 
a decision not to take part, will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
 
If you choose to take part in this study, we will take up to 3 blood samples from a vein in 
your arm. The care and tests you get for your symptoms will be unaffected by the 
results of the blood test. We will contact you in 3 months time to see how well you are
recovering from your symptoms. We will contact your GP before contacting you again.
We will usually send you a questionnaire by post, and we will make a telephone 
reminder should there be no response. We may contact you to see how well you are 
and invite you for further studies one more time over the next 18 months. 
 
What are the possible benefits of taking part? 
 
We cannot promise the study will help you. We will pay very careful attention to the 
diagnosis of every patient who joins the study. We feel that this should help make sure 
that your diagnosis will be as accurate as possible. We hope the results of this research 
will improve the treatment of people with suspected stroke in the future. 
 
What will happen if I don’t want to carry on with the study? 
 
If you withdraw from the study, we will destroy all your identifiable samples if you wish, 
but we will need to use the data collected up to your withdrawal. We will not contact you 
again. 
 




Investigation of Blood Biomarkers in Suspected Stroke 
 
 
What happens when the research study stops? 
 
When the study stops, we will keep your information in the Department of Clinical 
Neurosciences. It will be kept securely and in strict confidence. The blood samples will 
be stored for a further 10 years before they are destroyed. 
 
Will my taking part in this study be kept confidential? 
 
Any information you give us as well as the results of the scans and blood tests will be 
treated as confidential and will only be available to the doctors looking after you and the 
research staff involved in the project. Information that could identify you as an individual 
(your name, date of birth, address or hospital number) will not leave the University 
department. Blood collected during the study will be transferred to researchers in 
Glasgow. 
 
What will happen to any samples I give? 
 
Blood samples taken at your entry into the study will be taken and stored in the 
Wellcome Trust Clinical Research Facility. The samples will be stored for 10 years and 
then destroyed. Part of the sample will be sent to the University of Glasgow for analysis. 
The remaining blood samples will be analysed by researchers in the University of 
Edinburgh looking at the changes found in blood soon after acute stroke. The samples 
will be kept anonymous, though linked to information held by the person in charge of the 
study. The samples may be used in future studies. If a test is developed from the blood 
sample you have given, you will not benefit financially. 
 
Will information from the study be given to my GP? 
  
We will write a letter to you GP to tell them that you are involved in this study.  
 
How will information from this study be published? 
 
Once the study has been completed and the information analysed, the results of the 
study will be published in medical journals, so other doctors can make use of the 
information. None of your personal information will be used in these articles. 
 
Complaints 
If you have a concern about any aspect of this study, you should ask to speak with the 
researchers who will do their best to answer your questions (Dr W. Whiteley 
0131532912).  If you remain unhappy and wish to complain formally, you can do this 
through the NHS Complaints Procedure. Details can be obtained from the hospital. 
Who has reviewed the study?  
 
This study has been reviewed by the Multicentre Research Ethics Committee for 
Scotland A. If you wish to talk to a doctor independent of the study, please contact Dr 
Sarah Keir, Consultant Stroke Physician at the Western General Hospital. The 
telephone number is 0131 5371000. 
 
Thank you for reading about this study 
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Appendix 7.  Search Strategy, Systematic review of blood 
markers for the prognosis of ischemic stroke 
MEDLINE 
1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or exp brain 
ischemia/ or carotid artery diseases/ or carotid artery thrombosis/ or carotid 
stenosis/ or cerebrovascular accident/ or exp brain infarction/ or exp hypoxia-
ischemia, brain/ or exp intracranial arterial diseases/ or exp "intracranial embolism 
and thrombosis"/  
 2 ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or 
intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or 
anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or 
hypoxi$)).tw. 
 3 (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or 
attack$)).tw.  
4 1 or 2 or 3  
5 exp biological markers/  
6 biomarker$.tw.  
7 ((biochemical or clinical or immun$ or laboratory or biologic$ or serum or 
surrogate or viral) adj6 marker$).tw.  
8 ((blood or plasma) adj6 marker$).tw.  
9 Fructose-Bisphosphate Aldolase/ or activins/ or inhibin-beta subunits/ or Inhibins/ 
or Adiponectin/ or Antiplasmin/ or alpha-Macroglobulins/ or alpha 1-
antichymotrypsin/ or alpha 1-antitrypsin/ or Orosomucoid/ or Peptidyl-Dipeptidase 
A/ or Fibroblast Growth Factor 2/ or angiotensins/ or angiotensin i/ or angiotensin ii/ 
or angiotensin iii/ or Antithrombin III/ or apolipoproteins/ or apolipoproteins a/ or 
apolipoprotein a-i/ or apolipoprotein a-ii/ or apolipoproteins b/ or apolipoprotein b-
48/ or apolipoprotein b-100/ or apolipoproteins c/ or apolipoprotein c-i/ or 
apolipoprotein c-ii/ or apolipoproteins d/ or apolipoproteins e/ or apolipoprotein e2/ 
or apolipoprotein e3/ or apolipoprotein e4/ or beta 2-Glycoprotein I/ or Natriuretic 
Peptide, Brain/ or Brain-Derived Neurotrophic Factor/ or caspases, effector/ or 
caspase 3/ or caspase 6/ or caspase 7/ or caspase 14/ or Cathepsin B/ or antigens, 
cd40/ or cd40 ligand/ or Ceruloplasmin/ or Chitinase/ or Cholesterol Ester Transfer 
Proteins/ or Chromogranin A/ or Clusterin/ or Fibronectins/ or Chimerin Proteins/ 
or Chimerin 1/ or complement system proteins/ or anaphylatoxins/ or complement 
activating enzymes/ or complement c1/ or complement c2/ or complement c3/ or 
complement c4/ or complement c5/ or complement c6/ or complement c7/ or 
complement c8/ or complement c9/ or complement factor b/ or complement 
inactivator proteins/ or complement membrane attack complex/ or properdin/ or C-
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Reactive Protein/ or Fibrin Fibrinogen Degradation Products/ or phosphopyruvate 
hydratase/ or tau-crystallins/ or cell adhesion molecules/ or antigens, cd22/ or 
antigens, cd24/ or antigens, cd31/ or antigens, cd146/ or antigens, cd164/ or 
cadherins/ or carcinoembryonic antigen/ or cd4 immunoadhesins/ or cell adhesion 
molecules, neuronal/ or integrin alpha beta2/ or intercellular adhesion molecule-1/ 
or receptors, lymphocyte homing/ or selectins/ or vascular cell adhesion molecule-1/ 
or endothelins/ or endothelin-1/ or endothelin-2/ or endothelin-3/ or Erythropoietin/ 
or E-Selectin/ or Factor XI/ or Factor IX/ or Factor XII/ or Factor V/ or Factor VII/ or 
Factor VIII/ or Factor X/ or Factor XIIa/ or exp Interleukins/ or exp Fibrinogen/ or 
Antigens, CD95/ or exp Ferritins/ or fibrinopeptide a/ or fibrinopeptide b/ or exp 
Fibronectins/ or exp Follistatin-Related Proteins/ or exp Follistatin/ or exp Fatty 
Acids, Nonesterified/ or exp Glial Fibrillary Acidic Protein/ or exp Glutathione 
Transferase/ or Granulocyte-Macrophage Colony-Stimulating Factor/ or exp 
Selectins/ or Platelet Glycoprotein GPIIb-IIIa Complex/ or growth hormone/ or 
human growth hormone/ or exp Haptoglobins/ or Hemopexin/ or Heparin Cofactor 
II/ or exp Intercellular Adhesion Molecule-1/ or exp Immunoglobulin G/ or 
Laminin/ or Leptin/ or Macrophage Colony-Stimulating Factor/ or 
Malondialdehyde/ or exp matrix metalloproteinases, secreted/ or exp Monocyte 
Chemoattractant Proteins/ or Myelin Basic Proteins/ or Peroxidase/ or exp S100 
Proteins/ or Neurotrophin 3/ or 9 Nitric Oxide/ or Nucleoside-Diphosphate Kinase/ 
or Aryldialkylphosphatase/ or Phosphoglycerate Mutase/ or Pregnancy-Associated 
Plasma Protein-A/ or Plasminogen Activator Inhibitor 1/ or Plasminogen/ or 
Plasminogen Activator Inhibitor 2/ or Platelet Activating Factor/ or Antigens, CD31/ 
or Platelet-Derived Growth Factor/ or Platelet Factor 4/ or Protein C/ or Protein S/ or 
Prothrombin/ or Resistin/ or Plasminogen Inactivators/ or Platelet Activation/ or tau 
Proteins/ or Thrombin/ or Thrombomodulin/ or Thromboplastin/ or TUMOR 
NECROSIS FACTOR-ALPHA/ or Transforming Growth Factor beta/ or Vascular 
Endothelial Growth Factor A/ or Vitronectin/ or von Willebrand Factor/ 
10 (Aldolase A or aldolase b or aldolase c or fructose bisphosphonate aldolase or 
activin$ or inhibin$ or adiponectin or adipocyte specific secretory protein or 
gelatine binding protein or adipocyte complement related protein or alpha 2 
antiplasmin or Alpha-2-antiplasmin precursor or Alpha-2-AP or Alpha-2-PI or 
Alpha-2-plasmin inhibitor or pigment epithelium derived factor or plasmin 
inhibitor alpha 2 or alpha-macroglobulin$ or alpha 2M or antichymotrypsin or 
alpha 1-antichymotrypsin or alpha 1-antitrypsin or Seromucoid or serum 
sialomucin or alpha 1-acid glycoprotein or alpha 1-acid seromucoid or a 1-acid 
seromucoid or acid alpha 1-glycoprotein or alpha 1 -acid glycoprotein or alpha 1-
acid glycoprotein acute phase or alpha 1-glycoprotein acid or angiotensin 
converting enzyme or cd143 or cd143 or kininase ii or angiotensin i-converting 
enzyme or carboxycathepsin or dipeptidyl peptidase a or kininase a or ACE or 
kininase 2 or Dipeptidyl carboxypeptidase I or basic fibroblast growth factor or 
fibroblast growth factor, basic or hbgf-2 or cartilage-derived growth factor or class ii 
heparin-binding growth factor or fgf-2 or fgf2 or fibroblast growth factor-2 or 
Whiteley W.N. Blood Markers in Stroke University of Edinburgh 2010 
 
Appendices 324 
heparin-binding growth factor class ii or prostate epithelial cell growth factor or 
prostatropin or Fibroblast Growth Factor 2 or heparin-binding growth factor 2 or 
angiotensin$ or antithrombin ii or heparin cofactor i or at iii or antithrombin iii, 
human plasma or antithrombin iii-alpha or atenativ or baxter brand of antithrombin 
or bayer brand of antithrombin or factor xa inhibitor or grifols brand of 
antithrombin or heparin co-factor i or pharmacia brand of antithrombin or 
thrombate iii or antithrombin 3 or antithrombin-3 or antithrombin iii or 
apolipoprotein$ or beta 2 glycoprotein$ or beta 2-Glycoprotein I or brain natriuretic 
peptide or nesiritide or b-type natriuretic peptide or bnp gene product or bnp-32 or 
brain natriuretic peptide-32 or natrecor or natriuretic factor-32 or natriuretic peptide 
type-b or type-b natriuretic peptide or ventricular natriuretic peptide, b-type or 
Brain-Derived Neurotrophic Factor or casp3 or apopain or caspase-3 or pro-caspase-
3 or procaspase-3 or caspase 3 or cathepsin b-like activity or cathepsin b-like 
proteinase or cathepsin b1 or cathepsin b or amyloid precursor protein secretase or 
endoglin$ or CD105 or cd40 or Bp50 or caeruloplasmin or caeruloplasmin or 
ferroxidase or ceruloplasmin ferroxidase or ceruloplasmin oxidase or ferroxidase i 
or alpha 2 -ceruloplasmin or endochitinase or chitinase$ or chitotriosidase or 
cholesterol ester transport protein or cetp or cholesteryl ester exchange protein or 
cholesteryl ester transfer protein or parathyroid secretory protein or secretory 
protein i, parathyroid gland or Chromogranin A or pancreastatin or parastatin or 
Pituitary secretory protein I or vasostatin or apoj protein or apolipoprotein j or 
complement lysis inhibitor or complement-associated protein sp-40,40 or ionizing 
radiation-induced protein-8 or mac393 antigen or sgp-2 protein or sp 40,40 protein 
or sulfated glycoprotein 2 or sulfated glycoprotein-2 or trpm-2 protein or 
testosterone-repressed prostate message-2 protein or x-ray-inducible protein 8 or 
xip8 protein or aging-associated protein 4 or Complement cytolysis inhibitor or 
clusterin or cold-insoluble globulins or lets proteins or fibronectin or opsonic 
glycoprotein or opsonic alpha 2 sb glycoprotein or alpha 2-surface binding 
glycoprotein or c-fibronectin or c fibronectin or cellular fibronectin or alpha-1 
chimerin or alpha-2 chimerin or alpha-chimerin or arhgap2 protein or n-chimerin or 
rhogap2 protein or chimaerin 1 or alpha-1 chimaerin or alpha-2 chimaerin or alpha-
chimaerin or alpha1-chimaerin or n-chimaerin or chimerin or chimerin$ or collagen 
synthesis byproduct or complement or c reactive protein or c-reactive protein or 
CRP or antithrombin vi or fibrin degradation products or fibrin fibrinogen split 
products or Fibrin Fibrinogen Degradation Products or D-dimer or D dimer or 
enolase or neuron-specific enolase or 2-phospho-d-glycerate hydrolase or cobalt 
enolase or nervous system-specific enolase or non-neuronal enolase or alpha, alpha-
enolase or beta-enolase or gamma, gamma-enolase or Phosphopyruvate Hydratase 
or Neuron specific enolase or Neurone specific enolase or Neurone-specific enolase 
or endothelial protein c receptor or endothelial cell protein c receptor or protein c 
receptor or centrocyclin or CD201 antigen or antigens, cd106 or cd106 antigens or 
vcam-1 or cd106 antigen or incam-110 or inducible cell adhesion molecule 110 or 
vascular cell adhesion molecule or big endothelin or big endothelin-1 or et-1 
endothelin-1 or endothelin type 1 or endothelin, big or preproendothelin or 
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preproendothelin-1 or proendothelin 1-38 or proendothelin-1 precursor or 
Erythropoietin or antigens, cd62e or cd62e antigens or e selectin or elam-1 or 
endothelial leukocyte adhesion molecule-1 or lecam-2 or cd62e antigen or 
endothelial leukocyte adhesion molecule 1 or e-selectin or selectin e or 
autoprothrombin ii or christmas factor or coagulation factor ix or ptc or plasma 
thromboplastin component or blood coagulation factor ix or factor ix complex or 
factor ix fraction or coagulation factor xi or plasma thromboplastin antecedent or 
blood coagulation factor xi or coagulation factor xii or hageman factor or blood 
coagulation factor xii or coagulation factor v or proaccelerin or ac globulin or blood 
coagulation factor v or factor pi or factor v or factor ix or factor xii or factor xi or 
coagulation factor vii or proconvertin or stable factor or blood coagulation factor vii 
or factor vii or antihemophilic factor or coagulation factor viii or factor viii clotting 
antigen or factor viii coagulant antigen or factor viii procoagulant activity or 
thromboplastinogen or blood coagulation factor viii or f viii-c or factor viii-heavy 
chain or factor viiic or hemofil or hemofil hm or hemofil m or hemophil or humate-p 
or hyate-c or hyatt-c or monoclate or factor viii or autoprothrombin iii or 
coagulation factor x or stuart factor or stuart-prower factor or blood coagulation 
factor x or stuart prower factor or factor vii activating protease or coagulation factor 
xiia or factor xii, activated or activated factor xii or blood coagulation factor xii, 
activated or hageman-factor fragments or prekallikrein activator or factor xiia or 
interleukin or fibrinogen or coagulation factor i or factor i or blood coagulation 
factor i or gamma-fibrinogen or apo-1 antigen or apoptosis antigen 1 or cd95 
antigens or receptors, fas or tumor necrosis factor receptor superfamily, member 6 
or fas antigens or fas receptors or cd95 antigen or tnfrsf6 receptor or fas antigen or 
fas receptor or basic isoferritin or ferritin or isoferritin or isoferritin, basic or 
fibrinopeptide or cold-insoluble globulins or lets proteins or fibronectin or opsonic 
glycoprotein or opsonic alpha 2 sb glycoprotein or alpha 2-surface binding 
glycoprotein or activin-binding protein or follistatin or fatty acids, free or free fatty 
acids or nefa or glial fibrillary acidic protein or GFAP or glial intermediate filament 
protein or astroprotein or gfa-protein or glial fibrillary acid protein or glutathione s-
alkyltransferase or glutathione s-aryltransferase or glutathione s-epoxidetransferase 
or ligandins or s-hydroxyalkyl glutathione lyase or glutathione organic nitrate ester 
reductase or glutathione s-transferase or glutathione s-transferase 3 or glutathione s-
transferase a or glutathione s-transferase b or glutathione s-transferase c or 
glutathione s-transferase iii or glutathione s-transferase p or glutathione transferase 
e or glutathione transferase mu or glutathione transferases or heme transfer protein 
or ligandin or b-glutathione-s-transferase or csf-gm or colony-stimulating factor, 
granulocyte-macrophage or gm-csf or histamine-producing cell-stimulating factor 
or csf-2 or tc-gm-csf or tumor-cell human gm colony-stimulating factor or 
granulocyte macrophage colony stimulating factor or antigens, cd62p or cd62p 
antigens or gmp-140 or lecam-3 or p selectin or platelet alpha-granule membrane 
protein or cd62p antigen or padgem or antigens, cd62l or cd62l antigens or lecam-1 
or cd62l antigen or l selectin or lam-1 or leu-8 antigen or leukocyte adhesion 
molecule, lam-1 or mel-14 antigen or tq1 antigen or antigens, cd62e or cd62e 
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antigens or e selectin or elam-1v or endothelial leukocyte adhesion molecule-1 or 
lecam-2 or cd62e antigen or endothelial leukocyte adhesion molecule 1 or gp130 or 
sgp130 or interleukin 11 receptor or gpiib-iiia receptors or integrin alphaiibbeta3 or 
glycoproteins iib-iiia or integrin alpha-iib beta-3 or pituitary growth hormone or 
somatotropin or growth hormone, pituitary or haptoglobin or haemopexin or 
hemopexin or heparin co-factor ii or antigens, cd54 or cd54 antigens or icam-1 or 
cd54 antigen or intercellular adhesion molecule 1 or gamma globulin, 7s or igg or 
allerglobuline or igg t or igg1 or igg2 or igg2a or igg2b or igg3 or igg4 or 
immunoglobulin gt or polyglobin or immunoglobulin g or insulin or ischaemia 
modified albumin or merosin or glycoprotein gp-2 or laminin m or laminin m chain 
or laminin or leptin or ob protein or obese protein or ob gene product or obese gene 
product or lipoprotein associated phospholipase or lipoprotein lipase or csf-1 or csf-
m or colony-stimulating factor 1 or colony-stimulating factor, macrophage or m-csf 
or macrophage colony stimulating factor or malonaldehyde or propanedial or 
malonylaldehyde or malonyldialdehyde or sodium malondialdehyde or 
Malondialdehyde or interstitial collagenase or mmp-1 metalloproteinase or mmp1 
metalloproteinase or matrix metalloproteinase-1 or pro-matrix metalloproteinase-1 
or promatrixmetalloproteinase-1 or prommp-1 or matrix metalloproteinase 1 or 
gelatinase a or 72-kda gelatinase or 72-kda type iv collagenase or mmp-2 
metalloproteinase or mmp2 metalloproteinase or matrix metalloproteinase-2 or 
matrix metalloproteinase 2 or stromelysin 1 or transin or mmp-3 metalloproteinase 
or mmp3 metalloproteinase or stromelysin or matrix metalloproteinase 3 or 
gelatinase b or 92-kda gelatinase or 92-kda type iv collagenase or mmp-9 
metalloproteinase or mmp9 metalloproteinase or matrix metalloproteinase-9 or 
matrix metalloproteinase 9 or metallopeptidase 9 or monocyte chemoattractant 
protein-1 or myelin basic protein or encephalitogenic basic proteins or basic protein, 
encephalitogenic or basic proteins, encephalitogenic or encephalitogenic basic 
protein or neuritogenic protein or protein, encephalitogenic basic or proteins, 
encephalitogenic basic or myeloperoxidase or hemi-myeloperoxidase or Peroxidase 
or antigen s 100 or nerve tissue protein s 100 or s-100 protein or s100 protein family 
or s 100 or ngf-2 or nerve growth factor 2 or neurotrophin 3 or neutrophil gelatinase 
associated lipocalin or neutrophil protease 4 or deoxynucleoside diphosphate 
kinases or gdp kinase or nucleoside diphosphokinases or nucleoside-diphosphate 
kinases or oxidised ldl or osteoprotogerin or aryl-dialkyl phosphatase or 
arylalkylphosphatase or homocysteine thiolactone hydrolase or opa anhydrase or 
oph enzyme or organophosphorus acid anhydrase or organophosphorus acid 
anhydrolase or organophosphorus acid hydrolase or organophosphorus hydrolase 
or paraoxonase or paraoxonase-1 or paraoxonase-2 or glycerate 3-2 -phosphomutase 
or phosphoglyceromutase or phosphoglycerate phosphomutase or 
phosphoglycerate mutase or papp-a or igfbp-4 metalloproteinase or igfbp-4 protease 
or igfbp-4-specific proteinase or insulin-like growth factor-dependent igf binding 
protein-4 protease or insulin-like-growth factor binding protein-4 protease or papp-
alpha or pregnancy associated alpha plasma protein or pregnancy-associated alpha-
plasma protein or pregnancy associated plasma protein a or profibrinolysin or glu-
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plasminogen or glutamic acid 1-plasminogen or glutamyl plasminogen or agepc or 
acetyl glyceryl ether phosphorylcholine or paf-acether or phosphorylcholine, acetyl 
glyceryl ether or 1-alkyl-2-acetyl-sn-glycerophosphocholine or platelet aggregating 
factor or platelet aggregation enhancing factor or platelet-activating substance or 
thrombocyte aggregating activity or platelet activating factor or cd31 antigens or 
pecam-1 or platelet endothelial cell adhesion molecule-1 or cd31 antigen or platelet 
derived microvesicles or platelet derived growth factor or antiheparin factor or pf 4 
or heparin neutralizing protein or pf4 or gamma-thromboglobulin or prorenin or 
Protein C or Protein S or Protein Z or coagulation factor ii or factor ii or blood 
coagulation factor ii or differentiation reversal factor or prothrombin or adipocyte 
cysteine-rich secreted protein fizz3 or resistin or receptor of AGE or RAGE or 
receptor of advanced glycation end products or secretagogin or plasminogen 
activator inhibitors or bae-pai or endothelial plasminogen activator inhibitors or 
placental plasminogen activator inhibitors or plasminogen activator inhibitors, 
endothelial or plasminogen activator inhibitors, placental or platelet activation or 
PARK 7 or SCD40L or Tau or thrombase or thrombinar or thrombostat or alpha-
thrombin or beta,gamma-thrombin or beta-thrombin or gamma-thrombin or 
thrombin or thrombin-antithrombin complex or Thrombomodulin or antigens, 
cd142 or cd142 antigens or coagulation factor iii or factor iii or tissue factor or tissue 
thromboplastin or blood coagulation factor iii or coagulin or glomerular 
procoagulant activity or prothrombinase or tissue factor procoagulant or 
urothromboplastin or thromboplastin or tissue factor pathway inhibitor or tissue 
inhibitor of metalloproteinase or cachectin or tnf-alpha or tumor necrosis factor 
ligand superfamily member 2 or cachectin-tumor necrosis factor or tnf superfamily, 
member 2 or tumor necrosis factor or bone-derived transforming growth factor or 
platelet transforming growth factor or tgf-beta or milk growth factor or tgfbeta or 
Transforming Growth Factor beta or ubiquitin fusion degradation protein 1 or 
Vascular Endothelial Growth Factor A or vascular endothelial growth factor or 
vascular endothelial growth factor-a or gd-vegf or glioma-derived vascular 
endothelial cell growth factor or vegf or vegf-a or vascular permeability factor or 
vasculotropin or vitronectin or factor viii-related antigen or f viii-vwf or factor viiir-
ag or factor viiir-rco or plasma factor viii complex or ristocetin cofactor or ristocetin-
willebrand factor or vwf ag or von willebrand factor type iib or von willebrand 
protein or von Willebrand Factor).tw.  
11 Incidence/ or exp mortality/ or follow up studies/ or mortality/ or prognos$.tw. or 
predict$.tw. or course.tw or rankin.tw or Glasgow outcome scale.tw or NIHSS.tw 
12 5 or 6 or 7 or 8 or 9 or 10  
13 4 and 11 and 12 
14 limit 13 to humans 
 
EMBASE 
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1. cerebral artery disease/ or cerebrovascular accident/ or stroke/ or vertebrobasilar 
insufficiency/ or wallenberg syndrome/ or exp brain infarction/ or exp brain 
ischemia/ or exp occlusive cerebrovascular disease/ or cerbrovascular disease/ or 
exp carotid artery diseases/ 
2. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or 
intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or 
anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or 
hypoxi$)).tw. 
3. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or 
attack$)).tw. 
4. 1 or 2 or 3 
5. disease Marker/ or biochemical marker/ or biological marker/ or molecular 
marker/ or marker/ 
6. biomarker$.tw. 
7. ((biochemical or clinical or immun$ or laboratory or biologic$ or serum or 
surrogate or viral) adj6 marker$).tw. 
8. ((blood or plasma) adj6 marker$).tw. 
9. (Aldolase A or aldolase b or aldolase c or fructose bisphosphonate aldolase or 
activin$ or inhibin$ or adiponectin or adipocyte specific secretory protein or 
gelatine binding protein or adipocyte complement related protein or alpha 2 
antiplasmin or Alpha-2-antiplasmin precursor or Alpha-2-AP or Alpha-2-PI or 
Alpha-2-plasmin inhibitor or pigment epithelium derived factor or plasmin 
inhibitor alpha 2 or alpha-macroglobulin$ or alpha 2M or antichymotrypsin or 
alpha 1-antichymotrypsin or alpha 1-antitrypsin or Seromucoid or serum 
sialomucin or alpha 1-acid glycoprotein or alpha 1-acid seromucoid or a 1-acid 
seromucoid or acid alpha 1-glycoprotein or alpha 1 -acid glycoprotein or alpha 1-
acid glycoprotein acute phase or alpha 1-glycoprotein acid or angiotensin 
converting enzyme or cd143 or cd143 or kininase ii or angiotensin i-converting 
enzyme or carboxycathepsin or dipeptidyl peptidase a or kininase a or ACE or 
kininase 2 or Dipeptidyl carboxypeptidase I or basic fibroblast growth factor or 
fibroblast growth factor, basic or hbgf-2 or cartilage-derived growth factor or class ii 
heparin-binding growth factor or fgf-2 or fgf2 or fibroblast growth factor-2 or 
heparin-binding growth factor class ii or prostate epithelial cell growth factor or 
prostatropin or Fibroblast Growth Factor 2 or heparin-binding growth factor 2 or 
angiotensin$ or antithrombin ii or heparin cofactor i or at iii or antithrombin iii, 
human plasma or antithrombin iii-alpha or atenativ or baxter brand of antithrombin 
or bayer brand of antithrombin or factor xa inhibitor or grifols brand of 
antithrombin or heparin co-factor i or pharmacia brand of antithrombin or 
thrombate iii or antithrombin 3 or antithrombin-3 or antithrombin iii or 
apolipoprotein$ or beta 2 glycoprotein$ or beta 2-Glycoprotein I or brain natriuretic 
peptide or nesiritide or b-type natriuretic peptide or bnp gene product or bnp-32 or 
Whiteley W.N. Blood Markers in Stroke University of Edinburgh 2010 
 
Appendices 329 
brain natriuretic peptide-32 or natrecor or natriuretic factor-32 or natriuretic peptide 
type-b or type-b natriuretic peptide or ventricular natriuretic peptide, b-type or 
Brain-Derived Neurotrophic Factor or casp3 or apopain or caspase-3 or pro-caspase-
3 or procaspase-3 or caspase 3 or cathepsin b-like activity or cathepsin b-like 
proteinase or cathepsin b1 or cathepsin b or amyloid precursor protein secretase or 
endoglin$ or CD105 or cd40 or Bp50 or caeruloplasmin or caeruloplasmin or 
ferroxidase or ceruloplasmin ferroxidase or ceruloplasmin oxidase or ferroxidase i 
or alpha 2 -ceruloplasmin or endochitinase or chitinase$ or chitotriosidase or 
cholesterol ester transport protein or cetp or cholesteryl ester exchange protein or 
cholesteryl ester transfer protein or parathyroid secretory protein or secretory 
protein i, parathyroid gland or Chromogranin A or pancreastatin or parastatin or 
Pituitary secretory protein I or vasostatin or apoj protein or apolipoprotein j or 
complement lysis inhibitor or complement-associated protein sp-40,40 or ionizing 
radiation-induced protein-8 or mac393 antigen or sgp-2 protein or sp 40,40 protein 
or sulfated glycoprotein 2 or sulfated glycoprotein-2 or trpm-2 protein or 
testosterone-repressed prostate message-2 protein or x-ray-inducible protein 8 or 
xip8 protein or aging-associated protein 4 or Complement cytolysis inhibitor or 
clusterin or cold-insoluble globulins or lets proteins or fibronectin or opsonic 
glycoprotein or opsonic alpha 2 sb glycoprotein or alpha 2-surface binding 
glycoprotein or c-fibronectin or c fibronectin or cellular fibronectin or alpha-1 
chimerin or alpha-2 chimerin or alpha-chimerin or arhgap2 protein or n-chimerin or 
rhogap2 protein or chimaerin 1 or alpha-1 chimaerin or alpha-2 chimaerin or alpha-
chimaerin or alpha1-chimaerin or n-chimaerin or chimerin or chimerin$ or collagen 
synthesis byproduct or complement or c reactive protein or c-reactive protein or 
CRP or antithrombin vi or fibrin degradation products or fibrin fibrinogen split 
products or Fibrin Fibrinogen Degradation Products or D-dimer or D dimer or 
enolase or neuron-specific enolase or 2-phospho-d-glycerate hydrolase or cobalt 
enolase or nervous system-specific enolase or non-neuronal enolase or alpha, alpha-
enolase or beta-enolase or gamma, gamma-enolase or Phosphopyruvate Hydratase 
or Neuron specific enolase or Neurone specific enolase or Neurone-specific enolase 
or endothelial protein c receptor or endothelial cell protein c receptor or protein c 
receptor or centrocyclin or CD201 antigen or antigens, cd106 or cd106 antigens or 
vcam-1 or cd106 antigen or incam-110 or inducible cell adhesion molecule 110 or 
vascular cell adhesion molecule or big endothelin or big endothelin-1 or et-1 
endothelin-1 or endothelin type 1 or endothelin, big or preproendothelin or 
preproendothelin-1 or proendothelin 1-38 or proendothelin-1 precursor or 
Erythropoietin or antigens, cd62e or cd62e antigens or e selectin or elam-1 or 
endothelial leukocyte adhesion molecule-1 or lecam-2 or cd62e antigen or 
endothelial leukocyte adhesion molecule 1 or e-selectin or selectin e or 
autoprothrombin ii or christmas factor or coagulation factor ix or ptc or plasma 
thromboplastin component or blood coagulation factor ix or factor ix complex or 
factor ix fraction or coagulation factor xi or plasma thromboplastin antecedent or 
blood coagulation factor xi or coagulation factor xii or hageman factor or blood 
coagulation factor xii or coagulation factor v or proaccelerin or ac globulin or blood 
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coagulation factor v or factor pi or factor v or factor ix or factor xii or factor xi or 
coagulation factor vii or proconvertin or stable factor or blood coagulation factor vii 
or factor vii or antihemophilic factor or coagulation factor viii or factor viii clotting 
antigen or factor viii coagulant antigen or factor viii procoagulant activity or 
thromboplastinogen or blood coagulation factor viii or f viii-c or factor viii-heavy 
chain or factor viiic or hemofil or hemofil hm or hemofil m or hemophil or humate-p 
or hyate-c or hyatt-c or monoclate or factor viii or autoprothrombin iii or 
coagulation factor x or stuart factor or stuart-prower factor or blood coagulation 
factor x or stuart prower factor or factor vii activating protease or coagulation factor 
xiia or factor xii, activated or activated factor xii or blood coagulation factor xii, 
activated or hageman-factor fragments or prekallikrein activator or factor xiia or 
interleukin or fibrinogen or coagulation factor i or factor i or blood coagulation 
factor i or gamma-fibrinogen or apo-1 antigen or apoptosis antigen 1 or cd95 
antigens or receptors, fas or tumor necrosis factor receptor superfamily, member 6 
or fas antigens or fas receptors or cd95 antigen or tnfrsf6 receptor or fas antigen or 
fas receptor or basic isoferritin or ferritin or isoferritin or isoferritin, basic or 
fibrinopeptide or cold-insoluble globulins or lets proteins or fibronectin or opsonic 
glycoprotein or opsonic alpha 2 sb glycoprotein or alpha 2-surface binding 
glycoprotein or activin-binding protein or follistatin or fatty acids, free or free fatty 
acids or nefa or glial fibrillary acidic protein or GFAP or glial intermediate filament 
protein or astroprotein or gfa-protein or glial fibrillary acid protein or glutathione s-
alkyltransferase or glutathione s-aryltransferase or glutathione s-epoxidetransferase 
or ligandins or s-hydroxyalkyl glutathione lyase or glutathione organic nitrate ester 
reductase or glutathione s-transferase or glutathione s-transferase 3 or glutathione s-
transferase a or glutathione s-transferase b or glutathione s-transferase c or 
glutathione s-transferase iii or glutathione s-transferase p or glutathione transferase 
e or glutathione transferase mu or glutathione transferases or heme transfer protein 
or ligandin or b-glutathione-s-transferase or csf-gm or colony-stimulating factor, 
granulocyte-macrophage or gm-csf or histamine-producing cell-stimulating factor 
or csf-2 or tc-gm-csf or tumor-cell human gm colony-stimulating factor or 
granulocyte macrophage colony stimulating factor or antigens, cd62p or cd62p 
antigens or gmp-140 or lecam-3 or p selectin or platelet alpha-granule membrane 
protein or cd62p antigen or padgem or antigens, cd62l or cd62l antigens or lecam-1 
or cd62l antigen or l selectin or lam-1 or leu-8 antigen or leukocyte adhesion 
molecule, lam-1 or mel-14 antigen or tq1 antigen or antigens, cd62e or cd62e 
antigens or e selectin or elam-1v or endothelial leukocyte adhesion molecule-1 or 
lecam-2 or cd62e antigen or endothelial leukocyte adhesion molecule 1 or gp130 or 
sgp130 or interleukin 11 receptor or gpiib-iiia receptors or integrin alphaiibbeta3 or 
glycoproteins iib-iiia or integrin alpha-iib beta-3 or pituitary growth hormone or 
somatotropin or growth hormone, pituitary or haptoglobin or haemopexin or 
hemopexin or heparin co-factor ii or antigens, cd54 or cd54 antigens or icam-1 or 
cd54 antigen or intercellular adhesion molecule 1 or gamma globulin, 7s or igg or 
allerglobuline or igg t or igg1 or igg2 or igg2a or igg2b or igg3 or igg4 or 
immunoglobulin gt or polyglobin or immunoglobulin g or insulin or ischaemia 
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modified albumin or merosin or glycoprotein gp-2 or laminin m or laminin m chain 
or laminin or leptin or ob protein or obese protein or ob gene product or obese gene 
product or lipoprotein associated phospholipase or lipoprotein lipase or csf-1 or csf-
m or colony-stimulating factor 1 or colony-stimulating factor, macrophage or m-csf 
or macrophage colony stimulating factor or malonaldehyde or propanedial or 
malonylaldehyde or malonyldialdehyde or sodium malondialdehyde or 
Malondialdehyde or interstitial collagenase or mmp-1 metalloproteinase or mmp1 
metalloproteinase or matrix metalloproteinase-1 or pro-matrix metalloproteinase-1 
or promatrixmetalloproteinase-1 or prommp-1 or matrix metalloproteinase 1 or 
gelatinase a or 72-kda gelatinase or 72-kda type iv collagenase or mmp-2 
metalloproteinase or mmp2 metalloproteinase or matrix metalloproteinase-2 or 
matrix metalloproteinase 2 or stromelysin 1 or transin or mmp-3 metalloproteinase 
or mmp3 metalloproteinase or stromelysin or matrix metalloproteinase 3 or 
gelatinase b or 92-kda gelatinase or 92-kda type iv collagenase or mmp-9 
metalloproteinase or mmp9 metalloproteinase or matrix metalloproteinase-9 or 
matrix metalloproteinase 9 or metallopeptidase 9 or monocyte chemoattractant 
protein-1 or myelin basic protein or encephalitogenic basic proteins or basic protein, 
encephalitogenic or basic proteins, encephalitogenic or encephalitogenic basic 
protein or neuritogenic protein or protein, encephalitogenic basic or proteins, 
encephalitogenic basic or myeloperoxidase or hemi-myeloperoxidase or Peroxidase 
or antigen s 100 or nerve tissue protein s 100 or s-100 protein or s100 protein family 
or s 100 or ngf-2 or nerve growth factor 2 or neurotrophin 3 or neutrophil gelatinase 
associated lipocalin or neutrophil protease 4 or deoxynucleoside diphosphate 
kinases or gdp kinase or nucleoside diphosphokinases or nucleoside-diphosphate 
kinases or oxidised ldl or osteoprotogerin or aryl-dialkyl phosphatase or 
arylalkylphosphatase or homocysteine thiolactone hydrolase or opa anhydrase or 
oph enzyme or organophosphorus acid anhydrase or organophosphorus acid 
anhydrolase or organophosphorus acid hydrolase or organophosphorus hydrolase 
or paraoxonase or paraoxonase-1 or paraoxonase-2 or glycerate 3-2 -phosphomutase 
or phosphoglyceromutase or phosphoglycerate phosphomutase or 
phosphoglycerate mutase or papp-a or igfbp-4 metalloproteinase or igfbp-4 protease 
or igfbp-4-specific proteinase or insulin-like growth factor-dependent igf binding 
protein-4 protease or insulin-like-growth factor binding protein-4 protease or papp-
alpha or pregnancy associated alpha plasma protein or pregnancy-associated alpha-
plasma protein or pregnancy associated plasma protein a or profibrinolysin or glu-
plasminogen or glutamic acid 1-plasminogen or glutamyl plasminogen or agepc or 
acetyl glyceryl ether phosphorylcholine or paf-acether or phosphorylcholine, acetyl 
glyceryl ether or 1-alkyl-2-acetyl-sn-glycerophosphocholine or platelet aggregating 
factor or platelet aggregation enhancing factor or platelet-activating substance or 
thrombocyte aggregating activity or platelet activating factor or cd31 antigens or 
pecam-1 or platelet endothelial cell adhesion molecule-1 or cd31 antigen or platelet 
derived microvesicles or platelet derived growth factor or antiheparin factor or pf 4 
or heparin neutralizing protein or pf4 or gamma-thromboglobulin or prorenin or 
Protein C or Protein S or Protein Z or coagulation factor ii or factor ii or blood 
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coagulation factor ii or differentiation reversal factor or prothrombin or adipocyte 
cysteine-rich secreted protein fizz3 or resistin or receptor of AGE or RAGE or 
receptor of advanced glycation end products or secretagogin or plasminogen 
activator inhibitors or bae-pai or endothelial plasminogen activator inhibitors or 
placental plasminogen activator inhibitors or plasminogen activator inhibitors, 
endothelial or plasminogen activator inhibitors, placental or platelet activation or 
PARK 7 or SCD40L or Tau or thrombase or thrombinar or thrombostat or alpha-
thrombin or beta,gamma-thrombin or beta-thrombin or gamma-thrombin or 
thrombin or thrombin-antithrombin complex or Thrombomodulin or antigens, 
cd142 or cd142 antigens or coagulation factor iii or factor iii or tissue factor or tissue 
thromboplastin or blood coagulation factor iii or coagulin or glomerular 
procoagulant activity or prothrombinase or tissue factor procoagulant or 
urothromboplastin or thromboplastin or tissue factor pathway inhibitor or tissue 
inhibitor of metalloproteinase or cachectin or tnf-alpha or tumor necrosis factor 
ligand superfamily member 2 or cachectin-tumor necrosis factor or tnf superfamily, 
member 2 or tumor necrosis factor or bone-derived transforming growth factor or 
platelet transforming growth factor or tgf-beta or milk growth factor or tgfbeta or 
Transforming Growth Factor beta or ubiquitin fusion degradation protein 1 or 
Vascular Endothelial Growth Factor A or vascular endothelial growth factor or 
vascular endothelial growth factor-a or gd-vegf or glioma-derived vascular 
endothelial cell growth factor or vegf or vegf-a or vascular permeability factor or 
vasculotropin or vitronectin or factor viii-related antigen or f viii-vwf or factor viiir-
ag or factor viiir-rco or plasma factor viii complex or ristocetin cofactor or ristocetin-
willebrand factor or vwf ag or von willebrand factor type iib or von willebrand 
protein or von Willebrand Factor).tw. 
10. Fructose Bisphosphate Aldolase/ or ACTIVIN A/ or ACTIVIN/ or INHIBIN A/ or 
INHIBIN/ or INHIBIN B/ or ADIPONECTIN/ or ANTIPLASMIN/ or ALPHA 2 
ANTIPLASMIN/ or Alpha 2 Macroglobulin/ or Chymotrypsin A/ or Alpha 1 
Antitrypsin/ or OROSOMUCOID/ or Dipeptidyl Carboxypeptidase/ or Fibroblast 
Growth Factor 2/ or ANGIOTENSIN I/ or ANGIOTENSIN/ or ANGIOTENSIN 
BLOOD LEVEL/ or ANGIOTENSIN II/ or Antithrombin III/ or exp Apolipoprotein/ 
or Beta2 Glycoprotein 1/ or exp Brain Natriuretic Peptide/ or Brain Derived 
Neurotrophic Factor/ or exp CASPASE/ or Cathepsin B/ or CD40 LIGAND/ or CD40 
ANTIGEN/ or exp CERULOPLASMIN BLOOD LEVEL/ or exp CERULOPLASMIN/ 
or CHITINASE/ or Cholesterol Ester Transfer Protein/ or Chromogranin A/ or exp 
CLUSTERIN/ or Fibronectin/ or Chimerin/ or exp COMPLEMENT/ or 
COMPLEMENT BLOOD LEVEL/ or Anaphylatoxin/ or PROPERDIN/ or C Reactive 
Protein/ or Fibrin Degradation Product/ or Enolase/ or TAU PROTEIN/ or Cell 
Adhesion Molecule/ or Cd22 Antigen/ or Cd24 Antigen/ or Cd31 Antigen/ or 
antigens, cd164/ or Cadherin/ or Carcinoembryonic Antigen/ or Cd4 
Immunoglobulin/ or Nerve Cell Adhesion Molecule/ or Integrin/ or Intercellular 
Adhesion Molecule 1/ or Homing Receptor/ or Selectin/ or Vascular Cell Adhesion 
Molecule 1/ or ENDOTHELIN 2/ or BIG ENDOTHELIN 2/ or ENDOTHELIN 1/ or 
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BIG ENDOTHELIN 1/ or ENDOTHELIN 3/ or ENDOTHELIN/ or 
ERYTHROPOIETIN/ or P SELECTIN GLYCOPROTEIN LIGAND 1/ or L 
SELECTIN/ or SELECTIN/ or exp Blood Clotting Factor/ or exp Cytokine/ or exp 
Fibrinogen/ or Antigens, CD95/ or exp Ferritin/ or fibrinopeptide a/ or 
fibrinopeptide b/ or exp Fibronectins/ or exp Follistatin-Related Proteins/ or exp 
Follistatin/ or exp Fatty Acids, Nonesterified/ or exp Glial Fibrillary Acidic Protein/ 
or exp Glutathione Transferase/ or Granulocyte-Macrophage Colony-Stimulating 
Factor/ or exp Selectins/ or Platelet Glycoprotein GPIIb-IIIa Complex/ or growth 
hormone/ or human growth hormone/ or exp Haptoglobins/ or Hemopexin/ or 
Heparin Cofactor II/ or exp Intercellular Adhesion Molecule-1/ or exp 
Immunoglobulin G/ or Laminin/ or Leptin/ or Macrophage Colony-Stimulating 
Factor/ or Malondialdehyde/ or exp Matrix Metalloproteinase/ or exp Monocyte 
Chemoattractant Proteins/ or Myelin Basic Proteins/ or Peroxidase/ or exp S100 
Proteins/ or Neurotrophin 3/ or 9 Nitric Oxide/ or Nucleoside-Diphosphate Kinase/ 
or Aryldialkylphosphatase/ or Phosphoglycerate Mutase/ or Pregnancy-Associated 
Plasma Protein-A/ or Plasminogen Activator Inhibitor 1/ or Plasminogen/ or 
Plasminogen Activator Inhibitor 2/ or Platelet Activating Factor/ or Antigens, CD31/ 
or Platelet-Derived Growth Factor/ or Platelet Factor 4/ or Protein C/ or Protein S/ or 
Prothrombin/ or Resistin/ or Plasminogen Inactivators/ or Platelet Activation/ or tau 
Proteins/ or Thrombin/ or Thrombomodulin/ or Thromboplastin/ or TUMOR 
NECROSIS FACTOR-ALPHA/ or Transforming Growth Factor beta/ or Vascular 
Endothelial Growth Factor A/ or Vitronectin/ or von Willebrand Factor/ or Tissue 
Plasminogen Activator/ec [Endogenous Compound] 
11. 5 or 6 or 7 or 8 or 9 or 10 
12. Incidence/ or exp mortality/ or follow up studies/ or mortality/ or prognos$.tw. 
or predict$.tw. or course.tw. or rankin.tw. or Glasgow outcome scale.tw. or 
NIHSS.tw. 
13. 4 and 11 and 12 
14. limit 13 to human 
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Appendix 8.   Modified REMARK questionnaire 
Was the study prospective? 
YES: The study reports that patients and blood samples were collected prior to the 
development of an outcome 
NO: No report or clearly retrospective (e.g. patients with poor prognosis collected 
prior to biomarker measurement) 
Was the evaluation of prognostic marker blinded to patient outcome? 
YES: The study reports an attempt to blind the person measuring the level of 
biomarker to patient outcome  
NO:  There is no such report. 
Was there a defined time period during which patients were enrolled? 
YES: Study define time period, end of follow up period and median follow up time 
NO: Does not define above criteria 
Were there precisely defined clinical outcomes at the beginning of the study? 
YES: Study defines which clinical endpoints are to be measured 
NO: No such definition 
Did the study provide a rationale for study sample size? 
YES: Evidence of a sensible sample size calculation (e.g. 10 outcomes/variable in a 
multiple regression model) 
NO: no attempt to define sample size 
Did the study provided a list of candidate variables? 
YES: A list of variables to be considered in multiple regression analysis is provided 
at the beginning of the study 
NO: evidence that variables were measured and not reported 
Were the methods for measuring the prognostic marker adequately described and 
referenced? 
YES: reporting of the source an ELISA, or a reference to it 
NO: no such reference 
Cases unselected/unbiased? 
YES No attempt to select patients with exclusion criteria 
NO only a subset of stroke patients enter the study 
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Appendix 9.   Studies in systematic review of prognostic 
markers for ischaemic stroke 
(1) Abraha HD, Butterworth RJ, Bath PM, Wassif WS, Garthwaite J, Sherwood RA. 
Serum S-100 protein, relationship to clinical outcome in acute stroke. Ann 
Clin Biochem 1997 September;34(Pt 5):546-50. 
 (2)  Anuk T, Assayag EB, Rotstein R, Fusman R, Zeltser D, Berliner S, Avitzour 
D, Shapira I, Arber N, Bornstein NM. Prognostic implications of admission 
inflammatory profile in acute ischemic neurological events. Acta Neurologica 
Scandinavica 2002 October;106(4):196-9. 
 (3)  Audebert HJ, Pellkofer TS, Wimmer ML, Haberl RL. Progression in lacunar 
stroke is related to elevated acute phase parameters. European Neurology 
2004;51(3):125-31. 
 (4)  Barber M, Morton JJ, Macfarlane PW, Barlow N, Roditi G, Stott DJ. Elevated 
Troponin Levels Are Associated with Sympathoadrenal Activation in Acute 
Ischaemic Stroke. Cerebrovasc Dis 2007;23(4):260-6. 
 (5)  Barber M, Langhorne P, Rumley A, Lowe GDO, Stott DJ. Hemostatic 
Function and Progressing Ischemic Stroke: D-dimer Predicts Early Clinical 
Progression. Stroke 2004 June 1;35(6):1421-5. 
 (6)  Blanco M, Castellanos M, Rodriguez-Yanez M, Sobrino T, Leira R, Vivancos 
J, Lizasoain I, Serena J, Davalos A, Castillo J. High blood pressure and 
inflammation are associated with poor prognosis in lacunar infarctions. 
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Appendix 10.  Future plans 
TITLE 
Targeted treatment for acute stroke: development of prognostic models and decision 
support tools 
BACKGROUND 
Each year, 135,000 people in the UK have an acute stroke: their care costs the NHS £2.8 
billion. Thrombolytic, antithrombotic and antiplatelet drugs are effective for the treatment of 
acute stroke by reducing the risk of thrombotic events. However, each drug is associated 
with an increased risk of serious intracranial and gastrointestinal haemorrhage. Better 
targeting of these therapies, by stratifying patients according to their risk of these events, 
could increase their net population health gain by (a) reducing avoidable haemorrhagic and 
(b) arterial and venous thrombotic events. 
The National Institute for Clinical Excellence recently recommended, for the prevention of 
venous thrombo-embolism, ‘offer[ing] prophylactic-dose [heparin] to patients in whom a diagnosis 
of haemorrhagic stroke has been excluded, [and] the risk of bleeding (haemorrhagic transformation of 
stroke or bleeding into another site) is assessed to be low.’1.  
Currently, clinicians do not have the tools available to them to trade the risk of all 
haemorrhagic against the risk of all thrombotic events after stroke, as there are no reliable, 
valid models. This study seeks to determine whether new prognostic models based on 
clinical variables and novel biological markers can usefully provide sufficient gain in 
predictive power to influence clinical decisions in the use of thrombolytic, antithrombotic 
and antiplatelet drugs in acute stroke. 
The MRC Methodology Hub, based in Edinburgh under the leadership of Professor Gordon 
Murray (co-sponsor) has extensive experience in predictive model building and meta-
analysis of large studies. My own experience of prognostic model development2 experience 
within the department3 and experience amongst my collaborators4 makes Edinburgh a 
strong base for this research. 
Current treatments have modest net effects: After acute ischaemic stroke, 79 patients need to 
be treated with aspirin (started <24 hours) to prevent one dying or becoming dependent on 
others5 and 10 with rtPA (<3 hours) to prevent one becoming dependent on others6. 
Haemorrhagic events reduce the clinical efficacy of these drugs. When heparin is used in 
unselected patients with acute stroke, the reductions in arterial and venous occlusive events 
are offset by similar increases in intra- and extra- cranial haemorrhages. We could improve 
the net clinical benefit of antiplatelet, antithrombotic and thrombolytic treatments by 
targeting them to those who are more likely to have a thrombotic than a haemorrhagic event 
with the prognostic models developed in this project.  
Serious thrombotic events after stroke are common: Patients with ischaemic stroke are at 
risk of recurrent ischaemic stroke (15% in the first year), myocardial infarction (MI) (2% per 
year), and deep vein thrombosis (DVT) and pulmonary embolus (PE) (18% in the first 
month7).  
Haemorrhagic complications after ischaemic stroke are common: In cohorts of acute stroke 
patients, serious intracranial bleeding occurs in 2-8%8 and gastro-intestinal (GI) 
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haemorrhage requiring treatment in 39-8%10. These serious events are in part due to the 
stroke, and part due to treatment with antiplatelet agents, heparin, and recombinant tissue 
plasminogen activator (rtPA) (Table 1).  
Table 1 Relative and absolute risk of major bleeds in patients with ischaemic stroke 
 




GI bleed  Symptomatic ICH*  Major GI bleed 
†
 
          














  23 10  22 92 
rtPA 3.37
6




  - - 
          
I derived estimates by applying relative risks seen in trials (from systematic reviews) to absolute risks from cohort 
studies with different levels of baseline risk of bleeding. I have assumed all patients in cohort studies took aspirin.  
*symptomatic ICH proportion in untreated patients (at any time) 1.5%12 in low risk and 7%12 in high risk 
population.  
†GI bleed proportion in untreated patients (~1st year) 1.6%9 in low risk, and 4.6%10 in high risk population  
‡Estimates for ICH after rtPA are from trials, which may underestimate their frequency in practice. 
 
  
Clinical prediction is imperfect: The prediction of outcome in an individual patient – hence 
choice of treatment - is usually based upon clinical experience informed by current evidence. 
However, clinicians do not perform as well as prognostic models in predicting recurrent 
vascular events13, as analysing many variables simultaneously is difficult without the 
support of a model. Prognostic models to predict adverse outcomes after stroke could 
improve treatment decisions particularly by less experienced doctors, nurses and other team 
members. 
Prognostic models may help decision making: The use of prognostic models to predict 
thrombotic and haemorrhagic complications after stroke could (i) identify patients at a high 
or low risk of thrombotic or haemorrhagic events, which could influence medical treatment 
– for example avoiding thrombolytic treatments in ischaemic stroke patients at high risk of 
haemorrhage, or starting antiplatelet treatment in intracerebral haemorrhage patients at high 
risk of subsequent thrombotic events, (ii) adjust data for baseline prognostic variables for 
audit or research purposes which may improve the power of randomised controlled trials14, 
(iii) define groups at high risk of  particular outcomes, in whom new treatments could be 
tested and, (iv) inform patients and their families of their future risks.  
The addition of biologically relevant markers to prognostic models: Selecting patients for 
treatment based upon levels of relevant blood or imaging biological markers, rather than 
clinical variables such as age or stroke severity, could lead to better use of existing 
treatments. Markers of thrombosis, lipid fractions and others could be useful when selecting 
patients for treatments to prevent arterial and venous thrombosis after stroke. For example 
D-dimer is associated with a risk of early recurrent ischaemic lesions (OR=3.2 per log unit) 15. 
Evaluating prognostic models: A prognostic model must be carefully developed in 
appropriate data sets and the predictions validated in separate cohorts. However, the real 
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test of a model is its impact on outcomes including clinicians’ behaviour, quality of care and 
most importantly patient outcome16. Models that achieve this are more likely to be adopted 
by the NHS. 
AIMS 
The aim of this project is to determine whether prognostic models can be developed that 
provide clinically useful guidance and are able to increase net health gains from more 
effective application of existing treatments for stroke, which could be incorporated into NHS 
electronic patient record systems. 
This aim is timely and relevant. The General Medical Council17 obliges doctors ‘to share with 
patients’.. ‘the information they want or need to know about their condition [and] its likely 
progression’. Without reliable means of predicting outcome, most clinicians will find this 
difficult. With reference to the MRC Strategic Plan (2009), this project aims to translate work 
from epidemiological studies into tools for use by clinicians, and target particular disease 
subtypes using biomarkers and other measures of risk (so-called ‘stratified medicine’). We 
will also exploit existing population data sets though the SCOPE collaborative (containing data 
from several MRC funded studies: IST, IST-3, CLOTS) the Kadoorie Study of Chronic 
Disease in China and the VISTA collaboration. Scotland is an ideal base for this research: 
electronic clinical records are part of the eHealth strategy (expected in some health boards by 
2011) and the NHS Scotland CHD and Stroke Strategy. There is therefore a clear pathway for 
the implementation of the successful predictive models by embedding them within e-forms 
for use by frontline clinicians in the NHS. 
OBJECTIVES 
The objectives of this project are to: 
(1) Develop models to predict haemorrhagic and thrombotic events from data in: (i) the 
Stroke Complications and Outcomes Prediction Engine (SCOPE) collaboration (ii) 
The Kadoorie Study and (iii) the Virtual Internet Stroke Archive (VISTA) (see below 
for study details). 
(2) Determine whether prediction of haemorrhagic events based on clinical and imaging 
data has a significant interaction with the treatment benefits of intravenous rtPA, 
heparin and aspirin with data from the MRC-funded First International Stroke Trial 
(IST), Third International Stroke Trial (IST-3, data available 2012) and Chinese Acute 
Stroke Trial (CAST).  
(3) Create a decision tool for use in clinical practice, based on the prediction models for 
haemorrhagic events and arterial and venous thrombosis developed in parts 1-3 
(4) Pilot the application of the decision tool in clinical stroke practice in NHS Lothian 
with a view to establishing a larger scale randomised multi-centre evaluation study. 
PLAN OF RESEARCH 
(1) Development and validation of clinical prognostic models to predict haemorrhage and 
thrombosis after stroke 
Systematic reviews: With my experience in systematic reviews of prognostic studies18,19 , I 
will perform systematic reviews of prognostic models in acute stroke to predict (i) 
haemorrhagic events and (ii) arterial and venous thrombotic events after stroke, to ensure no 
potentially useful model is missed. I will develop protocols for this type of review with 
colleagues from the Cochrane Prognostic Methods Group. 
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To develop prognositic models for the prediction of haemorrhage and arterial and venous 
thrombosis after stroke I will develop these models using clinical variables that could be 
collected at the bedside.  
I will use three data resources: 
(i) Stroke Complications and Outcomes Prediction Engine (SCOPE): Based at the Western General 
Hospital (PI Professor Martin Dennis, a collaborator on this fellowship) this major 
international collaboration has collected data from 24 large randomised controlled trials and 
observational cohort studies of patients with stroke. It includes baseline and outcome data 
from over 40,000 patients who are representative of the clinical spectrum of acute stroke. 
Baseline data include measures of age, pre-morbid function, stroke severity, and medical 
history. Baseline variable and outcome definitions were similar across the studies, reducing 
methodological heterogeneity.  
(ii) The Kadoorie Study20:  This is a bio-banking study of 515,000 people with no major 
disability between 35-74 years old from 10 regions of China, run from the Clinical Trial 
Service Unit in Oxford by Professor Zhengming Chen (a collaborator on this project) with 
the close involvement of the China Center for Disease Control. Sites were chosen to reflect a 
range of exposures and economic development and participants recruited between 2004 and 
2008; to date there has been on average 2.8 years of follow up. Events are collected through 
established death and disease registers and routinely collected healthcare data. Each 5 years, 
10,000 surviving study participants are invited for review, and baseline measures – 
including blood samples – will be repeated to take account of regression dilution bias.  
(iii) Virtual Internet Stroke Archive (VISTA) Based in Glasgow, VISTA contains data from 28 
randomized clinical trials in acute stroke. Data are available on 21,822 patients, of whom 
18,937 (90.5%) have ischaemic stroke and 1,933 (9.4%) have intracerebral haemorrhage. It 
includes the German Stroke Registry, the validation dataset for the Essen Stroke Risk Score 
(which predicted only recurrent stroke, and lost power by dichotomisation of variables, in 
part leading to its poor predictive performance). 
Developing prognostic models: Using data from the SCOPE collaboration, I will build 
prognostic models using standard statistical methods to predict GI haemorrhage, 
intracerebral haemorrhage, recurrent stroke, MI and DVT. Informed by results from 
systematic reviews and inspection of the datasets, I will select variables with: face validity, 
few missing data, that are easily measured at the time of assessment at a low cost, with a 
wide range and with low inter-observer variability. I will avoid stepwise selection methods22 
and will not dichotomise continuous variables, as this process risks loss of information and 
hence power21. The source studies have made strenuous efforts to ensure completeness of 
data. Where, despite this, important variables have missing values, I will use imputation 
methods (either simple or multiple) to mitigate the selection bias associated with complete 
case analyses. I will examine the effects of source study, as well as the effect of predicting 
only fatal events. Pre-specified first order interactions include severity with time of 
presentation after stroke and baseline stroke subtype.  
To validate the statistical models developed: Initially, I will develop prognostic models in 
the SCOPE dataset, and then examine for external validity in the Kadoorie study and the 
separate VISTA collaboration. I will assess the performance of models using measures of: 
calibration by comparing predictions from the prognostic model with observed outcomes, 
both in development and validation datasets, and discrimination measuring the area under 
the receiver operating curves. The threshold for a ‘good model’ is unknown, but should at 
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least improve upon clinicians’ predictions. The Edinburgh Stroke Study (PI Dr. Cathie 
Sudlow) recorded clinicians’ predictions of recurrent vascular events, which I will compare 
with the predicted probability of vascular events from prognostic models and the observed 
rate of events. Finally, I will calculate a ratio of predicted probabilities from models 
predicting haemorrhagic events and models predicting thrombotic events, to see whether 
individuals can be accurately classified into those more likely to have subsequent 
haemorrhage and those more likely to have subsequent thrombotic events. I will estimate 
the weight to place on outcomes of different severity by their effects on the length of stay in 
hospital and quality of life. 
Blood markers: Models with clinical variables alone are likely to be robust, and applicable to 
clinical practice. However, blood or imaging markers that reflect particular pathological 
processes after stroke could: (i) improve the performance of these models and (ii) give 
insight into the pathology of stroke. Within the Kadoorie study, all participants had serum 
stored at the time of recruitment to the study. Markers of thrombosis (fibrinogen), lipids and 
other markers of cardiovascular risk (e.g. inflammation, vitamins etc.) will be measured as 
part of incident stroke studies, and studies of stroke recurrence will ‘piggy back’ on these 
analysis. I will determine whether the measured markers improve the prediction of 
recurrent vascular events after stroke over prognostic models with only clinical variables. 
Opportunities for novel observational epidemiology: Whilst the primary aim of this project 
is to develop predictive models, it is also an opportunity to explore the epidemiology of 
recurrent stroke. For example, it is uncertain whether the risk factors of subsequent 
ischaemic events in participants with baseline haemorrhagic strokes and haemorrhagic 
stroke in participants with baseline ischaemic strokes are different. Even non-analytical 
studies of recurrence rates alone after haemorrhage are small relative to the Kadoorie 
study23. Collaboration with senior stroke epidemiologists (Dr Cathie Sudlow and Dr. Rustam 
Al-Shahi-Salman, Edinburgh) will add to the analysis of these data. 
Feasibility and statistical power: (i) Model building the feasibility of model building to 
predict individual complications has been shown in preliminary analysis in a subset of 
SCOPE. Within the datasets of FOOD and IST-1 (168 bleeds), the developed model correctly 
predicted GI haemorrhage in ~70% of patients. This is sufficiently promising to justify 
further exploration of models to predict thrombotic and haemorrhagic events post stroke. 
The sample sizes of the SCOPE and VISTA collaborations are sufficiently large to allow 
robust model building. A rule of thumb in model development is there should be at least 10 
events per outcome per variable24; with ~1705 recurrent haemorrhagic and thrombotic events 
in VISTA and ~3,700 in SCOPE, there is clearly sufficient power to develop a model with a 
practical (<10) number of variables. With these sample sizes, I will have >80% power to 
detect a decrease in the c-index by 0.03722. (ii) Observational epidemiology The Kadoorie study 
expects 12,000 incident strokes by the time planned for analysis (2013) of which a larger 
proportion will be due to haemorrhage (about 30%) than in studies based in Europe (6.7% of 
strokes25). Over an average of 2.8 years of follow up, 11% (383/3447) of people with incident 
stroke have had recurrent stroke. A similar proportion of those with a history of stroke have 
had stroke recurrence (826/9056 or 9.1%) over 2.5 years of follow up. If events continue to 
accumulate in a similar fashion, the power of Cox regression analysis to detect variables for 
predicting recurrence is shown in table 3. 
 
 
Table 3. Study power to detect a 20%, 50% or 75% effect size at α=0.01 (two sided) in Kadoorie dataset 
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Baseline stroke type HR=1.2 HR=1.5 HR=1.75 
    
Ischaemic  50% 99% 100% 
ICH  20% 89% 100% 
    
The final output from this period of research will be: A family of validated prognostic models 
based on clinical variables for the prediction of haemorrhagic and thrombotic events after 
stroke, which could be used for (a) the development of clinical prediction rules in parts 4 
and 5 (b) baseline adjustment in future stroke research and (c) insights into the epidemiology 
of recurrent stroke. 
(2) Prediction of haemorrhagic complications after treatment with heparin, aspirin or rtPA 
Thrombolysis: The absolute excess of 
symptomatic intracerebral haemorrhage due to 
intravenous rtPA in acute stroke is between 2% 
and 16%6. This complication has led many to 
avoid the use of rtPA for the treatment of acute 
ischaemic stroke26. A model to predict 
intracerebral haemorrhage after treatment with 
rtPA could change practice if those with the 
highest predicted risk of intracerebral 
haemorrhage had a poorer outcome than those 
with a lower predicted risk, and so avoid rtPA 
treatment (Fig 1). 
Whilst there are a number of clinical and 
imaging predictors of intracranial haemorrhage 
after treatment in iv rtPA in stroke27, whether 
those predicted to have a haemorrhage would 
benefit from treatment as much as those who 
were not is uncertain. By developing a 
multivariate prognostic model to predict 
haemorrhage after rtPA within the IST-3 dataset, 
with the methods in (1) I will create a tool for 
use by clinicians. 
Aspirin and heparin: Using existing data from the CAST and IST studies, I will take a similar 
approach to study the effect of aspirin and heparin in acute stroke. I will build models to 
predict intracerebral haemorrhage and test for evidence of an interaction between predicted 
risk of intracerebral haemorrhage and treatment effect. 
Feasibility: IST-3 is the largest (3,100 by 2012) trial of thrombolysis in ischaemic stroke, run 
by Professors Sandercock, Wardlaw (both collaborators) and Lindley. It has complete 
baseline clinical and imaging data collection, with imaging follow up for intracerebral 
haemorrhage at 24 hours and reports of clinical deterioration. In the most recent Cochrane 
review of thrombolysis for ischaemic stroke5, the range of symptomatic intracranial 
haemorrhage was 2.4-19.8% in treated and 0.2 to 6.5% in control patients; applying these 
figures to IST-3 gives a range from 40 to 407 intracranial haemorrhages. I would therefore be 
able to reliably develop a model with, at the very least, 4 variables. Data are available from 

















Figure 36 Characteristic of a useful model 
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the CAST and IST studies on over 40,000 patients. The sizes of an interaction between 
predictions of intracerebral haemorrhage with treatment effect that could be reliably 
detected relative to the overall effect of treatment are shown in table 4. 
Table 4 Interaction relative to overall treatment effect (Overall trial power 80%)28 
  
 1.1 1.5 2.0 3.0 
Chance of a significant interaction test 
(p<0.05)30 
30% 55% 80% 95% 
     
The final output of this period of research will be: (i) A validated model for the prediction of 
intracerebral haemorrhage after rtPA, heparin and aspirin from clinical and imaging 
variables (ii) Whether, by predicting intracerebral haemorrhage and avoiding treatment in 
some, one could improve patient outcome. 
(3) To develop an interface for the presentation of the results of the prognostic models. 
Validated clinical models would be useful in clinical practice, if there is a threshold above 
which models predict a higher probability of haemorrhagic than thrombotic events. I aim to 
develop a prediction tool to present the risks of thrombosis versus those of haemorrhage 
with recommendations to guide doctors’ decision making29. This will be web-based, with a 
link from the electronic record, to allow easy collection of data, in collaboration with the 
very strong information technology department in the Division of Clinical Neurosciences 
who have experience developing these interfaces. I will pilot the tool with scenarios with 
doctors of different levels of experience as subjects, measuring decision performance using a 
within subject pre- and post- design in collaboration with Dr. Shaun Treweek from the 
University of Dundee. 
(4) A pilot clinical trial of the provision of the result of prognostic models to stroke units. 
I aim to pilot the interface developed in (3) to (i) test data-collection and randomisation 
systems (ii) assess problems with the use of the prediction tool in practice and (iii) obtain 
data to choose an easily measured outcome measure to allow sample size calculations for a 
larger randomised trial. NHS Lothian is an ideal test bed for this pilot, with (i) a single 
information technology department and; (ii) electronic patient-records for use in 
neurovascular clinics and an electronic patient record for acute stroke units soon to be 
introduced.  
The main aim of a large scale multi-centre randomised controlled trial of a clinical prediction 
model would be to measure improvements in practice. Possible outcome for a trial after 
stroke include adherence to number of evidence based guidelines, collected through the 
routine audit system already in place in NHS Lothian e.g. % of ischaemic stroke patients on 
aspirin, % of ischaemic stroke patients discharged on aspirin, antihypertensive and statin 
medication. With a sample size of 200 patients, I expect to be able to test the feasibility of, 
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